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ABSTRACT
The aim of this research was to measure and describe the impact of screening for
cystic fibrosis (CF) carriers in pregnancy and to assess the implications for midwifery
practice. Women were invited to be screened by an information leaflet sent with their
booking clinic appointment. The midwife booking a woman at the clinic offered
further information and counselling. Male partners of women identified as carriers
were also invited to be screened and heterozygous couples were offered prenatal
diagnosis.
A cohort of 2,058 women offered screening completed a self administered
questionnaire which measured their knowledge and attitude to screening and
described their reasons for accepting or declining the test. Psychological status, prior
to testing, was measured by the General Health Questionnaire (GHQ) and the
Symptom Rating Test (SRT).
Women 16-20 years were significantly less likely to have heard of CF; significantly
more likely to find the information leaflet difficult; and significantly less likely to have
a partner who read the leaflet or to discuss the test with him. Women 16-25 years
were significantly less likely to know their risk of being a CF carrier. 27% of all
women discussed the test with no one other than the midwife. 25% felt anxious about
being screened. 62% of those accepting, wished to determine fetal CF status, of
whom 10% wished to prepare for an affected child. 54% who declined were opposed
to abortion - (43% totally and 11% specifically for CF). 30% of those totally opposed
accepted maternal serum alpha-fetoprotein (MSAFP) screening. 32% of women
showed signs ofpsychological disturbance prior to screening.
The psychological response of 64 women identified as CF carriers and their partners
who received a negative test result were assessed together with selected controls on 4
XV
further occasions: 1) on receiving the carrier's positive test result; 2) on receiving the
partner's negative test result; 3) six weeks later; 4) six weeks after delivery.
Knowledge of the genetics of CF and attitude to having been screened were measured
by self administered questionnaire. Compared to control subjects carriers showed a
significant increase in generalised psychological disturbance attributed specifically to
symptoms of anxiety and depression during the period awaiting their partner's test
result but returned to control levels on receipt of a partner's negative test result.
Although there was no significant difference in generalised psychological disturbance
between partners and their selected controls, partners did become significantly more
anxious and manifested signs of inadequacy while awaiting their own test result.
All four groups were well informed about the genetics of CF and the significance of
being a gene carrier, although 23% of carriers felt information given at the booking
clinic was insufficient. 20% of carriers felt regret or ambivalence about having been
screened. There was a consensus that screening should be routinely offered to
pregnant women but should also be made available in family planning clinics and GP
centres.
Results showed that the implications for midwifery practice focus on 3 areas of care:
information giving; counselling; and emotional support. Practical guidelines for the
presentation of screening within these three areas are outlined.
Concerns which arise are: current irregularities in the presentation of screening tests;
genetic screening focusing on pregnancy and placing women in an unfair position of
responsibility for genetic disease; information overload causing blockage or
misinterpretation of other antenatal health care messages; the expansion of genetic
screening tests could cause an imbalance of antenatal information toward the
abnormal rather than the normal.
xvi
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When a child is born with a genetic disease parents search for the presence of a family
history. For over 50 years cystic fibrosis (CF) has been recognised as a genetic disease.
In Britain, about one child is born each day with CF; yet, in 4 out of 5 affected infants
the parents have no family history of the disease (Boat et al 1989). Understandably,
these parents ask "why us?"
Parents of a child with CF are, by definition, obligate CF carriers. They have no
symptoms of the disease but, with each pregnancy they have a 1 in 4 chance of having a
child with CF. Until recently there was no way to detect the presence of the CF gene in
a family before an affected child was born. Then, in 1989 the gene which causes CF
was identified on chromosome number 7 (Rommens et al 1989; Riordan et al 1989).
Following this discovery the development of a test to detect carriers of the CF gene
meant that individuals in the general population could be screened and couples at risk
of having a child with CF could be identified. Since 1 in 25 individuals in the United
Kingdom carry a CF gene (Boat et al 1989), the test had the potential to detect a
majority of the 1 in 625 couples at risk of having an affected child. These couples could
then be offered prenatal diagnosis to detect the presence or absence of the disease in their
unborn child.
Immediately important questions arose concerning population carrier screening for CF.
Could and should population carrier screening be implemented? If so should it be
offered selectively or universally, and at what stage - birth, school, pre-pregnancy or
prenatally? What would the level of uptake and public attitude be to such screening?
Although genetic screening programmes existed for the genetic disorders beta-
thalassaemia, sickle cell disease and Tay Sachs disease they were restricted to the ethnic
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minority groups in which these disorders are prevalent. Thus, there was no precedent for
a large scale genetic screening programme in the United Kingdom. The consensus
was that pilot programmes were urgently needed to investigate these fundamental
questions about CF carrier screening. Consequently, the Cystic Fibrosis Trust invited
interested parties to submit protocols for screening trials for their approval and
financial support. Three pilot projects were selected for funding by The Trust, each
designed to examine differing approaches to carrier screening. In Cardiff and London
the feasibility of screening in general practice was assessed. In Edinburgh, the director
of the third programme advocated a prenatal approach to screening based on the belief
that pregnant couples coming through an antenatal clinic are more motivated and
more in need of this type of information and more likely to make immediate use of the
information provided through screening (Brock et al 1991). In addition, the concept of
maternal serum alpha-fetoprotein screening delivered by midwives had been
successfully initiated by the director in the same hospital as that in which the CF carrier
screening trial was to operate (Brock and Sutcliffe 1972). Thus, there were already in
place midwives experienced in the presentation of prenatal screening.
The researcher was appointed as co-ordinator of the prenatal CF carrier screening trial.
Her role was to design and evaluate a screening protocol and clarify what
information should be provided to the target population and evaluate ways of
presenting that information. In addition, she was required to design a study which
would answer the question: 'is this form of prenatal screening acceptable to women and
their partners?' It is this study which forms the broad substance ofthis thesis.
Since the prenatal CF carrier screening trial was to be presented by midwives it seemed
appropriate to approach the study from this perspective. Nursing and midwifery has a
commitment to the philosophy of holistic care. Nurses and midwives recognise that a
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person can be viewed as having psychological, social, spiritual and physical domains
and that when problems arise in any one ofthese domains it affects the individual and
significant others in one or more of the other domains (Price 1990). Effective care
depends upon nurses and midwives having the knowledge and the ability to assess and
diagnose before they can plan, implement and evaluate interventions to help the
individual. Presently it is not possible to suggest ways that midwives might best help
those who undergo genetic screening because we have little or no understanding of
what, if any, the range of associated problems might be. Before the profession can
consider taking responsibility for the delivery of prenatal genetic screening it needs
to acquire information relevant to a midwifery perspective of the screening
process.
Research has been defined as: "an attempt to increase the sum of what is known,
usually referred to as 'a body of knowledge' by the discovery of facts or relationships
through a process of systematic scientific enquiry, the research process." (Hockey
1991 page 4). Nursing research aims to increase the sum of what is known about the
professional activity of nurses, which may be nurse education, nursing
administration or nursing practice in its many forms and settings (Hockey 1991).
The purpose of research is to develop theories for nursing and midwifery practice
which establishes the association between individual or patient needs, nursing
intervention and individual or patient outcome (McFarlane ofLlandaff 1991).
This thesis considers the consequences to women and midwives of offering genetic
screening in the context of an antenatal clinic. It describes and examines factors
which emerged from studying a cohort of approximately 2,500 women who were
offered prenatal CF carrier screening and 64 women who were identified as CF carriers.
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The broad aim of the work was to contribute to the body of knowledge about the
midwife's role in presenting prenatal genetic screening.
The thesis begins (Chapter 2) by outlining the background to the study. It describes the
disease cystic fibrosis (CF) and the development of a test to screen for CF carriers in the
general population. It reviews genetic screening tests and pregnancy screening tests, and
describes a trial of a prenatal model of CF carrier screening which presented the
opportunity to undertake this research. From this description of the background to the
study a number of key questions emerge relating to midwifery care and these are
addressed. A major concern is that screening may cause distress which could persist
throughout pregnancy.
Chapter 3 focuses on the subject of stress, in response to initial concerns that the major
impact of prenatal CF carrier screening was likely to be a psychological one. Models of
stress and coping are reviewed and the conceptual framework for the study is drawn from
a model of stress, coping and mental health. The model is used to formulate an outline for
a more extensive literature review.
Chapter 4 is devoted to the literature review which focuses on a number of key areas
which were identified using the conceptual model. These key areas of genetic screening,
genetic disease, prenatal screening, early infant loss, pregnancy and concurrent life events
are reviewed in relation to their impact on an individual or couple. The conclusions drawn
are used to frame a number of broad based questions relating to prenatal genetic
screening .
Chapter 5 deals with the process of refining these broad questions in the context of the
conceptual model. The research methodology selected to conduct the study is outlined.
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The questions asked are:
1 Are there pre-screening variables which influence a woman's response to
prenatal CF screening?
2 What factors influence a woman to accept or decline prenatal CF carrier
screening?
3 Will identifying a woman as a CF carrier during pregnancy provoke a stressful
response both in her and her partner?
4 Do carriers and their partners understand the essential facts concerning CF
carrier screening and what is their attitude toward having been screened?
Chapter 6 presents the results of the study by addressing each question in turn and
discussing the findings.
Chapter 7 focuses on how the results of the study contribute to nursing knowledge about
the midwife's role in prenatal genetic screening. Firstly a number of ethical issues which
emerged from the study are discussed; the intent being to create an awareness of these
ethical themes which thread through the whole prenatal genetic screening process. The
conceptual model is used to provide a framework to assess how the results of the
research contribute to midwifery practice. Practical guidelines for the presentation of
prenatal genetic screening are proposed on the basis of the results. Implications for
midwifery managers and educationalists are discussed and suggestions are made for
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BACKGROUND TO THE STUDY
2.1 Cystic fibrosis
Cystic fibrosis (CF) is a multi-system disease, first described in the 1930s (Andersen
1938). It affects the respiratory, gastrointestinal and reproductive systems, as well as
the sweat glands. It is the most common life shortening, recessive genetic disorder
among Caucasians ofEuropean descent, occurring in 1 in 2,500 live births in the United
Kingdom (Beaudet 1989). The disease does occur in other races but at a lower
incidence. Cystic fibrosis varies in severity from patient to patient and to the extent to
which different organs are affected. There is no cure for CF, but treatment of the
respiratory and digestive symptoms has lengthened life span considerably.
2.1.1 Pathology
Although the disorder is present at birth, only 10 per cent of infants are born with a
detectable symptom of the disease called meconium ileus. The baby fails to pass
meconium and there is increasing abdominal distension and bileus vomiting. A
few cases can be treated with gastrografin (sodium and methyl glucamine diatrizoates)
enemas but the majority require surgery (Hodson 1993). By the age of 3 years most
affected children have developed symptoms, although in a minority these are not
apparent until later in childhood, adolescence or even adulthood (Boat et al 1989).
CF occurs because of a dysfunction of the exocrine glands. These glands secrete into
ducts or onto specific organ surfaces and include the lacrimal glands, sweat glands, part
of the pancreas and the mucus producing cells lining the respiratory and gastro-intestinal
tract. In CF secretions from the serous glands have an increased salt content. In contrast,
the mucus secreting glands have a normal or diminished salt content and, in addition,
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thicker than normal mucus secretions. The latter leads to obstruction of the gland ducts
resulting in the varied clinical features of the disease (Goodchild and Dodge 1985).
2.1.2 Clinical features
Respiratory system
The thick, sticky mucus produced in the respiratory tract of affected individuals
obstructs breathing and interferes with the normal exchange of gases and removal of
bacteria from the airways. Chronic lung infection, subsequent inflammation and resulting
lung tissue damage limits pulmonary function and finally causes respiratory and heart
failure. It is the severity of respiratory involvement which is the life threatening
component of CF, ultimately determining quality of life and survival (Penkeith et al
1987).
Gastrointestinal system
In childhood, digestive difficulties may predominate over respiratory symptoms.
Eighty five to 90 per cent of cases manifest some pancreatic involvement related to
inadequate quantities of pancreatic enzymes being released to digest food (Taylor
1993). Poor nutrition and impaired growth is the result of fat and protein not being
broken down and absorbed by the body. Nutritional status is now regarded as central
to prognosis. Poor nutrition intensifies respiratory disease and a balanced diet with
extra calories and protein, sufficient to promote normal growth and weight gain,
will help the individual withstand chest infections (Taylor 1993). Diabetes occurs
in approximately 12 per cent of adult CF patients. Older patients are also susceptible
to bowel obstruction which can sometimes be treated orally or failing this by enema.
In the majority of adult patients there is also some degree of liver involvement,
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characteristically biliary cirrhosis, resulting from blockage of the ducts that transport bile
into the intestine (Hodson 1993).
The reproductive system.
Cystic fibrosis manifests itself in the reproductive system of males and females. In 95 per
cent of males the Wolffian duct is damaged (Boat et al 1989). The vas deferens are
often absent, incompletely formed or blocked by mucus (Rigot et al 1991) and in
addition it is thought that sperm may be formed imperfectly in men with CF (Trezise
and Buchwald 1991). Consequently, only 2 or 3 per cent of males with CF are
fertile (Boat 1989). Women with CF may produce thick dehydrated mucus which
can impede sperm migration and plug the opening to the uterus thus reducing the
chance of a pregnancy (Boat et al 1989). Women may also develop amenorrhoea
secondary to poor nutritional status or pulmonary disease. Lastly, pregnancy
imposes an added burden on the respiratory system and can result in deterioration of
health in a women with CF (Cohen et al 1980). Those with poor lung function are
advised to avoid pregnancy (Hodson 1993). In recent years a number of CF adults
have successfully had children (Duncan-Skingle and Foster 1991). The risk of a parent
with CF having an affected child is 1 in 50 (Brock 1993).
2.1.3 Diagnosis
The sweat test was until recently the most common method of con firming a suspected
diagnosis of CF. Excess sodium and chloride are lost in the sweat. A raised sweat
chloride confirms the diagnosis of CF along with typical clinical findings (Gibson and
Cooke 1959). Sweat testing in the new-bom is ineffective and the immunoreactive
trypsin test (IRT), which measures levels of pancreatic trypsin, elevated in CF, is
performed by Guthrie spot (Crossley et al 1979) but is not routinely offered. Direct gene
analysis, now the most precise diagnostic test, is described in section 2.2.4 page 17.
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2.1.4 Medical management
The medical management of CF focuses on impeding loss of lung function by daily
physiotherapy to promote mucus clearance, together with appropriate bronchodilator
therapy. Antibiotic therapy varies from intermittent use to repeated sustained
use, however, bacterial resistance to treatment is a major problem As the affected
individual's condition deteriorates they develop chronic hypoxia and respiratory
failure. At this stage heart-lung transplantation is the only option (Duncan-Skingle
and Foster 1991). Both heart-lung, and double-lung replacement surgery have been
performed (Wrightson et al 1993). As with all organ transplantation, rejection is the
greatest problem to survival.
Digestive therapy strives to achieve ideal weight, normal growth, sustain
respiratory muscle strength and maintain immunity. An important adjunct is a high
calorie, high protein diet and pancreatic enzyme replacement to counteract
malabsorption. Food supplements and occasionally intravenous nutrition may become
necessary. Enteric coated enzymes are taken with each meal and snack, and
supplementation of the diet with fat soluble vitamins is required. The nutritional needs of
the CF child are fully described by Taylor (1993).
2.1.5 Prognosis
Since the arrival of antibiotics in the 1940's, the introduction of chest physiotherapy
in the 1950's and advances in nutritional management in the 1970's and 1980's, the life
expectancy of those with CF has increased. Some believe that earlier diagnosis and
hence treatment improves prognosis, but many believe that the advent of CF centres has
had the greatest single impact; demonstrated by the differences in survival between
countries (Boat et al 1989; George 1990; Dodge et al 1993).
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It is estimated that there are some 6,000 CF sufferers in the United Kingdom, among
whom 34 per cent are aged 15 years and over. By the turn of the century the total
number of affected individuals is expected to rise to around 7,000. The average life
expectancy is currently estimated to be 25 years for males and 24 years for females
(Dodge et al 1993). Cystic fibrosis can no longer be considered solely a paediatric
problem and recommendations for the care of adults with CF have been made (Royal
College of Physicians 1990). Now the identification of the CF gene promises to
have an even greater impact on the treatment of this disease.
2.1.6 Burden of the disease
As with any chr onic disease CF has a profound effect not only on the lives of the
individual sufferers but also on their families, resulting from physical symptoms,
psychological and social consequences. For the affected person a chronic productive
cough, offensive stools with flatulence, short stature, delayed puberty and infertility can
combine to create a life long struggle for many sufferers, resulting in depression, anxiety
and feelings of stigmatisation (Smith et al 1983). Children may resist the stringency of
daily physiotherapy and rebel against the constant ingestion of digestive enzymes
placing a strain on the patience of parents and disrupting family life. One study
reported those with CF to be more socially isolated and dependent upon their mothers
than their peers (Cappelli et al 1989). This, it was claimed, was a consequence of
the great amount of time and management their condition demanded. CF requires
daily treatments; even mildly affected individuals require pancreatic enzymes and
usually chest physiotherapy which affects the daily fives of both patient and family.
Fifty per cent of mothers in one study complained about the time they spent on their
affected child, leaving little time to look after the rest of their family. One-third of
these mothers stated that they felt genuinely stretched to cope (Andesson-Segesten and
Plos 1988). These findings are significant in view of recent work which shows that
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balanced family coping and resulting compliance with therapy optimises child health
outcome (Patterson et al 1993). Balanced family coping was defined by Patterson and
colleagues as parents who: "tried to maintain family integration and worked
together to meet the medical needs; they attended to their own personal esteem and
support needs; and they sought medical consultation from doctors and others" (p 388).
Adverse emotional responses of parents to the birth of a child with CF can have a
pervasive effect on the family making them vulnerable to crisis. Whyte (1992) revealed
how parents, when their child is diagnosed as having CF, often respond with fear and
denial. The source of these emotions came from a sense of threat which parents felt from
the loss of their child's health.
As the life expectancy for sufferers of CF has improved, it has become increasingly a
disease of young adulthood rather than a disease of childhood. Because CF is
a progressive disease, young adults find they are increasingly less fit and yet the demands
of daily therapy are just as important, if not more so than before. At a time when
the emphasis is on education, employment and independence extra demands are placed
upon the adolescent and young adult sufferer (Lewiston 1990; Shepherd et al
1990). Nonetheless, a recent survey reports many young adults are as healthy
psychologically as their peers and are living full and productive lives (Walters et al
1993). Walters and colleagues found that 55 per cent of sufferers in their study, over the
age of 16 years, were working and 56 per cent of them had less than two weeks sick
leave a year. Of those not employed, 50 per cent gave ill health as the reason. Ill health
caused more CF sufferers to leave school without qualifications than in the general
population and a higher proportion remained within the parental home.
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The average annual cost of treating someone with CF is estimated to be £4-6,000 (Office
of Health Economics 1986). However, there is the inestimable non-medical cost of
family care giving time. It is estimated that parents need to spend about 2 hours every day
on therapy for a child with CF (United States Congress, Office of Technology
Assessment, 1992a). In addition, family members lose time from work or home
commitments when the CF sufferer is sick.
Death among their peer group is a reminder to CF sufferers of their own shortened life
expectancy. Those who receive donor organs for lung transplantation must face another
set of emotional problems such as altered body image from scarring and steroid side
effects, uncertain prognosis, guilt and grief relating to the donor, as well as financial,
family and employment difficulties (Wrightson et al 1993). It is understandable that the
identification of the CF gene has lead to high expectations among patients, their
families, physicians and nurses for dramatic improvements in treatment.
2.2 The Genetics of CF
2.2.1 The inheritance of CF
An individual has two copies of chromosome 7, one inherited from their father and one
from their mother. Individuals with CF inherit a defective gene on each of their
chromosomes number 7. This happens in 1 in 2,500 babies in the United Kingdom
(Boat et al 1989). An individual may have a CF gene on one of their number 7
chromosomes and a normal gene on their other number 7 chromosome; these individuals
are CF gene carriers but have no symptoms of the disease. One in 25 of the UK
population are carriers and in 1 in 625 couples both partners are carriers. Couples
where both partners are CF gene carriers are at a 1 in 4 risk at each pregnancy of
bearing a child with the disease and a 2 in 3 chance that an unaffected child will be an














Figure 2.1 Inheritance of CF
Most couples with an affected child have no family history of the disorder and have no
idea that the genetic trait exists in the family. The risk of couple having a child with CF
given a variety of situations is shown in table 2.1.
Table 2.1 Risks to couples of having a CF child
(adapted from Brock L993)
Couple Risk of CF child
Couple have one or more affected 1 in 4
children
Both partners have affected siblings 1 in 9
Both partners have carrier siblings 1 in 16
One partner has an affected sibling 1 in 150
One partner has a carrier sibling 1 in 200
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2.2.2 Identifying the CF gene
In genetics the search for how specific traits are passed from one generation to the next
has been greatly assisted by the new technology of molecular biology. Geneticists now
have techniques which will allow them to locate and isolate a single gene from one of our
46 chromosomes. Genetic diseases arise as a result of changes (mutations) in the
deoxyribonucleic acid (DNA) that comprises a gene. Approximately 4,000 known human
disorders result from genetic causes (McKusick 1990). Disorders which arise from a
mutation in one gene are called monogenic or single gene disorders. CF is such a
disorder.
Genes produce a set of instructions or molecular code which specify the manufacture of
a particular protein to function in the cells of different organs. When a gene is defective
or faulty it can affect the structure, regulation, function or synthesis of a protein which in
turn can lead to malfunction of a particular organ. In CF the exocrine glands are affected.
In 1989 the gene responsible for CF was isolated on chromosome 7 and the most
common mutation identified. The product of the CF gene is a membrane-transport
protein which has been named the cystic fibrosis transmembrane conductance regulator
(CFTR) The tissue expression of the gene is compatible with the
pathophysiology ofthe disease. (Riordan et al 1989).
2.2.3 Current genetic research
As the workings of the CF gene are better understood, new possibilities for treatment are
emerging and gene therapy has moved from theory to clinical and therapeutic
experimental application (Anderson 1992; Davies and Williamson 1993). The
development of a cystic fibrosis mouse allowed copies of the normal human CFTR
gene to be introduced into the lungs using liposomes (lipid vesicles which fuse with
the epithelial cells), leading to the ion transport defect being corrected in some cases
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(Hyde et al 1993). Ill 1992 the 'Clothier Committee' reported on the ethics of gene
therapy and stated they found "no new ethical issues" raised by somatic gene therapy (see
footnote 1). Protocols for gene therapy trials are currently being submitted for
approval and funding (Davies and Williamson 1993).
2.2.4 The CF carrier screening test
The discovery of the CF gene means that scientists have been able to improve CF
diagnosis, including prenatal diagnosis and devise screening tests to identify people
who carry a defective copy of the gene and run the risk of having a child with the
disease.
A laboratory technique, the polymerase chain reaction (PCR), has proved critical
for carrier detection and diagnosis by direct gene analysis (Saiki et al 1988) (see
footnote 2). Over 400 mutations have been identified in the CF gene, but many have
been detected in only 1 family. Some five mutations were commonly found in the
Scottish population allowing some 85 per cent of carriers to be identified. This rate of
detection was considered adequate to allow a screening trial to commence (Shrimpton et
al 1991).
1. There are two approaches to gene therapy: somatic gene therapy aims to correct the cells of specified
affected organs such as the lungs in CF. There is no attempt to correct the defect in egg or sperm cells and therefore
the correction is not transmitted to any children of an affected individual. In contrast, germ line gene therapy
would lead to the correction of all cells in an individual including the germ line. This correction would be
passed on to following generations (Coutelle et al 1993).
The remit of the Clothier Committee was to consider the ethics of gene therapy; to consider proposals for treatment;
and to provide advice on safety and efficacy (The Clothier Report 1992).
2. The CF carrier test involves directly analysing the gene. DNA can be obtained from any nucleated cell in the
body. White blood cells or buccal cells are most commonly used for carrier screening or diagnosis and amniotic
fluid cells or chorionic villi for prenatal diagnosis. After the DNA is extracted, key segments containing
mutations are amplified using the polymerase chain reaction technique (PCR). This technique amplifies specific
areas of DNA to increase the amount available for test purposes. The amplified DNA can be visualised by a
number of different laboratory techniques to detect a specific mutation (Saiki et al 1988).
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2.2.5 Options available to carrier couples
In the case of carrier couples with a I in 4 risk of an affected child, prenatal diagnosis can
predict with 100 per cent accuracy if the fetus is affected. The choice of technique to
obtain a sample of DNA from the fetus depends upon the gestation of pregnancy and
consideration of procedural risk. Fetal cells can be obtained via chorionic villus sampling
(CVS) performed from 8-10 weeks gestation of pregnancy onwards. The biopsy is taken
under ultrasound guidance via a transcervical route or via a transabdominal route. CVS
has a procedural associated risk of spontaneous abortion of 2 to 4 per cent (Lilford
1991). An alternative method of obtaining fetal cells is by amniocentesis, the withdrawal
of amniotic fluid, performed from 14 weeks gestation of pregnancy. A needle is
introduced under ultrasound guidance into the amniotic cavity via the maternal abdomen.
The risk of spontaneous abortion occurring as a result of amniocentesis is 1 per cent
(Lilford 1991).
Some couples may decide against prenatal diagnosis and opt to continue the pregnancy
without confirming the status of the fetus. It is important in those pregnancies which
may result in an infant with CF to alert neonatal paediatricians to the risk of meconium
ileus. Although the knowledge gained through prenatal diagnosis has the potential to
offer relief from the apprehension of having an affected child, it can present agonizing
dilemma among families who already have a child with CF and who by considering
termination of pregnancy feel they might be seen to devalue their affected child (Whyte
1992).
Couples who are screened prior to conceiving confront a wider variety of options. Figure




































2.2.6 The initiation of population carrier screening trials.
New technologies bring new challenges to society. Almost immediately the CF gene was
identified, it became apparent that there was a realistic means of detecting many of those
couples who were at risk of having a child with the most common of lethal autosomal
recessive disorders, before an affected child was born. Such a development has prompted
the comment that within the next 10 years genetic screening will affect the majority of
people in developed countries (Wertz and Fletcher 1990). However well intentioned,
implementing genetic screening programmes prematurely could cause harm and has led to
recommendations that well designed pilot trials should be undertaken to address pertinent
issues such as autonomy and informed consent; confidentiality, psychological effects and
evaluation of outcome (Baird 1990). Before looking to the future the different types of
genetic screening tests already available and those groups of individuals at whom they
were targeted was reviewed.
2.3 SCREENING
Definition ofscreening
Screening has become a popular concept in health care and now has wide acceptance hi
our society (Holland and Stewart 1990). Screening is defined as the identification
among apparently healthy people of those at sufficient risk of a specific disorder to
warrant tests and treatment (Cuckle 1990). A screening test is not usually a diagnostic
test, for example if a cervical smear test or mammogram is positive, further
investigations such as a colposcopy or biopsy are required to confirm and determine the
nature of the abnormal findings. Once the diagnosis is confirmed treatment or
preventive advice or action can be offered (Chappie 1992).
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2.3.1 Genetic Screening
Screeningfor the disease state
Some genetic screening tests determine whether an individual carries a gene which will
cause a specific disease. Screening programmes for a number of genetic diseases have
been running for many years using tests which detect a metabolic product, for
example, neonatal screening for phenylketonuria in which a raised phenylalanine level is
detected in the blood of infants. The benefit is to the individual who can then be treated
and mental retardation avoided (Guthrie 1968). More recently, as genes that cause
certain diseases have been identified, it is possible to diagnose the disease state by the
presence of the mutant genes, for example, cystic fibrosis in a child suspected of having
the disorder (Rommens 1989). A further use of genetic testing is in screening individuals
at high risk of developing a genetic disorder because of a family history, to determine if
they are negative or positive for the disease state before they manifest symptoms of the
disorder. Presymptomatic genetic testing for late onset genetic disorders such as
Huntington's disease and myotonic dystrophy requires very careful pre-test counselling
and follow-up support (Harper 1984).
Genetic carrier screening
In contrast, genetic carrier screening does not test for the disease state; rather it identifies
individuals who carry one normal and one aberrant copy of a gene, but not the disorder
which results from having two aberrant copies of the gene. Cystic fibrosis is an example
of such a recessive disorder where carriers can be identified either from the general
population or within families where there is a family history. There is no direct benefit to
the individual from carrier screening, rather it allows them to make reproductive
choices (Chappie 1992). These choices have been outlined in figure 2.2.
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There are a number of turnstiles in life when screening can easily be offered. Birth is an
efficient time to carry out screening and many countries screen for phenylketonuria using
blood spots which test almost 100 per cent of infants, and treatment for the disease can
then be initiated (Guthrie 1968). However, screening for CF carriers at birth
provides information which is not relevant to the child until reproduction.
Alternatively, screening in high schools could be easily administered and combined with
an educational programme. Pilot projects in Canada indicate minimal problems,
providing there is careful counselling and support available (Kaplan 1992).
During pregnancy, screening can be offered to a woman and if she tests positive her
partner can be screened. Those couples who wish to avoid having an affected child can be
offered prenatal diagnosis.
Primary health care services provide screening through the family doctor which
allows individuals or couples to choose for themselves the most appropriate time to be
screened (Watson et al 1991)
Finally, cascade screening concentrates on testing relatives of those already identified as
CF carriers (Super et al 1992). As the siblings of CF carriers have a 50 per cent chance
of being carriers and cousins a 1 in 4 chance, this can be an effective method of
screening.
2.3.2 Prenatal screening and diagnosis
Two to five per cent ofbabies are born with a genetic disorder or a condition where there
is a substantial genetic influence (Pembrey 1987). Figure 2.3 shows the relative
frequency of those which are common and serious (Cuckle 1992).
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18%
E9 Spina bifida 24%
Q Anencephaly 18%
■ Down'3 syndrome 16%
□ Fragile X 8%
□ Cystic fibrosis 7%
ED Muscular dystrophy 6%
9 Haemogiobinopathy 6%
B Hydrocephaly 4%
■ Trisomy 18 4%
a Hypothyroidism 3%
B Trisomy 13 3%
B Turner's syndrome 3%
Figure 2.3 The relative frequency at birth of common serious fetal
abnormalities (adapted from Cuckle 1992
A prenatal screening test aims to identify among pregnant women, who are collectively
at low risk of a particular fetal abnormality, those at a higher risk. Further prenatal
diagnostic tests are then offered to those who screen positive, to confirm if the fetus
has a particular disorder (Donnai 1992). In the past twenty years technological
developments have provided new techniques which can diagnose many fetal
abnormalities. These diagnostic tools provide prospective parents with information
about the risks of bearing child with a particular congenital or genetic disorder.
Women come to have prenatal diagnosis via one of two routes. They may be identified
as being at risk of fetal abnormality through a screening programme (i.e. a testing
programme directed at the pregnant population as a whole). Or a woman may be
deemed to be at risk because she has an affected child; has a family history or is a
known carrier for a genetic disorder; or she may be of advanced maternal age.
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The most widely used prenatal screening procedure is the ultrasound scan, which can
estimate gestational age and identify multiple pregnancies. It can be used as a diagnostic
tool to detect structural abnormalities in the fetus (Crespigny and Dredge 1991). It is
frequently used in conjunction with diagnostic procedures namely amniocentesis or
chorionic villus sampling already described (page 18).
Screening may commence prior to conception with a comprehensive serum screen
(toxoplasmosis, rubella, cytomegalovirus, herpes virus) if appropriate. ABO blood
group and rhesus factor can also be determined. Genetic carrier screening for
haemoglobinopathies, CF and Tay-Sachs disease can be carried out. Carrier status for
genetic conditions where there is an established family history for example: Fragile
X syndrome, Huntington's disease, polyposis coli, muscular dystrophy (Becker,
Duchenne or myotonic), neurofibromatosis and haemophilia A and B can also be offered.
At the first antenatal clinic visit a blood sample is taken for full blood count, ABO and
rhesus grouping, determination of rubella state (if not already known) and serology for
syphilis. Testing for toxoplasmosis is carried out, if indicated. Screening for hepatitis
B is routine in some areas and it seems that HTV state may also be routinely offered in
high risk areas in future (Bull 1990; Goldberg and Johnstone 1993). A urine sample is
taken to exclude diabetes or nephropathy and asymptomatic bacteriuria. Urine testing is
routine at every antenatal examination and blood samples are taken at regular intervals
to exclude iron deficiency or other anaemia (table 2.2).
There are a number of optional screening tests during pregnancy. Ultrasound scan may
be offered at 18-20 weeks gestation to exclude fetal anomalies (cardiac, renal, limb
reduction defects). Amniocentesis should be offered to women over the age of 35
years or with a history of chromosome or gene defects.
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Maternal serum alpha-fetoprotein (MSAFP) screening consists of taking a blood
specimen at about 16 to 18 weeks of pregnancy and biochemical serum estimations
of a number of markers allows detection of about 60 per cent of Down's syndrome
pregnancies and approximately 85 per cent of cases of open spina bifida and
effectively all cases of anencephaly. Alpha-fetoprotein (AFP) is a glycoprotein
synthesised in the fetal liver and gastro-intestinal tract. It is found in amniotic fluid and
in smaller amounts in maternal blood which it enters through the placenta. There is
an association of an abnormally increased amount of AFP in maternal serum in a
variety of fetal disorders.
An elevated maternal serum AFP (MSAFP) can indicate an open neural tube defect or
an abdominal wall defect in the fetus. Abnormally low MSAFP levels are associated
with fetal chromosomal abnormalities such as Down syndrome. About 4-5 per cent of
women have high initial MSAFP values ofwhom about halfwill continue to have a high
value on repetition of the test and will require ultrasonography. Because MSAFP
levels must be calculated precisely with gestational age and number of fetuses,
ultrasonography will provide the reason for raised MSAFP because of incorrect
dating of last menstrual period or multiple fetuses. Around 1-2 per cent of women will
require an amniocentesis to assess AFP concentration in amniotic fluid and about 1 in
10 will ultimately be found to have a fetus with a neural tube defect. At the other end
of the curve another 5 per cent of all women screened will have an abnormally low
AFP level. Ultrasonography will eliminate half of these women from further
evaluation because of inaccurate gestational dating and the other half will be offered
amniocentesis for fetal karyotyping of whom around 1 in 40 will have a
chromosomally abnormal fetus. (Cunningham and Gilstrap 1991). The tests which are
available during pregnancy are summarised by gestational age in table 2.2.
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Table 2.2 Screening before and during pregnancy
(adapted from Bull 1990)
























































2.3.3 Planning a genetic screening programme
There are numerous sets of criteria published for determining the benefits of a
genetic screening programme (Cuckle and Wald 1984; Holland and Stewart 1990;
Simpson 1991). The disorder should be well defined and considered an important health
problem Important means that either it is prevalent in the population or that it is a
serious problem Cystic fibrosis fulfils both criteria.
26
The actual screening test must meet certain criteria (Cohen 1984). The test should be
simple and rapid and use easily available specimens. The CF carrier test involves a
simple mouth-wash of 10 millilitres of water from which sufficient buccal cells are
obtained to provide DNA analysis. Carrier test results are available in one week.
Ideally the test should be highly sensitive and highly specific, thus having a low
percentage of false positive and false negative results.
The prenatal screening trial invited women to be screened for five common CF alleles
representing 85 per cent of mutations, thus, the test failed to account for 15 percent
of CF carriers. This meant that a negative test result did not guarantee that an
individual was not a carrier but reduced their risk from 1 in 25 to 1 in 167.
There must also be benefits resulting from screening. For genetic disorders, like CF,
genetic counselling and either reproductive decision making or prenatal diagnosis are
considered acceptable screening benefits.
The infrastructure of any screening programme requires planning and
organisation. Screening and testing facilities must be available along with appropriate
education of both professionals and the lay target population. Pre-screening
information and counselling should provide the target population with knowledge
and understanding of the risks, as well as the benefits of screening. In addition,
provision for confidentiality of records and informed consent must be made, as well
as counselling, diagnostic referral and follow-up of positive cases (Modell 1990).
The requirements of a genetic screening programme infrastructure are summarised
in table 2.3.
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Table 2.3 Infrastructure required for a genetic screening programme
(adapted from Modell 1990)
• Information and education of health professionals and the target population
• System for collecting samples and delivering them to the laboratory
• Diagnostic laboratory and quality control system
• System for notifying and storing results
• Information storage and retrieval system
• An information and counselling service for carriers
• Expert counselling for at-risk couples and provision of prenatal diagnosis
• A system for monitoring the service
2.3.4 Nurses and Genetic Screening
During the 1970's there was a shift in emphasis from 'content oriented genetic counselling1
which concentrated on the medical aspects of genetic disease and risk estimation, to
'person oriented counselling' with a greater emphasis placed upon the psychological
aspects of genetic counselling (Emery and Pullen 1984). This move marked a steady
increase in the number of nurses recruited into clinical genetic services. Nurses were
considered to be ideally suited to collecting relevant pedigree and medical details and
initiating preliminary investigations prior to counselling. Nurses could use their skills to
assess the extent of social or psychological problems, physical or mental handicap, or
anticipate language difficulties among prospective counselees. They could also assess
individual knowledge, understanding and attitude toward a genetic condition as well as
individual perceptions and objectives in seeking genetic counselling. Nurses could provide
bereavement counselling and assess the state of grieving prior to and after counselling
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The genetic nurse's overall aim was to ensure that the clinic consultation was geared to
the particular needs of the individual.
In addition the genetic nurse provided clinical assistance during examination and
diagnostic procedures and by being present during the counselling session facilitated
assessment of individual comprehension and impact and follow-up requirements. Post
counselling support of individuals and liaison with other health care professionals is now
considered an important role ofthe genetic nurse (Guilbert 1988).
Health visitors have been a popular choice for genetic nurse specialist positions of which
there are currently around 100 posts in the UK (Genetic Nurses and Social Workers
Association 1994). It has been suggested that the role of the genetic nurse be reserved in
genetic screening programmes to the follow up of those who receive a carrier result
(Ellis 1991). This proposal stems from a concern about whether the current number
of health care professionals in genetics can handle the increase of work that CF
carrier screening could potentially generate. Similar misgivings have been voiced in
the United States (United States Office of Technology 1992). An additional concern, in
Britain, revolves around what has been described as a serious deficiency of teaching of
clinical genetics in medical schools such that medical geneticists are reluctant to rely on
primary care doctors to provide genetic advice (Johnston 1990). In nursing this worry
also prevails and is reflected in an article devoted to genetic screening for sickle cell
disease, in which midwives and health visitors are encouraged to understand the
implications of the disorder and to empathise with couples at risk, but to refer to a
sickle cell counsellor (Stirk 1991).
There is evidence to support these concerns from a survey of health visitors which
showed that generic health visitors (those not working in genetics) have a reasonable
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knowledge of the more obvious aspects of genetic services but their general awareness
and perception of clinical genetic services was poor (Guilbert and Cheater 1990).
Many felt their knowledge of genetics was inadequate, a factor thought to account
for their failure to recognise that they themselves could initiate referral of clients for
genetic counselling or screening.
The success of most preventive forms of health care depends upon public
awareness, and understanding and acceptance obtained through informed
discussion and consent (Rosenstock et al 1975). It is now recognised that this area is
one in which the midwife, family planning clinic nurse and health visitor have a
primary role and that medical genetics should be included in their core curriculum
(Royal College ofPhysicians 1989). A community genetic counselling course for primary
health workers is now available in London (Anionwu 1991). More recently, an MSc
Course in Genetic Counselling has been initiated at Manchester University. Students are
taught case work in human and clinical genetics, and counselling, with fieldwork in
community placements and genetic clinics (Manchester University 1993). Currently,
the Royal College of Physicians is carrying out an enquiry into counselling for genetic
disorders with the aim of auditing the counselling that people at risk of genetic disease
receive from health professionals other than clinical geneticists. The Royal College of
Midwives is supporting this enquiry which is investigating specific cases where
individuals are identified with one of seven genetic conditions namely: cystic fibrosis,
familial adenomatous polyposis, multiple endocrine neoplasia type 2A, Down's syndrome,
haemophilia, thalassaemia and neural tube defect. (Royal College Physicians 1993).
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2.4 A Prenatal trial of cystic fibrosis carrier screening
The prenatal CF carrier screening trial was undertaken by the University of Edinburgh
Human Genetics Unit. It was conducted through the antenatal clinics of a
large Edinburgh maternity hospital, the Simpson Memorial Maternity Pavilion.
In addition to the researcher, a genetic nurse was appointed to carry out the day-to-day
running of the trial working alongside the midwives in the antenatal clinic. A midwife
with appropriate clinical and counselling experience, she was also responsible for
the major genetic counselling component of the trial. It was felt that the researcher
was better to be an outsider rather than a participant group member. Firstly, it was
thought that women and their partners could become confused between the genetic nurse
and the researcher. Secondly, within the antenatal clinic the staff had expectations of the
genetic nurse regarding her contribution to the work. Finally, it is considered difficult for
a researcher to be immersed in a work role and maintain objectivity (Field and Morse
1990).
2.4.1 An outline of the screening procedure
The principal steps in the screening procedure were as follows: a) to offer pregnant
women attending the antenatal booking clinic a CF carrier test, b) to offer the partners
of women who tested positive for the CF gene a CF carrier test, c) to offer prenatal
diagnosis to carrier couples (Brock 1990b). The major questions to be addressed
during the trial are detailed in table 2.4.
31
Table 2.4 The major questions to be asked in the prenatal CF carrier screening
trial
1 Is it possible to organise antenatal clinics in such a way as to offer and deliver heterozygote
testing to a high proportion of pregnant women?
2 Can heterozygote testing be delivered to a high proportion of the partners of women who
test positive?
3 Can effective methods of counselling be established so that pregnant women and their
partners have a full understanding of what is involved on entering the programme?
4 Is this form of prenatal screening acceptable to women and their partners?
5 To what extent is the programme invalidated by the incomplete nature of heterozygote
testing?
6 What are the costs of the different parts of the programme?
7 How can this form of prenatal screening be integrated into National Health
Service antenatal care?
Source: Brock (1990b) Unpublished research proposal submitted to the Cystic Fibrosis Trust
It was question 4: 'Is this form of prenatal screening acceptable to women and their
partners' which formed the initial concept for this study. Before any initiative could he
taken to answer this question the researcher reviewed in detail the discrete stages of the
CF carrier screening process.
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2.4.2 Organisation of the screening trial
2.4.2.1 The trial setting.
The trial was carried out in the antenatal clinic of the Simpson Memorial Maternity
Pavilion, Edinburgh which has approximately 5,000 deliveries a year. An estimated
1,000 of these women booked at one of 6 peripheral antenatal clinics and were not
included in the trial. The screening trial was introduced in October 1990 in one
antenatal clinic and gradually expanded to run in all nine weekly antenatal clinics held in
the hospital. An outline of the principal stages of the screening protocol is shown in table
2.5.
Table 2.5. Outline of the principal stages of the screening protocol
1. Invite participation with booking appointment letter
2. At clinic, collect signed consent form
3. Mouthwash sample from woman
4. Ifnegative for mutant alleles, no further action. Ifpositive invite couple for
counselling session. Mouthwash sample from partner
5. Ifpartner negative, counselling but no further action
6. Ifpartner positive, refer to obstetrician
Women were offered testing by means of a leaflet sent with their booking clinic
appointment (see appendix). They were asked to discuss it with their partners and were
invited to join the trial by signing a consent form. Women were advised not to enter
the trial if they were more than 18 weeks' gestation of pregnancy or if they could
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not identify the baby's father. Other reasons for exclusion are shown in figure 2.5 page
46.
2.4.2.2 The role of the midwife in the screening trial
The midwifery team in the antenatal clinic consisted of a sister, a specialist midwife
in prenatal diagnosis, and six stalf-midwives. Education of clinic staff was initiated by a
lecture and an educational package containing the patient information leaflet, a leaflet
devoted to the disease CF, a hand-out describing the CF carrier test and outlining the
delivery ofthe CF trial in the antenatal clinic.
The midwife's role is concerned with all aspects of antenatal care: clinical,
educational and advisory. Midwives are qualified to assess the health of the mother and
baby and to recognise those signs of abnormality in either which necessitate referral to
medical staff for advice or treatment. (Robinson et al 1983). Midwifery training
prepares midwives to advise women individually on matters such as health care
during pregnancy and preparation for after delivery. They are ideally placed to
recognise the emotional needs of individual women and develop a supportive and
continuing relationship with them during their pregnancy at the same time as
monitoring and assessing their physical well-being and that of the fetus (Sweet 1988).
In the study setting, midwives worked with doctors in obstetrician led antenatal
clinics. A midwife responsible for booking a woman took a general medical
history, gave general advice on diet, welfare benefits, antenatal and parent craft
classes, and details of future visits. The midwife discussed routine prenatal
screening tests and optional screening tests such as maternal-serum alpha-fetoprotein
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and CF carrier screening. An ultrasound scan was performed to estimate gestational
age and a venous blood sample taken (table 2.2). Cervical cytology was recommended
and carried out if appropriate.
During the prenatal history taking the midwife obtained socio-demographic
details including ethnic background, occupation and religious beliefs of both
partners. She discussed a woman's or couple's expectations concerning the pregnancy
and the care they hoped to receive. This information provided insight into the stability of
a woman's relationship with her partner and the significance of the pregnancy to them
both. Other details relevant to the CF carrier screening trial were a couple's ethnic origins
in relation to gene frequency, availability of the male partner, and a couple's attitude
toward fetal abnormality and termination of pregnancy.
Women who were greater than 18 weeks' gestational age, as estimated by
ultrasound scan, were advised not to enter the CF screening trial because of the
emotional implications of termination of pregnancy late in the second trimester (Donnai
1981; Lloyd and Lawrence 1985; lies 1989). Rather, they were advised to be screened
after the delivery of their baby and before a subsequent pregnancy.
The maternity hospital hi which this study took place was situated within a health board
area which had developed a shared record system. Under this scheme one copy of
a specially designed antenatal card was held by the hospital in the patient's
antenatal records, another by her general practitioner and both copies were kept up to
date from a master record held by the woman and presented by her at each clinic visit.
On the rear of the woman's liaison card the midwife responsible for booking her
recorded whether or not she wished to participate in the maternal serum
alpha-fetoprotein screening programme. A study concerning the attitude of general
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practitioners to screening for genetic diseases revealed that not all regarded the
management of tested patients to be the sole responsibility of the genetic services.
Thirty per cent of general practitioners stated they wished to carry out post-test
counselling support and a further 11 per cent wished to disclose the test result (Mennie
et al 1990). Provision was, therefore, made to inform GPs of their patient's decision to
accept or decline CF carrier screening by recording it on a woman's antenatal liaison
card. Before the trial commenced, GPs were informed of the objectives ofthe trial in their
monthly newsletter circulated to each practice.
2.4.2.3 The specialist midwife in prenatal diagnosis
A specialist midwife was responsible for giving information about prenatal
diagnostic procedures. The growth of prenatal screening and diagnosis has created
a specialist role for the midwife (Whelton 1989). The specialist midwife provided care,
advice and support for mothers and couples considering or undergoing prenatal
diagnostic tests. Her role was also one of liaison with the midwives working in the
antenatal clinic and the medical staff.
Prenatal diagnosis is a screening facility for any pregnant mother at risk of delivering a
baby with an abnormality. Thus women with a raised or lowered maternal-serum alpha-
fetoprotein screening result, or of advanced maternal age, or with a known risk of fetal
abnormality by virtue of a previous pregnancy or family history come under the care of
the specialist midwife.
Fetal medicine is the management offered upon detection of problems which, with
therapy, may result in a successful pregnancy outcome; for example rhesus
isoimmunization and fetal urinary obstruction. The specialist midwife will care for
36
mothers during fetal operative procedures and give the necessary counselling and
support to enable them to cope with the procedure.
In addition the specialist midwife's role is that of educator and counsellor. The
invasive prenatal diagnostic procedures of amniocentesis and chorionic villus sampling
require explanation to couples about the procedure itself the risks and the
significance of a positive and negative fetal test result. The counselling role revolves
around the decision making process of whether such screening is a practical and
acceptable course of management for a pregnancy. The dilemma of whether a couple
decide to terminate or continue an aflFected pregnancy is frequently a counselling role
undertaken by the specialist midwife as well as bereavement counselling.
The specialist midwife's role was to liaise with the antenatal clinic and the laboratories
where fetal diagnostic tests were carried out and communicate results to the
obstetrician, general practitioner and patient. In conjunction with the obstetrician the
clinical specialist midwife undertook counselling and arranged for further
investigations if deemed necessary. Being conversant with the clinical significance of
genetic screening tests, the specialist midwife was frequently involved in explaining
these tests to women and their partners.
Close liaison with the specialist midwife was established early on in the CF screening
trial. Couples where both partners proved to be CF carriers were introduced to the
specialist midwife who gave more detailed information and counselling about diagnosing
CF in the fetus by chorionic villus sampling or by amniocentesis. The specialist midwife
haised with the genetic nurse to ensure that those patients undergoing prenatal
diagnosis for conditions other than CF, were also offered CF carrier screening, and that
those who wished their CF carrier status determined were promptly screened.
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2.4.2.4 The role of the genetic nurse
The genetic nurse was on duty at each antenatal booking clinic to discuss concerns with
both women and antenatal clinic staff. Studies have shown that women are not always
aware of what antenatal tests they have undergone or what the results mean,
often because of an insufficiency of information provided by obstetricians and
midwives (Marteau et al 1992c). The genetic nurse was available to reinforce
information which set out the options and factors involved in CF screening and to
encourage informed decision making. Using a felt board as a visual aid the genetic
nurse was able to explain genetic concepts, in a simple and non-threatening way, to
those who experienced difficulty in comprehending the information leaflet. Moreover,
she was available to identify and respond to staff difficulties.
Counselling carriers and their partners
In a number of cases the genetic nurse had already met a woman or couple at
the antenatal booking clinic; for some it was their first face-to-face meeting with her. The
overall objective of counselling was: to provide the couple with information about the
meaning of a woman's positive CF carrier test result; to explore the medical and genetic
aspects of CF; to prepare the couple factually and emotionally for the period awaiting
the male partner's test result; and to explore the social and emotional impact of having
received a positive CF test result.
During the first minutes of the counselling session the genetic nurse learned the details of
the couple's experience of having received the woman's positive carrier test result. This
enabled the genetic nurse to become aware of the emotional impact on the couple. Such
knowledge helped judge a couple's ability to assimilate information which may have
to be repeated or stressed to ensure comprehension. A number of important facts were
emphasised during the initial stages of the counselling session. These were that the test
38
result was not a fetal indicator and that being a single gene carrier was of no great
significance unless both partners were carriers. It was also stressed that all individuals
carried a number of aberrant genes. A felt board was used as a visual aid to explain the
possible consequence of the fetus being a single gene carrier if one parent was a CF
carrier, and the significance if both partners were shown to be carriers. The availabihty
ofprenatal diagnosis was highhghted at this juncture. Detailed information about fetal
diagnostic tests were discussed only if the couple wished; some couples regarded this
information as inappropriate at this early stage of the screening process.
The 50 per cent chance of siblings of a carrier also being carriers was explained.
Flowever, supplying this information to relevant third parties was left to the couple.
Details of carrier testing for relatives was outlined in a patient information leaflet issued
to all couples.
Regarding information about the disease CF, the prevailing approach was to tailor
information to meet the needs of individual couples. Explicit details were requested by
some; conversely, others deemed this information unnecessary, preferring that
these particulars be given if both were identified as carriers. A leaflet describing the
disease was issued to all couples which granted them freedom to confront or ignore the
information.
It was emphasised that a negative carrier test result was not a guarantee against being a
carrier. The false negative rate of the test was explained and male partners were asked
to sign a consent form before giving a mouthwash sample for DNA analysis. Helping to
make the period of days awaiting the male partner's test result more tolerable was an
important role of the genetic nurse. A reassurance leaflet was issued to all carriers.
Information included a contact telephone number and all couples were invited to
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telephone if they had questions, anxieties or simply needed to talk. Couples were told
that they would be contacted by telephone within 1 week to report the male partner's
test result. Alternative arrangements were made with couples who did not have a
telephone. Test results were reported in writing to both partners and to their
respective GPs as well as to the consultant obstetrician. All counselling
information was documented in a patient information leaflet issued to all couples.
2.4.2.5 Pre-screening information
When pre-screening information and counselling is structured around a single session, as
is the case with prenatal CF carrier screening, the counselling component may be
attenuated. The accuracy of information about the purpose and procedure for testing
are of paramount importance in helping women make an informed decision about
screening. What is perhaps less obvious is that for the process to be effective, as well as
accurate, counselling must take place. The counselling process is one that should not be
forced, skimped or hurried (Kelly 1977) and herein may he a problem. In a busy antenatal
booking clinic there is limited opportunity for lengthy discussion. Moreover, extension of
the average booking time of each patient would create mayhem in a clinical area already
considered to be suffering from an excessive workload resulting in public dissatisfaction
(Scottish Home and Health Department 1983). Providing women and their partners with
adequate information which would enable them to make a decision regarding genetic
carrier testing for CF provided a challenge.
The concept of a study to assess the attitude of the target population to a draft
information leaflet, originated from research into designing protocols for breast feeding
(Houston and Field 1988). Findings showed that only too frequently educational
protocols were developed without seeking the reaction of the target population. It was
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felt that for information and education to be effective, women should be consulted to
determine what they thought they needed to know.
A draft leaflet outlining the aims of the test and describing the screening procedure was
sent to 200 women along with their booking clinic appointment. Twenty women were not
eligible for CF carrier screening for reasons of late gestation (greater than 18 weeks),
abnormality of pregnancy (for example, blighted ovum), or unavailability of their partner.
Questionnaires were issued to all remaining 180 women along with a stamped addressed
envelope. The women were asked to complete the questionnaire and return it. They were
not asked to identify themselves because it was thought they would feel free to comment
honestly if they knew their identity was concealed. A total of 145 (81%) returned
questionnaires ofwhom 135 were screened and 10 declined to be screened. Details of this
study have been published (Mennie et al 1992a). On the basis of this study a printed
leaflet was designed describing the aims of prenatal CF carrier testing and outlining the
screening procedure (see appendix).
The printed leaflet was sent to all women along with their booking clinic appointment;
they were asked to discuss it with their partner and were invited to join the trial by
signing a consent form which was incorporated in the leaflet. At the clinic the midwife
responsible for booking a woman asked if she had read the leaflet, understood it and
wished to join the trial. Women who had not read the leaflet either because of visual
or reading difficulties, or who found it too complex were counselled by the
genetic nurse who was separate from the nurse researcher. Signed consent forms
were filed in the woman's antenatal records.
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2.4.2.6 Sampling and laboratory analysis
Prior to each clinic a sample form was placed in a woman's antenatal records. A
patient identity label was secured to the form and details of the patient's partner and
general practitioner obtained. Participants were asked to rinse out their mouths briefly
with 10 mis of tap water which was transferred into a universal container. Acceptance
or refusal of the test was recorded on the patient's antenatal liaison card.
Mouthwash samples along with the sample forms were posted to the laboratory
for analysis as described by Shrimpton et al 1991 and Ferrie et al 1991.
Patients were told that initial testing would take 7 days and that at that time they
could assume that their test was negative. The leaflet intimated to women that they
could receive their negative test result if they brought a stamped addressed envelope
to the clinic. Only 1 per cent of women made use of this facility to receive their
negative test result a majority requesting confirmation of their negative result at a
subsequent clinic visit. Women with a poor obstetric history, a history of psychological
disturbance or who appeared, to the midwife, to be anxious were informed by the
genetic nurse of their negative test result by telephone call or letter. Specimen forms
reporting the test result were returned from the laboratory to the hospital and filed in
the antenatal records. The laboratory were responsible for recording all samples
tested, along with their result, on a dedicated computer.
Women who tested positive were informed by telephone, if possible, or by letter
otherwise. An appointment was made for counselling at the hospital, together with then
partner. Counselling was carried out by the genetic nurse. The couple were given two
additional leaflets, a reassurance leaflet and an information leaflet which
reiterated the counselling information and outlined the screening procedure for
relatives. A contact telephone number was clearly advertised on the front of the
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leaflets and couples were encouraged to call if they had any concerns while awaiting the
partner's test result. Partners who wished to be screened signed a consent form
which was filed in the antenatal records. Partners' samples were tested as quickly as
possible (average 4 days) and the results communicated by telephone. Results were
recorded on the partner's specimen form which was filed in the carrier's antenatal
records. Carrier and partner test results were communicated by letter to the woman
and her partner, to the general practitioner (GP) and the consultant obstetrician.
2.4.2.7 Management of carrier couples
The protocol for the management of heterozygous couples is outlined in figure 2.4. In
the event of a couple both being identified as CF carriers the consultant obstetrician and
GP were contacted by telephone and letter. The couple were then contacted by
telephone, and seen the same day at the hospital for counselling by the consultant
obstetrician and genetic nurse. Additional counselling by a consultant paediatrician
and clinical geneticist were offered in all cases. Ifprenatal diagnosis was requested it
was carried out as quickly as possible by chorionic villus biopsy or amniocentesis. An
appointment was made in advance with the couple to attend the hospital to receive
the prenatal diagnosis result on the status of the fetus. Results were available in 48 hours
and if the fetus was unaffected the couple were informed immediately by telephone and
by letter. The result was also reported by telephone and letter to the consultant
obstetrician and GP. An appointment was given to the couple for a follow-up
ultrasound scan one week later to ensure the pregnancy was continuing uneventfully. A
six week follow-up appointment with the genetic nurse was routinely given to all
couples and an assessment interview schedule was completed at that time for both
partners.
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Prenatal Cystic Fibrosis Carrier Screening
Couples with a 1 in 4 Risk of a CF Child





Couple informed of result
I
























Figure 2.4 Protocol for management of heterozygous couples
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In the event of the fetus being affected the GP and obstetrician were
informed immediately. The couple were seen, as arranged by the consultant
obstetrician and genetic nurse, for further counselling. If the couple wished to
terminate the pregnancy arrangements were made to carry out the procedure at the
convenience of the couple. Further discussion with a paediatrician or genetic counsellor
was offered in all cases. The genetic nurse took responsibility for initial bereavement
counselling, and arrangements were made for long term follow-up either through the
GP or with a self-help group. All couples were given a six week follow-up appointment
with their consultant obstetrician. If a couple requested termination of pregnancy to
be carried out, fetal tissue was forwarded to the laboratory for confirmation of
diagnosis.
2.4.3 Uptake of screening by women during the trial
From October 1990 to December 1992, a total of 7,094 women received an
information leaflet inviting them to participate in the screening trial (Figure 2.5). A total
of 1089 (15%) women declined the invitation to be screened. Reasons why they declined
are addressed in a study reported in this thesis. A further 1027 women were not screened
because they were over 18 weeks gestation of pregnancy at booking (723), because the
pregnancy was not viable (127), or because they were not in contact with the father
of the baby (133). Forty four women were also excluded from the trial for a variety of




* declined offer 1089 (15%)
accepted offer
6005 (85%)













* 28 from ethnic minority groups where incidence of CF low and whose command ofEnglish was poor; 9 with
low I.Q.; 1 not pregnant; 3 pregnant by artificial insemination by donor; 1 triplet pregnancy; 1 male partner
screened instead; 1 HTV positive.
Figure 2.5 Uptake of screening by women during the prenatal screening trial
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Among the 4,978 women tested there were 191 CF carriers identified. Partners of
these 191 carriers were invited to be screened. In four cases appointments for counselling
were ignored and in all cases the GP and consultant obstetrician were informed. Of
the 187 partners screened 6 were found to be positive. All 6 of these couples opted
for prenatal diagnosis, 5 via amniocentesis and 1 via a trans-abdominal chorionic villus
biopsy.
The gestational time schedule for the carrier women from the time they were first
screened to the date of prenatal diagnosis is recorded in Table 2.6. One woman was
found to be carrying an affected fetus and she and her partner decided to terminate
the pregnancy. The diagnosis was confirmed on fetal tissue. The other 5 women
were carrying unaffected fetuses and proceeded to term and have subsequently
delivered live infants. No attempt was made to monitor these infants directly but
follow-up via the GP has confirmed uneventful neonatal periods in all cases.









1 13 weeks 14 weeks 15 weeks 15 weeks unaffected
2 10 weeks 11 weeks 12 weeks 12 weeks affected
3 12 weeks 13 weeks 14 weeks 15 weeks unaffected
4 13 weeks 14 weeks 15 weeks 18 weeks unaffected
5 10 weeks 11 weeks 11 weeks 14 weeks unaffected
6 12 weeks 13 weeks 13 weeks 16 weeks unaffected
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2.5 Some key questions relating midwifery care
Prenatal CF carrier screening aims to detect couples who are at a 1 in 4 risk of having
an affected child and to offer prenatal diagnosis. To identify just one couple at risk of
having a child with CF, many hundreds of women are screened. Although a majority
are reassured in the long term, they have to decide whether to accept the screening
test in the first place. Screening should be voluntary, but do women who are offered
carrier screening perceive that they have freedom of choice to accept or decline
testing?
Informed choice means being given clear accurate information tailored to suit the needs
of the individuals concerned, and thus enabling them to make a fitting decision. Can
pre-screening information and counselling be satisfactorily presented by midwives in a
busy antenatal clinic?
Although the purpose of genetic screening is theoretically to benefit families, screening
has the potential to reassure or threaten an individual (Stoate 1989). Regardless of a
majority of individuals indicating that they are in favour of general health screening
(Levine 1991), the public has yet to judge genetic carrier screening. Proponents of
screening are alerted to the ethical obligation to ensure that the benefits of a screening
test outweigh the harm (Mant and Fowler 1990) and of the necessity of monitoring
the psychological stress which screening may engender (Marteau 1989a). A majority of
women who undergo any prenatal screening test will receive a negative result and
reassurance, but for those who receive a positive result studies which have measured their
responses show that women find it is a distressing experience (Robinson et al 1984;
Marteau et al 1989b).
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If 5,000 women are screened for the CF gene only an estimated 8 who screened
positive will have a partner who is also a CF carrier. These couples face the dilemma of
prenatal diagnosis. However, an estimated 170 women are identified as single CF
gene carriers and enter a period of uncertainty while their partner is screened. If the
male partner's test result is negative he could still carry one of the rarer gene
mutations which the test did not identify. Consequently these couples are left with a
residual risk of around 1 in 640 of having an affected child, substantially higher than
their starting risk of 1 in 2,500. These couples are ofparticular concern because doubt
may be raised about the health of the fetus and residual anxieties could persist throughout
the remainder of the pregnancy and perhaps even after delivery.
The question of whether offering prenatal screening generated anxiety among the
pregnant population as a whole has not been addressed and if women who perceive it as
stressful avoid being screened? (Marteau and Slack 1992a). For midwives the potential
that the prospect of being screened creates stress among the pregnant population as a
whole would raise serious questions about the advisability of offering CF carrier
screening during pregnancy.
Apart from perception of the benefits or harms which can result from screening, the
decision to be screened may be influenced by a person's perception of their risk of being
a carrier rather than the actual risk (Marteau et al 1991a; Wertz 1984). It has been
shown that when an individual is confronted with the risk of genetic disease in their
offspring, they tend to be influenced more by their perceived ability to cope with an
affected child than by numerical risk. Thus, their focus of concern shifts from the
probability of being at risk to that of actually being at risk and the potential to bear an
affected child (Lippman-Hand and Fraser 1978). In turn a woman's knowledge and
perception of the effects of the disorder may also influence her decision to be screened.
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A genetic screening test differs from most other prenatal screening tests in that it has a
potential impact not only on the fetus but also the partner, parents, grandparents,
siblings and children of the woman being screened (Elias et al 1991). With whom will
women discuss the test before deciding to accept or decline the invitation to be screened?
In compliance with the philosophy of nursing and midwifery, the care of women who
are offered any prenatal test should reflect their individual needs. It was clear that
determining what these needs were in relation to genetic carrier testing could only be
revealed by drawing on the experience of women who participated in the screening
trial. The significance of such findings could reflect upon midwifery care which no
longer concentrates on physical safety in childbirth but in meeting the demands of
today's parents who seek from pregnancy an enriching, fulfilling experience
(Sweet 1988). The previous section considered the scientific and technological
advances which have already made a major impact on the care of the pregnant woman
who is subject to a wide variety of investigations throughout pregnancy. An increasing
number of these investigations detect abnormal conditions which could have an adverse
effect on the developing fetus. It is to the midwife that women may turn for help in
deciding how to use these tests wisely and selectively. But, just because care in
pregnancy has become increasingly sophisticated, it does not mean that women no
longer experience minor disorders of pregnancy which can cause physical and
emotional discomfort and for which they also turn to the midwife for advice and
comfort. Increasingly demands are being placed upon the skills and knowledge of the
midwife, but, as genetic technology advances and more tests which promise to
raise fundamental ethical issues become available, further demands are placed upon the
attitudes of midwives. As midwifery moves from a traditional to a woman-centred
approach, midwives have to strike a balance between the needs and demands of women
and the major scientific and technological advances sometimes thrust upon them
50
In Britain, population screening for genetic disease has been confined to the ethnic
minority groups who are most at risk for the following conditions: sickle cell disease,
thalassaemia and Tay-Sachs disease, thus, the concept of genetic screening is not one
with which most individuals are familiar. But perhaps the greatest concern must be that
technological advances may run ahead of nursing and midwifery knowledge and genetic
screening for CF is already underway before the profession has had time to
consider the implications for patient care and nursing commitment.
The impetus for research is its valuable role in defining and limiting problems which new
procedures in prenatal care may generate (Sweet 1988). Exploring the elfects that a
new technology in reproduction has upon women and their partners may generate
knowledge which will enable midwives to provide the best possible care to mothers,
fathers and babies.
Although the researcher was separate from the genetic nurse who was responsible for the
delivery of the screening test, the two worked closely together. The advantages of
developing a complementary partnership between nurse practitioner and researcher has
been highlighted (Tierney and Taylor 1991; Titchen and Binnie 1993). In a study
designed to improve nursing practice on the basis of research, the practitioner was found
to provide a clinical perspective to the research issues and questions while the researcher
provided academic input. Although the researcher and practitioner had differing interests
and priorities, neither found this to inhibit close collaboration (Tierney and Taylor 1991).
Similar mutual benefit was experienced in an action research study to alter nursing
methods in an acute medical unit from a traditional approach to a patient-centred
approach (Titchen and Binnie 1993).
The collaboration between the genetic nurse and researcher hi the present study quickly
revealed mutual advantages. The researcher found that having a colleague who was
familiar with the antenatal clinic setting, its day-to-day workings and the patient
population was invaluable. The genetic nurse could advise on whether a model of
research would be acceptable to pregnant women and antenatal staff. Furthermore, she
was able to check the relevance and readability of educational materials designed for
women and staff. The advantages to the practitioner were that she benefited from the
feedback of the researcher's findings and observations and was able to integrate these into
clinical practice. The added advantage of both parties sharing the same beliefs, concepts
and ability to compromise cannot be overstated. Consequently it was possible to design a
study which was an integral part of the delivery of the screening trial and which would







It was apparent from an initial literature review that most women who receive a positive
prenatal screening test result receive the news with some degree of distress. Whether the
offer of screening itself could generate stress among the pregnant population as a whole
had not been answered. This led to a review of the subject stress and coping and models
of stress and coping. The conceptual framework for the study was drawn from a
model of stress, coping and mental health (Cochrane 1983). The model was used as a
frame of reference to help understand and interpret participants' reactions to CF
carrier screening and develop the research questions.
3.1 The effect of stress on pregnancy outcome
Work to date indicates that stressful events may have a detrimental effect on the
outcome of pregnancy, particularly in relation to pre-term labour (Newton et al 1979;
Berkowitz and Kasl 1983). Mothers who have delivered pre-term infants have stated
that they had experienced a period of stress more frequently than a control group.
Moreover, compared to controls, these women expressed more negative feelings
toward the pregnancy. Also of significance was a feeling of apprehension about labour,
delivery and motherhood (Muylderl989). The possibility that maternal stress may have
a direct effect on the fetus is an additional concern. Increased maternal arterial
pressure and increased maternal muscle tone reducing intrauterine space has been
demonstrated (Hepper 1989) and, it has been suggested that pregnancy anxiety is
associated with increased fetal activity, as well as hyperactivity and irritability in the
neonate (Field and Garcia 1985).
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3.2 Stress
Stress tends to be referred to in an abstract way and needs to be defined. Stress has
been defined as "a fashionable term denoting usually disagreeable stimuli;
physiological, behavioural and subjective responses to these; or the whole stressful
situation." Four types of stress can be recognised: 1) acute time-limited, for example,
awaiting surgery, 2) sequential - one event initiating others that occur over a period,
for example bereavement, 3) chronic intermittent, for example conflicts with neighbours
and 4) chronic, for example, being disabled"(Wilkinson 1992 page 9).
Goldberg and Huxley (1992) propose a triad of elements which determine the
sequence of events that evolve when an individual is faced with a stressful situation.
The first is 'vulnerability to provoking agents' which is determined by several
factors in an individual: genetic factors, experiences of parenting and experiences
during childhood, personality variables, and the individual's current social situation.
Thus, an event may cause a stressful reaction in one individual but not in another.
The second element is 'destabilisation' which refers to the process of the individual
beginning to experience symptoms, which is determined by the severity of the
provoking agent and the vulnerability of the individual. Thus, the individual meaning
of a stressful event will vary. Moreover, a stressful event may have a negative
consequence or a positive consequence (Lennon 1989). The third element in the triad
is 'restitution' which refers to the process of losing symptoms. The factors which
determine how long a stressful reaction lasts are, to some extent, dependent upon
vulnerability and the provoking agent, however, social factors are also crucial
(Goldberg et al 1990).
Social support both before and after a crisis is a factor in restitution, as is crisis support of
an ongoing and constant nature (Brown et al 1986). Stress occurring during
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ongoing difficulties may cause delay in restitution; for example, physical illness, social
problems such as housing, unemployment, financial difficulties, bereavement and
problems with interpersonal relationships (Goldberg and Huxley 1992). Conversely the
occurrence of positive life events can contribute to rapid restitution (Brown et al
1988; Brown et al 1992).
3.3 A review of models of stress and coping
3.3.1 Stress as a response.
This approach treats stress as a dependent variable. Stress is described as the individual's
response to disturbing stimuli. One of the founding fathers of stress research, Hans Selye,
postulated a General Adaptation Syndrome (GAS) of somatic symptoms produced
by 'non-specific stress' (Seyle 1974). This was the first attempt to explain the process
of stress-related illness. Seyle suggested that the body's adaptability was limited and
if exposed to constant stress exhaustion would result. Seyle's GAS model is divided into
three stages of stressful response. The first phase is one of alarm reaction during which
the individual is in an initial shock phase of lowered resistance. This is followed by a
counter-shock reaction during which the individual's defence mechanisms are
activated. Severe and prolonged stress may result in the individual's resistance
collapsing. The second phase is one of resistance and involves maximum adaptation
during which the individual may return to a state of equilibrium. However, if the
stress continues or the individual's defence is inadequate they will move onto the third
phase which is one of exhaustion in which the adaptive mechanisms fail or collapse and
the signs of the alarm reaction reappear. More recently researchers have challenged
Seyle's theory by suggesting that the presence of stress alone does not determine
these physiological responses, but rather the psychological impact of stress upon
the individual (Cox 1978).
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3.3.2 Stress as a stimulus
This approach views stress as an independent variable. External forces are seen as placing
pressure on the individual and the response of the individual will depend upon his or her
individual make-up along with the severity and duration of the pressure. Stress is seen as
something which happens to an individual and not something which happens in him or
her. Individual variation of response is explained in terms of specific personality
attributes, early formative experiences, and inheritance (Cooper and Marshall 1978). The
drawback with both these approaches to stress is that neither takes into account
individual perception of a situation. Stress has to be perceived or recognised by man (Cox
1978).
3.3.3 An interactionist approach to stress.
Tliis is now the most popular model of stress. It is able to account for
individual differences both in perception and in response to stressful situations. Lazarus
(1966) is one of the best known proponents of the interactionist approach to
the stress phenomenon. Lazarus does not see stress simply in terms of environmental
pressure but rather it depends on the perception of the individual and upon the
individual's physical and cognitive coping abilities. The intensity of the stress
experience depends on the degree ofperceived threat. If individuals have confidence in
their coping ability then they are less threatened. However, if they are unsure about
their coping ability they feel defenceless and overwhelmed by the threatening situation.
The stress and coping theory of Lazarus (1966) is based on the view that stress is
a relationship between the person and the environment which is appraised by the
individual as exceeding his or her resources, and thus endangers well- being. Coping
refers to the cognitive and behavioural efforts of the individual to manage stress.
Subconsciously an individual will assess a stressful situation immediately (primary
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appraisal) and evaluate it in relation to well being. Therefore an event may be
appraised as irrelevant, harmless, or harmful. The individual then carries out a second
appraisal during which he or she evaluates the adequacy of their resources either to
prevent harm or to improve their prospect of a beneficial outcome. Thus during
secondary appraisal the person evaluates their coping options. Coping is seen as a
buffer which moderates the impact of stress. Lazarus (1982) proposes two methods of
coping. The first he terms 'emotion focused coping', when the individual attempts
to alleviate emotional distress. For example, denial can alleviate stress in a
particularly stressful situation by allowing an individual to continue rather than
become overwhelmed. The second method Lazarus terms, 'problem focused coping'
when the individual attempts to deal with the problem causing the distress. Problem
focused coping is an active confronting process that gathers and uses new information to
respond to a stressful event. Genetic counselling contains a major information giving
component. Frequently genetic counselling takes place in the wake of stress, as a result of
fetal or infant loss, loss of a child's health or loss of individual health. Both emotion
focused and problem focused coping takes place as individuals strive to understand the
cause of their loss and come to terms with it.
3.3.4 Cochrane's model of stress and coping
Cochrane proposes that an individual's response to a stressful event will be influenced by
pre-existing vulnerability, personal and social resources and the availability of alternative
responses (Cochrane 1983). Thus the immediate stressor may occur in the context of
other recent events (bereavement, unemployment) which if not yet resolved may make
the immediate stressor particularly threatening. The individual is already at a high level of
arousal and may already be anxious or depressed. In addition past coping experience and
the individual's perception of their own coping ability will influence their response. But, if
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they are already attempting to cope ail individual could quickly become exhausted of
those resources which would allow them to deal effectively with the new stressful
episode. The intervening variables described by Cochrane which may affect both the
response and outcome to a provoking event are illustrated (Figure 3.1). The value
of Cochrane's model of stress and coping to the researcher is that it details those
factors which should be taken into consideration in measuring reaction to stress.
The premise of Cochrane's model that individual response to stress does depend upon
the person's perception of how threatening a situation is, but in addition, must take
into account concurrent stress, was considered an appropriate conceptual model for
helping to understand how a pregnant woman might respond to CF carrier screening.
The immediate stressor, receiving a positive CF test result, could occur in the context
of other recent events (symptoms of early pregnancy, recent bereavement, poor
obstetric history, unemployment, to name only a few possibilities). If not successfully
resolved this could make CF carrier screening particularly threatening. This was
considered highly relevant to the present study because pregnancy itself is recognised as
a time of psychological upheaval (Blumberg 1984). If a woman felt she was coping
satisfactorily with the physiological and psychological changes associated with
pregnancy this would contribute favourably to her self esteem and attitude to pregnancy
and, in turn, contribute to her emotional well being and ability to cope with a positive
screening test result. If. however, she were to experience quite the opposite and in
addition receive a positive CF test result this could affect her ability to cope.
Cochrane acknowledges that there are individual and biological differences in the extent
to which an individual is vulnerable to stress but that the impact of other factors (namely





























































social support) are important. This is supported by the results of numerous studies
(Cobb 1976; Bebbington et al 1981; Cochrane and Stopes-Roe 1981; Goldberg and
Huxley 1992). These factors were also considered highly relevant to the present study.
3.4 Crisis intervention
A woman who receives a positive CF carrier test result during pregnancy may experience
an acute stress reaction. Such a reaction is defined by Wilkinson as the result of being
exposed to " an exceptional medical or physical stressor followed by the onset, within
one horn", of generalised anxiety and/or any two of the following : social withdrawal;
narrowing of attention; apparent disorientation; anger or verbal aggression; despair or
hopelessness; inappropriate or purposeless overactivity; and uncontrollable and excessive
grief." (Wilkinson 1992, plO). The author advocates supportive treatment and gives the
prognosis as favourable.
Receiving a positive CF test result during pregnancy may be regarded as a potential
situational crisis. For some individuals their perception of the event, their available coping
methods and available support systems may counteract a crisis (Aguilera 1990). Caplan
(1964) defines crisis as a period when an individual encounters an obstacle to important
life goals and failing to find a solution by usual coping mechanisms experiences upset to
their emotional equihbrium. Tension occurs and is manifest by symptoms of anxiety, fear,
guilt, shame and helplessness (Caplan 1964). The individual must either find a solution to
the problem or adapt to failure to solve it. Either way a new state of emotional
equilibrium results which may leave the individual in a better or worse state of mental
health.
Caplan also advises that crises have particular relevance for therapeutic intervention
(Caplan 1964). The result of a crisis is generally not the result of preceding factors such
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as the nature ofthe problem, the individual's personality or experience. These factors may
influence the outcome but the actions of the subject and the intervention of others are
more important. Situational support from those who are key figures in an individual's
environment is pivotal to the process of coping. There is an increased desire to be
helped by others; the individual signalling this by typically being more open and amenable
to outside intervention than during periods ofpsychological equilibrium (Caplan 1964).
Caplan (1964) also observes the considerable impact of prevention on a favourable
outcome and he specifies three levels of prevention: primary prevention may either alter
stressful conditions or attempt to strengthen the individual so they can resist stress and
cope in adversity; secondary prevention consists of detecting problems early before they
become serious; and tertiary prevention seeks to reduce the long term consequences of
stress. The aim of crisis prevention is to assist the individual maintain a state of emotional
equilibrium, whereas crisis intervention assists the individual attain a state of crisis
resolution and regain a state of emotional equilibrium (Aguilera 1990).
Anxiety in response to receiving a positive test result could be considered healthy. Such a
response has been shown to be a positive coping response to threat and contributes to a
better overall outcome. Women who experienced premature birth were observed to cope
better overall if distressed at the time their infant was in most danger (Caplan 1964).
Those who denied the existence of any danger fared worst. In addition, women who had
a supportive partner adjusted better to the crisis.
Situational crisis can result from status or role change. Threat or danger is perceived
when an unacceptable role is forced on an individual causing anticipatory grief (Aguilera
1990). A woman who receives a positive CF test result during pregnancy may perceive a
threat to her role ofhealthy mother to disease carrying mother; of mother with a healthy
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pregnancy to mother with a pregnancy at risk; ultimately she may feel her role as a
mother is threatened by fetal loss. Aguilera outlines the anticipatory grief which
situational crisis can engender (Aguilera 1990). In relation to CF carrier screening it
could be all too easy for a woman to focus on the threat of loss of a healthy baby and to
withdraw from establishing a relationship with the fetus. Concern associated with this
withdrawal, coupled with the label of'gene carrier'; her perception of failure to proceed
uneventfully through pregnancy; and her possible perceived inability to cope with the
whole situation could precipitate a crisis.
Aguilera (1990) also identifies the influence of the value which a woman or couple place
on their role, which will reflect upon the impact of a change in role. Thus a woman's
attitude to pregnancy at the outset could influence her response. The greater the conflict
between a woman's expectations of her role and the change she perceives brought about
by receiving a positive screening test result, the harder she may find it to cope and adapt.
Thus a woman's vulnerability, the circumstances of the event as interpreted by her and her
subsequent perception of the threat will influence the impact of the event (Cochrane
1983).
3.5 Using Cochrane's model of stress, coping and outcome to formulate a literature
review
Using Cochrane's model a number of areas related to prenatal carrier screening which
could be defined as stressors or stimuli were identified. Li addition, a number of
concurrent stressors were identified which could reflect on an individual's response to
prenatal carrier screening. These key areas are listed (Table 3.1).
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Table 3.1 Key areas reviewed in relation to prenatal genetic screening.








From these key areas a number of questions emerged: genetic disease, genetic screening,
prenatal screening and diagnosis all generate their own set of tensions. What are these
elements of tension? What lessons can be learned from previous genetic and
prenatal screening programmes about the effects on participants?
Early infant loss may be experienced through termination of pregnancy for fetal
abnormality, or loss of infant health through diagnosis of a congenital or genetic
disorder. Either may occur as a consequence of prenatal genetic screening. What is
known about stress and coping in individuals who experience this loss ?
It is well recognised that pregnancy can be a time of psychological upheaval. What is
known about stress in pregnancy? In addition, women may also be experiencing stress in
their lives which is unconnected with pregnancy. What are these stressors likely to be?
A literature review was undertaken which explored each of these topics in relation to
stress and coping. The aim was to use the findings of the review to define a series of
questions which would measure and describe the impact of prenatal CF carrier screening







The literature review detailed in this chapter focuses on those areas listed in table 3.1
of the previous chapter and considers the effects of each circumstance on an individual
or couple.
4.1 Genetic screening
In the 1970's carrier screening became possible for a number of genetic disorders
namely Tay-Sachs disease, and the haemoglobinopathies such as sickle cell disease, and
thalassaemia. Within the United Kingdom these disorders are limited to ethnic minority
groups. However, screening programmes were initiated in countries where these at-
risk populations were either indigenous or had formed large communities. CF carrier
screening can, at least to some degree, benefit from the lessons learned from these early
genetic screening programmes.
4.1.1 Tay-Sachs disease carrier screening
Tay-Sachs disease is a lethal genetic disorder which is inherited, like CF, in an autosomal
recessive fashion. It affects the nervous system causing mental retardation, blindness,
seizures and ultimately producing a vegetative state with the child dying at 2 to 4 years of
age (Gelehrter and Collins 1990). Predominantly Jews of Eastern and Central
European descent (Ashkenazi Jews) are affected, among whom about 1 in 30 are single
gene carriers, although it does occur infrequently in the general population.
In the 1970's by measuring the deficient enzyme in Tay-Sachs disease, hexosaminidase
A, and later in the 1980's when the gene was identified, by DNA based analysis, single
gene carriers could be identified. The Jewish population made a concentrated effort
to screen whole communities (Kaback et al 1974). In New York, matchmakers arranged
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for individuals to be screened prior to making arranged marriages (Merz 1987) and
in Montreal a school based approach estimated that 75 per cent of pupils were
tested. Studies related to the elfects of screening among pupils cited a loss of self-image
among 10 per cent at the time of learning of their carrier status. However, an 8 year
follow-up of these pupils found they had a positive attitude toward screening and had
subsequently made use of the results (Scriver and Clow 1990; Zeesman 1984).
Widespread screening among the Ashkenazi Jewish population has virtually
eliminated Tay-Sachs disease in this group over the last 20 years (Gelehrter and Collins
1990). Pivotal to the success of the Tay-Sachs screening programmes was the
education effort devoted not only to those screened, but also to the general public.
This effort continues today through nationwide mailing to community and religious
organisations, colleges, schools and libraries. Despite this, a study revealed that the
trend in Tay-Sachs screening suggests that both the public and health care
professionals perceive genetic carrier testing as part of prenatal, rather than pre¬
pregnancy care (Clarke et al 1989; Shapiro and Shapiro 1989).
A group of 404 physicians of whom 231 were obstetricians and 173 were family
physicians or internists (junior hospital doctors) in the New York State Health Services
Area, where a Tay-Sachs carrier detection screening programme had been in operation
for the past 10 years, were sent a questionnaire. The questions were designed to
ascertain whether or not subjects referred patients for Tay-Sachs carrier screening; and
why they tended not to refer them; to assess the frequency and objective of each referral;
to explore reasons why referral was delayed until pregnancy; and to determine whether
doctors had a method of identifying those who should be screened. A majority of
obstetricians (77%) referred patients for Tay-Sachs screening while a majority of
internists or family physicians (89%) did not. More than 80 per cent of cases referred
were pregnant women and their partners. Although 61 per cent of physicians stated they
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did not deal with the target population, more than half indicated that they were unable to
identify who the target population were. The authors suggest that physicians who believe
they are not dealing with the target population may not actually recognise who they are.
Moreover, of those non-referring physicians 21 per cent were unaware of the availability
of Tay-Sachs screening and those who were aware tended to refer once a woman was
pregnant. This study highlighted the need for education among both the public and health
care professionals about the availability of pre-pregnancy screening and to clarify who
might benefit (Shapiro and Shapiro 1989).
4.1.2 Sickle cell disease carrier screening
Sickle cell disease affects haemoglobin (Hb) in red blood cells. Haemoglobin A is
found normally in red blood cells, but in sickle cell disease Hb S is found, causing the
cells to become deformed (sickle shaped). The sickle shaped cells become trapped in
the circulatory system resulting in poor oxygen transport which can ultimately damage
organs and tissues with episodes of extreme pain in the limbs, back, abdomen and chest
lasting days or weeks. There is no cure for the disease and up to 30 per cent of children
die in the first years of life from bacterial infections. Sickle cell disease is also an
autosomal recessive disorder with the mutation occurring in the beta globin gene on
chromosome 11. Sickle cell carriers have red blood cells containing both Hb A and Hb
S and are usually healthy individuals (Weatherall 1991b) although defects in urine
concentration, haematuria and minimal sickling of red blood cells have been reported
(Sullivan 1987).
Around 1 in 12 individuals of African descent are carriers of sickle cell disease
(Gelehrter and Collins 1990). Correspondingly, it became possible in the early 1970's to
identify carrier and non-carrier sickle cell individuals by screening blood samples for Hb
S (Weatherall 1991b). However, while Tay-Sachs disease screening programmes were
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labelled successful, sickle-cell disease programmes were referred to as "screening gone
wrong" (Roberts 1990 page 18). The problem was that many states in the USA passed
laws making screening of new-borns, pre-school children, pregnant women and
couples applying for marriage licences compulsory. These laws were passed at the
height of the American civil rights movement and were perceived as racist, and
eugenic, aimed at reducing the Black population. Whereas the Jewish community had
developed an infrastructure of education and counselling for Tay-Sachs screening, no
such supporting system existed within the sickle cell testing programmes. As a result,
confusion arose over the distinction between sickle cell disease and sickle cell carriers.
Moreover, there was a singular lack of public education input which resulted in
discrimination and stigmatisation of carriers through public ignorance. These
shortcomings were rectified by the late 1970's but the reputation of sickle cell carrier
programmes was badly damaged (Rowley 1984). Today, new-bom screening
programmes and prenatal screening are delivered within an infrastructure of education
and counselling and mandatory privacy of screening results (United States
Congress Office of Technology Assessment 1992).
4.1.3 Thalassaemia carrier screening
Beta-thalassaemia is also a haemoglobinopathy causing dhninished haemoglobin and
resulting in anaemia, frequent infections, splenomegaly and growth retardation. There is
no cure and therapy revolves around transfusions, folic acid supplements and antibiotic
therapy. Beta-thalassaemia is inherited as an autosomal recessive disorder. The mutation
causing the disease also occurs in the beta globin gene but, unlike sickle cell disease,
there are a large number of mutations and these determine the severity of the disease
which ranges from mild to severe (Cao et al 1989).
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Each ethnic group has its unique distribution of mutations. Beta-thalassaemia occurs
most frequently among Mediterranean, African and Asian populations. In Cyprus 1
in 7 individuals is a carrier and in Sardinia, prior to the initiation of carrier screening, 1 in
every 250 live births was affected. The programmes run in these countries warrant
examination especially with regard to education. In Cyprus, the Greek Orthodox
Church recognised the problems associated with the high incidence of the disease.
Although reluctant to endorse termination ofpregnancy, they used their influence to insist
that couples presenting for blessing of marriage or engagement produce a certificate
proving they had been screened and had received genetic counselling. The
prevention rate of affected births hi Cyprus is estimated to be 97 per cent (Angastiniotis
1990). Also of note is the reported decrease in time spent on counselling which is
attributed to extensive public education programmes.
In Sardinia, screening programmes have actively pursued relatives of identified
earners and encouraged them to be screened. A mass public education programme has
resulted in a decrease of affected births from 1 in 250 in 1974, to 1 in 1,200 in 1991
(Cao et al 1989). Both countries report that those few affected births are primarily
due to unawareness of screening and to a much lesser extent because of ethical
reasons where couples decide against abortion. With so few affected babies bom, the
question of freedom of choice arises. How difficult is it for a couple to continue an
affected pregnancy in a society which so aggressively promotes screening?
In the United Kingdom, screening programmes for beta-thalassaemia have included
treatment and prevention incorporated into primary health care. Education
through schools, information posters and self-help groups has alerted relevant families,
couples and communities to genetic risks and services. Fewer births have been
avoided in the UK but perhaps this is not surprising given that those at risk are not
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the indigenous population, but ethnic minority groups dispersed around the country
many ofwhom find prenatal diagnosis and abortion socially and religiously unacceptable
(Modell and Petrou 1988). The United States, Canada, Southeast Asia, Hong
Kong, South China and East Mediterranean countries all have beta-thalassaemia
screening programmes (Chan et al 1991; Loukopoulos 1991; Zhang et al 1991).
The conclusions that can be drawn from reviewing these antecedent genetic screening
programmes are that participation in genetic screening programmes should be
voluntary, not compulsory. This important element of a screening programme has been
emphasised by many (Colten 1990; Hodgkin and Yoxen 1985; Kings Fund 1987;
McGregor 1990; Sutton 1990; Weatherall 1991a). Those programmes which have relied
on voluntary participation (Tay-Sachs disease and thalassaemia) have been more
successful and avoided major stigmatisation problems than those (sickle cell screening)
where screening was compulsory. Informed consent should, therefore, be obtained prior
to screening.
Public education is necessary to avoid stigmatisation of carriers and to promote
familiarity with the disease. Moreover the various options which screening can offer is
limited if carried out during pregnancy as outlined in figure 2.2 page 19. Education of
health care professionals is required if those who might benefit from screening are to be
referred at all and pre-pregnancy screening encouraged. Consumer knowledge, not only
about the availability of screening but about the disease itself, has been shown to be
important. As sickle cell screening in the United States revealed, it is only too easy for
carriers to see their status as a health risk. Thus it appears that consumer understanding
of the disease and in addition the harmlessness of the single gene state is crucial.
Moreover, parallel pubhe understanding is needed to help avoid stigmatisation of carriers.
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Perhaps the most important conclusion thus far is that information and education are
essential components of any screening programme if adverse consequences of
screening are to be avoided. In relation to the CF carrier prenatal screening trial, the
intention was that the responsibility for much of the pre-screening information and
counselling, which is a necessary prerequisite to informed consent, would rest with
midwives.
4.1.4 Cystic fibrosis carrier screening
One of the main aims of those CF carrier screening trials funded by the Cystic Fibrosis
Trust was to look at a variety of settings in which testing could be offered. From other
screening programmes it is clear that the setting does influence both uptake and
acceptance. Those programmes involving the community in the delivery of screening
(Tay-Sachs disease and thalassaemia) fared better than those run by governments, being
imposed and controlled by a group outwith the target population (sickle cell screening in
the USA). This situation would not arise in Britain where the target population
are indigenous, nonetheless, how and where screening is delivered is likely to affect
public acceptability.
Two British studies prospectively assessed the attitude of the pubhc to CF carrier
screening. The first by Williamson and co-workers questioned 166 males and females
from two schools, two doctors surgeries, and a family planning clinic about their
knowledge of CF and attitude to carrier screening. Participants were from inner city and
suburban areas and from a variety of ethnic backgrounds. Over two thirds had heard of
CF. Females, Caucasians and those in the older age groups were more likely to have
heard of the disease. Only 50 per cent of subjects knew it was an inherited disorder while
a third knew it was serious and a quarter that it affected the lungs. Over 80 per cent of
subjects expressed interest in finding out if they were CF carriers but stated a preference
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for screening to be carried out through their GP. None of the participants were pregnant.
(Williamson et al 1989).
A study by Cobb et al (1991) involved a random sample of school children aged 14 to 16
years who were asked to complete a series of questionnaires designed to determine their
knowledge about CF and their attitude to screening. Of 216 participants 75 per cent had
heard of CF but only 17 per cent knew that the condition affected the lungs. Familiarity
with the disease corresponded with knowledge of an affected individual. After a short
lecture 88 per cent understood what recessive genes were, 98 per cent that carriers were
not affected by the disease, and 99 per cent knew that an affected individual's life span
was reduced. Ninety five per cent were in favour of neonatal screening and 86 per cent
were in favour of carrier screening, with 87 per cent agreeing that prenatal diagnosis
should be offered to couples where both partners were CF carriers. The importance of
community education prior to population carrier screening commencing is emphasised
and the need for non-directive counselling support. The researchers recognised the
important role that school teachers might play in promoting community education and
advocated that the offer of carrier screening be made in schools (Cobb et al 1991).
A study from Belgium of 385 students in psycho social studies age 20 to 57 years of
whom 78 per cent had children assessed by questionnaire their knowledge about CF and
attitude to carrier screening and prenatal diagnosis. 59 per cent were familiar with the
name CF, but only 38 per cent could cite at least one feature of the disease and only 12
per cent were aware that CF was caused by a gene abnormality. 63 per cent expressed
interest in knowing their carrier status, but only 2 per cent would choose to be screened
at the beginning ofpregnancy. Approximately half indicated they would forego pregnancy
if both they and their partner were carriers, with an equal number stating they would
make use of prenatal diagnosis. Only 4 per cent would have opted for a pregnancy
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without prenatal diagnosis. Choosing to forego pregnancy was associated with perceived
burden of the condition and with age; younger participants were more likely to opt for
pregnancy with or without prenatal diagnosis. The perceived burden of the condition did
not correlate with socio-demographic features but did with life values. CF was perceived
most burdensome by those who valued pleasure and relaxation or a healthy life. The
population studied were biased toward the older age group (20% were less than 30 years
of age) and only 19 per cent were contemplating a pregnancy making it difficult to draw
similarities with a child bearing population. Nonetheless, this was a group of well
educated individuals who as psycho social students might be expected to know more
about a disease like CF than the general population would. Two findings are of interest:
firstly, the correlation between life values and perceived burden of CF which may be an
influencing factor among pregnant women also; secondly that younger individuals felt less
disposed to foregoing pregnancy and would opt for prenatal diagnosis. The 19 per cent of
the population who were said to be "still contemplating pregnancy" in all likelihood were
the younger age group (Decruyenaere et al 1992).
Based on the experience of screening for thalassaemia in Italy Modell (1990) proposes
that "there is no single right approach" to screening for CF carriers (page 477).
4.2 GENETIC DISEASE
The writings of early societies are evidence that for centuries people have recognised and
taken a keen interest in genetic traits, particularly in relation to providing rules for
choosing a spouse. Hindu sacred books dating back 2,000 years, provided instructions
that when choosing a wife no heritable illness should be present and that the family should
show evidence of good character for several preceding generations. Indeed the ancient
Hindu caste system is based on the assumption that desirable and undesirable traits are
passed from generation to generation and that an individual's worth is determined at birth.
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The ancient Greeks in their poetry and philosophical literature recognised the
heritable traits in humans. In Homer's Odyssey the hero Ulysses encounters the Cyclops,
a giant with one eye placed in the centre of his forehead and this was recognised as
inherited since the story tells of an entire race on an island where Ulysses landed. The
Jews in the Talmud gave genetic advice and described the inheritance of haemophilia
(Cummings 1988; Pierce 1990).
Genetic diseases have a major impact not only on the affected individual but on the
parents, grandparents, siblings and children of the individual. The psychological
impact of genetic disease varies with its severity and ability to treat, and within
families there is the potential for individuals to react uniquely to corresponding
situations. The suggestion of genetic disease can be perceived as a threat and may
arouse emotions. During pregnancy such a threat may be particularly intense. Thus,
"exploring these feelings (about the birth of a child with a birth defect) may be far more
important than providing a statistical estimate of the risk, and somewhere during the
counselling process there should be an opportunity to do so" (Fraser 1974 p 639).
4.2.1 Genetic counselling
The aims of genetic counselling have been outlined (Antley 1976; Fraser 1974). These
are to help the individual: 1) comprehend the medical facts, including the diagnosis,
probable course of the disorder, and available management; 2) appreciate the way
heredity contributes to the disorder, and the risk of occurrence or recurrence; 3)
understand the alternatives for dealing with the risk of occurrence or recurrence; 4)
choose the alternative which seems appropriate to them in view of their risk and their
family goals, and act in accordance with that decision; 5) make a healthy adjustment
to their decision. Antley acknowledges that this definition is broad and
encompasses long-term medical, psychological and sociological adaptations.
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Nowadays, those involved in counselling individuals, at risk of developing or passing on a
genetic disorder to their children, are aware that "it is no longer sufficient to be
conversant merely with genetic and medical aspects of a problem. It is also important to
be fully aware and appreciative of the psychological effects on the individual" (Emery
1984 p 5). For the midwife concerned with counselling for genetic disorders this reaffirms
the value of the professions' commitment to the philosophy ofholistic care.
The psychological aspects and techniques to manage individuals and couples within the
field of genetic counselling have been presented (Emery and Pullen 1984). These are of
particular relevance to this study given that CF is a genetic disorder. Moreover, studies in
relation to other prenatal screening programmes, however relevant, do not involve
screening for a single gene disorder, nor generating risks of occurrence as high as 1 in 4,
nor do they introduce implications for other family members.
Two central themes in relation to genetic counselling are decision making and loss.
Decision making can correspondingly be considered a central theme of prenatal CF
carrier screening. Firstly, a woman must decide whether or not to be screened. If she is
screened and receives a positive result she and her partner must decide if he, the male
partner should be screened. If he is a CF carrier they must decide on the best
available course of action. If a couple favour prenatal diagnosis and the fetus is
shown to be affected, they are faced with a further decision: to continue or to
terminate the pregnancy. Such a couple face profound loss. Loss has wide
connotations in relation to genetic disease; loss of their child's health, loss of
reproductive choice, loss of dreams and aspirations, altered body image and loss of
self-esteem. For some young couples the birth of, or the risk of giving birth to a
child with a genetic disease may be the first significant disappointment in their lives
(Targum 1981).
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Falek describes the sum and substance of genetic counselling as "the counsellor's ability
to transmit genetic information about an inherited disorder of concern to the
counsellee(s) so that it will be incorporated into decision making." (Falek 1984 p23).
Falek recognises the difficulty of new information being received and incorporated on
both cognitive and emotional levels at a time when individuals are under stress.
4.2.2 Loss in relation to genetic disease
The coping responses of individuals under stress in relation to genetic disease are
described and compared to that of any loss or bereavement (Falek (1984). The initial
response is shock and disbelief and frequently denial. Denial is used as a protective
mechanism to maintain psychological equilibrium. The duration of the denial period
depends upon the individual and the circumstances (Falek 1984). There is evidence
that genetic information may be given too early during the coping process to be
retained. One study reported that of 130 families followed up after having received
genetic counselling for a serious genetic disorder diagnosed in their child, 25 per cent
considered that counselling was given too early on in the grieving process to retain the
information (Fraser and Levy 1972). Other researchers have found from 8 per cent to 15
per cent of families denied even having been counselled (Leonard et al 1972; Antley and
Hartlage 1973).
Reynolds and co-workers carried out a retrospective study on 101 families who had
received genetic counselling to assess the impact and effectiveness of the service. Sixteen
per cent had either distorted or rejected the information and two per cent had repressed
the entire counselling experience (Reynolds 1974). Several participants felt that a period
of 3 to 6 months was needed to allow couples to adjust to the discovery of a birth defect
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or genetic disorder and that for the duration assimilating genetic information or planning
for the future was difficult.
Most couples do not consider the possibility that they may carry abnormal genes and
often perceive their children as "self-enhancing extensions of themselves." (Antley 1976
page 112). They do not embark upon a pregnancy with the idea of taking a risk ofhaving
a child with a serious genetic disorder or congenital abnormality. When this occurs a
couple's concept of an ideal family is shattered and major emotional adjustment is
necessary. These findings raise concern in relation to prenatal CF carrier screening
because couples who are identified as carriers are likely to be shocked and therefore may
experience difficulty in absorbing information on which to base a decision about the
future of their pregnancy. Moreover little time is available to make an emotional
adjustment before reaching a decision.
The second stage of the coping process occurs when the individual begins to realise
the circumstances of his or her stress and undertakes a cerebral approach to dealing with
the situation. The individual responds by manifesting symptoms of anxiety
including nervousness, over activity, irritability, headache, fatigue, insomnia, loss of
appetite and somatic complaints (Falek 1984; Wilkinson 1992). Caplan alerts us to the
fact that although anxious, the individual's need to formulate events initiates a
search for information (Caplan 1964). Now the content of genetic information and
discussion on available options and courses of action can be initiated. In so doing, the
counsellor should be aware that those who are particularly anxious may continue to
block information (Falek 1984).
The third stage of coping is manifest as anger. Anger may be directed outwardly
or inwardly and in both cases there may be outward signs of hostility (Falek 1984;
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Wilkinson 1992). Anger directed inwardly may result in guilt. Feelings of guilt in relation
to genetic disease have been reviewed (Kessler et al 1984). These merit examination
in relation to CF carrier screening and the care of those who receive a positive test
result. Kessler and colleagues advise that general reassurance concerning feelings of guilt
being normal is not sufficient; that time should be taken to establish exactly how
an individual is feeling and to constructively tackle this in order to dispel these
feelings. They submit that guilt is often confused with shame. Shame is defined as that
which results from failure to reach goals whereas guilt arises when the individual feels
that their behaviour has fallen short of their internalised ideal of what their behaviour
should be. Therefore, they maintain that much ofwhat is labelled guilt may be shame.
Distinguishing between guilt and shame is significant with regard to stress intervention.
Parents normally invest of themselves (narcissistic investment) in a pregnancy
(Raphael-Leff 1991). If the outcome is successful it leads to joy and fulfilment and
parents feel pride in themselves and child. If pregnancy leads to disappointment and
despair, parents feel a sense of failure and shame. Couples who receive a positive CF
prenatal screening test result find themselves singled out and advised that they require
special attention and counselling around their present and future reproductive decision,
a decision over which most others normally exert autonomous control. It is possible that
such couples could experience guilt and shame. Any measure of the psychological impact
ofprenatal CF carrier screening would require to take these feelings into account.
Kessler suggests a number of guilt alleviating tactics which the health care professional
may use. Use of authority, where the professional uses the full force of his or her
role to tell the couple they are guiltless. Normalisation, when the couple are reassured
that their feelings are normal. Reframing can be used when a couple voice feelings
that they "are responsible" by saying, "yes you are responsible - responsible human
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beings," and reassures in this way. Limiting liability, simply acknowledges that the
couple are responsible for bearing a child, but are not responsible for the genes they
transmit to the child. Any or all of these strategies may assist in dispelling an emotion
which can have a pervasive influence on a couple's perception of genetic information.
The fourth stage in the coping process, described by Falek, is the shift from guilt or anger
to depression. This is the signal that the individual is entering the next stage in the coping
process and is considered a "normal phase" in achieving restitution. Depression results
from "the repeated frustration of attempts to resolve the problem." (Falek 1984 p 29).
The individual will appear sad, withdrawn and seem uninterested in his or her
environment and daily activities.
The final or fifth stage of the coping process as described by Falek is one
of psychological homeostasis. Now the individual is likely to be receptive to the
genetic counselling process. Falek cautions that reversion to earlier coping phases
during this stage is a normal part of attaining psychological homeostasis.
The conceptual model outlines those factors which determine an individual's response to
a stressful event (Cochrane 1983). The contribution of Falek's work to this study is to
describe in more detail those manifestations of stress which can be expected and which
need to be recognised and acknowledged before intervention strategies can be initiated to
assist coping.
4.2.3 Decision making in genetic counselling.
The objectives of genetic counselling may be clear but what is not so apparent is how
couples come to make their choice or decision. Perceived risk rather than actual risk
of occurrence is thought to assume more importance in the decision making
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process (Marteau and Slack 1992a). It is believed that couples do not base their decisions
solely on medical facts, but on complex, deeply personal interpretations of these facts
(Wertz et al 1984). Anecdotal evidence that instinct and emotion rule, rather than risk
factors and percentages, was given by a young doctor who described how she and her
partner, faced with a positive maternal serum alpha-fetoprotein screening
result, were overwhelmed with the emotional considerations ofpotential fetal abnormality
and unable to base their decision to undergo prenatal diagnosis on the factual
data offered (Anonymous 1989).
The conclusions drawn about the impact of genetic disease are: that couples who leam
that there is a high risk of their child being born with a genetic disorder have to come to
terms with a sense of loss and have to consider the options open to them; they experience
shock and frequently guilt and shame. Counselling can help couples firstly come to
terms with their emotions, to understand the disorder in question, the options open to
them and the implications of these options. Couples who choose to continue a
pregnancy without intervention need help to prepare for their possible future role as
parents of a child with special needs and will require further consultation and
counselling. Couples who choose fetal diagnostic testing will need psychological
counselling during the diagnostic process. Those who receive reassurance regarding the
health of the fetus will require further consultation and counselling to allay any residual
concerns. Those confronted with a positive test result may require crisis counselling and
help in reaching a decision regarding the continuance or termination of their pregnancy.
Regardless of their decision ongoing support and counselling would need to be made
available in the months ahead.
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4.3 Prenatal screening and diagnosis
One of the fastest growing areas of medicine has been the development of techniques for
fetal diagnosis of genetic diseases and congenital malformations, yet relevant social
science research has been limited to small and often selective samples (Richards 1987).
The early studies to which Richards referred were, nevertheless, testimony to the
psychological impact on women who experienced these new prenatal tests (Beeson and
Golbus 1979; Farrant 1985; Rothman 1988). Since then, an increasing amount of
research into the psycho-social aspects of prenatal screening and diagnosis have
confirmed and augmented their findings.
4.3.1 Factors influencing uptake of prenatal screening and diagnosis
From some of these studies it is useful to focus on data pertaining to factors which appear
to influence uptake of testing as these may also apply to prenatal CF carrier testing.
Availability
Firstly, a test may be available in theory but not in practice (Flolland and Stewart 1990).
The prenatal screening tests which women experience, to some extent, depend on the
region in which they five and the hospital at which they book. UK health regions vary in
the tests offered and what is available in one hospital may not be available hi another
(Cuckle et al 1989). Consultant obstetricians differ in their stance with respect
to timing and frequency of ultrasound scanning and the maternal age at which
amniocentesis is suggested. A consultant's attitude toward granting a request for
prenatal screening and diagnosis can vary, especially towards the 'anxious woman'
who may request a test on the grounds of wishing reassurance, rather than because she
is at increased risk of fetal abnormality (Sjogren and Uddenberg 1990).
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Availability of a test may be dependent on the gestation of a woman's pregnancy. For
example, if a woman presents too late in pregnancy maternal serum alpha-fetoprotein
screening (MSAFP) (most accurate between 16 and 20 weeks) would not be available.
Although accuracy of the CF carrier test would not be influenced by pregnancy
gestation, selective abortion would. There is substantial evidence that therapeutic
termination for fetal abnormality in the second trimester has a profound and lasting
effect on women (Blumberg et al 1975; Domiai et al 1981; Adler and Kushnick 1982;
Leschot et al 1982; Jorgenson et al 1985; Lloyd and Lawrence 1985). Men too have
been shown to experience symptoms of stress subsequent to their female partner having
undergone termination of pregnancy for fetal abnormality (White-Van Mourik et al
1992). Consequently, women presenting after 18 weeks of pregnancy were advised
against CF carrier testing, resulting in around 10 per cent of women not being
screened for this reason (figure 2.5. page 46).
Attitude and knowledge ofhealth care professionals
The attitude of obstetric staff toward a prenatal screening test can influence uptake.
For example, a test may be offered as if it is routine, rather than voluntary and
requiring a decision. A study recording the offer of maternal serum alpha-fetoprotein
screening by midwives and obstetricians found that in half of 102 consultations the test
was presented as a routine test with little explanation (Marteau et al 1992c). Limited
professional awareness, and severely limited technical, educational and
counselling resources are also blamed for deficiencies in prenatal screening and
diagnosis. Shortcomings can be blamed to some extent on under funding but
missed opportunities arise because basic clinical genetic knowledge is lacked by
both the medical and nursing profession (Guilbert and Cheater 1990; Johnston
1990; Royal College Physicians 1989).
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Farrant (1985) observed that obstetricians perceived the significance of prenatal
screening as one of diagnosis and abortion of affected fetuses. In contrast, most
women perceived it as a means of receiving reassurance. Among obstetricians there are
those who hold the view that "prenatal diagnostic procedures may be of
significant benefit to both mother and child even when the detection of an
abnormality would not lead to pregnancy termination" (Clark and DeVore 1989 p
1035). However, there are those who are reluctant to carry out a risk-associated
procedure under these circumstances and will attempt to discourage a couple opposed to
termination of pregnancy from pursuing prenatal diagnosis (Crawfiird 1983; Thorp and
Bowes 1989). Similarly the attitude of the midwife regarding which conditions she
regards as serious and considers justify termination of pregnancy may influence the
way she presents a particular test (Marteau and Slack 1992a).
Attitude and knowledge ofwomen
Surveys have shown that a majority of women wish prenatal screening. Attitudes
toward maternal serum alpha-fetoprotein screening in a cohort of 2254 pregnant
women found 98 per cent wished to be screened (Bennett et al 1980). In a later survey
98 per cent of 1235 women booking for prenatal care were in favour of MSAFP
screening (Kyle et al 1988).
Whether a woman accepts MSAFP screening or amniocentesis is believed to depend
upon her knowledge of the test, her perception of the risk and burden ofhaving an
affected child, the reliability of the test and in the case of amniocentesis her concern
about miscarriage (Marteau and Slack 1992a). Understanding the risk of fetal
abnormality was cited as an important factor in a woman's decision to undergo prenatal
screening or fetal diagnostic testing (Marteau et al 1988a), but more recent research by
Marteau indicates that a woman's perception ofher risk rather than knowledge of actual
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risk, influences her decision regarding the uptake of amniocentesis for reasons of
advanced maternal age (Marteau et al 1991a). Attitude to termination ofpregnancy is a
major influencing factor as to whether a woman declines or accepts a prenatal screening
test (Davies and Doran 1981; Faden et al 1987; Kyle et al 1988).
Studies of parental perceptions of genetic disease have discovered that burden of the
condition influences whether women accepted or declined amniocentesis for diagnosis of
a serious congenital abnormality. A group of 252 women, who had received genetic
counselling after the birth of a child with Down's syndrome or genetic disease amenable
to prenatal diagnosis, were interviewed to explore factors which influenced the decision
of 202 to accept and 50 to decline amniocentesis in a subsequent pregnancy (Ekwo et al
1987). Those conditions which resulted in a prolonged illness or early death were
considered to be most serious and warranted prenatal diagnosis, those resulting in a
physical handicap or a facial disorder least burdensome, while those conditions associated
with childhood mental retardation fell in between. Thus women who perceived a
disorder as too burdensome accepted the offer of prenatal diagnosis. The researchers
concluded that couples' perceptions ofhow they would cope with the medical and social
consequences of a disease should be an integral part of counselling. This study
corresponds to that of the findings of Decruyenaere and co-workers (1992) which was
discussed on page 73 of this text, and in which the perceived burden of CF was
associated with choosing the option to forego pregnancy in the event of confronting a 1
in 4 risk of a child with CF.
Women will vary in their perception of which conditions justify termination of
pregnancy. Faden and co-workers (1987) questioned 490 women, among whom 300
accepted the offer of MSAFP screening, about their attitude on abortion for varying
degrees of disability and certainty of diagnosis. A woman's religious beliefs were found to
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influence attitude. The more severe the disability the more termination of pregnancy was
considered justifiable. Notably certainty of diagnosis was found to be an important factor
in a woman's decision to terminate a pregnancy. For example, 6 per cent of respondents
considered termination of pregnancy justifiable if the diagnosis of a neural tube defect
was 25 per cent certain, this figure rose to 56 per cent if the diagnosis was 95 per cent
certain and to 80 per cent if certainty of diagnosis was 100 per cent.
It is thought that women frequently participate in prenatal screening programmes in
order to avoid regret at not having done so (Tymstra 1989) and because the
availability of screening raises their awareness of fetal abnormality (Rothman 1988).
Many women will enter a prenatal screening programme with the primary goal of
being reassured about the normality of their fetus (Davies and Doran 1981). In a
majority of cases the experience results in reassurance but for the 5 to 10 per cent who
receive bad news it causes distress. It is, therefore, critical that women are aware of the
reason for being screened, the chances of receiving a positive test result and are
encouraged to give some thought as to what they might do if faced with a poor result
(Donnai et al 1981).
4.3.2 The psychological impact of prenatal screening.
The similarity between MSAFP screening and prenatal CF carrier screening is that all
pregnant women are potentially eligible for screening. The major differences are that the
CF test can be performed outwith or during pregnancy, whereas MSAFP screening
cannot be carried out before 16 weeks gestation of pregnancy. In addition the
significance of a positive test result differs: a positive MSAFP result is a fetal indicator of
possible neural tube defect or Down's syndrome; whereas the CF test result screens the
mother not the fetus. Nonetheless, a positive CF test result could be perceived as a threat
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to the fetus and generate a similar emotional response to that shown by women who
have received a positive MSAFP result.
Whether offering prenatal testing is, in itselfl, stress provoking has not been fully
investigated (Marteau and Slack 1992a). One study measured levels of anxiety in
women who accepted MSAFP screening compared to women who declined the test,
and found no significant difference (Berne-Fromell and Kessler 1984). Another study
by Burton et al (1985b) also compared similar groups of women and suggested that
those who were screened tended to be less anxious than those who declined. One
reason for this may be that women who feel anxious toward screening may avoid
prenatal tests on the grounds that it could generate stress. However, because of the
lack of research it is difficult to draw firm conclusions.
A significant finding in relation to prenatal screening is: that women are more
distressed if shown to be at risk of fetal abnormality through a screening programme,
compared to those who were previously aware of their risk (Farrant 1985; Tsoi et al
1987b). The shock element is thought to be critical. Women who know that there is a
risk of a fetal disorder prior to conception may feel differently about the fetus than a
mother who learns of this possibility during pregnancy (Richards 1987). An additional
distinguishing factor is that women who know they are at risk are more likely to
be knowledgeable about the condition and are not confronted with having to
assimilate information when they are distressed (Mouzouros et al 1980).
Studies devoted to assessing the psychological effects of prenatal screening and fetal
diagnosis have been reviewed (Green 1990b; Tunis and Golbus 1991). Level of anxiety
has been the variable most frequently measured and The State-Trait Anxiety Inventory
(STAI) (Spielberger et al 1983) has been the measure of choice in a majority of studies.
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Anxiety has been shown to rise when a positive test result is received, and subside after a
negative outcome is known ( Fava et al 1982; Veijaal et al 1982; Robinson et al
1984; Burton et al 1985a; Tsoi et al 1987b ). In one study reassessment of anxiety later
in pregnancy showed a further rise (Tabor and Johnsson 1987). Variations within
studies may reflect the way in which women are managed, particularly with regard
to how results are conveyed and the quality of counselling at that time.
Summarising genetic information in writing for patients has been recommended (Hecht
and Holmes 1972; Reynolds et al 1974).
There are numerous studies which attest to the distress which a positive prenatal
screening test result engenders. MSAFP screening began in the late 1970's with little
or no attention being paid to the psychological impact of testing, rather
concentrating on availability and uptake of screening. The first study devoted to
women's experiences of the MSAFP screening process was by Fearn and colleagues
(1982). The results showed high levels of anxiety in those women who received a
positive test result. Anxiety levels remained high among those who experienced a false-
positive result and were subsequently reassured. Results such as this led to the concern
that having once cast doubt on the health of the fetus it may be difficult to completely
reassure a woman.
A British study assessed the knowledge, attitude and levels of anxiety among 161 women
aged less than 38 years who were offered MSAFP screening. Twenty per cent declined
the offer and differed from those who accepted in their attitude to termination of
pregnancy. They were also less likely to attend antenatal classes although no difference
was detected in the health-related behaviour of the two groups. Levels of anxiety were
monitored by the Spielberger State-Trait Anxiety Inventory (STAI) (Spielberger 1983)
which was administered at booking, 17 weeks, 28 weeks, 38 weeks gestation and 2 days
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postpartum. Of the 128 women who were screened, 10 received a positive test result and
after retesting they received a negative test result. All 10 women manifested anxiety at
the time of receiving their positive test result. Subsequently they showed a decline in
STAI scores at the remaining three assessment points similar to women who were only
tested once. Conversely, those who declined the invitation to be screened showed a rise
in anxiety at 38 weeks gestation and were somewhat less positive in their attitude toward
the pregnancy (Marteau et al 1989b).
Studies from other countries have reported similar findings: a rise in anxiety at the time of
receiving a positive test result but a return to control levels once a negative result is
received; and a tendency for screened women to be less anxious during the later stages of
pregnancy compared with those who were not screened (Beme-Fromell et al 1983a,
1983b, and 1984; Burton et al 1985a and 1985b)
The implications of MSAFP screening have widened since low levels of MSAFP were
found to be associated with Down's syndrome. Results from one study compared
women who were identified at increased risk of Down syndrome through MSAFP
screening and women over 35 years. Findings revealed the screened group to be
significantly more anxious than those who had not undergone screening despite then-
having similar statistical risks (Abuelo et al 1991). Again the element of shock was
thought to be a major factor, supporting earlier findings. (Farrant 1985; Tsoi et al
1987b).
Women receiving false positive MSAFP results indicative of Down syndrome were
compared with a group aged 38 years and older. The younger screened group were
significantly more anxious both at the time of receiving their test result and three
weeks later when a normal result was known. Older women who had been routinely
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treated as being at risk of having a baby with Down's syndrome were considered to be
better informed and prepared for bad news (Marteau et al 1988b). The conclusion
drawn was that understanding of screening tests is a major factor in preventing an
adverse psychological response to a positive screening test result. Those previously aware
of their increased risk were better able to formulate information and prepare
psychologically for prenatal diagnosis than those younger women who, detected through
a screening programme, were taken unawares and had to assimilate information and make
a decision whilst under stress.
It seems probable that most women will receive news that they are a CF carrier with
shocked surprise. If they feel threatened, or perceive that their pregnancy is threatened
they are liable to manifest symptoms of anxiety, and if they suffer from anticipatory loss
then they may manifest symptoms of depression. If their partner receives a negative test
result the evidence is that their distress will subside. However, it may resurface because
the risk of a CF child cannot be eliminated only reduced. To what extent couples in this
situation will dwell on the residual risk, which has after all increased from their starting
risk is difficult to anticipate. There is certainly evidence that if a woman perceives that
doubt has been cast on the health of the fetus then it is difficult for her to be fully
reassured. CF carrier screening differs from other prenatal screening tests in that it does
not screen the fetus only the parents, but this may present a subtlety which some could
find difficult to understand. Another difference is that these couples where one is a carrier
and the other screens negative are left in limbo because there are no further tests which
could be offered to further clarify the position. This contrasts with maternal serum
screening tests for Spina Bifida and Down's syndrome where a positive screening test
result can be clarified by offering ultrasound examination, amniocentesis or chorionic
villus biopsy to establish the status of the fetus (Crespigny and Dredge 1991).
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4.3.3 The psychological impact of prenatal diagnosis
Early studies on the emotional effects and experiences of women who had
undergone amniocentesis were retrospective and tended to be based on anecdotal
evidence. Without exception they showed that women found the procedure and the
period awaiting the test result stressful (Robinson et al 1975; Chevrin et al 1977;
Goodmillow et al 1978; Vinson et al 1980; Farrant 1980). Correspondingly, studies
measuring the psychological impact of prenatal diagnosis have focused on levels of
anxiety generated by the diagnostic procedure (Astbury and Walters 1979; Beeson
and Golbus 1979; Fearn et al 1982; Black and Furlong 1984; Burton et al 1985
a,b; Phipps and Zinn 1986; Tabor and Jonsson 1987; Marteau et al 1989b; Abuelo et
al 1991). Of 90 women who underwent amniocentesis because of a raised MSAFP
result, 68 per cent felt their health had suffered during that period. This compared
to 22 per cent of women who underwent the same procedure for reasons of advanced
maternal age (Farrant 1980), a finding which has resulted in the previously mentioned
theory that women who already perceive themselves to be at risk of fetal abnormality
find prenatal diagnosis less stressful than those ascertained through a prenatal
screening programme.
The emotional response of a group of women undergoing amniocentesis for advanced
maternal age and a control group drawn from non-participants were studied (Phipps
and Zinn 1986). Amniocentesis subjects were more anxious at the time of the procedure
than control subjects, but became less anxious than their control subjects at the time
of receiving a negative amniocentesis result. Notably, both subjects and controls with a
history of previous fetal loss from spontaneous abortion showed the highest anxiety
scores.
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A follow up study of 164 couples to evaluate reproductive decision making after genetic
counselling, found that 43 per cent had experienced difficulty making a decision. Among
those 109 (66%) who had decided to have further children 45 per cent of couples who
knew that prenatal diagnosis was available had found the decision difficult, compared to
23 per cent of couples for whom no prenatal diagnostic test was available (Frets et al
1991). The issues facing couples for whom prenatal diagnosis is an option is discussed by
Rothman (1988) hi an anthology of accounts of women who experienced prenatal
diagnosis. The major issue is that of abortion which is assumed to be an integral part of
prenatal diagnosis. Rothman postulates that the public are more accepting of abortion in
this circumstance and in turn presume it to be less traumatic psychologically. She argues
that in no sense does it make abortion any easier as women with an unwanted pregnancy
see it as an accident "a by product of contraception that did not work" (p5) and the
abortion as a solution, whereas women who plan a pregnancy want and perceive the fetus
as their baby and to abort their baby even if it is imperfect is a tremendous struggle. She
quotes one woman who had undergone amniocentesis:
"By the time the results came in the baby had been leaping in my womb for a
month During one of the sleepless nights before the results were in I decided I would
raise the child if it looked like E. T. " (p7).
The period of waiting for the test result and the burden of selective abortion cannot be
underestimated. Rothman's findings contradict any idea that prenatal diagnosis may offer
an easy way out.
The conclusions which can be drawn from reviewing the impact ofprenatal screening and
diagnosis are foremost, that whether offering a prenatal test in itself creates stress is
difficult to answer because studies have not directly addressed this question. For the
present, what little evidence there is would suggest not. It would appear that women
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who receive a positive test result are more likely to experience a stressful reaction if
they are found to be at risk of fetal abnormality through a screening programme and
did not previously consider themselves to be at risk. Perception of risk is,
therefore, an important factor and allied to this younger women are likely to perceive
themselves at lower risk than are older woman. The evidence that women who have
suffered a previous fetal loss find prenatal diagnosis particularly stressful is a notable
finding and it seems reasonable to theorise that this group may also find prenatal
screening stressful.
The impact of prenatal screening and diagnosis upon a woman or couple seems
to be influenced by a number of factors: their reason for undergoing the
test; their understanding of the test result; and the care they receive from health
professionals (Marteau 1991b). Some women will receive written information and
counselling before deciding to undergo these procedures and afterwards, while others will
not. Lack of understanding about the test is liable to contribute to a stressful reaction.
4.4 Early infant loss
Early infant loss includes all reproductive losses: spontaneous abortion; death of an
infant; termination of pregnancy; the birth of a child with a congenital or genetic
abnormality which constitutes loss of infant health or normality; and loss through
relinquishing a baby for adoption. Loss associated with the latter often fails to be
recognised. The assumption that voluntarily parting precludes the need to grieve
(Mander 1991a).
4.4.1 The psychological impact of early infant loss
It is now recognised that the parent who loses a baby early on through spontaneous
or therapeutic abortion grieves as those who lose an infant at or after birth and should
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be offered the same opportunities afforded to couples losing a baby in later pregnancy
or post-delivery (Bluglass 1984; lies 1989). lies found evidence that psychiatric
morbidity was higher among those where termination was carried out later in the
second trimester. Moreover, levels of anxiety and depression were greater if the fetal
condition was compatible with extrauterine life; for example when a baby had spina bifida
rather than anencephaly (lies 1989). This finding has particular relevance to prenatal
carrier screening for CF which offers the potential to prevent the birth of a child suffering
from a condition where, increasingly, affected individuals survive into adulthood. It
demonstrates the need for stress intervention strategies by midwives in caring for those
who undergo termination of pregnancy for conditions such as CF. There is evidence that
midwives experience difficulty in initiating stress interventions which might help the
bereaved mother adjust to her loss. (Mander 1991b). Midwives feel an underlying
awkwardness which stems from having to adjust from caring for the mother who has
experienced a successful pregnancy to caring for the bereaved mother. Alfred to this is a
reluctance to burden the grieving mother with decisions about her care (Mander 199 lb).
A programme of prenatal screening or prenatal diagnosis should have, as part of its
infrastructure, a termination service. This service should ensure that where a fetal
disorder exists the most appropriate technique for terminating the pregnancy can
be offered. The primary objectives of the service and various procedures available to
terminate a pregnancy are outlined by Mackenzie (1992). The primary aims are: that
therapeutic termination can be carried out without contravening the law; with minimal
immediate and long-term risks to the mother's health; in a manner which is
acceptable to the mother; and that prenatal diagnosis can be confirmed following the
termination. The psychological consequences of termination for fetal abnormality
indicate that patients frequently experience residual feelings ofguilt and distress relating
to failure to produce a healthy child and the decision to end the pregnancy (lies 1989).
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These feelings are more acute after therapeutic termination than those carried out
for social reasons (Blumberg et al 1975; Donnai et al 1981; Lloyd and Laurence 1985;
lies 1989). Reasons for this were recounted on page 92 as exposed by Rothman (1988).
A recent retrospective study on a cohort of women who underwent
therapeutic termination of pregnancy in the second trimester merits review (White-
Van Mourik 1992). Twenty per cent of 84 women interviewed claimed to
experience tearful episodes, sadness and irritability 2 years after their loss. Male
partners reported increased listlessness, loss of concentration and irritability up to 12
months after the termination. Twelve per cent of couples reported marital
disharmony. Younger women (less than 20 years) or immature women were more
vulnerable to prolonged grieving. Notably, younger women also reported feeling
they had been pushed into the decision by well meaning individuals around them.
Couples identified several themes as important. They wished their feelings of grief
acknowledged and time needed to come to terms with their loss. They wanted
information and communication about the fetal disorder, implications for future
pregnancies, prenatal diagnostic and termination procedures, and information regarding
post-termination psychological and social sequelae. They expressed need for reassurance
that psychological symptoms were a normal aftermath of termination, and sought
advice on coping strategies and hope regarding future pregnancies.
4.4.2 Nursing intervention for those who suffer early infant loss
Although bereavement counselling has similarities to genetic counselling it involves
more listening and less talking. The individual or couple are given time to reflect upon
the circumstances of their loss. Parkes (1975) describes grief as a process, not a
state, which can be expressed in different ways at different stages in the process.
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Moreover, the loss experienced by bereavement frequently results in secondary
loss such as dissolution of reproductive choice, dreams and aspirations.
The role of the nurse in counselling and supporting couples who have experienced early
infant loss has been sensitively outlined (Hopper 1991). For those couples who face
therapeutic termination of pregnancy it is a sad and lonely episode with an inevitable
unhappy end. Hopper describes the basic needs ofmost couples as: trust in those caring
for them; to reflect upon their loss; to be allowed to remember; and to assimilate the
events. The importance of a couple's unique circumstances which in turn
determines their own special needs are emphasised and attention drawn to the fact that a
couple is composed of two individuals whose reactions and needs may vary. Hopper
advises that both partners should be consulted individually to determine what they feel
their needs are at each stage of the episode.
Hopper also highlights the importance of encouraging couples to reflect upon their loss
and to express what the loss of their baby means to them individually and as a couple.
The midwife can, she suggests, best achieve this by giving couples a licence to talk about
the hopes and aspirations they held for their child. The creating of memories is
considered beneficial to the grieving process and encouraging a couple to accept
tangible evidence of their experience such as a sonogram picture can be consoling.
Finally assimilation of the events is a normal and necessary process in coming to terms
with grief. As Hopper states, "every story needs a beginning, a middle and an end." (page
21). This means allowing a couple the opportunity to recount the sequence of events in




The CF carrier test is offered to pregnant women at their first antenatal clinic
visit (average 12 weeks gestation) when the early psychological and physical
changes associated with pregnancy are experienced. The literature about pregnancy is
immense and this literature search concentrated particularly on the early stages of
pregnancy and on the stresses which the state ofpregnancy itself could create.
Pregnancy is seen as a life event and transitional period when a woman prepares for the
maternal role (Blumberg 1984). This transition involves widespread psychological
changes and a reappraisal and redefinition of identity, particularly in a first pregnancy
when there may be a certain amount of conflict and stress. Physical discomfort is
reported by substantial numbers of women. In a study of 105 pregnant women 68
per cent complained of lethargy, 68 per cent of leg cramps, 66 per cent of urgency of
micturition, 48 per cent of backache, 46 per cent of breathlessness and 43 per cent of
indigestion. Apart from these physical discomforts, the same subjects being
interviewed on a number of occasions during pregnancy also reported crying
(53%), misery (50%), nervousness (34%) and worrying (29%) as psychological
manifestations of the second and early third trimester (Wolfkind and Zajicek 1981).
Green found that early in pregnancy 74 per cent of women reported feeling happy
but 46 percent felt anxious. Their major worries were miscarriage (31%), something
being wrong with the baby (28%), financial concerns (26%), concerns about going
into hospital (14%) and internal examination (18%) (Green 1990d).
According to a recent study involving obstetricians, midwives and pregnant women,
attitudes between the three groups differed with regard to the riskiness of
pregnancy. Obstetricians perceived pregnancy as significantly more risky than did
midwives and pregnant women. Female obstetricians perceived pregnancy as
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significantly more normal than their male colleagues. In addition, the views of
obstetricians and midwives tended to be associated with number of years practising, with
longer practising obstetricians seeing pregnancy as 'more risky1 and longer practising
midwives perceiving it as 'less risky1 (Schuman and Marteau 1993). Offering prenatal
screening for fetal disorders emphasises afresh the risks associated with pregnancy. For
the midwife being asked to present yet another prenatal screening test, in the form of CF
carrier screening, means that an increasing amount of the booking procedure is spent
discussing abnormality rather than normality.
4.5.1 The Psychological processes of pregnancy
Each woman's experience of pregnancy takes place within the context of different
emotional, psycho social and physical circumstances. Pregnancy means that the woman,
especially the primigravida, has to " find a way of incorporating the idea, and bearing the
reality of another being sharing her inner space and becoming part ofher internal world"
(Raphael-Leff 1991 page 45). In traditional societies there are ceremonies and rituals
which help a woman to adjust to these experiences, but in our society each pregnant
woman has to find her own means of coping (Jiminez and Newton 1979). Field (1990)
states that the whole area of psycho social support has been neglected in the provision
of antenatal care and states that "midwives need to understand the processes involved
in becoming a mother. " (p 219). Field argues for continuity of care which will allow a
woman to build a trusting relationship with the same midwife and discuss concerns
relating to all stages of pregnancy. In turn this will allow midwives to make a significant
contribution to the psychological care of mothers. Sweet (1988) advises that by giving
the mother an opportunity to address and understand her own fears and concerns, the
midwife can help a woman to increase her control. Feeling in control have been shown
to be associated with positive psychological outcomes of childbirth (Green 1990a).
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During the early months of pregnancy unfamiliar physical changes can be especially
disturbing and physical examinations may be seen as invasive and particularly stressful to
the primigravida (Green 1990d). Emotional disequilibrium causes inexplicable mood
swings, intense urges, memory lapses and sudden flashes of insight. Frequent, vivid
dreams may be disturbing to some women and in waking life she may relate more keenly
to her environment (Lederman 1984). Some women never experience negative emotions
during their pregnancy but rather a heightened feeling ofpsychological well-being (Elliot
et al 1983; Condon 1987).
The diversity of the psycho social processes of pregnancy are outlined by Raphael-Leff
(1991) and using anecdotal evidence she highlights how each woman responds in her
own individual fashion. This is an important consideration for the presentation of
prenatal screening as each woman will view it from her own particular perspective. This
could in turn determine her overall response in terms of uptake of the test, her
expectations of the test and the psychological impact of the test. Raphael-Leff also
focuses on defining women who are particularly at risk of a stressful reaction
(Raphael-Leff 1991) and who, she suggests, can be identified by careful history-taking at
the antenatal booking clinic by sensitive questioning, and observation by midwives
during subsequent antenatal encounters. Careful assessment of a woman's support
systems, her feelings toward pregnancy and changes in lifestyle is considered paramount
in providing supportive care and assisting women to make the transition to
successful motherhood (Field 1990). Women who enter pregnancy already experiencing
stress or for whom pregnancy induces stress will also perceive the advantages and
disadvantages of screening from their own particular perspective. The cause of their
stress or their reaction to it may influence their attitude. Indeed being aware of any
stress, the amount of it and nature of it could influence pre-screening counselling. If a
woman were identified as a CF carrier, previous awareness of ongoing stress could be
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taken into account in assessing her emotional response and in her ongoing management
during the screening process.
Jones (1990) proposes that psychological self-assessment should be an integral part of
antenatal care. A descriptive study was carried out by Jones to assess if women would
benefit from completing a self assessment form designed to identify their concerns about
pregnancy and to identify the type of woman best suited to self-assessment. Twenty five
women who attended an antenatal clinic, who were admitted to an antenatal ward, or
were visited during the postnatal period within their own home were asked to complete a
self-report assessment form over a period of a week. The form consisted of a series of
headings which were explained to the women by the researcher. These were: self concept,
body image, sexuality affect and mood, pain, spiritual feelings, ability to cope, stress
reactions, role function and relationship with others. Participants were asked to complete
details about their educational background and career to " identify the type of woman
most suited to self-assessment." (page 37). Other than reporting that these data did not
influence the number who responded to the study, Jones fails to report whether any
correlation was observed between educational background and career and women's
responses to the discrete areas of psychological assessment. Moreover, there was no
indication that data such as age, parity, marital status or obstetric history had been
collected which might have influenced the response of women to the assessment
schedule. For example social class was found to influence the attitude of a group of
working-class women in Glasgow who considered childbirth "a hurdle to be surmounted
on the way to motherhood" (Mcintosh 1989 page 193). How a woman responds to
prenatal screening for CF may be influenced by her psychological attitude to pregnancy
and this in turn may be influenced by her educational and social background and
previous obstetric experience. Situations which could cause women to present at the
booking clinic suffering from psychological disturbance were, therefore, reviewed. The
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researcher was guided by those categories of women cited by Raphael-Leff (1991) as
being particularly at risk of a stressful reaction during pregnancy.
4.5.2 Stress in pregnancy
The untimely pregnancy
At present a quarter of all births in the UK are to single women and of these a quarter
are to mothers under 20 years of age. Most are to teenagers over the age of 16 years
(Lawson 1990). The emotional upheaval of pregnancy and adolescence together may
precipitate a crisis (Bury 1984). Age has been cited as a factor in a woman's prenatal
adjustment to the maternal role. Women below the age of 25 years were
significantly more likely to report their pregnancy as unplanned, had significantly
fewer years of education, relationships of shorter duration, and were less likely to
have read about pregnancy and fetal development (Gottesman 1992). Younger women
tended to rely more on the experiences of their mothers and sisters as guides for their
own pregnancy experiences, whereas, older women more often relied on the
experiences of friends. Younger women were less likely to notice patterns in their
partner's response to the pregnancy and were less likely to describe having any
relationship with their fetus, being more likely to describe their feelings as "scared
and apprehensive."
Conversely, the older woman too may experience additional physiological and
psychological stresses (Michelson and Gee 1984). This is often because they choose to
delay having a baby in order to establish a career, or because they have not met the right
partner, or cannot afford it, or because they do not feel ready for parenthood. She may
feel torn between the conflicts of the biological clock and pursuing a career and worry
about the increased risk of age-related fetal abnormality, of coping physically with
pregnancy, and how she will cope with sleepless nights and a career. Their age and
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experience of life makes them aware of the risks of pregnancy, moreover, they are more
likely to experience greater medical intervention than younger women. Women report
feeling that they were viewed negatively by the medical profession and society
(Berryman and Windridge 1991) suggesting an element of perceived irresponsibility
which apparently contrasts with actual findings which show that pregnancies of older
primigravidae are carefully planned (Kitzinger 1982).
Unplanned pregnancies can pose moral and emotional dilemmas, economic and career
sacrifices, and change in life style. An unsound relationship may not stand the strain and
in what has appeared to be a happy marriage or partnership discord may arise.
An ongoing pregnancy does not automatically mean acceptance and some women will
deny the pregnancy exists and may appear quite late for antenatal care. Lester and
Farrow (1988), studied women who had presented for antenatal care at 18 weeks
gestation or later. Fifty two per cent claimed their pregnancy was unplanned. The
proportion of unplanned pregnancies was greater among those belonging to the lower
social class groups and among women whose partners were unemployed. Failure of
contraception was not a problem, with 79 per cent of participants confessing to having
themselves failed to use any form of contraception, or admitting to inconsistent use of
contraception.
An untimely pregnancy may be too soon after a stillbirth or a neonatal death. If mourning
is properly achieved a pregnancy can offer consolation and fulfilment, however, a new
pregnancy can cut short the grieving process and predispose to psychological
disturbance. Other family members such as grandparents may mourn deeply or push for
another pregnancy (Oglethorpe 1989). Studies show that in a hasty subsequent
pregnancy it can be difficult for a woman to come to terms with her feelings toward her
lost infant, and adjust to her thoughts and feelings about the new baby with whose
102
safety she is concerned (Bourne and Lewis 1984). Good midwifery care in a
subsequent pregnancy is reassuring and part of that care should allow couples to express
specific anxieties and ask questions. Bourne and Lewis advise that persistently repeated
questioning can indicate underlying anxieties or grievances which are being missed and
need to be addressed by the midwife.
Wolff examined rates of conception following cot deaths and found 34 per cent of their
sample of mothers were unable to conceive after trying for one year and 31 per cent
had spontaneous abortions, compared with an expected rate of infertility of 10 per cent
and a spontaneous abortion rate of 12 tol5 per cent (Wolff et al 1970).
Pregnancies which occur as a result of rape or incest can generate feelings of hate or
repulsion toward the fetus (McMahon 1992). Pregnancy and birth can also evoke
memories among women who have suffered sexual abuse causing anxiety and depression,
alongside emotional conflicts and worry about the baby. McMahon urges midwives to
take on the issue of sexual abuse rather than ignoring it, and to be aware that therapy
is available.
Overvaluedpregnancies
Frequently these are long-awaited conceptions as a result of infertility, recurrent
congenital abnormality or chronic disease, or a primigravida in whose immediate family a
pregnancy or delivery has failed. Anxiety among these women is common (Oglethorpe
1989). In Britain it is believed that more than one in ten couples experience difficulty in
either achieving or having a five born child (Page 1988). Studies indicate that
couples who undergo infertility investigations and subsequently encounter
prenatal diagnostic procedures experience elements of the psychological trauma
associated with their infertility (Sandelowski et al 1991). Although, the older mother
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may be anxious about the increased risk of obstetric problems, she may be ambivalent
about undergoing invasive tests with an associated risk of miscarriage particularly if
she experienced difficulty in achieving her pregnancy (Lilford 1991).
Women who are themselves adopted, though they yearn for a child of their own,
often feel disadvantaged because they lack knowledge about their mother's or
immediate family's obstetric history. Moreover, pregnancy may trigger emotional
repercussions arising from her own adoption (Stewart 1992). Research into mothers who
relinquish their baby for adoption reveals a reluctance by midwives to discuss
interventions which might assist a woman cope with her grief response (Mander 1991b).
Thus a mother may embark on a subsequent pregnancy not having come to terms with
the loss ofher baby.
Couples who already have a child with a chronic illness or disability may be particularly
sensitive about prenatal screening and diagnosis. A study exploring attitudes toward
alpha-fetoprotein testing among parents who already had a child with spina bifida, found
that the majority would have accepted testing had it been available to them, and a large
majority stated they would use testing if they became pregnant again. However,
these couples expressed strong feelings in relation to whether they viewed abortion
as an option. Half stated they would not consider terminating an affected pregnancy and
many found themselves faced with anguish, confusion and ambivalence regarding
termination (Van Cleve 1993). Whyte (1992) similarly found among couples who had a
child with CF that the prospect of prenatal diagnosis in a subsequent pregnancy created
painful dilemmas because it implied a devaluation of the worth of their affected child.
These findings demonstrate a need for midwives to be aware of the sensitivity of
information about prenatal testing among couples when there is an affected child in the
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family This need not necessarily mean a child belonging to the couple themselves, the
affected individual may be a sibling or more distant relative.
Unsupported women
Woman who are alone in their pregnancy either because of death, divorce
or abandonment by their partner are already undergoing a loss-related crisis and
are particularly vulnerable. Conversely, there may be a husband or a partner but he may
be unsupportive emotionally, absent, or worse abusive (Bewley and Gibbs 1991;
Bohn 1990). Many, ifnot most, battered women are of childbearing age and some studies
quote very high incidence figures. Campbell (1986) estimated that in the United States
one in every 50 pregnant women may be beaten. Andrews and Brown in 1988
conducted research into marital violence in Islington, London. Of 286 working class
women with children who were interviewed, 25 per cent had been subjected to
violence by their partner. Pregnancy is reported to be a time when abuse begins or
escalates (Hillard 1985). Attacks to the abdomen can cause miscarriage, placental
abruption and premature labour or stillbirth. Frequently abused women exhibit stress
and clinical depression and reluctance to discuss the issue (Andrews and Brown 1988).
Concurrent life events
Concurrent life events, such as moving house, or a new job, are major stressful events in
anyone's life, but coupled with pregnancy they can prove too much and may lead to
crisis (Robinson 1984). Pregnancy related events such as spontaneous abortion,
stillbirth, fetal abnormality, or positive screening test results invoke a grief reaction
which needs to be worked through (Hopper 1991).
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Substance abuse and risky behaviour.
Eating disorders and substance misuse pose serious risks to the fetus. Women suffering
from either problem need help with their unresolved conflicting emotions of satisfying
their own need with that ofprotecting their unborn child. Frequently they suffer from
social isolation and a lack ofunderstanding by their families and friends (Ho 1985;
Merlin 1992; Laryea 1991). Women who are HIV positive tend to have multiple social
problems and a high incidence of intravenous drug abuse (Johnstone et al 1992).
They may worry about infecting their baby and be apprehensive about both future care of
their baby and the possibility of their own untimely death.
The rate of risky health behaviour appears to be significantly related to a woman's internal
belief concerning her control over pregnancy outcome. Work by Tinsley and
colleagues indicates that this belief affects a woman's adherence to prenatal health care
and in turn the number of periods of hospitalisation during pregnancy, as well as
outcome of pregnancy. Drugs, smoking, and poor diet are related to low birth weight,
premature labour and other negative fetal outcomes such as sluggish respiration at
delivery. Social class is a factor, with those from the lower social classes more likely to
attribute health and illness to chance than middle class women (Tinsley et al 1993).
Social class also affects both social support and information which, in turn, affects
women's satisfaction with the quality of the birth experience. According to one study,
women from lower social classes feel less well supported and less well informed than
those of the middle classes (Quine et al 1993). Ley's work on communicating with
patients shows that understanding and memory determine patient satisfaction with
information. Failure to understand is, according to Ley, the result of three
interrelated problems: the material is often too difficult for the individual to
understand; the individual lacks elementary medical knowledge about their body;
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the individual has active misconceptions that are so incorrect as to interfere with
proper comprehension (Ley 1988). Ways of improving communication, content and
style of information in relation to prenatal care, with particular attention as to how
best to communicate with lower social class women, is felt to require further research
(Quine et al 1993).
Pregnant disabled women
Disabled or chronically ill women can face, or perceive that they face, disapproval for
having become pregnant (Rotheram 1989). Moreover, pregnancy may place an added
strain on their physical condition as in maternal cystic fibrosis (Cohen et al 1980).
Pregnancy can often restore confidence to a disabled or chronically ill woman as proof
that she is feminine, has a body that can carry a pregnancy and produce a healthy child
(Raphael-Leff 1991). Failure on the part of professionals to accommodate the
handicapped in the delivery of antenatal care is a sobering criticism ( Kelsall 1992).
Carty and colleagues describe the pregnant woman who is disabled as a "physically or
sensory challenged individual," and the care provider's role as "challenging" (Carty et al
1990, p 133). They provide a constructive set of guidelines to assist the midwife who
can then adopt the same positive approach to pregnancy as she would among able bodied
women. For example, women with hearing impairment require an interpreter and
the woman herself will need to decide if she is more comfortable with a woman, a
friend, family member or professional interpreter (Carty 1990; Kelsall 1992). In relation
to explaining prenatal tests it is important to speak directly to the woman herself and not
to the interpreter. Women suffering from visual impairment do not gain from the
printed materials provided either pre-pregnancy or during pregnancy. As a result they
may have limited background knowledge about the anatomy and physiology of
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their bodies, the changes to expect in pregnancy and the examinations and tests offered.
The use of tactile models to aid explanation wherever possible is helpful (Carty 1990)
A guide to pregnancy and birth for women with disabilities emphasises that disabled
pregnant women have the same concerns as able-bodied women and devote attention to
how women with a disability feel about the idea of having a disabled child (Rogers and
Matsumura 1991). The authors suggest that disabled women just as able bodied women
need to ask themselves the questions: "How would having a disabled child change my
life? How is this different from having an able-bodied child? Would it be possible to
provide the extra care a disabled child might need?" (page 67).
Mental Health and Pregnancy
Studies have found psychological disturbance among pregnant women to be widespread.
Anxiety, depression, worry and impaired concentration have been observed (Kumar and
Robson 1984; Tunis and Golbus 1991). Between 10 per cent and 15 per cent of
women have been shown to be depressed postnatally (Cox et al, 1982; Watson et al
1984) and a substantial number of these become depressed during pregnancy (Watson et
al 1984). Mental illness associated with pregnancy and childbirth is reviewed
comprehensively. (Kumar and Robson 1984; Brockington et al 1990).
Sharp (1988) in a longitudinal study of childbirth-related affective disorders used the
General Health Questionnaire (GHQ) to screen a cohort of predominantly white
British, working class women attending, for the first time, a South London antenatal
clinic. Thirty five per cent of women scored positive on the GHQ at their first visit
among whom 29 per cent were diagnosed as psychiatric 'cases', mainly neurotic
depression. Both this study and others found factors such as unemployment, financial
difficulties, housing, poor social support and poor marital relationship to be
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associated with symptoms of stress (Paykel et al 1980). Although support of a
woman's partner is recognised as significantly influencing the quality of both
physical and emotional well-being of a woman during pregnancy (Brown et al 1986),
the needs and vulnerability of men during pregnancy are being recognised and
acknowledged (Raphael-Leff 1991). This comment was considered highly relevant to this
study in view of the necessary participation of at least some male partners in the screening
procedure.
4. 6 Men and pregnancy
Unlike other prenatal screening tests, the CF carrier test requires that the male partner be
available for testing. If a woman is identified as a CF carrier it is of no consequence
unless her partner is also a earner. The information leaflet outlining the test and inviting
women to be screened was sent with a woman's booking clinic appointment so that her
partner was given the opportunity to read the leaflet and become involved from the
outset. Prenatal CF carrier testing coincides quite incidentally with an increase in the
participation of the father in all aspects of birth and childbearing. The researcher
considered the degree to which fathers became involved in the decision to accept or
decline CF carrier screening was an important aspect of the study and, therefore,
experiences of men during pregnancy merited review.
Couvade syndrome
In traditional societies, men undergo rituals signifying their transition to fatherhood.
Anthropologists have documented the ritual known as Couvade during which special
observances and restrictions are performed (Bothamley 1990). Couvade is derived from
the French word 'couver' meaning to breed or hatch. In some cultures the ritual entailed
simulated childbirth by the father-to-be at the time of labour (Zalk 1980). Frequently
there was abstinence from certain activities such as hunting, or dietary restrictions.
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Couvade provided public recognition, social concern and most importantly an emotional
outlet for the father-to-be (Raphael-Leff 1991). Psycho-somatic symptoms among
expectant fathers are attributed to the underlying need to experience the pregnancy
physically. Often the symptoms involve the alimentary tract; swellings, dental
problems, backache, vomiting and weight gain are also documented (Trethowan
1968). The symptoms usually appear around the third month of pregnancy, are less
severe in the middle, become more intense in the third trimester and disappear after
delivery. The incidence is reported to range from around 10 per cent to 1 in 3
expectant fathers (Trethowan and Cordon 1965).
One study revealed up to 65 percent of prospective fathers developed
symptoms resembling pregnancy (Shershevsky and Yarrow 1973). Other studies have
looked at expectant fathers and a non-expectant control group and found no significant
difference during pregnancy; however, in the immediate post-natal period
expectant fathers manifested a significant difference in psychological symptoms
(Clinton 1987; Gerzi and Berman 1981). In our modern society the past cultural and
religious ceremonies which both marked and assisted coping with life transitions have
all but disappeared. Nothing has replaced them and so individuals have to cope with
transitional crisis alone (Blum 1980). It has been suggested that midwives and other
health care professionals should offer anticipatory health counselling for expectant fathers
(Clinton 1987).
Men, stress and pregnancy
The opportunity for men to voice difficulties in adjusting to pregnancy is
often overlooked. "Society sanctions the symptoms experienced by women," but, " the
male partner is expected to be the healthy provider and caretaker for his family " (Drake
et al. 1988, p 438). Indeed, in one study men reported working longer hours
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during pregnancy in response to anticipated financial expenditure or as a result of
anxiety (Bothamley 1990) and in another, concerns about the risk ofpregnancy and birth
associated with a feeling of helplessness about, and responsibility for, the mother and
fetus was voiced by men (Lewis 1986).
Nowadays the ultrasound scan allows the father early visual confirmation of
the pregnancy. One study reported up to 84 per cent of partners attended the first
ultrasound scan and found it a worthwhile experience. Most partners (68%) felt
adequately prepared for the birth and ready to cope, but 22 per cent felt inadequate
and unsure about what to expect (Pratt 1990). The conclusion drawn from this study
was that a booklet should be designed which was devoted to fathers-to- be.
The pregnant woman's role is considered critical in involving the male partner
"bringing her mate into the spotlight or keeping him in the wings" (Jordan 1990, p
14). Fathers in Jordan's study felt that health care providers viewed the mother and
baby as their client and perceived his presence at prenatal visits as "cute or novel". They
felt they were regarded only as in a supportive role to their partner and not treated as
central to the proceedings.
A study which compared male and female psychological and emotional symptoms
experienced during pregnancy found fewer than 15 per cent of women and only
10 per cent of men reported increased psychological well-being during pregnancy
(Condon 1987). Marital insecurity was a significant fear among men who were
concerned that "closeness" with their partner would suffer, or that their partner would
become closer to the child. Men in this study also reported concern regarding future
financial security and many were found to "work harder" (36%) and some "very much
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harder". A significant finding was that multiparous couples reported a higher rate of
psychological symptoms leading to the conclusion that the tendency to focus antenatal
support on primiparous couples was a mistaken one.
It has been suggested that the sequence from pregnancy stress to parenting stress
among pregnant women is important, more so than the stress of labour or delivery
(Younger 1991). The identification of factors causing pregnancy related stress among
men may well have similar implications. With regard to this study the researcher felt
that any assessment of the impact of prenatal CF carrier screening should not focus
entirely on the pregnant woman, but should include the male partner.
4.7 Questions emanating from the literature review
A lack of critical analysis of the literature reflected the potential difficulty of undertaking
a study which was at the cutting edge of research. The researcher was unable to present a
critical state-of-the-art summary of knowledge on a topic which had not previously been
studied. There were no studies which directly addressed the impact of the offer of CF
carrier screening on pregnant women. Despite this, the literature survey enabled the
researcher to elicit a number of broad questions pertaining to cystic fibrosis screening
from studies of previous genetic screening programmes among other ethnic groups; the
psychological impact of being at risk of passing on a genetic disease to a child; prenatal
screening and diagnosis; fetal or infant loss; pregnancy; and lastly, concurrent stressors.
Genetic screening
Screening should be voluntary, but will women who are offered carrier screening
perceive that they have freedom of choice to accept or decline testing? Informed choice
means being given clear accurate information tailored to suit the needs of the individuals
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concerned, and thus enabling them to make a fitting decision. Pre-screening information
and counselling is pivotal to informed decision making. Can the content and delivery
ofpre-screening information be tailored to suit the needs ofthe target population?
Pre-screening information and counselling is also crucial to ensure that the target
population and those identified as carriers understand the harmlessness of being a single
gene carrier. Can this be achieved?
Other genetic screening programmes have shown the benefits of community
education in the uptake of screening and in avoiding public misconceptions about
gene carriers. Where do women glean most of their information? Are they even familiar
with the name "cystic fibrosis"?
The stage of life and the setting in which a test is offered also influences acceptability.
Will women and their partners feel that an antenatal clinic is an acceptable environment
to offer genetic screening, and pregnancy an acceptable time? From previous screening
programmes it seems that pregnancy may be perceived both by the public and health
care professionals as the optimum time to offer genetic screening. Will those who are
identified as carriers agree?
Genetic Disease
Couples at risk of having a child with a genetic disorder have to come to terms with a
series of losses. This loss is frequently combined with the need to assimilate information
to enable them to make a decision regarding the continuation or termination of their
pregnancy. How much information do these couples retain? Do they have any
misconceptions ? Do they feel the information they received prior to screening and on
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receiving their carrier test result met their particular requirements? On reflection do
they regret having been screened?
Prenatal Screening and Diagnosis
Do women perceive the screening experience as stressful? The literature does not give an
answer to this question. Will pregnant women's primary appraisal of CF carrier screening
be that it is anxiety provoking or reassuring, or do they feel indifferent?
There is evidence that women who are identified as being at an increased risk of fetal
abnormality through a screening programme find the experience particularly stressful.
How will women who receive a positive CF carrier test react? Most studies have
concentrated on measuring levels of anxiety but it is recognised that situations an
individual deems as threatening generate feelings of anxiety and those experienced as
loss generate depression (Brown et al 1988). What form intensity and duration of
psychological reaction will emanate from being identified as a CF carrier during
pregnancy? Can this be satisfactorily identified and measured? Do women adjust to
their carrier state and can this be satisfactorily determined?
Which tests do women choose for then unborn baby? Are they selective about which
screening tests they choose? What factors influence a woman's decision to decline or
accept a voluntary screening test? Does comprehension of risk affect this decision? Are
there socio-demographic factors which influence this decision?
Pregnancy
Pregnancy itself can be a time of conflict and stress. The CF carrier test is offered at
the woman's first antenatal visit at a time when the majority of women are making
adjustments to being pregnant and are experiencing the early emotional and physical
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symptoms of pregnancy. Will the pregnant population of women find pregnancy an
acceptable time to be screened? (This question is distinct from that of identified
carriers who should be given the opportunity to reflect on whether pregnancy was the
optimum time to be screened).
The support of the male partner is known to be an important factor in contributing to a
woman's well-being during pregnancy. The CF carrier test differs from most other
prenatal screening tests in its potential to involve the male partner. To what degree will
male partners enter into the decision to accept or decline screening?
In attempting to assess stress in relation to a specific event it is necessary to take account
of concurrent stressors. What percentage of the screened population will manifest signs
of psychological disturbance at the time of screening? What are the major causes of
concurrent stress among the pregnant women screened? Does concurrent stress
influence a woman's reaction to being told she is a CF carrier?




QUESTIONS AND SELECTION OF RESEARCH METHODOLOGY
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Formulating the research questions
The opportunity to carry out this study arose from the researcher's involvement in a trial
of prenatal carrier screening for cystic fibrosis presented by midwives in an antenatal
booking clinic. One of the major questions which it was anticipated the trial would
answer was: 'is this form of prenatal screening acceptable to women and their partners?'
(page 32, table 2.4, question 4). It was this broad question that initiated a preliminary
review of the literature and an overview of the screening trial. From this arose a number
of key questions concerning the presentation of the screening test by midwives to the
pregnant population and the care of those identified as carriers (page 48). A pivotal
question revolved around the emotional impact of offering genetic carrier testing during
pregnancy. This led the researcher to review the subject of stress and coping. A model of
Stress, Coping and Outcome (Cochrane 1983) was used as a conceptual model for the
study. The model helped delineate a number of areas which could affect the emotional
response of women and their partners to prenatal CF carrier screening (table 3.1 page
64). A literature search of these areas clarified those questions which needed to be
answered and these were refined in the context of Cochrane's model of stress and
coping (Figure 5.1). The questions and areas of concern polarised around three discrete
stages of the screening process: the pre-screening or threshold stage; the CF test
result stage; and the post-screening result stage.
The Pre-screening stage
The literature search showed that previous knowledge; pre-screening information;
perception of risk; reason for being screened; concurrent stress; demographic factors




Figure 5.1. The application of Cochrane's model of stress and coping in formulating
the research questions (adapted from Cochrane 1983).
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The test result stage
The nature and level of a stressful response to receiving a positive test result would
require to be assessed at the test result stage.
The post-screening result stage
The duration of a stressful response, acceptance of the single gene state and satisfaction
with the screening process would require to be assessed after the partner's negative test
result was known. Within the context of these three screening stages the questions were
refined.
5.2 Research questions
1. Are there pre-screening variables which influence a woman's response to
prenatal CF screening?
2. What factors influence a woman to accept or decline prenatal CF carrier
screening?
3. Will identifying a woman as a CF carrier during pregnancy provoke a stressful
response both in her and her partner?
4. Do carriers and their partners understand the essential facts concerning CF
carrier screening and what is their attitude toward having been screened?




A cohort of women who were offered CF carrier screening during the trial were studied.
The study employed a descriptive, exploratory approach and was conducted
prospectively using structured and semi-structured self-report methods.
5.4 Setting
Women were recruited from the antenatal clinic of the Simpson Memorial Maternity
Pavilion in Edinburgh where a prenatal CF carrier screening pilot trial was in operation.
During an 8 month period, from the beginning of May 1991 to the end of December
1991, women who received an invitation to enter the trial were recruited for this study.
5.5 Sample
Women were included in the sample if they met the following criteria:
1. They were English speaking
2. They were not more than 18 weeks gestation ofpregnancy
3. They were in contact with their male partner
4. There was no abnormality ofpregnancy detected at booking
Out of a total of 2,541 women 334 (13%) were not eligible to enter the study. Of
2207 eligible women 2058 (93%) participated.
5.6 Ethical Approval
Ethical approval was sought to carry out this study as an integral part of the screening
trial from the Paediatric Reproductive Medicine Ethics of Medical Research Sub-
Committee (Protocol 27/90). A standardised form was submitted on 1st June 1990
giving information on the significance of the study, confidentiality, informed consent
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and the method to be used. Ethical committee approval was granted on 6th August
1990.
5.7 Access
The researcher met with the Director ofMidwifery at the recruiting hospital and outlined
the objectives, methodology, instruments and storage of data to be used during the
study. Freedom of access to a woman's antenatal records was discussed. The
researcher acquainted the antenatal clinic staff in the hospital with the nature of the
study and comments and questions were invited.
5.8 Confidentiality and Informed Consent
Women were invited to participate in the study by means of an information leaflet
outlining the trial. The leaflet (Appendix 1) was sent to them with their booking clinic
appointment. The leaflet emphasised that one aim of the trial was to try to understand
how women and their partners felt about the offer of cystic fibrosis carrier testing during
pregnancy. A consent form was included in the leaflet which emphasised that a woman
could withdraw from the study at any time. All data collected were stored on a
dedicated computer and access was restricted to the researcher and the genetic nurse.
5.9 Constraints imposed by the study setting
The study setting imposed constraints on the choice of research methodology.
Research methods which caused minimum disruption of patient care and intrusion on the
midwife and pregnant woman were desirable. The researcher's schedule required to fit
around that of the pregnant woman and the clinic staff caring for her. Research
pertaining to carriers and their partners required to cause a minimum of intrusion on a
couple who might be shocked or distressed. It was felt that lengthy interviewing
would not be appropriate and could confuse a couple whose immediate need was that
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of emotional support and counselling from the genetic nurse. Thus the researcher tried
to balance the desire to obtain data for the study with the need to avoid disrupting
midwifery care or intruding into the interaction of the genetic nurse with a couple.
Continued follow-up of carriers and their partners needed to avoid carriers and their
partners feeling over-researched or being continually reminded of a potentially traumatic
episode in a pregnancy which was continuing normally.
5.10 Research instruments
The instruments chosen for answering the questions involved rating scales and specially
designed questionnaires. These will be presented by addressing each research question in
turn. All the questionnaires were submitted to a pre-test, to evaluate the adequacy of
the tools in measuring the research variables, isolating bias, vagueness or
inadequate questions as suggested by Barker (1991).
5.10.1 Question One:
Are there pre-screening variables which influence a woman's response to prenatal CF
carrier screening?
The literature review of previous genetic and prenatal screening programmes indicated a
number of variables which appeared to influence individual response in relation to both
uptake of screening and psychological response to receiving a positive test result.
5.10.1.1 Variables measured:
1. Respondents'prior familiarity with the name cystic fibrosis:
Pre-screening information is known to be one important factor. Although an information
leaflet will provide an introduction to screening, prior knowledge may be gleaned from
the media or other sources which may influence understanding.
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2. Women's opinion regarding the content of information in the pre-screening leaflet.
Women require information to help them to decide whether to accept or decline
the invitation to be screened for CF during pregnancy. Criticism has been made of
patient information leaflets for their tendency to be written in a format that health care
professionals see as being generally applicable, rather than attempting to meet
individual needs (Wilson-Barnett 1988). When the CF carrier screening leaflet was
designed, it was deemed important to regularly monitor women's satisfaction with the
content of information (Mennie et al 1992a) as this too could influence their whole
perception of the screening test.
3. Involvement of the male partner in the decision to undergo screening.
Distinct from some other prenatal screening tests, the CF test has the potential to
involve the male partner. Indeed availability of the male partner was a criterion for entry
to the screening trial. It has been suggested that a majority of men regard the decision
to accept or decline prenatal screening tests to be solely that of the woman (Sjogren
1992), therefore, the extent to which male partners became involved at the pre-screening
stage was considered highly relevant to this study.
4. Respondents'perception of their risk ofbeing a carrier:
Awareness of risk appears to determine, to some extent, women's emotional reaction to
a positive screening test result. Women who enter screening programmes aware of
their risk seem to find it less stressful than those who were unaware of their risk
(Farrant 1985). Apart from pre-test education a decision to be screened may be
influenced by a person's perception of the risk of being a carrier rather than the actual
risk (Marteau et al 1991a; Lippman-Hand and Fraser 1978). Moreover, when an
individual is confr onted with the risk of genetic disease in their offspring they tend
to be influenced more by their perceived ability to cope with an affected child than
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by numerical risk. Thus they simplify the focus of concern which shifts from the
probability of being at risk to that ofbeing at risk and the potential to bear an affected
child (Lippman- Hand and Fraser 1978). In turn a woman's knowledge and perception
of the effects of the disorder may also influence her decision to be screened.
5. Respondents' emotional response to the offer ofprenatal CF carrier screening:
A woman's awareness of a particular fetal abnormality is likely to increase with the
advent of a screening test. Some suggest that the very existence of a screening test
creates anxiety in a woman by alerting her to a condition about which she was
previously unaware (Rothman 1988). Yet, the lack of research means reserving
conclusions about whether screening is inherently stress provoking (Marteau and Slack
1992a). A woman's initial response to the offer of screening might influence her decision
to accept or decline the test and was thought a likely indicator of how she would feel
until her test result was known.
5.10.1.2 Research Instrument
A self - administered questionnaire called the pre-screening questionnaire was designed
to measure these five variables. The front cover of the questionnaire repeated the
aims of the study as outlined in the screening information leaflet. Care was taken to
comply with guidelines outlined in the literature which would assist in a high return
(Crossfield 1988; Rees 1990; Basford 1990). These were that the questionnaire
should aim for simplicity and clarity both in design and content and be kept as brief as
possible. That questions should be arranged in a logical sequence to allow the respondent
to develop thought processes and that they should not be loaded or biased so as to
avoid achieving a preconceived result. Finally a pilot trial should be carried out on the
target population to assess the usefulness of the questionnaire and identify any
problems. A pilot trial of 167 patients revealed that 25 (15%) patients did not know
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their risk of being a CF carrier and because this option bad not been made available to
them they bad written "don't know" on the questionnaire. Question six was
subsequently amended to include this option. The questionnaire was finalised and
functional at the beginning ofMay 1991 (see appendix ).
Demographic data
Age, socio-economic background, marital status and parity may influence a respondents'
attitude to screening, comprehension of information, and in turn influence the decision to
accept or decline a test. Marital status was considered an important variable because
CF carrier screening required that the male partner be both available and willing to be
screened if the woman was identified as a CF carrier. However, it was acknowledged that
an available and supportive male partner was not necessarily associated with marital
status.
Younger women and those with a higher level of education showed less inclination to
make use of prenatal screening (Tymstra et al 1991). In addition, educational
background of the male partner has been shown to influence a couples' comprehension
of genetic information (Emery et al 1979). During the booking procedure the
midwife collected an amount of demographic information and this was recorded on
a woman's antenatal haison card. A demographic information form was designed and
completed for each respondent from data recorded on her antenatal Haison card. Area
of residence was recorded by a numeric code; social class was assessed from the
occupation of the head of the household (Office of Population Censuses and Surveys
1980); and a woman's decision to accept or decline MSAFP screening was also noted.
Educational background data was forfeited because of appearing intrusive. Moreover, if
screening were to continue after the trial then patient assessment by the midwife
would be limited to information already recorded during the booking-in procedure.
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5.10.2 Question Two:
Whatfactors influence a woman to accept or decline prenatal CF carrier screening?
Why women choose a specific prenatal test is not entirely clear. There are no large
studies which have addressed this issue. Are women selective about the tests they
choose for their unborn baby or do they simply accept what is offered? A closed
question inviting respondents to select from pre-assigned categories of response was
considered. Such a method would have relied upon the researcher's interpretation of the
phenomenon rather than the subjects' interpretation. There were no grounds to believe
that a list of reasons why women might wish CF carrier screening in pregnancy as
perceived by a health care professional would truly reflect those ofpregnant women.
5.10.2.1 Qualitative Research Methodology
The fundamental characteristic of qualitative research is that it aims to take the subject's
perspective on a subject and has been described as 'seeing through the eyes of the people
being studied' (Bryman 1990). Qualitative research requires a minimum of structure and
research involvement as it aims to emphasise the perceptions and subjectivity of the
individual. The researcher tries to leam the experience of study participants and to
understand their perspective of a situation (Polit and Hungler 1989).
If a research topic lacks previous information, qualitative research methodology has
particular strengths which are lacking in quantitative methods of research (Field and
Morse 1990). In particular, quantitative research requires the researcher to make
theoretical assumptions whereas qualitative research does not. Thus, if an extensive
library search reveals very little information about a topic, Field suggests it is probably
not sufficiently developed to use quantitative research methods. Moreover, some assert
that there is a need for nurse researchers to generate nursing theory within nursing
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contexts rather than verifying theories developed outwith their own domain ((Duffy
1985).
Since the 1960's there has been a debate about these two major approaches to
research (Bryman 1990). Frequently researchers restrict their choice to one or other
(Field and Morse 1990), however, some suggest that when quantitative and
qualitative research are jointly pursued a more comprehensive account of social
reality emerges (Bryman 1990). Combining both research methods has been used to
further nursing knowledge. Hockey (1976) used structured interviews and incorporated
open-ended questions to collect data for a study entitled 'Women in Nursing.' Here,
use was made of a quantitative research tool to measure nurses' job satisfaction. By
Unking interview comments to the respective scores, Hockey was able to build a profile
of nurses in relation to job satisfaction. More recently, a major National Health Service
(NHS) Survey, involving nearly thirty eight thousand NHS staff combined both
methods most effectively. The study was designed to glean insight into both
knowledge and impact on staff ofNHS reforms. The qualitative research study, based
upon subjects comments, revealed a rich source of information about individual
perceptions and anxieties regarding NHS reforms. Quantitative research
methodology would not have demonstrated the emotional impact inflicted upon NHS
staffby a major shift in organisation (The National Health Service Scotland 1992).
Women telling of their experiences of prenatal diagnosis has given insight into how one
simple procedure can completely change a woman's experience of pregnancy (Rothman
1988). Women report being oveijoyed by being pregnant but within a short time were
faced with a test which led them into an ethical conundrum of astounding proportions.
Rothman interviewed more than 120 women who were at risk of having a child with a
birth defect. Around half the women had accepted the offer of an amniocentesis and the
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remainder had declined intervention. Much of the interview data were collected by postal
questionnaire but women wrote vividly of their experience. Notably this study revealed
the variety ofways that women perceive this one procedure. It is the differing perception
of the meaning of a prenatal test which requires to be taken into account when
counselling women for prenatal screening and diagnosis. It was this diversity of
perception among women which the researcher wished to expose and examine.
5.10.2.2 Method of collecting data
Question 9 of the pre-screening questionnaire asked women 'to say in a few of their own
words' why they came to their particular screening decision. Although a qualitative
approach was used to obtain the data it was then analysed quantitatively.
Analysis of speech or written text demonstrates that an idea can be expressed in many
ways. The key word that actually defines it may not actually be used, thus an
individual may state they wish 'more information' yet never use the term 'information'
choosing instead: 'know more' or 'more facts'. This means the text must be examined
for topics rather than linguistic content and coded accordingly (Tesch 1991). A
computer database manager can efficiently store and retrieve information by searching
across stored records (Fielding and Lee 1991). For the purposes of this study the 'dBase
in plus' database management programme was chosen to store and analyse subjects'
quotations (Tsu-der Chou 1986). The programme which was in general use within
the researcher's department permitted two research colleagues familiar with the
programme access to the data for the purpose of 'peer examination' (Field and Morse
1990). This involved soliciting help from colleagues in examining data to see if they
can recognise the same topics and categories as those identified by the researcher
and is a means of ensuring the credibility of the data and avoiding potential bias.
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5.10.3 Question Three:
Will identifying a woman as a CF carrier during pregnancy provoke a stressful
response both in her and in her partner?
5.10.3.1 Variables measured
Cockrane's model of stress, coping and outcome recognises the importance of individual
perception of an event . The way in which an individual interprets a situation is the
key to determining whether or not they regard a situation as stressful. Clearly an
individual's own frame of reference is crucial to his or her initial attitude and is likely to
influence their response if the test result is positive. Thus different individuals may react
uniquely to a similar situation which is dependent upon the degree of perceived threat
(Cochrane 1983). Pregnancy itself is viewed as a psycho-biological crisis (Blumberg
1984) and therefore psychological response to pregnancy needs to be taken
into account. A further consideration is introduced in Cochrane's model of stress and
coping which emphasises the importance of recognising other provoking agents in an
individual's life. Cochrane states that these too must be considered when assessing an
individual's response to a stressful situation (Cochrane 1983). The criteria for selecting
an instrument was that it could detect a stressful response in an individual, identify the
nature of their response and measure the degree and duration oftheir response.
5.10.3.2 Research Instruments
The General Health Questionnaire
The General Health Questionnaire (GHQ) is a self-report instrument designed to detect
current short-term psychological disturbance of a non-psychotic nature (Goldberg
and Williams 1988). It identifies two main classes of problem: inability to carry out
one's normal 'healthy' functions and the appearance of new phenomena of a distressing
nature. Although originally developed for use in general practice settings, the GHQ has
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been used in both hospital and community settings in numerous surveys which indicate it
is suitable for use with men and women of all age groups in detecting
psychological distress (Thornley et al 1991; Maskey 1991; Gage and Leidy 1991;
Stoate 1989; Goldberg and Williams 1988). It has also been used with a multi¬
cultural sample of mothers with young children (Watson and Evans 1986). The
GHQ was designed to cover four identifiable elements of distress: anxiety,
depression, social impairment and organic symptoms. An individual with a positive GHQ
score might be said to be emotionally stirred up and altered in respect from his or her
normal self (McDowell and Newell 1987). The GHQ screens for acute rather than
chronic distress, and was meant to be a first-stage screening instrument, with emphasis
being on changes in condition not on the absolute level of the problem. Items compare
the person's present state to their normal situation with responses ranging from 'less than
usual' to 'much more than usual' (see appendix). The GHQ is a screening tool which is
used to identify individuals who then require more extensive examination in order to
ascertain the cause and nature of their psychological disturbance (Goldberg and
Williams 1988). Items on the GHQ can be scored using conventional 0-1-2-3 Likert
scores, but Goldberg recommends a simpler system of a two-point score, rating
problems as present or absent and ignoring frequency (Goldberg and Hillier 1979). Thus
in the original 60-item version of the questionnaire any 12 positive answers constituted
a positive GHQ score. Such an individual would then be interviewed to determine the
nature and cause of their response.
There are five versions of the GHQ ranging from the 60-item down to a 12-
item questionnaire. Given that time is at a premium in an antenatal booking clinic the
shortest version, the 12-item GHQ, which takes one and a half to two minutes to
complete, was selected (Goldberg and Williams 1988). A cut off point of 3 (i.e. 3 or
more is a case) has been tested for the GHQ-12 in males and females (Nott and Cutts
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1982; Banks 1983; Mari and Williams 1985). On the basis of an extensive review
Goldberg and Wilhams (1988) concluded that the validity of the GHQ-12 is
comparable with that of the longer versions. The 12-item GHQ has been used in a
number of studies (Banks 1983; Briscoe 1989; McGrath et al 1989; Stafford et al
1980) and found acceptable to both males and females in detecting stress. Critical to
this study was its previous use among populations of women during pregnancy and in
the immediate postnatal period (Sharp 1988; Briscoe 1989; Nott and Cutts 1982). The
30-item GHQ was validated in pregnancy by Sharp (1988). At their first antenatal visit
Sharp asked 179 women to complete the measure and 35 per cent were found to be high
scorers.
Briscoe found the instrument was acceptable to mothers and was particularly useful in
helping them to express their feelings. "Behind a smiling facade" she found women who
were severely depressed and guilt ridden. Such women seemed to find it easier to admit
their feelings in a pencil and paper test, a conclusion found in other studies of pregnant
women (Jones 1990). This reluctance to admit and seek help for emotional problems
is also confirmed by Nott and Cutts (1982). The 28-item GHQ has recently been used
to assess pregnant teenagers at 'booking' for psychological disturbance (Maskey 1991).
Goldberg has summarised data on the association between the GHQ and
demographic variables. Females tend to show higher scores; there was no association
between age and GHQ scores; there was a significant tendency for lower social class
respondents to have higher scores. The Manual of the General Health Questionnaire
gives the optimum cut-offpoint for the 12-item GHQ as 2 or 3 but emphasises the
need to recalibrate the measure in a representative sample of the population for
which it is intended. Therefore, a cohort of 167 antenatal patients and 77 male
partners were asked to complete a 12-item GHQ at their first antenatal visit. Using a
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cut offpoint of 2 items or more, resulted in 51 per cent of women scoring positive and
18 per cent of males. By raising the cut off point to 3 (3 items or more is a high
score), lowered the prevalence of high scorers to 31 per cent in females a figure
compatible with Sharp's study of antenatal patients, and 10 per cent in males (Sharp
1988). It was considered feasible to carry out more intensive investigations on around
thirty percent of women at the antenatal clinic but considered impractical to do so
on fifty per cent, therefore, a cut offpoint of 3 was chosen for this study.
The Symptom Rating Test (SRT)
The GHQ will identify cases of stress but it is not designed to measure symptoms and
symptom severity although it does monitor change (Goldberg and Williams 1988). The
Symptom Rating Test (SRT) (Kellner and Sheffield 1973) was developed to measure
distress. A self-report questionnaire, the SRT is based on a checklist of 30 symptoms,
7 somatic and 23 psychological (see appendix). These symptoms are then self-rated
for severity. Four subscales are included: anxiety, depression, inadequacy and
somatic concern. It has been used in a number of drug trials because of its great
sensitivity to change (Henderson 1982). It was considered unwise to ignore the
potential existence of depressive symptoms in both the pre-screening and post-
screening phases of the CF carrier testing procedure.
Studies have found psychological disturbance among pregnant women to be
widespread. Anxiety, depression, worry and impaired concentration having
been observed (Kumar and Robinson 1984; Tunis and Golbus 1991). Other studies
report that the incidence of depression rises significantly in early pregnancy and in the
first three months after delivery (10 percent and 14 per cent respectively) (Cox et al
1982; Watson et al 1984). To identify subjects suffering from depressive symptoms was
calculated to be of importance not only to the findings of the study, but of critical
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importance to a woman's well-being during pregnancy and in the post-natal period. To
focus only on symptoms of anxiety as an outcome of receiving a positive screening test
result was considered unwise because depression was regarded as a possible
manifestation of stress in relation to loss (Brown et al 1988). The SRT measured both
psychological states and in addition could detect change in feelings of inadequacy and
somatic symptoms. Unlike the GHQ the SRT was not designed as a case-finding
instrument (Thomson 1989) but to measure distress in such a way as to be able to
detect changes in the state of the individual (Kellner and Sheffield 1973). It has been
used in a number of epidemiological surveys which include psychological disturbance
as a variable. The questionnaire differentiates sensitively between levels of distress
in different groups (Kellner et al 1984; Magoi et al 1982). It has been used to
measure psychological disturbance in women undergoing amniocentesis and was
found to measure sensitively changes in distress (Fava et al 1983).
In the present study, the value of the SRT was its ability to detect symptoms of stress
which could be identified and measured for both degree and duration. There are 4
possible answers to each SRT question: not at all (score =0), slightly (score=l),
a great deal, quite a bit (score =2), extremely, could not have been worse
(score=3). Studies using the SRT have shown average total distress scores of 8 to 11
for the general population, and 49 for those with symptoms of psychological disturbance.
The SRT takes 2 minutes to complete and the 30 symptoms are defined in simple every
day language so as to be easily understood and non-threatening to the respondent
(Cochrane 1980). Incorporated in the pre-screening questionnaire was a 12-item
GHQ designed to assess the threshold emotional status of a woman prior to being
screened. The Symptom Rating Test (SRT) was used to identify the nature of distress
among women who presented at the clinic with a positive GHQ score.
133
5.4.4 Question Four
How well do carriers and their partners understand the essential facts concerning CF
carrier screening and what is their attitude toward having been screened?
Follow-up of individuals who have received genetic counselling has been recommended
(WHO 1969) as a valuable complement to genetic counselling. Only by assessment of
carrier's and partners knowledge and comprehension is it possible to learn how well they
understood the counselling information given to them. Moreover, insights gleaned from
recipients of screening may identify dissatisfactions leading to improvements in the
delivery of screening (Reynolds et al 1974).
5.10.4.1 Research instrument
A self report questionnaire was designed consisting of closed questions called the 'Facts
and Feelings Questionnaire'. The 'facts' section was composed of six statements derived
entirely from the pre-screening information leaflet and corresponded in sequence to
the information given in the leaflet. Respondents were asked to tick which
statements they thought to be true. Participants' attitudes toward the prenatal
screening trial specifically and towards CF carrier testing in general were assessed in a
section of the questionnaire entitled the 'feelings' section. A pilot trial tested the
questionnaire among 20 screened women and their partners. The initial lay-out of the
questionnaire caused some difficulty. The lay-out of the questionnaire was altered but the
questions themselves remained unchanged. The questionnaire was piloted for a second
time and was found by respondents to be simple and quick to complete. A computer
data base was designed for storage and analysis ofthe questionnaire data.
An outline of the study protocol is shown in figure 5.2
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CF earner testing leaflet / consent form




collect consent form and questionnaire
score threshold GHQ
Interview women with 3+ score


























Figure 5.2 Study Protocol
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5.11 Study protocol
Women were sent a pre-screening questionnaire incorporating a GHQ (termed threshold
GHQ) with the leaflet inviting them to participate in the screening trial. They were asked
to complete the questionnaire and bring it to the clinic. Women entering the trial who
had not completed a questionnaire were asked to complete one at the clinic. Signed
consent was obtained from women entering the study. The GHQ was scored by the
researcher. Those with a positive score (3 items or more) were interviewed to establish
the likely reason for their response and asked to complete a SRT (termed threshold
SRT). GHQ and SRT scores along with interview data were recorded on a computer
database for recall when a carrier was identified. Women identified as carriers were
contacted a week later by telephone or, in a minority of cases, by letter and invited to
attend the hospital, along with their partner, for genetic counselling. The couple were
seen prior to genetic counselling by the researcher and the aims and sequence of the
questionnaires explained. Male partners were asked to sign a consent form and both
partners were asked to complete a GHQ and a SRT (termed GHQ1 and SRT1)
On receipt of the partner's negative test result the genetic nurse contacted the
couple in all cases by telephone and informed them of the result. A letter was sent
confirming the partner's negative result. Enclosed was a stamped addressed envelope and
a GHQ and a SRT (termed GHQ2 and SRT2). Six weeks later the couple were sent
a further postal GHQ and SRT (termed GHQ3 and SRT3) and a Facts and Feelings
Questionnaire. Finally six weeks after the delivery of their baby the same two
psychological measures were sent (termed GHQ4 and SRT4). Controls were contacted
by telephone in all but 4 cases where contact was made by letter. Control couples
received a postal GHQ and a SRT at comparable intervals to carriers and partners.
The results of the research are presented in the following chapter.
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CHAPTER 6
PRESENTATION AND ANALYSIS OF DATA
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Presentation and analysis of data
The results of the study will be presented by addressing each research question in turn.
6.1 Question one: Are there pre-screening variables which influence a
woman's response to prenatal CF carrier screening?
6.1.1 Sample and method
A pre-screening questionnaire was sent along with the CF carrier test information leaflet
to 2,541 women who received an antenatal booking clinic appointment between May and
the end of December 1991. A total of 334 (13%) women did not meet the criteria for
entry to the study for reasons of late gestation of pregnancy, abnormality of pregnancy,
unavailability of the male partner or poor command of English. Of 2207 eligible women
2058 (93%) returned a questionnaire. Questionnaires were completed either in the
woman's home or in the antenatal booking clinic.
6.1.2 Presentation of data
The results for each variable measured will be presented in turn.
6.1.2.1 Characteristics of the study population
The characteristics of the study population are summarised in table 6.1. Significance of
differences in characteristics was evaluated by the Chi squared test.
Analysis of subjects' age and social class revealed that there was a significantly higher
proportion ofyoung women (16 to 25 years) among socio-economic groups 4 and 5 and
the unemployed (table 6.2)
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Table 6.2. Percentage of subjects in each socio-economic group; by age
socio-■economic group
age 1 2 3 4 5 U/E stud n P
% % % % % % %
16-20 1 5 30 18 11 32 3 146 <0.001
21-25 3 16 40 15 11 12 3 425 <0.001
26-30 13 34 35 7 4 5 2 846 NS
31-35 20 41 27 6 2 3 1 490 NS
36-44 27 40 24 3 1-5 3 1-5 151 NS
Analysis of subjects' age with marital status showed that younger women 16 to 25
years were significantly less likely to be married (table 6.3).














16-20 11 88 0-5 0-5 146 <0.001
21-25 56 41 3 0 425 <0.001
26-30 84 12 4 0 846 NS
31-35 87 8 5 0 490 NS
36-44 85 11 3 1 151 NS
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6.1.2.2. Prior information about cystic fibrosis
Eighty five per cent of subjects claimed to have heard of CF before reading the pre-
screening leaflet. Television was the medium most frequently cited as their source of
information about CF (Figure 6.1).
Source" Tele" News- Radio Woman's Charity Work Other
vision paper journal appeal
Sources of information about CF













Figure 6.1 Sources of information about cystic fibrosis
Women belonging to socio-economic groups 1 and 2 were more likely to cite radio and
newspapers as a source of information than women from other groups. However, almost
equal numbers ofwomen from all socio-economic groups had derived information from
women's journals and charity appeals. Of those who indicated that they had heard of CF
through their work, almost 70 per cent also belonged to socio-economic groups 1 and 2.
Young women (16-20 years) were significantly less likely (p = <0-001) to have previously
heard of CF than women who were older (Figure 6.2).
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)-i Previously heard CF by age
Figure 6.2. Women who had previously heard of CF; by age
6.1.2.3 Perceived understanding of the pre-screening leaflet
A majority of respondents (94%) stated they had found the leaflet easy to understand.
Women belonging to the younger age groups (16-20 years and 21-25 years) were
significantly more likely (p = <0-00land p = < 0-005 respectively) to state that they had
found the leaflet difficult to understand (Figure 6.3).





Figure 6.3. Women's perceived understanding of the leaflet; by age
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6.1.2.4 Male partners who read the pre-screening leaflet
A majority of male partners (1438, 69%) read the leaflet. Of these 94 per cent were
claimed to have found it easy to understand. Younger women (16-20 years) were
significantly less likely (p = <0-001) to have a partner who had read the leaflet (Figure
6.4).
Male partners who read leaflet by female
80 respondents' age
q laaaaa y//s/////i ty/y/////a ///////a
Age: 16-20 21-25 26-30 31-35 36-44
N= 146 425 *845 *489 151
*
no response 1 subject
Figure 6.4 Male partners who read the leaflet; by women's age.
Younger women (16-20 years and 21-25 years ) were significantly less likely o have
discussed the test with their partner (p = <0-001 and p = <0-005 respectively). A
significantly greater number of this age group were unmarried (Table 6.3) and this is
reflected in the fact that significantly more married women (75%) than single women
(51%) had discussed the test with their partner (p - <0-001) (Figure 6.5). However,
single women were more likely, though not significantly so, to discuss the test with a
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Figure 6.5. Involvement of male partner and significant others in screening decision;
by marital group
Most women who were separated or divorced had become pregnant through a new
relationship. A majority of their partners had read the leaflet and most had discussed the
test with him (Figure 6.5). Three women who were widowed had new partners all of
whom had read the leaflet and each of these women had discussed the test with their
partner and a significant other person. Fifteen per cent of married women and 20 per cent
of single, separated or divorced women claimed not to have discussed the test with anyone
other than the midwife or the genetic nurse at the booking clinic (Figure 6.5). Among this
group are an unestimated but probably small number of women who failed to receive an
information leaflet prior to the booking clinic. A more substantial number chose not to
read the leaflet prior to the clinic.
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Only 50 women, out of tlie total population of 2,058, had discussed the test with their
general practitioner and just 9 women discussed the test with their health visitor.
6.1.2.5 Women's perception of their carrier risk.
Most women (58%) knew that they had a 1 in 25 chance of being a carrier of a single CF
gene (Table 6.4).
Table 6.4 Women's understanding of their carrier risk
Risk options
1 in 4 1 in 25 1 in 100 1 in 200 don't know number
% % % % % respondents
18 58 1 1 22 2058
Women in the younger age groups (16-21 years and 21-25 years) were significantly less
likely (p = <0-001) to accurately know their carrier risk (Figure 6.6).
Correct perception of carrier risk by age
Age: 16-20 21-25 26-30 31-35 36-44
N = 146 425 846 490 151
Figure 6.6 Women who understood their carrier risk correctly; by age
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6.1.2.6 Emotional response to screening
Forty three per cent of women stated that they felt reassured by the invitation to be tested,
while 25 per cent felt anxious. A total of 31 per cent indicated that they did not know how
they felt emotionally toward being screened (Figure 6.7).
Emotional response to screeing test
80-,
Response: Anxious Reassured Don't know
N = 513 883 657











Figure 6.7 Women's emotional response to screening
There was no correlation between either a woman's age or knowledge of carrier risk and
emotional response to screening.
6.1.2.7 Additional information requested in the leaflet
More information was requested by 644 (31%) of women: principally about diagnosing
CF prenatally in the fetus; and the disease and treatment in a child bom with the disorder
(Figure 6.8).
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100-1 Additi°nal information requested in leaflet









































Figure 6.8. Topics of additional information requested in the leaflet.
Tliose who wished further information about prenatal diagnosis of CF were occasionally
concerned about the procedure:
"I'd like to blow how the unborn child is tested and the risk ofpossible miscarriage as a
result of the test. "
The majority of women who felt that the leaflet had provided them with sufficient
information made comments such as: "everything understandable" or "briefand clear"
Others commented in a similar fashion to the following women:
"I'd only want to blow more ifboth myselfand my partner were identified as CF
carriers."
Another concern voiced was:
"Wouldyou be sure (100%) that an unborn child had CF or is there a chance a healthy
child could be terminated. "
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Almost as many women (41%) wished to know more about the disease CF (Figure 6.8).
"I believe CF can vary in severity and would have liked to know more regarding this."
Forty per cent of those who requested further information in the leaflet requested more
facts about treatments for the disease:
"More information on the amount ofmedical care needed by babies with CF. "
The likelihood of curing the disease was also a concern:
"We would like to know about progress being made with research towards a cure. "
Twenty three (4%) women requested 'other information1 to be included in the leaflet.
They often requested more detailed information.
"Statistics relating to % ofbabies born with CF. Further statistics on range of life
expectancy."
Some offered constructive suggestions:
"The booklet mentions the rather alarming statistic of a 1 in 25 chance of being a
carrier and a 1 in 4 chance of a baby having CF if the 2 recessive genes meet. I do not
see a statistic to show how many babies (per 1000 for example) are born with CF. Ifeel
this statistic might well reduce any alarm caused by seeing a 1 in 25 carrier risk. "
Others had clearly misinterpreted the information outlined in the leaflet:
"If this is not a hereditary disease, then what causes some people to carry the disease?
gene? - diet? - living standards? etc. "
and one woman beseeched:
"What causes the disease? What hope ofhelp ifI had it? What hope ofhelp if the child
had it?"
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6.1.3 Discussion of results
The response to the questionnaire was very high with 93 per cent ofwomen completing a
questionnaire. Women who failed to complete a questionnaire prior to the clinic were
seen by the researcher who explained the aims of the study. Many were pleased to
complete the questionnaire at the clinic: "It will help pass the time" was a frequent
comment. The majority of women completed a questionnaire at home but an
unestimated minority completed it at the booking clinic before discussing the test with the
midwife. It could be argued that the environment in which the questionnaire was
completed would reflect upon the results. It was felt that this was more likely to affect
the outcome of psychological testing, the results of which will be discussed later in this
chapter.
There was a social class bias toward the upper socio-economic groups (table 6.1) which
may reflect both the fact that women from these groups tend to book earlier (before 18
weeks gestation) (Lester and Farrow 1988) and that a considerable group from the lower
socio-economic groups booked at another clinic. In addition, it may also mirror the
changing face of the division of social class in the U.K. In 1950, 65 per cent of individuals
were employed in manual jobs compared to 47 per cent in 1991 (Financial Times 1992).
One example cited is that over this period those employed in manufacturing or mining
fell from 29 per cent to 23 per cent.
Ofthe 7 per cent of women aged 16 to 20 years 61 per cent belonged to the lower soci-
economic groups, or were unemployed (table 6.2). In addition 88 per cent of them were
unmarried (table 6.3). One in 3 pregnancies occurring in the under 20 years age group is
terminated. However, where abortions are difficult to obtain, middle class girls are more
likely to have abortions than those from working class families who tend to have their
babies (Scottish Home and Health Department 1991). This too may be reflected in the
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social class break down of the younger age group in this study. A further consideration is
that the high number of unemployed within the younger age group (32%) could relate to
their not having had time to secure employment.
The concern with this age group is that within this study they can be identified as
potentially disadvantaged in relation to prenatal CF carrier screening. Firstly, almost 40
per cent had not previously heard of CF (figure 6.2) and in addition, were significantly
more likely to find pre-screening information difficult to understand (figure 6.3). Fifty per
cent of their partners had not read the leaflet (figure 6.4 ) which may reflect the fact that
only 11 per cent of 16 to 20 year old women were married (table 6.3). Despite single
women being significantly less likely to discuss the test with their partner (51%) than
those who were married (75%) more single women discussed the test with a significant
other person, usually a relative (figure 6.5). One study found that when teenagers were
asked to identify the first person to whom they would turn for questions about sex,
contraception and relationships a majority cited their mother (Allen 1987). Therefore,
among these young women, of whom few are married, parents may have an important
contribution to make in the screening decision process.
The significance of considering not only the mother but, in addition, other family
members during decision counselling has been communicated (Richards 1987). Previous
studies have found only a minority of women fail to discuss prenatal screening and
diagnostic tests with their partner (Rothman 1988; Elkins et al 1986). In this study a total
of 31 per cent of women stated that their partner had not read the leaflet (section 6.1.2.4
page 143) and approximately the same number had not discussed the CF test with him
This may reflect an apparent male perception that the decision to undergo prenatal
screening is predominantly a woman's responsibility (Sjogren 1992). Most married
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women stated that their partner had read the leaflet (73%) and that they had discussed
the test with him (75%). A 36 year old para 1+1 offered evidence of this when she wrote:
"On reading the leaflet my immediate reaction was that Ifelt I wouldfind coping with a
baby with CF very difficult. Having discussed the issue with my husband we are agreed
that I should have this test. "
A test which may necessitate the male partner's involvement could cause a dilemma for
women whose relationship with their partner is unstable. An 18 year old single
primigravida told the researcher that she had discussed the test with her partner and at
greater length with her mother and wrote:
"I woidd like to have this test but the father of the baby does not want to have it done - I
am very sorry."
Fifteen per cent of married women and over 20 per cent of single women claimed not to
have discussed the test with anyone other than the midwife at the booking clinic (figure
6.5). Brown (1986) revealed that male partner's sharing an interest in the pregnancy was
considered by women to be the most important indicator of their partners support during
pregnancy. Only 50 (2%) women claimed to have discussed the test with their general
practitioner. This may simply reflect a lack of opportunity to do so. Although general
practitioners were notified about the screening trial by an announcement in the local GP
newsletter, when a woman first visited her GP early in pregnancy she would not have
received the pre-screening leaflet and in most cases would be unaware of the test. Few
women consult with their GP between having their pregnancy confirmed and attending
the booking clinic. A mere 9 (0-4%) women had consulted their health visitor about the
test, yet 50 per cent of women in the study already had a child and would have been
expected to be in contact with a health visitor. Guilbert and Cheater (1990) found
that health visitors felt their knowledge of genetics was inadequate. It is possible to
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speculate that women were not encouraged to discuss genetic screening or, it may simply
reflect women's perceptions of health visitors as only interested in the child (Briscoe
1989). Further research is needed to explain why so few women either felt the need or
deemed it inappropriate to discuss the test with a health care professional outwith the
antenatal clinic.
Most women (60%) were aware of their carrier risk of 1 in 25. What was not clear was
how women perceived the degree of this risk. One study showed that the distinction
between actual risk and perceived risk was an important factor in the decision to undergo
prenatal diagnosis for Down's syndrome (Marteau et al 1991a). How individuals interpret
genetic risks has been explored by Pearn (1973). The conclusion drawn was that
individuals firstly form a subjective personal view ofthe disease in question and then form
a subjective interpretation of the risk for that concept of the disease. A study involving
1,000 women who had accepted the offer of prenatal CF carrier screening asked them to
state how they visualised a 1 in 25 risk of being a CF carrier: 84 (8%) women perceived
this to be a high risk; 126 (13%) thought it was a medium risk; 337 (34%) viewed the
risk as low; and 453 (45%) stated they had no perception of the risk (Mennie et al 1992
unpublished data).
No correlation was found between a woman's perception ofher risk ofbeing a carrier and
her emotional response to the screening test. This might have been anticipated among
women who stated that their carrier risk was as high as 1 in 4 (Table 6.4). One woman
wrote:
"I feel anxious in terms of what the result will be but reassured to have as much
information prior to the birth as possible. "
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Seventy one per cent of 16 to 20 year old women and 52 per cent of 21 to 25 year old
women were unaware of their carrier risk (table 6.4) This is a concern which when
coupled with the finding that 40 per cent had no prior knowledge of the existence of the
disease for which they were being screened (figure 6.2) and that 50 per cent of their
partners had not read the leaflet (figure 6.4) nor entered into discussion about the test
supports the need to explore how this group can best become informed before they are
screened. The concept of full genetic counselling for these women seems justified,
however, the draw back is that it is expensive, could cause psychological morbidity in
large numbers of women who have no need to be concerned because they are not CF
carriers, and would be difficult to incorporate into a busy antenatal clinic. A sobering
conclusion is that these women may experience corresponding difficulty with all other
prenatal screening test information leaflets and scant knowledge on matters relating to
pregnancy. Further research is required to explore a variety of approaches to delivering
pre-screening information to the younger mother. There is evidence that young women
retain information if presented in narrative form because they identify with the characters
in the stories (Crow et al 1972). In relation to general health information the poorly
informed report the use of television while the better informed report the use of print
media such as newspapers, books and magazines (Gombeski 1981).
A considerable majority ofwomen (85%) had previously heard of CF, and claimed to find
the leaflet easy to understand (94%). More stated that they felt reassured (43%) rather
than anxious (25%) about being screened. Flowever, this leaves 32 per cent of women
who seem not to know how they feel toward being screened. More detailed research
might reveal more precisely how this group feel and among those who feel anxious, what
exactly they feel anxious about. The results of a study examining the reasons why women
accepted or declined the CF carrier test are presented in the following section.
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6.2 Question two: What factors influence a woman to accept or decline
prenatal CF carrier screening?
6.2.1 The sample and method of collecting data
A pre-screening leaflet inviting women to be screened outlined the purpose of prenatal
CF carrier screening and explained the testing procedure. The leaflet emphasised that a
negative test result would not guarantee an unaffected child but would greatly reduce the
risk. It further emphasised that most couples who had a child with CF had no family
history of the disease. The leaflet also stated that if a woman did not know who the father
ofher baby was, then it was inadvisable to take the test. Prenatal diagnosis was discussed
as one option for couples where both partners were CF carriers and termination of
pregnancy cited as one option if the prenatal diagnostic test showed the baby had CF. At
this adjunct it was stressed that prenatal diagnosis was not recommended for couples who
found termination ofpregnancy unacceptable.
A self-administered questionnaire was enclosed with the CF leaflet. Question nine asked
if a woman: a) had decided to have the test; b) had decided not to have the test; c) had
not decided. It further asked if a woman would write in a few of her own words why she
had made this decision or remained undecided. Quotations were then transcribed
verbatim to a computer database and examined word by word to abstract meanings or
themes which were categorised and then coded according to Field and Morse (1990).
2,207 women who were eligible for CF carrier screening were invited to participate in
this study of whom 2,058 (93%) returned a questionnaire. Of these women, 1728 (84%)
decided to be screened and 1362 (79%) commented on their decision. 214 (10%) had
made the decision to decline the test and all commented on their decision. A group of 116
(6%) women were undecided about screening. Of these 116 women 70 (60%) were
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subsequently screened and 46 (40%) declined. All were counselled by the genetic nurse
and all commented on why they felt undecided. Reasons why women felt undecided were
of special interest since they might depend upon the midwife to assist them resolve their
uncertainty.
Themes were recorded in order of apparent emphasis which were, in the majority of cases
easily identifiable. The considerable number of comments enabled a quantitative analysis
ofthemes to be carried out.
6.2.2 Presentation of data
6.2.2.1 Characteristics of the study population
Data was available on the characteristics of all 2,058 women who returned a
questiomiaire of whom 1798 were ultimately screened and 260 women declined. These
are summarised in (Table 6.5). Significance of characteristics was evaluated by the Clii
squared test.
Analysis of subjects' parity showed that multiparous women (68%) were significantly
more likely to decline screening than primiparous women (60%) (X^, p < 0-05) Women
who declined the test were significantly more likely to decline MSAFP screening (X^, p <
0-001). Women who declined screening were significantly more likely to feel anxious
about being screened (X^, p < 0-01). There were no other significant differences between
those women who accepted screening and those who declined.
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Table 6.5 Characteristics of the study population n = 2058
(numbers and percentages)
accepted screening declined screening
n =1798 (87%) n = 260 (13%)
Age (years)
mean 28-7 + 5-56 27-74 + 5-14
range 16-44 16-41
Parity
0 + 0 720 (40%) 85 (33%)
0+ 1 > 196(11%) 30(11%)
1 + 0 > 882 (49%) 145 (56%)
Gestation (weeks)
mean 12-25 + 2-12 12-72 + 3-63
range 6-18 7-18
Marital status
married 1316 (73%) 199 (76%)
single 409 (23%) 49 (19%)
divorced 46 (3%) 7 (3%)
separated 24 (1%) 5 (2%)
widowed 3 (-) 0(-)
Social class
1 227 (13%) 35 (13%)
2 553 (31%) 80 (31%)
3 601 (33%) 73 (28%)
4 158 (9%) 25 (10%)
5 91 (5%) 14 (5%)
unemployed 141 (8%) 22 (9%)
student 27(1%) 11 (4%)
Religion
Protestant 997 (55%) 130(50%)
Roman Catholic 243 (14%) 50 (19%)
Christian 47 (3%) 13 (5%)
Other 42 (2%) 15 (6%)
None 469 (26%) 52 (20%)
MSAFP screening
accepted 1776 (99%) 142 (55%)
declined 22 (1%) 118(45%)
^Emotional response
to screening
Anxious 422 (23%) 99 (38%)
Reassured 880 (49%) 12 (5%)
Don't know 494 (28%) 146 (57%)
* 5 no response
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6.2.2.2 Reasons why women accepted CF carrier screening.
From the comments of 1,362 women who had already decided at booking to accept
screening, 7 themes emerged which influenced their decision to accept the offer of
prenatal CF carrier screening (table 6.6).
Table 6.6 Themes of women who accepted CF carrier screening
Themes Number of women
1. Early diagnosis 842 (62%)
a) prevention affected child 353 (42%)
b) knowledge about the baby 202 (24%)
c) to make an informed decision 127 (15%)
d) preparation for an affected child 87 (10%)
e) concern for the baby 49 (6%)
f) personal factors 24 (3%)
2. Reassurance 220 (16%)
3. Knowledge of carrier status 123 (9%)
4. Logic 70 (5%)
5. Simplicity of test 48 (4%)
6. Availability of test 34 (2%)
7. Precaution 25 (2%)
Total 1362 (100%)
la) Early diagnosis
The potential to diagnose CF in the fetus was the primary reason given by a majority of
women who were screened. A total of 842 (62%) women stated that they wished to
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know if their baby was at risk of having, or was affected by the disease. Within this
group varying reasons were given for wishing to acquire this information.
For 353 (42%) of 842 women who cited prenatal diagnosis as their reason for wishing to
be screened, the intention was to prevent the birth of an affected child or to have a
healthy baby. Evidence ofthis is apparent in the following statement:
" To spare the child and ourselves a difficult life ifpositive."
Some were quite blunt:
"Because we don't want a baby with CF genes."
Others took a moral stand:
"Ifeel that as a parent it is my responsibility to try and conceive a healthy child.
Bringing a child into the world with the knowledge that he or she has a serious
handicap and life threatening condition is selfish, affecting allfamily members
and the child."
Within this group, who wished to prevent the birth of an affected child, were 65 (18%)
women who revealed that they had personal experience of CF. One expressed her reason
for wishing to be screened as follows:
"A friend died at 15 with CF. I wouldn't wish this on any child. "
And another wrote:
"A close friend has this illness and I have seen how this has affected him, and I
would not like my own child to suffer like this."
A couple where both partners were doctors revealed the effect of their experience of the
disease:
"We have both seen and treated children with cystic fibrosis - we woidd wish
to terminate our pregnancy should the foetus be affected. "
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One young mother recalled a recent traumatic experience which influenced her screening
decision:
"I have already had my youngest son testedfor CF. He was clear but while waiting
for the result Ifound out a lot about the disease. I could not bring a child into
the world to suffer arid die prematurely."
Some wished to prevent the birth of an affected child on the grounds that they would be
unable to cope. This view was more prevalent among primiparous women. As one
woman stated:
"I do not think I could cope with a child with a major illness."
Others wanted a healthy baby:
"I basically want a healthy baby and welcome the opportunity to be screened at
an earlyfoetal date."
One woman indicated that she regarded the test as crucial in her pursuit of a healthy
baby:
" Will do everything to ensure my baby is healthy."
Another, wishing to achieve the same objective wrote:
"We want our child to be bornfit and healthy and have a chance in life
without anything like CF holding (him - her) back. "
lb) Knowledge about the baby
A total of 202 (24%) of women were influenced by the possibility of prenatal diagnosis
because they wanted to know before birth if their baby had CF.
One woman wrote:
"If there is anything wrong with the baby we would like to know in advance."
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and another similarly outlined her view :
"It will be good to know ifmy baby, before it is born, has any chance at all of
having the disease. My husband agrees with this as he is anxious to know
ofany abnormalities."
Women in this category unlike those in others, did not reveal what action they would take
as a result ofgaining this information. For example:
"I'd like to know ifour baby could be that I in 4 to have it. "
Another woman similarly stated:
"To have as much information as is available about our baby's health in the
early stages ofpregnancy. "
lc) To make an informed decision
To enable an informed decision was the reason 127 (15%) women cited early diagnosis
as influencing their decision to be screened. One woman wrote:
"If at this stage ofpregnancy, I discovered there was a good chance ofhaving a
child with cystic fibrosis then I woidd still have time to consider another option
or come to terms with it. It all comes down to having a choice."
Another echoed the same sentiment:
"I would like to know any conditions my baby has to allow time to decide whether
to terminate or be able to find out more about the condition and how to deal
with the problems associated before the birth of the baby. "
Id) Preparation
Preparation was a motivating factor among 87 (10%) women in this group who referred
to early diagnosis as their reason for wishing to be screened. Approximately 10% of them
wished to be wholly prepared, typically commenting as follows:
" To be preparedfor any eventuality."
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A number articulated their plan of campaign:
"We decided to have this test so ifwe are found to be carriers we could
prepare ourselves as much as possible, find out more information and
advice."
Preparing themselves for the birth of a child who suffered from CF was at the forefront of
the minds of a majority within this category who wished to be prepared. The following
statement is representative ofthis groups' comments:
"Ifour child was to be CF we would like to be prepared. "
Another echoed the thrust of this comment:
"I'd want to know if there was anything wrong with my baby, so that I can prepare
and learn how to cope with this illness and try to overcome the problems that
arise from it."
Others felt that they had a right to know if their child was affected:
"If it is possible to find out ifyour child is going to be born physically disabled,
then I think we have the right to know beforehand, so that we can at least be
slightly preparedfor what is to come."
A similar view was repeated in the following statement:
"I think my partner and I have a right to know ifwe are carriers of the CF
gene and so be preparedfor the possibility ofhaving a child with cystic
fibrosis."
le) Concern for the baby
For 49 (6%) of women who wished to avail themselves of early diagnosis through
screening, concern for the baby was uppermost in their minds:
"Mainly concern on the baby's behalf - shouldfind out as soon as possible."
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Others revealed more deeply their feelings of concern for the baby:
"IfI can prevent any sufferingfor my baby I will. It is wise to take the test
as a precaution but termination is still a difficult decision. "
A number felt responsibility toward then child's health:
"So that my husband and Ifeel reassured that we are doing everything
possible to safeguard our baby's health. "
If) Personal reasons
Twenty four (3%) women stated that they had personal reasons for wishing to know if
their baby had CF. Some already had a child with special needs.
"Well, my first baby has cerebral palsy and I don't want anything to happen
to this baby."
And another wrote:
"I have already lost a baby with osteogenesis imperfecta. "
Another voiced concern that:
"The father ofmy child is my cousin so I thought the test would be a good idea. "
2 Reassurance
A total of 220 (16%) of the 1,362 screened women respondents sought reassurance from
the screening test.
"I have decide to have the test done to reassure us a bit."
Although the limitations of the test were acknowledged it did not discourage this group
of women from being tested:
"Reassurance, although I know the test is not 100% guaranteed."
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Clearly the offer of the test increased awareness, which in turn was a motivating factor:
"Now that I am aware of the statistics concerning carriers, I wouldfeel
happier to know that I am not. "
Some expressed overt concern:
"I have decided to take the test to hopefullyfeel some reassurance at the
end residt - although I do not know what I would do if the test proved
positive -this makes me extremely anxious. "
Another echoed this feeling:
"I would like the testjust to reassure me and my husband a little. But I will
worry a lot until I get the residts."
Reassurance specifically about the health of the baby was being sought by some, as the
following statements indicate:
"Any test that can help you feel reassured that your unborn child is healthy
is worth having."
Another woman wrote:
"We are both anxious of the progress of the pregnancy and want to be
reassured that all is going well. "
Others sought reassurance about themselves:
"Just to make sure ifI am okay!"
and:
"Because I don't think I have it but would like to put my mind at ease. "
One woman appeared to be relating symptoms she experienced to those of CF and wrote:
"I have a lot ofbelly pain."
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The expression "peace of mind" was used by 50 per cent of women who sought
reassurance. Alternative statements were: "to put my mind at ease" or "to make my mind
rest." Many women used these expressions in conjunction with other statements:
"To find out ifI am a carrier and to give me peace ofmind that I will hopefidly
have a healthy child."
A further examples illuminates the need for reassurance:
"Cysticfibrosis is a very serious disease, would have peace ofmind if the
test proved negative."
3. Knowledge of carrier status.
The study revealed that 123 (9%) of those women who intended to be screened, wished
to know if they were a CF carrier:
"I think it is important to know ifyou or your partner have the CF genes."
Some indicated their reason for wishing to know if they were a carrier:
"I would like to know ifI was a carrier and ifI am I would like to know
my husband's carrier status so that we can be as aware as possible of
potential problems."
Others wished to know if they were carriers but indicated that the information would not
affect the outcome of the pregnancy:
"I would like to know ifI am a CF carrier. This would not change my
decision upon having the baby."
4. Logic
In total 70 (5%) women gave reasons of logic for accepting the screening test, for
example: "It appears logical" or "felt it was the sensible thing to do" or "there seems no
reason not to do so. "
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Aside from a few, this group of women offered terse statements containing little sign of
emotion. A rare exception to this commented thus:
"I think it's sensible to have the CF test seeing as other tests are carried out at
the same time. It helps to reassure you that every precaution is taken. "
5. Simplicity or non-invasiveness of the test
The non-invasive nature of the mouth wash test was an important factor in the decision of
48 (4%) ofwomen to be screened. Comments representative of these women were:
"The test is simple and reasonably reliable and there is no reason not to have the
test considering the consequences should the child be affected with the CF genes."
or:
"Because it is a simple mouth wash test which has no side effects on the baby."
Another wrote:
"I have no reason not to take the test. My GP says it won't harm me or the
baby. Ifanything was wrong I'd rather know about it."
6. Availability of the test
Thirty four (2%) women stated that they were being screened simply because the test was
available. A few appeared indifferent in their attitude toward the test:
"I am having the test simply because it is being offered to me. "
Others indicated they felt they did not wish to refuse something which was offered:
"I think it would be better to have the test and know you are not missing out on
anything and it's very simple. "
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Perhaps some felt the decision had already been made for them by offering the test:
"Because the test is available and Ifeel it must be important ifyou are
bringing it to our notice."
A majority of women who took the test because it was available viewed it
enthusiastically:
"Testing of this nature is a wonderful advance and should be taken advantage of
However, some were more discriminating:
"If the test is available I may as well have it, ifno risks are carried to myself
or unborn child."
7. Precaution
Twenty five (2%) women stated that they were accepting the test as a precautionary
measure but none gave any hint as to their likely action should the test prove positive.
Comments written were comparable to the following:
"To be on the safe side" or "Better to be safe than sorry. "
6.2.2.3 Reasons why women declined the test.
Of the 279 (13%) women who had made the decision to decline screening , 214 (77%)
commented on why they had declined the test. There were nine categories which
emerged. These are listed in table 6.7.
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1 against termination of pregnancy 124 (58%)
in general 98 (79%)
specifically for CF 26 (21%)
2 for reasons of male partner 17 (8%)
3 considered risk of a CF child low 15 (7%)
4 error rate of test unacceptable 14 (7%)
5 test would cause anxiety or worry 11 (5%)
6 don't want test dunng pregnancy 11 (5%)
7 don't want to know 9 (4%)
8 too difficult a decision if test positive 8 (4%)
9 no reason 5 (2%)
total 214 (100%)
1. Against termination of pregnancy.
The main reason why respondents declined screening was opposition to termination
ofpregnancy. A total of 124 (58%) women who had made the decision to decline the test
cited this reason. Most (79%) of this group were against termination in general. As one
woman wrote:
"For us killing our unborn child because ofany disability is not an acceptable
option. I know ofno other reason why the test would be helpful, so I wouldn't
have it."
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Against termination of pregnancy for CF
A further 26(21%) women opposed to termination stated that they held this opinion
specifically with regard to the disorder CF. The following comment typifies statements
made by this group:
"I don't think in these circumstances I wouldfind termination acceptable, so
I'dprefer not to start on this route."
2. For reasons of partner
The CF earner test is distinct from most other prenatal screening tests with respect to
involving the male partner. Indeed prior indication that a woman's partner would be
willing to be screened if indicated, was paramount.
Seventeen (8 per cent) of those who declined screening did so because their partner
had indicated his reluctance to participate. More than one woman commented along
the following lines:
"My husband would be far too busy to have the test done if it became necessary"
Another explained:
"It's my partner - he doesn't really know about the pregnancy and he says he
hasn't got anything like that - he says it will take some time for him to think
about it."
3 Considered risk of having a child with CF was low.
Perceiving one's risk of having an affected child as low clearly influenced women to
decline the test. A total of 15 (7%) respondents who planned to decline the test stated
this was their reason for refusing. Of these, 14 (93%) were multiparous women. A
typical statement was as follows:
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"As I already have a completely healthy child I don't think I am at high risk of
having a child with CF. Also there is no family history."
4 Error rate of the test unacceptable.
The inability of the CF carrier test to detect all carriers was a factor which influenced
14 (7 %) to refuse the invitation to be screened. This reason frequently overlapped
with their concern that an inconclusive test result would generate anxiety throughout
the remainder of the pregnancy. One woman summed up the general view of this group:
"As only 85% ofcases tested are successful, ifmy test is negative I'm going to be
anxious that I might be that 15% and as you state you can't guarantee the child
will not have CF."
5 Test caused anxiety or worry
Eleven (5 %) women stated that the test would generate unacceptable levels of anxiety
and for this reason they would prefer not to be screened. One woman envisaged the
following scenario:
"The worry offinding out I have a single gene until my partner is tested. If
the test is negative the worry is unnecessary. Ifhe is positive, even more
worry would result until the prenatal diagnosis when if the baby is negative,
again the worry has been unnecessary. "
6 Don't want test during pregnancy.
Eleven (5 %) respondents who declined the test stated they did not wish to be tested
during pregnancy. Six (55%) women indicated that they would have accepted screening
either before pregnancy, or in the postnatal period as part of future reproductive
decision making. One subject explained:
"I feel it is now too late for the test to be relevant. If the test was available
for someone intending to become pregnant but not yet pregnant I would have
had it at that stage. "
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7 Don't want to know
Nine (4 %) women simply said "don't want to know" but gave no reason for their
decision.
8 Too difficult a decision if test positive
The thought of being screened in pregnancy concerned a group of 8 (4
because of the prospect of having to decide among options raised by
result. One woman reasoned:
"I think I wouldface a very difficult moral dilemma ifI discovered whilst
pregnant, that both my husband and I were CF carriers. I woidd then want
to have the baby screened and if it had CF I would be very worried about
making a decision to have an abortion, which in theory Fm opposed
to, but realistically, don't know what I'd do."
Of this group, slx (75%) had either a history of infertility or previous pregnancy loss
which they felt contributed to their apprehension which revolved around the prospect of
having to confront a dilemma about continuing a much wanted pregnancy. One woman
wrote poignantly:
"My husband and I have decided against the test because we have waited a while
for this baby. Tofind out something was wrong would be shatteringfor us both,
we would rather take our chances and hope everything will be okay. "
9. No reason.
Five (2 %) women stated they had no reason for refusing claiming they simply did not
wish to be screened. One lady stated:




6.2.2.4 Reasons why women were undecided about screening
A total of 116 (5%) women who were initially undecided about being screened could
be divided into 12 categories (Table 6.8). These were considered an important group
who might require additional information or counselling from the midwife.
Table 6.8. Themes of women who were undecided about CF carrier screening
Theme Accepted Declined Total
1 required more information 31 10 41 (35%)
2 for reasons of male partner 9 9 18 (16%)
3 agamst termination of pregnancy 17 17(15%)
in general 14
specifically for CF 3
4 considered risk of CF child low 7 4 11 (10%)
5 test caused anxiety or worry 6 2 8 (7%)
6 too difficult decision if test positive 4 2 6 (5%)
7 don't understand the test 4 4 (3%)
8 not screened in previous pregnancy 4 4 (3%)
9 just undecided 4 4 (3%)
10 error rate of test 1 1 (1%)
11 test might harm baby 1 1 (1%)
12 advances in treatment for CF 1 1 (1%)
total 70 46 116(100%)
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1 Required more information.
Of the 116 (5%) women who were undecided about CF carrier screening 41 (35 %)
wished more information about the implications of screening.
One woman stated:
"Want to know more about the tests that are carried out before making a
decision."
Another echoed the same thrust:
"Because I would like more information on the subject ifpossible as the
leaflet does not explain enough. "
Thirty one (76%) of those who required more information accepted the test and 10
(24%) declined.
2 For reasons of partner.
Eighteen (16%) were uncertain for
up her situation when she wrote:
"Partner would rather not know,
happened."
And another wrote:
"I want to make sure all is well - to be able to make a well informed
decision if the need arises. I want the bestfor my baby. My husband is
away and won't be returningfor a few weeks. "
Of this group half accepted and half declined the test.
reasons of their partner. One woman summed
. I'd like to be preparedfor it if it
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3 Against termination of pregnancy.
Seventeen (15%) respondents stated that they were undecided about being screened
because they were either against or doubtful about termination of pregnancy. Most
14 (82%) were against abortion for any abnormality. Three (18%) women were doubtful
about termination specifically for CF. The following statements describe how many in
this group felt:
"Want to take the testfor reassurance ifnegative but, if its positive I doubt
ifI'd want an abortion so why have the test? "
Another commented:
"Although I can see the benefits in such a test Ifeelfor me it would be wrong as
Iwould not have an abortion even ifmy child had CF and it seems pointless to
know before the birth."
All the women in this group ultimately decided against being screened.
4 Consider the risk of a CF child low.
Eleven women (9%), among those who were undecided, felt they were probably at low
risk ofhaving an affected child. A number had not understood that a family
history of CF was not a prerequisite to being a carrier. As one woman wrote:
"Well none ofmyfamily have ever had it and I don't think the father of the
child or his family have got it."
Others, since they already had unaffected children, wanted to know how this affected
their risk:
"Having had 2 children already who are perfectly healthy, I am going to
check with the doctor, if there's more ofa chance or less ofa chance. "
Ofthese 11 women 7 (64%) were screened and 4 (36%) declined.
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5 Test causes anxiety or worry.
Eight (7%) women felt uncertain about being screened because of generating anxiety.
"Whilst we would rather know in advance ifour unborn child has CF, the
possibility of3 periods ofstress / anxiety awaiting test results doesn't appear
conducive to achieving the state ofmind desirable during pregnancy -
particularly as the chances of both partners being carriers is low."
This lady was among six (75%) women in this group who decided to be screened and
a further two (25%) women declined.
6 Too difficult a decision if the test was positive.
Six (5%) women were undecided about the test because of the anticipated dilemma they
might face if the test proved positive. One woman explained her uncertainty stemmed
from:
"Being worried about the decisions to be made as a result of the knowledge
it may give. Still undecided as to the best thing to do, consequences for
child affected etc."
Of this group 4 (67%) women decided in favour ofbeing screened and 2 (33%) women
declined the test.
7 Don't understand test.
Four (3 %) women expressed their lack ofunderstanding ofthe test. Two examples of
their statements help describe their difficulty:
" I don't know ifI want the test because I don't really understand the treatment.
In one part it says its just a mouth wash and in the next it goes on about a
screening test and I don't understand it. In fact I think it's quite frightening. "
And another wrote:
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"Because me and my partner don't understand the carrier testing. We would
change out desin (decision) ifyou could tell us more about it." (sic)
All 4 subjects in this group ultimately made the decision to be screened.
8. Not screened in previous pregnancy.
Four women (3%) stated that they were ambivalent about being tested because the test
had not been available at the time of their previous pregnancies. All subsequently
decided in favour of being screened. Their view is described in the following two
statements:
" Happy with my last two pregnancies and willjust have the usual tests."
and:
" Because this did nor exist when in my other 3 pregnancies. " (sic)
9. Undecided or Don't know what to do
Four (3%) women were undecided and confused about what to do for the best. One
young woman explained her dilemma:
"I don't know, because there are, or seem to be, so many diseases or
illnesses that coidd affect unborn babies - Ifind it all very worrying. "
and another said touchingly:
"Ijust want the bestfor my baby."
All four women decided to be screened.
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10 Error rate of test unacceptable.
The error rate proved to be unacceptable to one (1%) woman who ultimately decided
against being screened:
"The test is not 100% successful. If it can't guarantee diagnosing the
possibility of having a child with CF then I would notfeel reassured
to have a negative result even if the risk becomes less."
11 Because the test might harm the baby.
One (1%) woman who decided in favour ofbeing screened was initially uncertain
because of fears that the test might harm the baby commented:
"7 feel I would like to know more about the test e.g. is it simply a mouthwash
test or are there any follow-up tests further on into the pregnancy which might
harm the baby. Ifeel more disposed to having the test than not. "
12. Because of advances in treatment or research of CF.
Finally, one (1 %) woman who was undecided declined the test and did so because of
advances in treatment for CF and ongoing research. She wrote as follows:
"I would not terminate a pregnancy ifCF was diagnosed. Having worked
with cystic children and adolescents, medical advances are being made
which increase both the quality of life and the life expectancy of the CF
sufferer."
6.2.3 Discussion
A total of 1692 (77%) of the 2207 women eligible for screening, commented in writing
on their decision about the CF carrier test. Their comments gave an insight into their
own individual perceptions of the test and its appropriateness based on their own value
systems. The study revealed the many and varied factors which women stated were
important in their decision to accept or decline CF carrier screening during pregnancy.
176
These ranged from societal to individual. It also confirmed that women will voice their
opinion and feelings about new developments in technology when given the opportunity.
The invitation to pregnant women to write about their wishes and concerns has been
carried out in a previous study and found to be beneficial both to a woman and to the
health care professionals concerned (Jones 1990). During her study Jones examined the
antenatal records of 50 women to identify birth plan requests. In 45 cases the records
stated 'no specific requests'. Then, when subsequently asked to write their wishes
women did so in a clear and detailed account. Educational background and career
attainment did not affect the response rate.
Technological developments challenge women to confront issues which involve
questioning their feelings about motherhood (Rothman 1988). They are compelled to
confront their feelings toward the fetus and the normal process of maternal-fetal bonding.
But the fetus is not their sole consideration, women feel additional responsibilities to
other family members and are aware of their own coping ability. Most women appeared
to have had little difficulty in deciding whether not to be screened with only 5 per cent of
women intimating they had difficulty reaching a decision.
The factors influencing women in their decision were sometimes overlapping and
interlocking. Initially five fields in each database record were allocated to theme
categories but this was quickly reduced to three. Themes were recorded in order of
apparent emphasis which were, in a majority of cases, easily identifiable.
Kitzinger (1987) expresses the view that many women feel guilt that they may be seen
to cause delay in the clinic process by questioning or firmly pursuing what they want.
The invitation to respond in writing may have advantages over an inducement to
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respond verbally. First, it may be regarded as a more candid invitation, secondly it
allows the individual time to assimilate their thoughts, and thirdly, and perhaps most
importantly, it may encourage the individual to realise the implications of their decision
and hopefully avoid accepting a test simply because they feel a need to conform.
The reason most women (62%) accepted the test was for reasons of early diagnosis of CF
in the fetus. There was, however, a range of motives cited for wishing to know if the
baby was affected or at risk of having CF. These ranged from prevention of, to
preparation for the birth of an affected child. Although previous studies have indicated
that a majority of women accept prenatal screening to receive reassurance (Farrant 1985;
Davies and Doran 1981) only 16 per cent of women indicated that this was their sole
reason for accepting CF carrier screening.
The comments made suggest that women are discriminating in their reasons for
accepting prenatal tests. This is an encouraging finding because concern has been
expressed that women feel unable to exercise the options which prenatal screening and
diagnosis offered. This is blamed on a lack of information and emotional support which
reduces women's autonomy and ability to make free and informed choices (Farrant
1985). One reason for this variation could be that the media have played a significant
role in educating and enlightening women who may now recognise and apply their
consumer power.
A study of health related topics in six of the most widely read women's magazines in the
USA over a two year period found an average of three health related articles in each of
the magazines studied. There was an emphasis on health promotion and protection, family
and personal health practices. The best informed groups were women and young adults
(Miller et al 1981). Readers of these journals were found to be of the higher social
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classes and well educated. In the UK, newspaper articles about genetic screening for CF
carriers have appeared mainly among broad sheet newspapers in their science and health
columns (Wilkie 1992; Carrell 1992; Christie 1992; Cookson 1992).
Television has introduced genetic conditions including CF through documentary
programmes and popular drama programmes. Delivery of information particularly
through drama programmes or true stories may play a crucial part in individual retention
of information, particularly if viewers or readers identify with the characters portrayed
(Crow et al 1972). An article in the woman's journal "Family Circle" told the story of
how the actress Jenny Agutter discovered during her first pregnancy that she was a CF
carrier. The article gave a detailed description of the disease and the carrier screening test
and technical details were illustrated by colourful diagrams. A reassuring photograph of
the actress and her healthy son completed a presentation which women could easily relate
to (Family Circle 1992).
Six per cent of women were explicit about their wish to prepare for the birth of an
affected child; a further 127 (9 %) women wished to be able to make an informed
decision; and 202 (15 %) women wanted information about their baby (table 6.6). It
may be reasonable to assume a number of women in the latter two categories would
likewise use diagnostic information to prepare for the birth of an affected child.
Conversely, there were women who explicitly stated their intention was to terminate an
affected pregnancy.
Few women (2 %) stated they wished to be screened simply because the test was
available. Obtaining information about the baby early in pregnancy without having to
decide immediately on a particular strategy was favoured by some. As one woman
commented:
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"It's a non-invasive test and there are a number ofpoints where one can decide
whether or not to proceedfurther."
The difficulty of anticipating women's reactions based on hypothetical situations
has been acknowledged (Mclntyre 1987). Nonetheless, at this early juncture 26 per
cent of all women who wished to be screened stated that their intention was to prevent
the birth of an affected child. Reasons cited were: their experience or knowledge of the
disease; misgivings about their ability to cope with a child suffering from a chronic
illness, and perceived adverse effect upon their family. As one woman explained:
"We already have 4 healthy children. Ifeel I have a duty to myselfandfamily to
have this test. Giving birth to a CF child would have serious consequences
for the whole family - I wouldprefer to prevent this ifI can."
The options of whether or not to proceed with an affected pregnancy were influential:
"We wish to have the test since, ifwe were both found to be carrying the CF
gene and a prenatal diagnostic test was to show that the baby was going to
have CF, we would wish to cotisider a termination."
The following discussion combines data from tables 6.7 and 6.8. Unquestionably,
women's opinion on termination of pregnancy was the factor which motivated most to
decline the test. This is a similar finding to previous studies (Davies and Doran 1981;
Fadden et al 1987; Kyle et al 1988). Of the 112 women who were completely
against termination of pregnancy, 78 (70%) had declined MSAFP screening. In
contrast only six of the 29 (21%) who were against termination specifically for CF
declined MSAFP screening. It is interesting that 33 (30 percent) of those who stated
they were completely against termination of pregnancy, were planning to participate
in the MSAFP screening programme. One reason for this may be that no reference is
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made to termination of pregnancy in the Hospital's leaflet describing this test, whereas
the CF screening leaflet particularly draws attention to this as a possible consequence.
The incompleteness of CF carrier testing was not a major concern. Seven per cent of
women who declined the test did so for this reason. Frequently this reason was coupled
with the belief that being screened would generate anxiety:
"With the test only being 85% accurate I do notfeel it is worth putting
myself through the worry."
A total of 13 (5%) stated they had declined the test because they anticipated it would
provoke unacceptable levels of anxiety. It is interesting that so few women cited this as a
reason when significantly more women who declined screening stated, in the pre-
screening questionnaire, that the test made them feel anxious, when compared to women
who accepted the test (figure 6.7 page 146 and table 6.6 page 156). It would appear that
perhaps subconsciously women who are made to feel anxious avoid situations which may
induce stress. Further research is needed to ascertain whether these women are aware of
their behaviour and the reasons for their anxiety. Nine (69 %) of the 13 who refused on
the grounds of anxiety did. however, accept MSAFP screening. This could be accounted
for by the fact that neither the false positive or negative rates associated with MSAFP
screening were intimated in the hospital's booklet outlining this test, nor was termination
of pregnancy mentioned as a possible consequence. It would seem reasonable to
conclude that it was the candidness of the CF information leaflet which allowed women,
for whom this information created uneasiness, to make an informed choice. It is a
disappointing finding that women are denied the full facts about MSAFP screening.
Although they are granted the freedom to choose whether or not to accept the test,
women are disadvantaged ifnot in full possession of the facts.
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Prenatal CF carrier screening introduced a relatively new concept of screening in its
involvement of the male partner. Some women were reluctant to admit the
existence of a supportive partner for fear of jeopardising their entitlement to state
financial benefits. However, when asked about accessibility to the male partner if
screening was indicated, most claimed that their partner would be available.
Genetic conditions are frequently equated with a family history. Regardless of
emphasising that a family history was not a prior condition to being a CF carrier, this was
a difficult concept for some to comprehend. Multiparous women in particular were
inclined to perceive that their risk of having a child with CF was low. As one subject
stated:
" I have five healthy children already andfeel no needfor this test. "
In some instances multiparous women indicated that their satisfaction with the care
given in previous pregnancies was a factor:
" Happy with my last two pregnancies and willjust have the usual tests."
Only 11 (4%) women actually stated they were against being screened during
pregnancy and would therefore decline the test:
"Feel it is too late to be having the test. Before pregnancy I would have
wanted it, including testsfor other genetic diseases."
Nevertheless, others indicated that although they planned to be screened, they would
have preferred the option to have been made available prior to conceiving. A study of
attitudes of recent parents to CF carrier testing found that approximately half the
sample were in favour of screening in early pregnancy (Green 1992). In the present
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study, because the test was offered during pregnancy, some women may have presumed
that CF carrier screening was exclusively a prenatal test.
The literature search revealed that in Britain more than one in ten couples experience
difficulty in either achieving a pregnancy or having a live bom child (Page 1988).
Moreover, studies indicate that couples who have undergone infertility investigations
and subsequently encomiter prenatal diagnostic procedures experience elements of
the psychological trauma associated with their infertility (Sandelowski et al 1991).
The CF screening test is offered at a woman's first clinic visit. The prospect of being
confronted with a decision to continue or end the pregnancy was a situation which some
of these couples made clear they wished to avoid.
The importance of good pre-screening information cannot be over emphasised. Studies
indicate that informed decision making requires time (Lorenz et al 1985). The aim of
the pre-screening leaflet in this trial was to present a global view of CF carrier screening
to women and their partners well in advance of screening so that they might make a
decision with which they are happy. There was no indication that women felt constrained
in their decision to accept or decline the CF carrier test during pregnancy. Generally
then perspective was that screening granted them a measure of control over the
outcome oftheir pregnancy.
It has been suggested that it is doctors who wish perfect babies and not women
(Mclntyre 1987). This study revealed that 6 percent of women wished to be screened to
prepare for the birth of an affected child. Although this is a minority group they constitute
an important pre-screening counselling component. Although couples where both
partners test positive could be advised that the baby was at high risk of having the
disease and prepare themselves for such an event this goes against the primary objective
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of prenatal screening which is to prevent the birth of infants with conditions which
screening can detect. Although this objective may not be openly promoted in patient
leaflets, it is currently the method of evaluating genetic screening programmes and
prenatal screening programmes which are justified on the basis of the financial savings
achieved by reducing the birth incidence of a number of conditions such as Downs
syndrome, spina bifida, and CF (Gill et al 1987; Chappie et al 1987; Wald and Cuckle
1988; Goldstein and Philip 1990; Golbus 1992). Some recognise that there are significant
non-monetary costs and benefits and that these should be considered in the organisation
of such services (Clarke 1993). Indeed it is argued that economic factors should only be
considered in the light of improving efficiency and only after service goals have been
established (Phinn 1990). Evaluating health care services is not simply a technical,
professional matter, it includes interpersonal aspects where consumer opinion is as
important (Vuori 1989). The results of this study show that women have varying
objectives in undergoing screening and a minority are at variance with the objectives of
the providers. For a service to achieve its full potential providers need to be clear about
its values and objectives, but to supply a high quality service providers need to be aware
of consumer perception of its values and objectives (Vuori 1989).
Many women who accept CF carrier testing in order to promote a healthy outcome of
pregnancy may be unaware of the potential stress associated with receiving a positive test
result. Fortunately it is a small minority of women who ultimately have to wrestle with
the moral and emotional questions of abortion. Nonetheless, there are a substantial
number of women who are identified as CF carriers but whose partners will test
negative. If midwives are to help them, they need to be equipped with an awareness of
the possible stressful effects of being identified as a CF carrier during pregnancy. The
following section presents the results of a study which assessed the psychological impact
on women identified as CF carriers and their partners who received a negative test result.
184
6.3 Question three
Will identifying a woman as a CF carrier during pregnancy provoke a
stressful response both in her and in her partner?
6.3.1. Sample and method
Of 2,207 women who were eligible for CF carrier screening, 1,812 (82%) women
accepted the offer of testing and were invited to participate in this study. 1,798 (95%)
agreed to participate. Among these 1,798 women were 69 (4%) women who were
identified as CF carriers. In all cases their male partner was screened. Three couples
were identified where both partners carried a CF mutation and they were excluded from
this study. One couple suffered a pregnancy loss and one couple failed to complete the
questionnaires. A further exclusion was a male partner who expressed reluctance
to enter the study, however, his carrier partner wished to be included. A total of
64 carrier women and 63 male partners participated in the study.
For each carrier two control subjects of the same parity were selected. Control
subjects had attended the same antenatal booking clinic as the carrier, had received a
negative CF test result, and had a male partner willing to act as a control subject. A total
of 116 female controls and 115 male controls were recruited. Of these 13 couples failed
to complete all of the questionnaires and 2 couples suffered a pregnancy loss. A total of
101 female controls and 100 male controls participated in the study.
Socio-demographic data was obtained from carriers' and controls' antenatal records.
A self-administered pre-screening questionnaire was designed and sent to all women
along with an information leaflet describing the aims of the carrier test and outlining the
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screening procedure. Incorporated in the questionnaire was a 12-item General Health
Questionnaire (see appendix) designed to assess the threshold emotional status of a
woman prior to her being screened.
The Symptom Rating Test (SRT) (see appendix) was used to identify the nature of
distress among women who presented at the clinic with a positive GHQ score.
The significance of differences in GHQ scores between groups was evaluated by the Chi-
squared test. Symptom Rating Test (SRT) scores were not normally distributed (skew
to higher values), therefore the significance of differences between groups was assessed
by the median test.
Women were asked to complete the threshold GHQ at home and bring it with them to the
booking clinic. Those who had not completed a questionnaire were asked to complete
one at the clinic. Pre-screening counselling was carried out by the midwife responsible
for booking the patient and a mouth-wash sample was obtained. The threshold GHQ
was scored by the researcher and those women with a positive score (3 items or more)
were interviewed to establish the likely reason for their response. They were asked to
complete a SRT (termed threshold SRT) to determine the nature of their psychological
disturbance. GHQ and SRT scores along with interview data were recorded on a
computer database for ease of storage and recall when a carrier was identified.
Women identified as carriers were contacted a week later by telephone or, in a minority
of cases, by letter and invited to attend the hospital, along with their partner, for genetic
counselling. The couple were seen prior to genetic counselling by the researcher and
the aims and sequence of the questionnaires explained. Male partners were asked to
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sign a consent form and both partners were asked to complete a GHQ and a SRT
(termed GHQ1 and SRT1)
Counselling was then carried out by the genetic nurse and a mouthwash sample was
obtained from the partner. Couples were given a detailed information leaflet with a
contact telephone number.
On receipt of the partner's negative test result (average 4 days) the genetic
nurse contacted the couple in all cases by telephone and informed them of the result. A
letter was sent confirming the partner's negative result and reiterating the couple's
residual risk of 1 in 640 of having an affected child. Enclosed was a stamped addressed
envelope and a GHQ and a SRT (termed GHQ2 and SRT2). Six weeks later the couple
were sent a further postal GHQ and SRT (termed GHQ3 and SRT3) and finally six
weeks after the delivery of their baby the same two measures were sent (termed GHQ4
and SRT4).
Controls were contacted by telephone in all but 4 cases where contact was made by
letter. Control couples received a postal GHQ and a SRT at comparable intervals to
carriers and partners.
6.3.2 Presentation of data
6.3.2.1 Characteristics of the study population
The socio-demographic characteristics of the screened population, carriers and
controls are shown in Table 6.9. There was no difference in socio-demographic
characteristics between the total, carrier and control populations.
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6.3.2.2 Results of the General Health Questionnaire (GHQ)
6.3.2.2.1 GHQ results of the total screened population
A total of 576 (32%) of the screened population presented with a positive
threshold GHQ. Of these 519 (90%) women were interviewed at the clinic to elicit
reasons for their psychological distress. Failure to interview 10 per cent of women
occurred either because they had left the clinic before the researcher could speak
to them, or because the researcher was advised against interviewing women who
were experiencing a serious complication of pregnancy. Reasons cited for presenting
with a positive threshold GHQ are listed in table 6.10. Included in the total population
were the 64 CF carriers who participated in this study and their 101 controls. Fourteen
(22%) carriers and 25 (25%) controls presented before screening with a positive
threshold GHQ (table 6.10).
Among the total screened population 38 per cent cited symptoms of pregnancy as the
main cause for their psychological disturbance. Although most felt positive about their
pregnancy they complained of tiredness, nausea and emotional volatility (table 6.10).
Twelve per cent stated that their pregnancy was unplanned. Twenty two per cent were
anxious about the pregnancy for reasons of: poor obstetric history (58 women); no
specific reason (40 women); problems with the pregnancy such as threatened abortion (8
women); and awaiting the results of a chorionic villus sample or amniocentesis later in the
pregnancy (10 women). Four per cent of women had a history of a previous psychiatric
episode (Table 6.10).
189








symptoms of pregnancy 196 (38%) 5 (36%) 12 (48%)
anxious about pregnancy 116(22%) 1 (7%) 5 (20%)
unplanned pregnancy 69(13%) 2 (14%) 2 (8%)
active child at home 23 (4-5%) 1 (7%) 0
previous psychiatric episode 23 (4-5%) 0 1 (4%)
existing illness 12 (2%) 1 (7%) 1 (4%)
history of infertility 17 (3%) 0 0
strained relationship with partner 12 (2%) 0 1 (4%)
social or domestic problems 18(4%) 1 (7%) 2 (8%)
unemployment 10 (2%) 0 0
bereavement 8 (2%) 3 (22%) 0
child with special needs 4(1%) 0 0
job dissatisfaction 5(1%) 0 1 (4%)
involuntarily apart from partner 6 (1%) 0 0
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Older women (36-45 years) were significantly more likely than other age groups to present
with a positive threshold GHQ (Chi-squared test p=<0.005). Younger women (16-20
years) were more likely, though not significantly, to present with a positive threshold GHQ
at booking (Figure 6.9).
36-45
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Figure 6.9 Antenatal bookers with a positive threshold GHQ; with age
There was a trend for women who were single or separated to present at booking with a
positive GHQ score (Figure 6.10).
Marital status: Married Single Separated Divorced Widowed
N = 1316 409 24 46 3
Figure 6.10 Women with positive GHQ score; with marital status
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Socio-economic background did not significantly influence a woman's threshold GHQ
score (Figure 6.11).
Social class: 1 2 3 4 5 Unemployed Student
N = 227 553 601 158 91 141 27



























Figure 6.12 Women with a positive threshold GHQ score; with gestation of
pregnancy.
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Neither a woman's parity or her emotional attitude to being screened affected
participants' GHQ scores at booking (data not shown).
6.3.2.2.2. GHQ results of CF carriers and controls
Sixty four carriers participated in this study along with 101 controls. The control subjects
had attended the same booking clinic as the carrier but had received a negative test result.
Among the 64 carriers were 14 (22%) carriers who presented with a positive threshold
GHQ, compared to 25 (25%) of control subjects. The reasons these women were
experiencing stress at the time ofbooking are listed in table 6.10.
On receiving their positive test result, the proportion of carriers (53%) with a positive
GHQ1 score were significantly greater than the proportion of control subjects (27%)







































Figure 6.13 Carriers with a positive GHQ compared to controls at each of the five
assessment points.
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Following receipt of their partner's negative test result (GHQ2), at six weeks after the
test (GHQ3) and at 6 weeks post-delivery (GHQ4), carriers showed no significant
difference in the proportion of positive scores when compared to control subjects
(Figure 6.13).
Five (36%) of the 14 carriers who entered the study with a positive threshold GHQ and
11 (44%) out of 25 controls maintained these scores throughout the study for reasons
specified in table 6.11.
Table 6.11 Reasons why 5 carrier and 11 control subjects submitted positive
GHQ scores at each of the 5 assessment points.
Carriers Controls
First baby died previous year
Mother died recently
Recently widowed - unplanned pregnancy
Husband diagnosed as diabetic
ECG monitoring during pregnancy for
attacks ofbreathlessness
Chronically sick child
Hyperactive child - husband works away
Unplanned pregnancy (3 subjects)
Anxious about pregnancy (2 subjects)
Amniocentesis and domestic problems
Agoraphobia sufferer
Moved house (2 subjects)
There was no correlation between participant's age, social class and parity and
GHQ scores. However, women who perceived their carrier risk incorrectly were more
likely, though not significantly so, to have a positive GHQ1 score at the time of receiving
their positive test result, when compared to women who knew their risk of being a
carrier.
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6.3.2.2.3 GHQ results of male partners and controls
No significant difference was found between the proportion of male partners and their
selected controls with a positive GHQ score at any of the four assessment points (Figure
6.14). There was a tendency for male partners to show proportionately more distress at
the time of receiving the female carrier's test result but this was shown not to be
statistically significant (Chi-squared test p=<0.02). However, 14 of 15 (93%) partners
with a positive GHQ1 had a female earner partner who also had a positive GHQ
score. Males were, therefore, significantly more likely to manifest psychological distress
if their female counterpart was likewise distressed. (Chi-squared test p=<0.001).
60-1
GHQ1 GHQ2 GHQ3 GHQ4
Partners n=63 n=63 n=S3 n=52
Controls n=100 n=100 n=100 n=98
P = NS NS NS NS
Figure 6.14 Male partners with a positive GHQ score compared to control
subjects at each of the four assessment points
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6.3.2.3 Results on the Symptom Rating Test (SRT)
Of the 576 women who presented at the antenatal booking clinic with a positive
threshold GHQ 519 (90%) completed a threshold Symptom Rating Test (SRT).
One hundred women who presented with a negative threshold GHQ were
selected consecutively and asked to complete a threshold SRT for comparison (table
6.12).
Table 6.12 Median of threshold Symptom Rating Test (SRT) scores of
bookers who presented with a positive GHQ compared to a
cohort of 100 women with negative GHQ scores
Threshold Bookers with Bookers with
SRT score positive GHQ negative GHQ
total 13 4 p < 0-001
anxiety 4 1 p < 0-001
depression 4 1 p <0-001
somatic 2 0 p < 0-05
inadequacy 4 1 p <0-001
Women with a positive threshold GHQ had threshold SRT scores well below those
reported for psychiatric patients (Fava et al 1983; Kellner and Sheffield 1973). Those
with a negative threshold GHQ score submitted SRT scores below those of normal
subjects in previous studies (Cochrane 1980; Kellner and Sheffield 1973).
Fourteen (22%) carriers and 25 (25%) selected controls who presented with a positive
threshold GHQ at the booking clinic completed a threshold SRT. There was no
significant difference in the threshold SRT scores ofbookers, carriers and controls. When
carrier women received their positive test result (SRT1) there was a significant difference
between carriers and controls in the total SRT score for generalised psychological
disturbance (median test, p = <0-005) and specifically in the sub scores for anxiety and
depression (median test, p = < 0-001). On receiving their partner's negative test result
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(SRT2) the scores of carriers returned to control levels and remained there at the six
week post-test point (SRT3) and again at the six week postpartum assessment point
(SRT4) (Table 6.13).
Table 6.13 Median of Symptom Rating Test (SRT) scores of carriers and controls at
each of the 4 assessment points
SRT1 Carriers n = 64 Controls n = 101
total 11-5 7-0 p = <0-005
anxiety 4-5 1-0 p = <0-001
depression 4-0 2-0 p = <0.001
somatic 1-0 1-0 NS
inadequacy 2-5 2-0 NS
SRT2 Carriers n = 64 Controls n = 101
total 7-0 7-0 NS
anxiety 2-0 1-0 NS
depression 2-0 2-0 NS
somatic 1-0 1-0 NS
inadequacy 2-0 2-0 NS
SRT3 Carriers n = 64 Controls n = 101
total 5-0 7-0 NS
anxiety 1-0 1-0 NS
depression 2-0 2-0 NS
somatic 1-0 2-0 NS
inadequacy 2-0 2-0 NS
SRT4 Carriers n = 64 Controls n = 99
total 6-0 7-0 NS
anxiety 1-0 1-0 NS
depression 2-0 2-0 NS
somatic 0-0 0-0 NS
inadequacy 2-0 2-0 NS
Partners did not complete a threshold SRT because only a proportion of males attend
the antenatal booking clinics. There was no significant difference between later SRT
scores for generalised psychological disturbance of the partners of carriers when
compared with their selected controls. Anxiety and inadequacy sub scores were shown to
be significantly higher than control subjects at the time when carriers were given their
positive test results (median test, p = <0.05 and p = <0.02 respectively, table 6.14
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Table 6.14 Median of Symptom Rating Test (SRT) scores of partners and controls
at each of the four assessment points.
SRT1 Partners n = 63 Controls n = 100
total 5-0 3-0 NS
anxiety 3-0 1-0 p = < 0-05
depression 1-0 1-0 NS
somatic 0-0 0-0 NS
inadequacy 1-0 0-0 p = <0-02
SRT2 Partners n = 63 Controls n = 100
total 3-0 2-0 NS
anxiety 1-0 0-0 NS
depression 1-0 1-0 NS
somatic 0-0 0-0 NS
inadequacy 1-0 0-0 NS
SRT3 Partners n = 63 Controls n = 100
total 2-0 2-5 NS
anxiety 0-0 0-5 NS
depression 0-0 1-0 NS
somatic 0-0 0-0 NS
inadequacy 1-0 0-0 NS
SRT4 Partners n = 62 Controls n = 98
total 3-0 3-0 NS
anxiety 0-0 0-0 NS
depression 1-0 1-0 NS
somatic 0-0 0-0 NS
inadequacy 1-0 1-0 NS
There was a significant decrease in the sub scores of anxiety between SRT1 and
SRT2 scores both in carriers and in their partners (Table 6.15). This was thought to be
in response to the removal of threat to the fetus. Carriers similarly showed a decrease
in the sub score for depression between SRT1 and SRT2 scores which was recognised
as a subsidence of their feelings of loss of a normally progressing pregnancy.
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Table 6.15 Comparison of median of SRT1 and SRT2 scores in carriers and
partners
carriers n = 64 SRT1 SRT2
total 11-5 7-0 NS
anxiety 4-5 2-0 p = <0-001
depression 4-0 2-0 p = <0-02
somatic 1-0 1-0 NS
inadequacy 2-5 2-0 NS
partners n = 63 SRT1 SRT2
total 5-0 3-0 NS
anxiety 2-0 1-0 p = <0-005
depression 1-0 1-0 NS
somatic 0-0 0-0 NS
inadequacy 1-0 1-0 NS
6.3.3 Discussion
This study addressed the psychological effect upon 64 women who were told during
pregnancy that they were CF carriers. These women had partners who received a
negative screening test result and were reassured that it was unlikely that they were
carriers. These couples were given a residual risk of 1 in 640 ofhaving a child with CF.
There is an ongoing debate in relation to CF screening which centres on the
population to be advised about the availability of the carrier test and whether screening
should be concentrated on adults before pregnancy or pregnant women (Lipkin et al
1986; Brock 1984). Proponents of prenatal screening argue that pregnancy is the time
when most individuals will be motivated to seek and use information on their carrier
status But as new screening tests are developed and applied in pregnancy the
psychological impact of their use must be considered. Understanding the potential
emotional repercussions for women can help midwives offer enhanced support for
mothers who are offered these tests.
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Stress occurs when an individual perceives a threat that they will not be able to cope
with. However, the influence of external factors must also be appreciated in the analysis
of a stressful situation (Cochrane 1983). The threshold GHQ was used to detect stress at
the time of hooking before the screening test was carried out. Thirty two percent of
women who were screened presented with a positive threshold GHQ. This was
comparable with other studies in pregnancy (Sharp 1988).
It has been shown that randomly selected samples from the community will contain quite
high proportions of persons with degrees of psychological disturbance ranging from
mild to severe (Goldberg and Huxley 1992). Indeed it is estimated that 25 per cent of
patients seen in general practice have anxiety as a clinically significant component
of their condition (Wilkinson 1992) The GHQ revealed the value of using a
questionnaire in the clinical setting. It proved an acceptable instrument which
encouraged women to ventilate their feelings and could be considered for use as a quick
and efficient method for the midwife to identify women who may require further help
and support. Indeed, some have pleaded for psychological assessment to be an
integral part of a woman's assessment in the prenatal period (Campbell and Field
1989).
Symptoms of early pregnancy was the most common reason given by women who
submitted a positive GHQ score at booking (Table 6.10). "Normally I am a confident,
happy individual" explained a 25 year primigravida who was a self-employed florist.
"Suddenly I have lost confidence, I am tired and emotional andfind it difficult to make
decisions. " Her husband was amused by this transformation in his generally assured wife,
but she was plainly distressed about it. During discussion with the researcher it emerged
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that she was worried that this was a permanent change and she would find it difficult to
operate her successful business.
A substantial number ofwomen were suffering from concurrent stress such as a poor
obstetric history, difficulty conceiving, or an unplanned pregnancy. Older women were
significantly more likely to present with a positive GHQ (Figure 6.10). This may be
accounted for by the fact that women over the age of 35 years are more frequently
faced with the prospect of invasive diagnostic tests for chromosomal abnormalities. The
literature search revealed that older mothers may experience additional physiological and
psychological stress because their age and experience make them more aware of the
risks associated with pregnancy (Michelson and Gee 1984). Moreover, their pregnancy
may be viewed negatively by others (Berryman and Windridge 1991).
Although no correlation was found between parity and a positive threshold GHQ, a
poor obstetric history was cited by 10 per cent of women as the reason for then-
distress. The grief associated with an unsuccessful pregnancy is not a rare experience
for women. In the UK one in a hundred babies die in the latter part of pregnancy or
shortly after birth (Oakley 1984). Women are advised that spontaneous abortion is
extremely common, occurring in around 1 in 6 pregnancies and in most cases the
cause is not determined (Health Education Board 1993) Thus, many women are left
asking the question "why". One woman interviewed for this study was convinced she
had had 3 spontaneous abortions at approximately 8 weeks gestation. Because
products of conception had been identified on only one occasion she perceived the
medical profession were not convinced.
"I have a history ofearly miscarriage and I am offwork and a little below par"
wrote this 32 year old social worker. On questioning by the researcher she revealed that
she had "taken to bed" in an attempt to "hold on to this pregnancy". She gave evidence
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of the grief, mourning and despair that is experienced in early miscarriage; of feeling
that she was denied the right to grieve; and that there was an apparent "reluctant to
acknowledge" that she had a poor obstetric history because of a lack of pathological
evidence. It is this unwillingness among health care professionals to award early
miscarriage as a significant emotional experience which couples find so insensitive (Rajan
and Oakley 1993).
Other women had completed an uneventful pregnancy only to deliver a stillborn baby.
For many parents this loss was their first experience of death. The care of those
who experience pregnancy loss varies greatly and support has been shown to make a
dramatic and lasting difference (Rajan and Oakley 1993). Women in Rajan and Oakley's
study felt a need for more information from doctors and for continuity of care. Also
revealed was the need to be allowed to grieve in an emotionally-supportive
environment. The fact that they experience awkwardness and a lack of understanding
among relatives and friends requires that health care professionals do not appear
unsupportive. Moreover, this study revealed that an appreciable difference in
women's self confidence, and feelings of control over their lives which helped them
cope in a subsequent pregnancy could result from midwives providing non-directive
support. Although women entering the CF trial who had experienced infant loss felt
they had recovered sufficiently to embark on another pregnancy, many stated that
attending the booking clinic reawakened feelings of grief.
Some women were still adjusting to a loss or experiencing feelings of insecurity about
the future of their subsequent pregnancy which one woman described:
"Well they said the chance ofsomething like this (stillbirth) happening again
woxdd be very slight if any at all - but I think about it - I worry
about it happening again."
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Women who had experienced an unsuccessful pregnancy reported feeling a need to
have another baby: "to reaffirm" as one woman stated, "my ability to bear a healthy
child."
A number had experienced therapeutic termination of pregnancy for fetal abnormality.
Julie, a 21 year old and her husband had greatly felt the loss of their first baby at 19
weeks gestation when spina bifida was detected by maternal serum alpha-fetoprotein
screening. A 35 year old couple who had 3 healthy children, had also experienced a
therapeutic termination in their previous pregnancy when a fetal chromosome
abnormality was detected. Both couples viewed the prospect of amniocentesis as
a necessary and indeed welcome procedure to help ensure a healthy child but, as
Julie and her husband stated:
"It changes your experience of pregnancy - you don't want to tell people
just in case."
The reluctance to disclose a pregnancy that may end in abortion has been revealed in
other studies. (Rothman 1988). Women reported a reluctance to wear maternity
clothes and kept their pregnancy 'private'. More disturbingly she found many women
who underwent fetal diagnostic procedures were unwilling to form an attachment
to their pregnancy. The trauma for these women when ultrasound scan visibly
confirms the existence of their baby makes their denial more difficult and so they battle
with their own instincts.
On a positive note, ultrasound scan offers reassurance to women feeling anxious about
the viability of a pregnancy. One woman who presented with a positive threshold
GHQ had suffered a perforated uterus following dilatation and curettage for a blighted
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ovum. Having seen the fetus on the screen had reduced her anxiety and she expressed a
rush of relief to the researcher afterwards:
"Ifeel so much better!"
Thirteen per cent of women cited an unplanned pregnancy as the primary cause for
their psychological disturbance. Sarah, a 21 year old student explained:
"I'm feelingphysically fine but I've been getting a lot offlakfrom my parents.
I'd been travelling around the world and then came home to go to university,
so my parents thought I'd finally settled down - then Igot pregnant!
My mother isn't speaking to me and can't understand why I don't want to live
with the father of the baby."
A strained relationship with either the father of the baby or parents caused two per cent
of women to present at the booking clinic with a positive threshold GHQ. A further
five per cent stated this same circumstance as a secondary reason for their
distress. For example, twenty eight year old Doreen had 3 live children and had
experienced 6 spontaneous aboitions. She wished to terminate her 13 week unplanned
pregnancy. She stated she was "struggling with a 1 year old son who has a food
allergy, is sick a lot and doesn't sleep at nights. " She felt tired, irritable and ambivalent
about the pregnancy. Her husband was opposed to abortion for the reasons Doreen
had outlined but would countenance abortion for fetal abnormality. This couple were
in agreement about undergoing all prenatal screening tests and perhaps Doreen
perceived prenatal screening as a possible route to abortion.
Four per cent of women stated that having an active child at home was causing them
to feel stress. It was a more common secondary reason cited by 9 per cent of women
who submitted a positive threshold GHQ (data not shown). Having a child under the
age of five years was found in one study to be the most important adverse influence on a
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woman's mental health; more important than employment status or social class.
Although young children had a profound effect on the mothers psychological
health there was no significant effect on their physical health (Elliott and Huppert
1991).
This study commenced in 1991 and coincided with the Gulf War. Wives of soldiers
from a nearby barracks booked to have then babies at the hospital. A number were
anxious about their partners. Freda, a 23 year old felt bitter about her involuntary
separation from her husband:
"Rick was sent out at the end ofJanuary and Igot word the day Ifdled in
the questionnaire that he won't be back until the end of this month. I
feel really depressed about it - it's the third time we've been separated."
Two per cent ofwomen were suffering from an existing illness. Karen, had myocarditis 5
years ago (4 months after the birth ofher first baby). Since then she had suffered from
myalgic encephalomyelitis (M.E.) and had recently experienced a relapse:
"Ifeel absolutely shattered - I have to get other people to do things for me. I
want the CF test because I couldn't cope ifI had a baby with CF."
Women experiencing stress frequently stated they found it easier to express their feelings
by completing a GHQ and feeling encouraged to divulge their concerns during the
interview. The SRT was particularly well received. Women said it helped them to
formulate their feelings which some perceived as fiighteningly unique. One woman said:
"I thought I was going mad - it's such a relief to realise that others mustfeel the same."
Another expressed her relief in the following terms:
"Having myfeelings put into words - you know they exist - it's okay tofeel them."
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The psychological measures gave women a licence to admit feeling symptoms of stress
and an opportunity to analyse and express how they felt. The pregnant woman may feel
controlled by her pregnancy and not in full control of her life. A common occurrence
was for women to present with a positive GHQ but subsequently submit a low SRT
score. One reason for this may be that the GHQ acknowledges that women may feel
stress during pregnancy and this they find reassuring. A second reason may be that
talking to either the midwife or researcher helped decrease the focal stimulus.
Psychological assessment on all women screened served not only to ensure for the
purposes of this study that there was no significant difference between carrier and
control subjects at the outset, but proved valuable to the genetic nurse in the wider
screening trial.
This study has shown that identifying a woman as a CF carrier during pregnancy
does provoke a stressful response both in her and her partner. In 53 per cent of
cases the identified carrier showed a significant increase in generalised psychological
disturbance, specifically anxiety and depression, compared to 27 per cent of controls.
This reaction occurred in response to learning of their carrier status and lasted
for the period (approximately four days in this study) awaiting their partner's test
result. It is likely that these women were responding to feelings of threat to the fetus
resulting in anxiety, and to feelings of loss for a normally progressing pregnancy
resulting in symptoms of depression. One carrier described her feelings thus:
"My husband kept telling me that statistically the odds were in ourfavour but
I was convincing myself that Iwouldprobably end up having to have a
termination. I think I was simply preparing myselffor the worst."
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On receiving their partner's negative test result the distress subsided to control levels and
remained there at all the other assessment points. Although the longer term effects are
unknown, 12(19%) carriers from this study have subsequently embarked on a further
pregnancy.
Previous studies on patients undergoing prenatal screening have indicated that once a
woman perceives her pregnancy has been threatened she continues to be concerned
(Tabor and Jonsson 1987). The results of this study have shown a dramatic return to
normal once a negative result is given. This corresponds with the other studies (Fava et
al 1983; Burton et al 1985b; Tsoi et al 1987b). A probable reason for this is that
stressful events may have a negative or positive consequence (Lennon 1989). Being
identified as a CF carrier in the context ofpregnancy implies a threat to the fetus. When
the male partner receives a negative test result this is likely to be perceived as a
positive consequence regardless of the residual risk to the fetus. Thus restitution
ensues in the majority of cases. However, stress occurring during ongoing difficulties
may cause delay in restitution (Goldberg and Huxley 1992) as experienced by 5 carriers
who cited the presence of other life events as the major cause of their continuing
psychological disturbance (Table 6.11).
Women who perceived their carrier risk correctly were less likely, though not
significantly so, to present with a negative GHQ1 at the time of receiving their carrier
result. This may reflect a more realistic perception of their partner's carrier risk.
Previous studies suggest that women frequently accept prenatal screening tests to be
reassured and are subsequently shocked when they receive a positive test result
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especially when they did not consider themselves to be at high risk (Farrant 1985; Tsoi
et al 1987b).).
Prospective anxiety about the screening test had no significant effect on carrier's
GHQ1 scores at the time of receiving their positive test result. Women who had felt
reassured about screening were as likely to manifest signs of psychological disturbance
on learning they were a carrier as those who had felt anxious about being screened. The
long term psychological impact on those receiving a positive carrier test result is as yet
unknown. Loss of self-image and feelings of stigmatisation have both been cited as
possible aftermath of heterozygote genetic screening (Kenen and Schmidt 1978).
Will carriers view themselves as flawed? A number of empirical studies, mostly
associated with Tay Sachs carrier screening, indicate that few individuals feel
stigmatised or suffer a loss of self image on learning of their carrier status (Childs et
al 1976; Clow and Scriver 1977). Despite the entity of 'gene carrier' being a normal
fact of life it is likely to take time for the public to recognise this (Burn 1993). The
dangers of public misinformation leading to stigmatisation are recognised (Goflman
1963). Indubitably, the consequences of this are conveyed clearly in the following text
originating from a survey of genetic counsellors and nurses' views of CF screening in
in The United States:
"Carrier screening can be a loaded gun; just this week one ofour patients learned
he was a carrier of the delta F508 mutation and his fiancee broke off their
engagement. Now not only has he been dealt the bad news of being a
carrier, his personal life is in a shambles and we have spent a great deal of
time addressing his feelings of guilt, anger and betrayal."
(United States, Office of Technology Assessment, 1992b)
In contrast to male partners, SRT inadequacy subscores among carriers and their
controls failed to detect a difference at any of the assessment points. A central theme
throughout the trial during the pre-screening information and counselling stage and in
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counselling carriers and their partners was the harmlessness of the single gene carrier
state. Both verbal and written information given to carriers emphasised that they were
no different from anyone else; that every individual carried altered genes; and that their
health would not be affected. Nonetheless, follow-up will be required to evaluate if there
are longer term consequences resulting from a woman learning ofher CF carrier status.
Unlike most prenatal screening tests the CF carrier test involves the male partner. At the
first antenatal visit an ultrasound scan allows the father early visual confirmation of the
pregnancy which can initiate emotional involvement in the pregnancy (Pratt 1990).
Pregnancy is a time when men too experience stress (Condon 1987). Thus it
was considered important that this study focus on measuring the psychological
impact of prenatal CF carrier screening on partners as well as carrier women. Male
partners manifested symptoms of anxiety and inadequacy during the period
awaiting their test result, but this disappeared on receipt of a negative test result.
Both partners and male control subjects were significantly more likely to
manifest psychological disturbance if their female partner was distressed. Condon
(1987) studied the psychological and physical symptoms experienced by men and
women during pregnancy. He found that fears about fetal abnormality was a factor
which caused both sexes to manifest psychological symptoms. Marital insecurity was a
factor which caused males alone to manifest both psychological and physical symptoms.
Two men submitted positive GHQ scores throughout the CF study and both
subsequently separated from their partners. As a result, one partner did not complete a
GHQ 4 measure.
Almost without exception couples asked why they could not have been screened
together at the time of booking to avoid awaiting the male partner's test result. Most
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thought that on balance being given the test result prior to the counselling session
was the correct procedure. One male partner voiced his opinion thus:
"It gave us time to talk and come preparedfor the counselling session Ifeel it
woidd have been a less productive meeting ifyou had only revealed the result
at the time of the counselling session, whereas blowing in advance
allowed us to think about what we wanted to ask - read the leaflet again."
Genetic technology is making great leaps and it may only be a matter of time before it
becomes possible to screen the population for other genetic disorders. Individual and
social pressures to participate in screening programmes are considerable and a majority
ofwomen accept screening. There is a need for midwives to be able to assess and cope
with the psychological effects induced by these tests in the context of pregnancy. This
study has shown that for couples where the woman is identified as a CF carrier and her
partner receives a negative test result the problems are minor and short lived. But, if a
woman were to receive several positive screening tests during a pregnancy it could all too
easily become a major focus for a considerable period. The need for midwives to
appreciate and respond to the psychological needs of mothers undergoing these tests,
is as great as the woman's need for them to be met.
A crucial question was whether women and their partners would feel on hindsight that
pregnancy was a legitimate time to offer CF carrier screening and whether they had
regrets over their decision to be screened. The decision to be screened could be affected
by the way the test was offered, the accuracy of the information conveyed by the
midwife, and her ability to do so in a way that is easily understood. The knowledge and
attitude of carriers and their partners compared to selected controls was assessed. The
results of this study will be presented in the following section.
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6.4 Question 4: Do carriers and their partners understand the essential
facts concerning CF carrier screening and what is their attitude toward
having been screened?
6.4.1 The sample and methods
Between May 1991 and December 1991 a total of 69 women were identified as CF
carriers through a prenatal screening trial. In all cases the male partner was screened.
Three couples were identified where both partners carried a CF mutation and these were
excluded from this study. In one case the pregnancy did not continue and one couple
failed to complete the questionnaires. A further exclusion was a male partner who
expressed reluctance to enter the study, however, his carrier partner wished to
participate. A total of 64 carriers and 63 partners completed questionnaires.
Two control subjects were selected for each carrier. The controls had attended the
same booking clinic as the carrier, were of the same parity and had received a negative
test result. The male partners of these female controls were also invited to participate
in the study, and served as controls for the partners of carriers. In all 116 female
controls and 115 male controls agreed to take part, of whom 13 did not respond to
the questionnaire, while a further two couples had pregnancies which failed to
continue. A total of 101 female controls and 100 male controls completed the
questionnaires.
With their booking clinic appointment all antenatal patients attending the hospital
received a leaflet outlining the aims of prenatal CF carrier testing and describing the
screening procedure. The leaflet stated a population carrier frequency of 1 in 25 and
explained that carrier couples had a 1 in 4 risk of an affected child. The mode of
inheritance of CF was described in diagrammatic form The leaflet emphasised that a
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family history of CF was not a prerequisite to being a CF carrier. Care was taken to
stress the fact that being a carrier was unimportant unless the partner was also a carrier.
Women identified as CF carriers were invited to attend the hospital with their partner for
counselling. An additional leaflet was given to all carriers and their partners reiterating
in more detail the pre-screening information. This leaflet gave the risk of a carrier's
siblings also being carriers; recommended that relatives should be screened prior to
pregnancy; and advised on how relatives could initiate screening. Male partners received
their test result after an average of 4 days. Six weeks after screening carriers and their
partners were sent a "facts and feelings" questionnaire by post with a stamped addressed
envelope for return.
Socio-demographic data was obtained from women's antenatal records. Questionnaire
data was entered into a computer data-base for storage and analysis. Significance of
results was assessed by the Chi-squared test.
6.4.2 Presentation of data
6.4.2.1 Characteristics of study population
Socio-demographic data is shown in Table 6.16. There were no significant differences
between carriers and controls or between male partners and their respective controls in
any of the factors examined.
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Table 6.16 Characteristics of study population: carriers, partners and controls
Carriers Controls Partners Controls
n = 64 n = 101 n = 63 n = 100
Age (years)
mean 27-86 28-64 28-13 30-38
range 18-44 20-40 18-46 20-48
Parity
primiparous 35 (55%) 52(51%)
multiparous 29 (45%) 49 (49%)





married 48 (74%) 82 (81%) 48 (76%) 82 (82%)
single 14 (22%) 16(16%) 15 (24%) 17(17%)
divorced 0 3 (3%) 0 1(1%)
separated 1 (2%) 0 0 0
widowed 1 (2%) 0 0 0
total 64(100%) 101 (100%) 63 (100%) 100(100%)
Social class
1 5 (8%) 11 (11%) 6(10%) 11 (11%)
2 ■ 18(28%) 31 (31%) 16 (25%) 31 (31%)
J 23 (36%) 36 (35%) 22 (35%) 36 (36%)
4 10(16%) 16 (16%) 9 (14%) 16(16%)
5 4 (6%) 3 (3%) 3 (5%) 3 (3%)
student 0 1 d%) 0 1 (1%)
unemployed 4 (6%) 3 (3%) 7 (11%) 2 (2%)
total 64 (100%) 101 (100%) 63 (100%) 100 (100%)
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6.4.2.2 Facts Questionnaire
There were six questions in the " facts" questionnaire. Tables 6.17 and 6.18 show the
questions along with the responses. The correct response is highlighted.





















2 A couple can have a child with CF if:


































4. Even if you have no family history of











5. If both partners carry a single CF gene
their chance of having a child with CF
is: a) 1 in 2
b) 1 in 4
c) 1 in 20

















Chi squared test on case versus control: *p = <0-01, fp = <0-001
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Question 1 generated an unexpected range of responses which suggested ambiguity
which had not become apparent in the questionnaire pilot study.
Responses to question 2a indicated that overall there was a good understanding ofhow
CF was inherited. Carriers and male partners who answered "true" to this question
added comments which revealed that the false negative rate of the test had influenced
their response. During counselling carriers and their partners were told that if the
male partners test result was negative they still had a residual risk of 1 in 640 ofhaving a
CF child. This information was also reiterated in a letter reporting the partners test
result and in the patient information leaflet.
Question 2b showed the controls of male partners to be significantly more likely to
misunderstand the inheritance of CF (Table 6.17). There was no difference in the
proportion of male partners and their controls who had read the pre-screening
information leaflet (71% and 72% respectively) as analysed in the pre-screening
questionnaire (Section 6.1). However, an unknown number of males would have
attended the antenatal clinic and may have benefited from pre-screening information
and counselling from a midwife. Male partners, in addition, had undergone genetic
counselling and had been given a further detailed information leaflet.
Both carriers and their male partners were significantly more likely to know the
population carrier risk than their respective controls (Table 6.17 question 3). In
counselling of carriers and their partners the population carrier frequency was
emphasised because it equated with the partner's risk ofbeing a carrier.
It was encouraging to find from the response to question 4, that the vast majority of
subjects were aware that a family history was not a pre-requisite to being a carrier.
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Responses to question 5 showed that male controls were significantly more likely than
male partners to be mistaken about the risk of a carrier couple having an affected child
(Table 6.17 question 5). Fourteen percent thought the risk was substantially lower (1 in
20) than the actual risk (1 in 4). This may reflect the absence among a number of male
controls of pre-screening counselling received by their female counterparts at the
booking clinic.
A particularly encouraging response was obtained to question 6 (Table 6.18) which
indicated that, almost without exception, all subjects understood correctly the
significance of carrying a single CF gene.
Table 6.18 Percentage response to "facts questionnaire" question 6
Carrier Control Partner Control
Question n = 64 n = 101 n = 63 n = 100
1
If you carry a single a CF gene this true false true false true false true false
means:
a) your health will be affected 0 100 0 100 0 100 1 99
b) you will develop the disease CF 0 100 1 99 0 100 2 98
c) it is only important if your partner
carries a CF gene
100 0 96 4 100 0 93 7
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6.4.2.3 Feelings Questionnaire
Carriers were significantly more likely than their respective controls to feel that the
information given at the antenatal clinic was insufficient (Table 6.19 question lb).
Table 6.19 Percentage responding to "feelings questionnaire" question 1
I feel that the information I / my partner was given about the CF carrier test
a) before the antenatal clinic b) at the antenatal clinic was: 'about right,'
'too much' or 'not enough.'







earners n = 64 63 2 35
female controls n = 101 65 0 35
partners n = 63 62 2 36
male controls n == 100 54 0 46
b) at the antenatal clinic
earners n = 64 75 2 23 t
female controls n = 100 88 0 12 f
partners n = 63 87 2 11
male controls n = 99 87 2 11
Chi squared test on cases versus controls, t p =<0'001
A substantial number ofmale partners and their controls felt they had not understood the
nature and purpose of the test before their female partner was screened (Table 6.20
Question 2).
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Table 6.20 Percentage responding to "feelings questionnaire" question 2






earners n = 64 70 30
female controls n = 101 83 17
partners n = 63 54 46
male controls n = 100 60 40
Carriers were significantly more likely than their controls to have ambivalent feelings
about having been screened (Table 6.21 question 3).
Table 6.21 Percentage responding to "feelings questionnaire" question 3





carriers n = 64 80 20 f
female controls n = 101 97 3 t
partner n = 63 90 10
male controls n = 100 98 2
Chi squared test on cases versus controls, f p = <0-001
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Three carriers regretted having been screened and two had partners who felt similar
regret. Notably, these two male partners submitted positive GHQ 1 scores and high
SRT scores (SRT total = 48 and 38 respectively) Their scores were above those of
their particular female partners. One carrier who expressed regret had a partner who
stated he was " glad " she had been screened. Interestingly he, unlike the other two
partners, submitted a low SRT score (SRT total = 7). Ten women answered "don't
bicrw" to question 3 of whom seven had male partners who stated they were "glad"
they had been screened. Only one of their male partners expressed regret that his wife
had been screened and a further two male partners felt ambivalent. Despite this, 88 per
cent of carriers still felt that the screening test should routinely be offered to pregnant
women (Table 6.22 quest 4).
Table 6.22 Percentage responding to "feelings questionnaire"question 4
I feel that the CF carrier test should routinely be offered to pregnant women
Yes
%
No / don't know
%
carriers n = 64 88 12
female controls n = 101 96 4
partners n = 63 94 6
male controls n=100 94 6
There was strong support for carrier screening in family planning clinics and GP
health centres but less enthusiasm for screening in schools (Table 6.23 question 5).
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Table 6.23 Percentage responding to "feelings questionnaire" question 5
I feel that I am in favour of testing for CF carriers in: a) schools,
b) family planning clinics c) GP health centres
Schools Family planning GP health centres
clinics
% % %
earners n = 64 30 86 89
female controls n = 101 36 89 93
partners n = 63 32 81 87
male controls n = 100 38 81 89
Asked who they would tell if they found they carried a single CF gene, revealed that
carriers and their partners were significantly more likely than their respective controls to
tell their siblings and their children (Question 6.24 question 6).
Table 6.24 Percentage responding to "feelings questionnaire"question 6













carriers n =64 100 92 f 92 f 59 45
female controls n =101 100 78 f 78 f 53 31
partners n = 63 100 79 f 87 49 30
male controls n = 100 100 63 f 79 34 22
Chi squared test on cases versus controls (agreement / non agreement); f p = <0-05
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6.4.3 Discussion
This study attempted to assess two important aspects of prenatal screening for CF
carriers; the understanding by the participants of the essential facts concerning CF
carrier screening and their feelings about the delivery of screening information and
having agreed to take part. The four groups involved had rather different access
to information and also different experiences of the programme. Carriers and their
partners would be expected to be more motivated in their attempts to acquire,
comprehend and retain information.
Both carriers and their partners had been counselled in one-to-one sessions with a
genetic nurse and had received additional written information. In contrast, the two
control groups would have derived most of their knowledge from the information
leaflet sent out at the time of their booking appointment, two to three months before
they completed the "facts and feelings" questionnaire. Female controls received pre-
screening counselling delivered by a midwife at the booking clinic but their male partner
would only have done so if he had attended the clinic with her. It is therefore gratifying
that in some sections of the "facts" questionnaire, all four groups had near maximum
scores. This was seen in the response to whether it was possible to carry a CF gene if
there was no family history of the disease (question 4, Table 6.17) and in response to
the question about the effect ofbeing a CF carrier on general health (question 6, Table
6.18).
Concern has been raised that being a carrier of a recessive gene may cause an individual
to have a less positive view of his or her health (Marteau et al 1992b). In a study
involving 27 carriers of the recessive gene that causes Tay-Sachs disease, 55 non
carriers and 52 people who had not been screened, carriers were found to view their
future health less optimistically than the other two groups. Prior to screening most
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individuals do not consciously consider that they might carry any abnormal genes
and take for granted that all of their genes are functional. "A new dimension to
personal self has been actualised which may be perceived as defective, and for which
no previous allowance in self and family concept existed" (Antley 1976 page 112).
Three of the four groups had an excellent idea of the risk of having a child with CF
when both partners carried a mutant gene (question 5, Table 6.17). However, even
though controls of the female carriers were well informed on this point, the male
controls of their partners proved fallible. One reason may be that not all partners read the
pre-screening leaflet (71% partners of carriers and 72% of male controls). A second
reason is that whereas the partners of carriers received genetic counselling and a
more detailed information leaflet, their male controls did not. Thirdly, male controls in
contrast to the male partners had no reason to perceive themselves at risk and feel
the need to understand the consequences of screening.
The fact that controls scored poorly in comparison to cases in the question about the CF
carrier frequency in Britain (question 3 table 6.17) is not surprising. During
counselling and in the additional information leaflet given to carriers and then partners
this figure was stressed for two reasons. Firstly, to put the partners carrier risk into
perspective and secondly, to emphasise the "normality" of the carrier status: "Lots of
us are CF carriers - 1 in 25 people." Nonetheless, the first sentence of the pre-
screening information leaflet stated that: "One in every 25 men and women carry a
single cystic fibrosis gene." A similar finding was reported by Watson and colleagues
in a CF carrier screening trial delivered through primary health care services (Watson et
al 1992)
Responses to the "facts questionnaire" served also to evaluate the information leaflet.
Approximately 40% of all groups thought the statement "any couple can have a child
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with CF to be true (question 1, table 6.17 Although the leaflet showed in
diagrammatic form that each partner had to be a carrier in order to have a child with CF,
it also emphasised the incompleteness of the screening test: " testingfor the CF gene
is still only successful in 85% of cases Thus in a literal sense the statement is true,
even though we expected respondents to find it false. This illustrates how easy it is to
introduce ambiguities into a questionnaire and to fail to inspect in detail the content of
printed information issued to patients.
From the "feelings" questionnaire, it would seem that there is a desire amongst all four
groups for more information on the carrier test before attending the antenatal clinic
(question la, table 6.19). During the designing of the information leaflet a study was
carried out to assess the needs of the target population. Fifteen per cent of women
thought the pilot leaflet should give more information and a further 11 per cent
stated they did not know if additional information would be helpful. Of those who
wished more information a majority indicated that more details about the disease CF
was needed. A conclusion of that study was that regular evaluation of patient
information leaflets would continue to be a basic requirement of the screening
programme and that periodically the target population should be questioned about the
acceptability of the information leaflets issued to them.
There was a significant difference between carriers and their controls in feelings about
whether enough information had been supplied at the antenatal clinic (question lb,
table 6.19). Clearly considerable care is required to ensure women and their partners
understand the nature and reasons for undergoing a particular prenatal test. From
previous studies it is apparent that women commonly show quite major gaps in theft-
knowledge of prenatal screening tests. (Donnai et al 1981; Faden et al 1985; Marteau et
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al 1988a). In Donnai's study 12 women who had undergone therapeutic termination of
pregnancy for fetal abnormality were found in most cases to have understood the reasons
for the termination, however, a minority remained in doubt about the precise indication.
A much larger proportion of men than women did not feel that they knew what the CF
test was all about before either they or their partners were tested (question 2, table
6.20). Again this may reflect the fact that approximately 30 per cent of men did not
read the pre-screening information leaflet (section 6.1 figure 6.5 page 135) and an
unestimated number did not attend the booking clinic. Moreover, the leaflet invited
women to be screened not their partners, therefore males may have perceived themselves
to be at less risk.
A large majority of all four groups were apparently glad that they or their partner had
been screened (question 3, table 6.21). The only ambivalence appeared among carriers
themselves. The stress experienced by receiving a positive CF test result influenced the
attitude of 13 (20%) carriers among whom 3 women indicated they were " not glad "
to have been screened and the remaining 10 answered " don't know." (question 3 table
6.21). Each of these carrier women scored positive on the GHQ1 at the time of
receiving their positive test results, and 8 continued to score positive on the GE1Q2, at
the time of receiving their partner's negative test result. Positive GHQ results were
submitted throughout the study by two of these women for reasons of recent
bereavement one case, and attacks of breathlessness, one case. A further two women
decided against maternal serum alpha-fetoprotein screening because of the stress
experienced in undergoing CF carrier testing. Exactly how carriers perceive their newly
discovered genetic status was not explored. Interviews would have perhaps gleaned a
better understanding of women's attitude to this aspect of screening because nuances
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such as quality of feelings and emotional overtones often emerge which cannot be
conveyed by a questionnaire (Reynolds 1974).
It is interesting that despite 20 per cent of carriers indicating either regret or
ambivalence about having been screened, only 12 per cent implied a similar view about
routinely offering the test to pregnant women. There seems a considerable tolerance for
the timing of the CF carrier test, with high proportions of all four groups feeling that it
should be routinely offered in pregnancy. Screening through family planning clinics and
GP health centres were supported by the majority of groups. There was less
enthusiasm for screening in schools in contrast to other studies in which this was cited
as a popular option (Green 1992; Zeesman et al 1984). However, the consequences of
screening in any one of these situations and the decisions and actions which might
emanate were not outlined to participants, therefore, they may not have
considered these when responding.
Some are of the opinion that divergent approaches to carrier screening are likely to be
complementary (Burn 1993). The evidence from previous genetic screening programmes
is that the antenatal booking clinic are likely to be the ultimate option because
patients and physicians frequently regard genetic screening as part of reproductive care
rather than reproductive decision making (Shapiro and Shapiro 1989).
All respondents stated that they would tell their partner if they turned out to be a CF
carrier (question 6, table 6.24). Carriers and their partners were more likely to tell then-
siblings, children, other relatives and friends about being a carrier than were then-
respective controls. This finding is likely to be as a result of the one-to-one counselling
sessions with the genetic nurse during which a family pedigree was drawn out and
risks to siblings explained, hi addition the information leaflet issued to carriers outlined
the screening procedure for relatives.
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Data concerning the number ofmale controls who attended the booking clinic was not
collected making it impossible to assess whether this influenced knowledge and
comprehension. Nonetheless, the response from this group was extremely encouraging
with a majority answering the questions correctly. Criticism has been levelled by male
partners at the apparent lack of interest taken in them by obstetric staff (Jordan 1990).
The high level of comprehension by this group perhaps reflects the fact that the CF
test could potentially involve them and accordingly they were interested. It may also
support the concept that people accept preventive measures when they perceive the
disorder as serious, their being susceptible and that there are benefits (Childs et al 1976).
This study has shown that firstly a simple carefully designed leaflet can be one
effective way of communicating essential facts about prenatal screening, especially when
it is supported by counselling by a midwife. Both the leaflet and counselling had been
issued several months before the control subjects answered the questionnaire. Although
all female controls were also given a great deal of information on a variety of topics
during the booking-in procedure, in both verbal and written form, they apparently
retained and imderstood most of the information on CF carrier screening.
Although all four groups in this study had a favourable attitude toward CF carrier
screening in pregnancy such screening needs to be accompanied by educational
endeavour and sensitive application. All four studies presented in this thesis show how
genetic screening generates a complex range of ethical issues which confront
individuals, families and professionals. These and other aspects essential to the
judicious and sensitive application of prenatal CF screening by midwives are explored in






A strength of the research carried out in this thesis lies in the large sample size which
helped to clarify women's perceptions of screening and to quantitatively analyse their
responses in relation to a new prenatal screening test. The integration of qualitative and
quantitative research methodology enhanced the validity of the study findings by adding a
perspective that numbers alone could not have provide. Qualitative research clarified
important concepts through the exploration of pregnant women's individual perceptions
and personal reactions to the offer of prenatal carrier screening for CF. While facts and
figures were provided, the main concern was to convey the feelings, concerns and
experiences of women exposed to a recent development in medical technology and to
look beyond and consider the implications for midwives. At a time when midwives are
extending their skills to implement continuity of care which will facilitate the full
involvement of mothers in exercising choice (Scottish Home and Health Department
1993), the findings of the research presented in this thesis are especially germane. "The
motive for carrying out nursing research is not just to gain knowledge but to influence
what is practiced as a result ofwhat is learned" (Abbot and Sapsford 1992 p viii).
As additional prenatal screening tests become available and as society grapples with the
increasingly complex questions raised by the new techniques which provide the means
for these tests, individual women and couples are left to make their own particular
decisions. The findings in this thesis suggest that around 30 per cent of the women rely
upon the midwife to help them decide whether or not to be screened. Midwives are
confronted by ethical issues relating to the care of mothers and their babies at all stages
antenatal, intranatal and postnatal, but the new technology which facilitates an increasing
number ofprenatal screening tests poses yet more potential ethical dilemmas. To attempt
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to identify and explore all the ethical issues relating to prenatal screening is not possible in
this text. There are, however, a number of ethical considerations which thread through
the whole screening procedure and warrant exploration.
7.1 Ethical aspects of prenatal screening for CF carriers
Ethical issues in relation to genetic screening have been reported by the Nuffield Council
on Bioethics (1993). The report bases a considerable amount of its findings on
published excerpts from the results of this thesis. The committee acknowledge that
they could not hope to identify and attempt to answer all the ethical questions which
could confront individuals, families and professionals. There are additional issues
which the studies in this thesis expose and which will be addressed here. Some apply
solely to prenatal genetic screening and others are common to genetic screening per
se.
Ethics has been defined as "the study of the underlying reasons for deciding what is best
in the face of conflicting choices" (Wilday 1989 page 176). The principal reason for
addressing ethical issues raised by prenatal CF carrier screening relates to the
future care of individuals who are invited to be screened. Most research involves small
numbers of subjects which permit attention to important ethical details. Experiences
from previous genetic screening programmes show that fundamental issues such as
confidentiality, autonomy and consent can be neglected when research becomes service
(Rowley 1984; Roberts 1990). For example, public education, adequate counselling
and post-screening support are necessary infrastructures without which individuals
can all too easily misinterpret the meaning of a positive screening result (Whitten 1993).
Written consent to be screened is frequently abandoned once research becomes service.
In the hospital in which the prenatal CF carrier screening trial took place, women were
not asked for signed consent in order to undergo maternal serum alpha-
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fetoprotein screening A further concern was that the hospital leaflet outlining
MSAFP screening did not a) draw attention to termination of pregnancy as a possible
consequence of screening nor b) mention that the test could only detect 85 per cent
of pregnancies at risk of neural tube defects and 60 per cent of those at risk of a
chromosomal anomaly (Cunningham and Gilstrap 1991).
The aim of this discussion, about ethical issues raised by the research findings presented
in this thesis, is to highlight a number of ethical problems posed for midwives and for
the women they care for in relation to prenatal CF carrier screening. Questions will be
raised rather than necessarily answered.
7.1.1 To screen or not to screen
"Cystic fibrosis illustrates a moral paradox within medicine which on the one hand seeks
to screen and eliminate through abortion and on the other to treat and cure"
(Elborn 1991 page 40). Current treatment for CF and improving life expectancy,
coupled with the possibility that gene therapy may also improve the quality of life of
sufferers, leads to the argument that financial resources should be directed toward
therapy rather than carrier screening programmes (Elborn 1991). Conversely,
screening could be justified on the grounds that gene therapy is likely to be expensive,
and that lowering the incidence of CF could directly benefit surviving sufferers by
reducing the total number who stand to benefit from therapy. In the final analysis the
relative benefits and risks of gene therapy compared to the burden and prognosis of
the disease may determine the future of screening.
A response to population genetic screening is that it could cause the public to view CF as
a disease which should disappear and, therefore, they might consider targeting money
toward better treatment inappropriate (Wilfond and Fost 1990). Do the results of
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the studies in this thesis help answer the question: should society choose therapy
in preference to screening?
Participants in the prenatal CF screening trial chose to undergo prenatal carrier
testing for a variety of reasons (Chapter 6, page 149, table 6.6). Sixty two per cent of
women wished to be screened to find out during pregnancy if the baby had or was at
risk of having CF. Of these women 55 per cent were not pursuing the option of
terminating an affected pregnancy, indeed 10 per cent clearly stated that their reason for
being screened was to prepare for the birth of an affected child. These women gave
testimony to prenatal screening being perceived as of significant benefit to mother
and child, even when the detection of an abnormality would not lead to termination of
pregnancy.
One woman explained:
"As I understand the severity of the disease, I would like to know whether my
child or future children were at risk and even if I decided against
termination I would be mentally preparedfor a child with CF."
The worry of fetal abnormality can place a significant psychological burden on those
who have experienced it in a previous pregnancy:
"I really want to kriow more about the baby I am expecting. My previous baby
died at 3 days with an abnormality of the heart. "
An argument in favour of detecting a fetal condition prenatally is to allow perinatal or
neonatal medical intervention which would benefit the infant (Clark and De Vore 1989).
Ten percent of infants with CF are born with meconium ileus, a life
threatening condition requiring prompt neonatal therapy (Goodchild and Dodge 1985).
Yet, there is another very obvious direct benefit; the psychological and practical
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preparation of parents for the birth of a child with special needs. As yet no studies
have been carried out to reveal if there are measurable short and long term benefits to
parents, affected children and unaffected siblings in families where the results of
prenatal screening and diagnosis facilitate anticipation of a child with special needs. But,
evidence suggest that women and their partners connect prenatal screening for CF with
preparation for the birth of a child with special needs. A study of 135 couples who
accepted prenatal CF carrier screening revealed that 91 (67%) felt that gene therapy
would not influence their decision to be screened. Equal numbers, 21 (16%) couples
stated they would either decline to be screened or felt ambivalent toward screening. Even
if the life expectancy of CF sufferers increased to normal 78 per cent stated that they
would wish to avail th emselves ofprenatal CF carrier screening (Mennie et al 1994). The
desire to have information abut the baby before birth is a compelling reason for being
screened. As one couple stated:
"We think we would still opt to be testedfor CF even ifgene therapy was
available. Our reasonsfor having the test would be different though. If the
quality of life and extended life expectancy could be improved, the
question ofwhether or not to continue the pregnancy would no longer
be a consideration, rather that when the child was born we would be
preparedfor it to be ill and have to undergo treatment. This would be
much less distressingfor parents than finding out after the birth."
Although the primary goal of a screening programme is often perceived as a means to
promote informed choice and to prevent suffering whether it be physical or psychological.
It should never be organised in such a way that the birth of a CF child is seen as a
"missed prevention" (Van den Berghe 1987) or as the result of irresponsible
reproductive decisions (Wilfond and Fost 1990). The midwife can ensure that women
understand that they will not experience coercion to end a pregnancy at risk of a child
with special needs. There is a danger that screening may foster the attitude that a less
than perfect fetus should be prevented (Curry 1994).
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A further concern revolves around the potentiality of genetic screening becoming a
women's issue (Chappie 1992). Because new developments in health care depend upon
financial resources it may prove impossible to fund screening to the extent that it could
be offered to all sections of the childbearing community. If some form of rationing were
to be necessary then an obvious screening strategy would be a prenatal approach. This
could be argued on the basis that outwith pregnancy money could be spent on screening
individuals who may never use the information. If, however, screening were to focus on
pregnant women it could put both the burden of responsibility for genetic disease and the
emotional costs of screening on their shoulders. Thus choice should not simply involve
whether to accept or decline the offer of CF carrier testing but when the offer is made.
7,1,2 Physician versus patient perception of screening
Clearly some women perceive prenatal screening as a means whereby they can prepare
for the birth of an affected child. Immediately, this raises issues concerning physician
versus patient perception of prenatal testing. Among obstetricians there are those
who hold the view that it is inappropriate to carry out a risk associated procedure
such as chorionic villus sampling or amniocentesis in a continuing pregnancy.
They may advocate discouraging a couple opposed to termination from pursuing
this option (Crawfurd 1983; Thorp and Bowes 1989). Now this could arguably place a
midwife in a delicate situation. Given that prenatal CF carrier testing is presented to
women by the midwife, she is placed between the patient's wishes and the obstetrician's
opinion and this situation is not without its difficulties. The midwife is not free to take
the same initiative as the obstetrician, nonetheless, she may feel she has a better
understanding of what is, or is not, in the patient's and unborn child's best interest.
While the obstetrician will look to the patient's and unborn infant's medical welfare,
the midwife may look more to their general well-being (Sutton 1990). The Royal
College of Physicians state that prenatal diagnosis should be available to women who
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are completely opposed to termination of pregnancy, "since testing may provide
welcome reassurance, or an informed choice to care for a child with a known
handicap" (Royal College Physician 1989 page 49:8.6).
In a related vein a 25 year old para 1 stated:
"IfCF is detected at this early stage, I believe it is better thanfinding out
at birth."
Regarding midwives' professional responsibility The Royal College of Midwives
(1981) state that "in making a professional judgement (the midwife must consider)
certain factors: the professional code which demands that the midwife must not
harm the mother or baby; the primary responsibility of the midwife to use her
knowledge, skill and power to promote the well-being of the mother and baby."
Some perceive the advantage of screening as its capacity to allay worry and for those
who do not gain reassurance, advance knowledge provides the opportunity to
prepare themselves emotionally, physically and financially for the challenges that he
ahead. Although there is a pregnancy loss-related risk associated with prenatal diagnostic
procedures this may seem acceptable to some couples at a 1 in 4 risk of having a CF
infant, particularly if they perceive there are potential benefits in having prior
knowledge about the status of their unborn child.
Ideally, midwives and nurses should provide information and care in unison with other
health care professionals. Clearly, there may be situations when the midwife will be
obliged to initiate discussion, to take action and to raise objections in order to
safeguard the interests of the mother and infant (Sutton 1990). Increasingly, women
themselves are demanding more attention to their emotional needs in pregnancy, which
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corresponds with "an important change in emphasis from need-led to demand-led health
care." (Holland and Stewart 1990 chapter 1, page 6).
7.1.3 Access and demand
Resource constraints
"Individuals must have the right to choose whether or not to be tested and then-
choice will depend on the provision of complete information about the test and
particularly its consequences" (Haan 1990 page 177). Patient autonomy is a recurring
theme (Hodgkin and Yoxen 1985; Kings's Fund Forum 1987; Colten 1990; Sutton 1990;
Weatherall 1991a; McGregor 1990). An individual's choice not to be screened must be
respected and no pressure exerted. Given the increase in demand and the increasing
scarcity of resources some are concerned with the question - who is entitled to
prenatal diagnosis? (Fletcher and Wertz 1992). hi other words, rather than there
being a danger of patients being coerced into prenatal screening and diagnosis
there is a danger that they may not be offered this option. Should CF carrier
screening become an established part of pre-conceptual and prenatal care? Can
regional health authorities afford to fund it? Could couples who failed to be offered
screening sue for malpractice if they had a child with CF?
The Royal College of Physicians recommend that genetic screening and prenatal
diagnosis should be equally available to the whole community as an established part of
maternity care (Royal College Physicians 1989). Yet, currently screening for fetal
abnormalities varies considerably from one area of the United Kingdom to another
(Holland and Stewart 1990). Concern has been expressed that co-ordination, organisation
and evaluation is not ideal (Holland and Stewart 1990; Cuckle 1990). A
national screening body has been proposed to correct this situation (Cuckle 1990).
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Professional ignorance.
Problems of access to screening may arise from poor organisation, limited professional
and public awareness, and severely limited technical, educational and counselling
resources. Shortcomings can be blamed to some extent on underfunding but
missed opportunities arise because basic clinical genetic knowledge is lacked by
both the medical and nursing profession (Royal College Physicians 1989). If an
available prenatal test is not offered could this be cited as a cause of damage to the fetus
and constitute grounds for litigation? The right of the child to claim damages was
accepted in the United States when parents who underwent carrier testing for Tay-
Sachs disease claimed the tests were negligently carried out resulting in their infant being
born with the disease (Sutherland 1990). However, a UK case in which a child
claimed damages on the grounds of failure of the mother's physician to advise her of the
possible consequences of exposure to rubella was rejected, on the grounds that life
resulting insevere disability was better than no life (Sutherland 1990).
Again, in the United States there was refusal to permit recovery of damages where
a woman in her late thirties failed to be offered amniocentesis resulting in the birth of
a child with Down's syndrome (Sutherland 1990).
What if a mother declines a prenatal test? Mothers have been held liable where accidental
injury to the fetus resulted from her driving a motor vehicle. In such a case the insurance
company settles the claim. However, it is difficult to envisage a child claiming damages
as a result of the mother declining the offer of a prenatal screening test. Quite simply
who would pay compensation? A more conceivable situation is that of alleged
professional negligence, resulting in failure to provide or offer a test.
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7.1.4 Issues of informed consent
Providing information
Genetic carrier screening can generate information about one individual which may well
have implications for other related family members. Therefore, consent to be screened
differs from consent to undergo an operation or other treatment. Moreover, screening is
a process usually initiated by health care professionals. Ensuring that the
information is given is not sufficient, the midwife should present it in such a way
that women and their partners can appreciate the choices, and can make a decision which
they will not regret in future. The midwives' role, in this context, can be viewed as that
of a teacher.
Currently individuals in the prenatal CF screening programme are provided with
information by means of a leaflet and a one-to-one counselling session with a
midwife. As the pre-screening study described in chapter 6.1 revealed, 40 percent of
women in the 16 to 20 year age group had not previously heard of CF (figure 6.2)
and almost 16 percent of them found the leaflet difficult to understand (figure
6.3). This was reflected hi the fact that 70 percent of this age group either
perceived their carrier risk incorrectly or had no perception of their risk (figure
6.6). It is important that written and verbal information is in a language
appropriate to the individual (Nuffield Council on Bioethics 1993). In practice the mode
of delivery may be just as important. Many young people today are perhaps more
familiar and consequently more comfortable acquiring information from videos. Studies
indicate that a videotape containing the same information given in conventional
counselling can be an effective method of providing pre-screening information when it is
followed by an opportunity to question a health care professional (Fisher et al 1981;
Rowley et al 1984). Research comparing the retention of information and appeal of
237
this method of imparting information to younger women and their partners could be
valuable.
A recent review of Down's syndrome screening in pregnancy revealed that information
provided is either not always adequate, or not retained. Consequently, women are
not always sure what tests they have undergone and what the results mean (Statham
and Green 1993). Continuing evaluation of written information, verbal information
giving and counselling should be an integral part of any genetic screening programme.
Individuals with special needs
A not uncommon problem is providing information to women who have a learning
difficulty, are deaf or blind. This problem is not unique to prenatal screening, it can pose
an obstacle to providing general pregnancy care. Nine women in the trial were excluded
because they had severe learning difficulties. The decision was made hi all cases by the
obstetrician. But who should ultimately make this decision? The problem of genetic
testing of the mentally ill and those with severe learning difficulties has been addressed
(Nuffield Council On Bioethics 1993). They state that: "it is a matter of consideration
whether genetic tests on mentally ill individuals or those with severe learning disabilities
should be permitted in situations where the information gained would be of clear benefit
to other family members." Who does prenatal carrier screening for CF benefit? The
benefit is to the mother and the child. Does an obstetrician have a right to
withhold screening? Usually a relative, or surrogate decision-maker such as a close
friend may decide. Alternatively help may be obtained through the social work
department, or a court appointed legal guardian (Meyers 1990).
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How much information should be provided
Studies indicate that women frequently enrol in antenatal screening programmes without
being fully informed about the facts and issues (Marteau and Slack 1992a). There is a
tendency, particularly during pregnancy, to sanction information which is non-
confrontational and censor that which could be construed as alarmist. For example,
during the designing of the CF pre-screening leaflet the original wording with respect to
a female carrier's partner receiving a negative test result read: "If your partner's test
result is negative then your risk of having a baby with CF is low." Obstetric staff
wished this to read: " your risk of having a baby with CF is very low." As a
compromise the word "very was not underlined! The way statements are
phrased by health care professionals about reproductive risks can influence an
individual's perception ofthe degree of risk (Shiloh and Sagi 1989).
A failing ofmany information leaflets is that they classify prenatal screening tests along
with prenatal diagnostic tests. "Tests to detect abnormalities in the baby"
(Health Education Board for Scotland 1993). It is interesting that no attempt is
made to differentiate between the two. This is indeed a pity because it might go
some way to reducing the stressful reaction which most women experience when
told they have a positive screening test result. Nowhere is it explained that a screening
test is merely an indicator to carry out a further test and not a fetal diagnostic test.
In other words a screening test does not necessarily reflect the health of the baby.
Both in writing and during verbal pre-screening information and counselling the
midwife should specify the difference between a prenatal screening test and a prenatal
diagnostic test. Between 3 and 5 percent of women will receive a positive maternal
alpha-fetoprotein test result, but only 1 in 20 of these women will finally receive a
positive prenatal diagnostic result and be faced with the decision to continue or end
the pregnancy.
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There is a danger that opportunities may be missed to educate pregnant women simply
because health care professionals are inclined toward believing that too much
information is not beneficial to the individual. Frequently it is perceived to alarm or
confuse, but pregnant women are healthy and usually highly motivated individuals keen
to learn all they can about their unborn child. All too often fear of the unknown is
the cause of anxiety and this could arguably be alleviated by additional and accurate
information.
The decision to be screened must remain that of an individual woman and her partner.
But, should the amount of information given be left entirely to the wishes of individuals
concerned, or should the midwife endeavour to impose as much information as she deems
necessary for a woman to make an informed decision? For example, some women attend
the booking clinic having failed to read the pre-screening information leaflet and show
reluctance to address the counselling offered by the midwife. Despite the midwife
emphasising the importance of appreciating the pre-screening information, some prove
resistant. Yet, should they receive a positive test result they may express regret at
having been screened.
Studies show that it is all too easy for women to receive a positive screening test
result and only then realise they did not understand the implications of the test. A recent
study on the effects of Down's screening during pregnancy reported that one woman
did not read the information leaflet explaining serum screening for Down's syndrome,
assuming it to be about screening for spina bifida (Statham and Green 1993). This study
does not state whether participants signed a consent form.
It is easy to level criticism for misconceptions of screening tests at both staff and patients.
What is required is a system which will help ensure that such problems are not
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encountered. Signed consent may offer an important contribution to ensuring
an informed decision is made about having initial screening tests.
Signed consent
There is strong argument for ensuring that a consent form is signed before any prenatal
screening test is carried out. Indeed there is good reason to propose that separate
consent be obtained for individual screening tests. Provision for this could be made in a
booklet which outlined each screening test, and included separate consent forms for
each. A consent form would be signed only after the midwife had explained a particular
test and ensured a woman had both understood and had elected to have a test.
An additional safeguard would be to record those tests accepted and those declined on
a woman's antenatal liaison card. This would ensure that the general practitioner
was acquainted with the tests his patient had undertaken or wished to undertake. It
might also function as a valuable record for the woman herself providing she was made
aware that the information was recorded. During the prenatal cystic fibrosis screening
trial an infant was admitted to the local paediatric hospital with symptoms indicative
of cystic fibrosis. The mother informed the hospital that dining pregnancy she had
undergone cystic fibrosis carrier testing. When the woman's antenatal records were
checked it was clearly documented on the copy ofher liaison card that she had declined
CF carrier screening, but had accepted maternal serum alpha-fetoprotein screening. A
further check was that there was no signed consent form for the CF carrier test in her
antenatal records. It could be argued that had signing a consent form been a mandatory
procedure for maternal serum alpha-fetoprotein screening she would have been more
aware ofwhich tests she had chosen and which she had declined.
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7.1.5 Issues of confidentiality and autonomy
Genetic screening may result in information generated about one individual in a family
having implications for other family members. Genetic screening tests rely on nucleated
cells from which DNA is derived. A pertinent issue raised revolves around the
ownership of genetic material (Pullen 1990). Does this belong to the donor or to
the laboratory who carried out the test? In relation to samples obtained during the
prenatal screening trial it is believed that these are owned by the local health board.
Results of DNA analysis are filed in the patient's antenatal records. Carrier results are
reported to the individual concerned, their general practitioner and obstetrician.
No attempt is made to follow up relatives at risk. The individual carrier is informed
during counselling, and by way of a carrier information leaflet, that any siblings
have a 50 per cent chance of also being CF carriers. Details of how siblings can
initiate screening are provided in the leaflet.
Autonomy of the fetus and the woman in genetic screening can be diametrically opposed.
Some women clearly perceive that bringing up a child with a genetic disorder such as CF
could have a devastating effect upon their own and their families life and for this reason
will opt to terminate an affected pregnancy. The autonomy of the fetus is not, however,
best served by abortion. Some predict future alternatives to termination of pregnancy
which is currently a central issue of prenatal genetic screening. Rather they foresee
prenatal genetic screening being applied to diseases where preventive therapy is possible
for example, diet and cholesterol lowering drugs for ischaemic heart disease, early
diagnosis and treatment of diabetes, carcinoma of the colon and breast (Bell (1990). Bell
also identifies embryo selection for monogeneic disorders as an additional important
option in the screening process.
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A minority (9%) ofwomen chose to be screened in order to establish their own carrier
status, whereas 62 per cent sought information about the fetus (Table 6.6).
Further evidence of the lack of concern they show for themselves is manifest in the
psychological assessment of carriers where restitution occurs after receiving theft-
partner's negative test result (Figure 6.13). Because the focus of concern is not upon theft-
own individual carrier status it is unlikely that the implications to other family
members are seriously considered. Indeed it is arguably unfair for health care
professionals, relatives, or society to expect couples who undergo prenatal genetic
screening to calculate this aspect of genetic screening and to allow it to influence
their screening decision. Consequently, cascade screening, where relatives at risk
are systematically contacted and offered screening, should perhaps be restricted to
families where screening has been offered pre-conceptually.
7.1.6 Prenatal diagnosis
The attitude ofhealth care professionals toward pre-natal diagnostic techniques may also
influence how the benefits of chorionic villus sampling versus amniocentesis are
conveyed. There are a number of perceived benefits in the choice of chorionic villus
biopsy as a prenatal diagnostic procedure for a disorder such as cystic fibrosis;
the laboratory analysis is straightforward; the procedure is carried out in the first
trimester facilitating termination of pregnancy at an early stage. Counsellors frequently
offset the higher risk of spontaneous abortion against a 1 in 4 risk of CF occurring in
the fetus. However, the advantage of undergoing amniocentesis at a later stage of
pregnancy is the lower risk of spontaneous abortion (less than 1% ) (Lilford 1991).
Some women may favour second trimester prenatal diagnosis by amniocentesis
despite the possibility of a late termination of pregnancy.They may feel that
knowingly placing a possibly healthy fetus at risk of spontaneously aborting through
first trimester prenatal diagnosis is unacceptable. For those who wish to postpone
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their decision until the status of the fetus is known, second trimester prenatal
diagnosis may be preferable. It is only honest to highlight the advantages and
disadvantages of both procedures when counselling couples at risk of having an
affected child and providing there are no obstetric contra-indications to performing
one or other procedure. The final decision should be that of the parents.
There is currently no dispute that parents have a choice to continue or to end a pregnancy
where the fetus is affected by CF. But, regardless of their decision, are there adequate
resources to support them? Post termination support is often poor, and can result in
long term psychological sequelae (White-van Mourik 1992). By the same token the
provision for coping with an affected child will vary from one area of the country to
another. The Royal College of Physicians state that couples should never be pressed; on
the other hand they caution that any decision should take into account the long term
implications, such as care of the affected individual after their deaths (Royal College
Physicians 1989). If a couple have strong moral principles then this will almost
certainly regulate their decision to continue or end a pregnancy. Other couples will
base their decision on the perceived effect of an affected child on family and social life,
financial costs, and the problems of caring for the child at home (Wertz et al 1984).
The process of information giving and receiving can be impaired by the reactions
couples experience in the coping process (Pullen 1990). Counselling for prenatal
diagnosis has other goals, for example, the reduction of guilt, shame and anxiety as
well as helping couples adjust to the presence of a genetic disorder (Wertz 1984).
Prenatal diagnosis can be viewed as having a pro-life effect because couples who might
previously have avoided a pregnancy because of a known genetic risk may be more
willing to conceive.
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7.1.7 Evaluation of screening
It is ethically undesirable to evaluate a screening programme by cost-benefit analysis
which measures effectiveness by the number of affected pregnancies which are
terminated and the savings made from reducing the incidence of the disease. Nonetheless
evaluating screening in monetary terms has been carried out (Gill et al 1987; Wald and
Cuckle 1988).
A more acceptable method is by patient satisfaction (Shiloh et al 1990).
Reservations have been expressed by Clarke (1993) about the feasibility of quantifying
the evaluation of qualitative aspects of screening; work in this thesis indicates that
this is possible. The feelings questionnaire was designed to assess satisfaction with
information and counselling and in addition participant's attitude to pre-natal carrier
screening. A simple questionnaire which also offered the facility to express individual
opinions may not be perfect, but it can expose areas of dissatisfaction which may
subsequently be comprehensively examined.
The recent development ofpopulation genetic screening for carriers of cystic fibrosis is
only one of a number of recent developments in recombinant DNA technology.
Increasingly these developments are impinging on society and gradually the community
will become more aware of the role of genes in disease and of the implications of being
able to identify susceptible individuals. As these new technologies are implemented,
midwives should give careful consideration to the ethical issues which arise so that
maximum benefit can be obtained for the individuals for whom they care as well as the
wider community.
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7.2 Implications for midwifery
The conceptual model of stress, coping and outcome (Cochrane 1983) contributed to the
framework used to develop the studies which constitute this thesis. The model also
provides a framework to assess how the results of the studies contribute to midwifery
and nursing practice.
The results show that women who were offered cystic fibrosis screening during
pregnancy were confronted by problems that were psychological rather than physical.
Psychological adaptation is important not only in terms of the well-being of the
pregnant woman herself (Watson et al 1984), but the eventual well-being of her baby
(Newton et al 1979; Berkowitz and Kasl 1983; Muylder 1989). Using the conceptual
model as a framework the results of the studies can be summarised to contribute to a
knowledge base for the effective, judicious and sensitive presentation of screening, as
well as examining areas where knowledge is lacking and where further research is
indicated to understand these dimensions of prenatal genetic screening (figure 7.1). The
results of the studies allow the researcher to suggest guidelines for the presentation and
care of women who are offered prenatal genetic screening. Although these are consistent
with presenting genetic screening within an antenatal clinic setting, they could equally
apply to screening presented within an alternative setting, for example, in the community
by health visitors or practice nurses.
7.2.1 Preparation for screening: a basis for coping
The pregnant woman's interpretation ofevents
Knowledge, attitudes, beliefs, expectations and predictions all contribute to a woman's



























initially identified as the circumstance of receiving a positive screening test result. Since
twenty five per cent of all women felt anxious about being screened (figure 6.7) the actual
offer of the test itself must be viewed as an immediate stressor to a substantial number of
women. Indeed, of those who declined the test 38 per cent were made to feel anxious
and only 5 per cent felt reassured at the thought of being screened, compared to 23 per
cent and 49 per cent respectively of women who were tested (table 6.5). This finding has
implications for midwives in the initial presentation of the test. Individuals face difficulty
receiving and incorporating information on both cognitive and emotional levels if anxious
(Falek 1984). If a woman is made to feel anxious about the offer of the screening test
then she may have difficulty absorbing the information and counselling offered by the
midwife. For these women stress intervention should commence before pre-screening
information and counselling begins. This means establishing a woman's emotional reaction
to the offer of screening and acknowledging and identifying the likely source of her
apprehension.
Phipps and Zinn (1986) assessed mood disturbance in women undergoing amniocentesis
and compared them to a control group who were not undergoing the procedure.
Within both groups they identified two groups: "monitors" (information seekers) and
"blunters" (avoiders). It is beheved that some individuals seek out threatening
information and are more likely to show anxiety and depression (Tunis and Golbus
1991). Among the participants in the CF screening trial no correlation was found
between either a woman's socio-economic group or her age and feelings of anxiety
toward screening. There may, however, be other variables such as personality,
obstetric history or education which contribute to anxiety among a quarter of women
screened but further research is needed to establish if this is the case.
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Although feelings of anxiety are considered a natural response to any situation perceived
as threatening and only become a problem when they become extreme either in
duration or intensity (Cochrane 1983), how women cope with stress during pregnancy is
a concern. Smoking, alcohol and overeating should be discouraged and acceptable coping
strategies employed.
Reasons for wishing to be screened.
Women's written quotations revealed that they not only have diverse and often very
personal reasons for accepting or declining the test, but that individual knowledge,
understanding, values, expectations, and past experiences are equally germane and
disparate. Thus women who are offered an identical test in an identical situation
will perceive it very differently. Some are quite clear regarding their expectations:
"By having the test I will be able to 1) reassure myselfand my partner if the
expected baby does not have CF, 2) be given time to consider termination if
the baby has CF, 3) prepare myself and my family to cope with a CF baby
if termination is not a consideration."
Others wrestle over their decision because of a lack ofunderstanding:
"I don't blow what it means. And I haven't heard of it before."
By asking a woman to formulate their reasons for wishing to be screened, or indeed
declining to be screened, can assist the midwife detect if a woman has unrealistic
expectations of a screening test and allows her the opportunity to correct misconceptions.
Knowledge and understanding of the disorder
A substantial number of women (85 per cent) had previously heard of CF before they
were invited to participate in the screening trial. It may be significant that the major
source of their information was television, which as a visual medium, may facilitate a
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more integrated perspective of the disease, and in turn may influence uptake of screening.
Despite a lack of detailed knowledge many were aware from television that respiratory
problems were a main feature of the disease and that chest physiotherapy was pivotal
in the care of sufferers. Popular drama programmes on television such as 'London's
Burning' and 'Medics' have depicted the physical effects of CF and, in the former drama
series, the emotional strain placed upon the CF sufferer's family.
The younger age group 16 to 20 years were significantly less likely than older women
to have previously heard of the disease. An observational study of women in labour
found that women whose knowledge was scant were not given additional information
which would have increased their understanding because they were felt by staff to be
less likely to comprehend (Kirkham 1983). Questions are an obvious way to obtain
information but formulating questions requires a semblance of knowledge and
understanding. There is a danger that those women whose need is greatest may gain
inadequate information. Information should be tailored to meet individual needs and
ample opportunity offered to ask questions or to admit a lack ofunderstanding.
Some women will rely totally on the information given before and at the booking
clinic to formulate both their concept of the disease and the screening test. Around 35
per cent of carriers, controls and partners felt they had not received sufficient information
prior to attending the clinic and 23 per cent of carriers felt that on hindsight they had not
received enough information about the test at the antenatal clinic (table 16.19).
Vulnerability
Socialfactors
Women from the extreme ends of the age spectrum were significantly more likely to
present at booking with symptoms of stress revealed through the threshold GHQ (figure
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6.9). Younger women were significantly less likely to be married (table 6.3) and may
lack a supportive relationship. It is recognised that social factors impinge upon coping
response (Cochrane 1983) and social support is recognised as a buffer against stress
(Cobb 1976). Thirty per cent of all women had not discussed the test with anyone other
than the midwife (figure 6.5). This is evidence that a substantial number of women
depend upon the midwife for support during the decision making process. Midwives
may themselves be unaware of the assignment they undertake and the demand this places
upon them, in addition to providing practical care and emotional support to women
during the early stages of pregnancy. Midwives will require adequate professional and
personal support if they are to take responsibility for prenatal screening counselling and
continue providing the high standard of care their work demands.
There is evidence that nurses find caring for individuals' physical needs much less
stressful than care which involves more personal and emotional interaction (Menzies
1960). A study carried out in a gynaecological ward revealed that nurses are frequently
inexact in their perception of the worries of their patients; worries which fellow
patients easily related to (Johnston 1982). An additional concern is that role conflict
could arise for the midwife who finds herself wishing to spend longer with a woman
who needs her, yet is aware that there may be a backlog ofwomen waiting to be seen.
Younger women were significantly more likely to experience difficulty in comprehending
pre-screening information in the leaflet, and over 70 per cent of 16 to 20 year old
women and 56 per cent of 21 to 25 year old women either had no perception of their
carrier risk, or perceived it wrongly. There was no correlation between lack of
knowledge and the decision to decline screening which supports the evidence that some
women accept prenatal screening without fully understanding the implications (Marteau
et al 1988b). There may be an inherent problem regarding the current mode of delivery
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of information by leaflet and discussion. There is undoubtedly scope for research
concerned specifically with communication media. Research should seek to evaluate
the most suitable and acceptable forms of delivering information, taking into account
multiple variables such as age, socio-economic status, educational background, past
obstetric history and individual preference. A greater awareness of individual
requirements with a wider range of educational aids about prenatal screening is
needed.
Education is an important aspect of the midwife's work. Most women are receptive to
information in pregnancy because they wish to have a healthy baby. Indeed 26 per cent of
women who commented on their decision to be screened, either wished to prevent the
birth of an affected child or expressed the wish for a healthy baby. It is important that
the midwife explain the main symptoms and variable severity of the disease, along
with the possibility for treatment and current life expectancy of those with the disorder.
The availability of a leaflet detailing these facts can be a useful adjunct to a pre-
screening leaflet, which may offer only a brief outline of the disease. All leaflets should be
periodically revised to ensure that new developments in treatment and changes in
prognosis are up-to-date. In parallel, in-service education is required to ensure that there
are opportunities for midwives to update their knowledge. In a study of midwives
knowledge of maternal serum alpha-fetoprotein screening, 45 per cent lacked basic
knowledge about the test, even although all were involved in the delivery of screening
(Sanden 1985).
Individual counselling requires clear objectives (Jones 1991). With regard to pre-
screening counselling the objective is to help a woman and her partner decide whether
a test is right for them. In order to structure the counselling process the midwife
requires to "listen" to define what a woman needs to know. Counselling requires both
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time and space. It requires privacy and freedom from interruption a situation not always
possible in a busy antenatal clinic. Does an antenatal booking interview facilitate
counselling for genetic screening? This is an area which requires further research,
particularly in relation to midwifery staffs own perception regarding then eligibility
to deliver genetic screening. Within the antenatal clinic where this study took place, a
majority of midwives had attended counselling courses and were trained in how to
present information and discuss screening. In addition they had the support of a genetic
nurse for more sophisticated information and counselling. Without formal training,
delivering prenatal screening could be stressful for midwifery staff and result in
women being underinformed or suffering from screening related morbidity as a result of
poor preparation for screening. Access to appropriate training in genetics and genetic
counselling techniques should be available to staff through the regional genetics service
(Modell 1992).
The broad aim of pre-screening information and counselling is to meet the needs of
individual women through good communication, provision of adequate information
and emotional support. Knowledge is necessary to formulate accurate expectations,
make an informed decision and prepare psychologically for screening. Caplan (1964)
advises that primary prevention can either alter stressful conditions or strengthen the
individual to resist stress and cope in adversity. Primary prevention against a stressful
reaction to screening needs to commence during the pre-screening stage with
information about the objectives of screening, addressing reasons for wishing to be
screened, individual perception of risk, the meaning of a positive test result, the likely
course of action and the procedure for reporting a positive test result. Concurrent stress
should be identified and steps taken at this time to deal with the cause and alleviate
symptoms. In addition women and their partners should be encouraged to assess then-
own beliefs and values and their perceived ability to cope with a child with a chronic
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disease. Their attitude to termination of pregnancy should also be addressed. Adequate
pre-screening preparation will influence both primary appraisal and ability to cope
with a positive test result by ensuring that women are knowledgeable about the screening
process and feel in control.
A frameworkfor pre-screening counselling.
A woman should be given accurate and unbiased information so that an informed
decision can be made. Counselling should be non-directive, but should actively help
woman reach a decision in the context ofher unique social, cultural, personal, family and
obstetric situation. A woman has autonomy, that is she has the right to decide what
action or inaction she wishes to take. Screening information should be communicated in
such a way as to ensure a woman can understand it. Medical jargon should be avoided
and opportunity to admit difficulty in understanding should be offered. If a prenatal test
is a local screening policy it should be offered to all women. The decision to offer or not
to offer a test does not belong to the individual midwife or doctor but to the woman
herself. A woman has a right to confidentiality; test results should not be divulged to
any other party even if it has implications to other family members. The decision to
inform relatives even if the result has implications for them is that of the woman herself.
7.2.2 Care of women who receive a positive CF carrier test result: a basis for coping
When a woman receives a positive screening test result her understanding of her problem
will determine her reaction, the way she copes, and the type and amount of counselling
and support intervention she requires. Cochrane advises that how an individual deals
with the challenge of a stressful event depends on their psychological well being at the
time and upon their self-esteem. Belief in one's coping ability is also associated with
positive adaptation and well-being (Cochrane 1983). Thus, some women may have a
negative outlook about their ability to cope when they receive a positive test result and
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need help and encouragement. They may blame themselves, feel guilt or shame and
become extremely upset and confused. Alternatively they may blame the doctor or
midwife for thrusting this problem on them and become angry or non-communicative. A
woman may also be influenced by what she perceives to be an acceptable reaction and
hide her true emotions (Cochrane 1983). An awareness of the influences contributing to
a diversity of reactions, symptoms and ability to cope are a pre-requisite to providing
counselling and support to women faced with a positive test result.
The results of psychological assessment of women and their partners undergoing CF
screening in pregnancy concluded that 53 per cent of women experienced a stressful
reaction at the time of receiving their positive test result. Information and choices need to
be made available to these women and their partners but in conjunction with stress
intervention to manage their stress and facilitate coping. Once a favourable outcome
was known women identified as carriers regained psychological homeostasis and
maintained this for the remainder of their pregnancy (figure 6.13). Carriers and control
subjects who were experiencing concurrent stress continued to manifest symptoms
of psychological disturbance (table 6.10). This demonstrates a need for adequate
follow-up support to ensure emotional adjustment after the screening experience and
to monitor prolonged stress.
When a woman receives a positive test result symptoms of stress may be so
severe that she has lost sleep, taken time off work or had difficulty functioning as
normal. A woman's perception of the threat of her positive screening test result will be
influenced by her knowledge, beliefs, expectations, social support, present mood, her
confidence in the screening programme and staff and her past ability to cope with
stressful situations. From a midwifery care perspective, a woman will be susceptible to
change depending upon the influences of the variables outlined in the model.
255
Moreover, one partner's response can influence the other. Male partners were found to
be significantly more likely to manifest a stressful response if their female counterpart was
distressed. The midwife too has the capability to influence a woman's perspective of
her situation through stress intervention strategies. Within the model a woman may be
viewed as someone in a state of flux as she modifies her view of her situation through
new information, counselling and her attempts to cope.
Even prior to screening, it is important to gain a broad impression of a woman's
current thoughts and feelings about a screening test, her expectations and her belief
about her own ability to cope if she received a positive result. The conceptual model can
serve as a framework to consider those areas which may influence a woman's response to
a positive test result. These include the personal meaning of the test, the likely impact
if positive, the psycho-social context in which screening will be carried out, for example
her past obstetric history, present pregnancy and life events.
It is clear that a substantial number of women (32% of the screened population in this
study) present with signs ofpsychological disturbance before they are screened. Many
(44%) were suffering from early symptoms of pregnancy, others gave a variety of
reasons for their distress (Table 6.10). The significance of concurrent stress, in relation
to prenatal genetic screening, is that it may amplify the distress of receiving a
positive screening test result and the likelihood of inducing sequential stress.
A majority of carriers and partners (80% and 90% respectively) were glad they
had been screened. Nonetheless, 20 per cent of carriers either regretted or were
ambivalent about having been screened. Although pre-pregnancy screening is arguably
the ideal time to offer genetic carrier screening, for many individuals the first real
opportunity occurs post-conception.
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Psychological preparation has been shown to help patients undergoing a variety of
potentially stressful procedures (Ridgeway and Mathews 1982; Bailey and Clarke 1989;
Hunter 1994). The midwife is usually the first person that a pregnant woman consults
when she attends for prenatal care. The midwife has a crucial role to play in
providing unbiased accurate information about the various prenatal screening tests and
in guiding them through the procedures which he ahead. The results of this thesis show
that it is not sufficient for the midwife simply to equip women with the facts about a
screening test. If the midwife is to deliver screening with an element of caring,
psychological preparation of a woman for the unlikely event of a positive test result is
important if screening-related morbidity is to be avoided.
Stress interventions to assist patient coping
Midwifery interventions at this stage should involve giving thought to the timing of
reporting a positive test result. Choosing a time to divulge the test result when both
partners are at home will prevent a situation of a woman coping alone with her
feelings. Details of occupation will give some idea of a couple's routine. When the
result is divulged primary appraisal of the stressful situation will occur (Cochrane 1983).
If adequate pre-screening information and counselling has been carried out it should help
a woman feel more in control (Hunter 1994; Marteau and Chappie 1992a; Statham and
Green 1993).
By the time a couple are seen for counselling they will have had time to reappraise the
challenge of the woman's positive test result (secondary appraisal) and assessed their
ability to cope. Any symptoms of stress reaction to the threat will be felt as results of
the GHQ and SRT assessments showed (figure 6.13; table 6.13). Stress intervention
should deal with a couples emotional response first (Hunter 1994). Hunter advises that
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direct coping strategies should be employed. Direct coping strategies involve trying to
normalise emotional reactions and reassure that help is at hand to assist coping.
Providing a couple with a climate of safety and security by outlining briefly the agenda
of the counselling session, the testing procedure, and prevent them from feeling
overwhelmed by the situation. By breaking the crisis down into a series of steps can
make it feel more manageable (Hunter 1994). Reassurance that the pregnancy is not
under threat is an immediate task although false reassurance should be avoided. A
realistic comfort is that the CF carrier test has screened the mother not the baby.
Promoting objectivity and accurate secondary appraisal can help. Often the person in
crisis has a poor grasp of reality and thinks emotionally and irrationally. However,
Caplan (1964) advises that during a crisis the individual is open and amenable to outside
intervention. Many couples are unfamiliar with genetic terminology and concepts. Using
a visual aid such as a felt board is a non-threatening technique which can help reduce
anxiety about something intangible - an altered gene. Issuing a leaflet which reiterates the
counselling information is a reassuring additional source of information.
Discouraging loss of self-worth and promoting a positive self view can prevent self-
deprecation and diminished well-being (Kessler 1984). Explaining that all individuals
carry several altered genes and emphasising the normality of the 'carrier state' is vital in
preventing feelings of inadequacy or guilt and answers the question "why me?"
The conceptual model illustrates the ultimate goal of stress intervention is to help the
individual strive for effective coping (Cochrane 1983). Focusing upon certain short term
goals to increase mastery of the situation by advising a woman how to look after her
physical and psychological well being over the period awaiting the partner's test result is
important (Hunter 1994). Palhative coping strategies should be addressed not least to
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ensure that unsuitable methods such as smoking, drinking drug or exercise abuse are not
pursued. Discussing available social support and encouraging the use of the hospital
contact phone number to answer questions, concerns and give ongoing emotional
support are all positive interventions which aim to achieve the goal of effective coping
and reduce stress in the pregnant woman and her partner.
Although the studies in this thesis have concentrated upon the majority of women who
are offered a genetic screening test, and on those women who received a positive result
but whose partners received a negative test result, there is the small but important group
who ultimately face a 1 in 4 risk of having a child with CF. As the advent of team
midwifery allows the midwife to devote her time to the care of a small case load of
mothers (Department of Health 1993; Scottish Home and Health Department 1993)
some midwives will experience the anguish of the woman who is confronted with a high
risk of an affected infant. One woman whose partner was also found to be a CF carrier
described her experience as follows:
"I knew about cystic fibrosis but I didn't know that as many as one in
twenty-five people in Britain are carriers - even then Ijust thought I would
be one of the twenty-four. My reaction when Ifound my husband was also
a carrier was one of total disbelief After everything I had been through,
all I could think was why? why? I was heartbroken, I wept buckets."
(Bodmer and McKie 1994 page 229-230)
7.3 Final Conclusions
If genetic screening were to become focused on pregnancy it could place women in an
unfair position of responsibility for genetic disease in the community. Informed choice is
important in antenatal care and choice can only be exercised from a position of
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knowledge. To withhold information about a test which is available is wrong but on the
other hand women should not feel pressurised into accepting screening. There may be an
underlying assumption that genetic screening will develop if normalised into the package
of testing offered at booking. Screening should be offered through other channels such
as GP surgeries and family planning clinics. An alternative method of screening is to test
both partners of a couple, thereby avoiding the focus of attention to be solely on the
woman (Chappie 1992).
Most women want prenatal screening. Although there are practical, emotional and moral
reasons for not using it, it does seem that most women feel the need to know the
knowable (Rothman 1988). Many want information about their fetus because they want
to plan. The nursing and midwifery professions need to plan also for the advent of genetic
screening. Currently there is an imbalance between the rapid advance of knowledge and
practice in the research laboratory and the lack of knowledge and practice at the clinical
level, where both benefit and harm to the individual can occur. The need for counselling
and emotional support, along with detailed educational materials as an integral part of
genetic screening has implications for both nurse managers and nurse educationalists. At
the managerial level the cost of offering a screening programme poses a serious financial
decision.
Prenatal screening involves laboratory costs, staff time and education, patient information
and support services of prenatal diagnosis and termination of pregnancy. In addition
service monitoring must be organised and this requires clerical assistance and finance.
Thus the decision as to whether to fund new developments such as CF carrier screening
may create a problem. There is also a danger that in a stringent financial climate prenatal
CF carrier screening programmes may be initiated without proper education of staff and a
counselling framework. For nurse educationalists and managers there is the responsibility
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of ensuring that staff have the necessary knowledge and training to present the complex
issues of genetic screening. Most allegations of negligence in the field of prenatal
diagnosis, rather than related to misdiagnosis or fetal loss, have revolved around failure to
screen, misinformation, risk assessment or counselling. Few examples have been
published as a result of out of court settlements (Modell 1992).
As midwives enter into a new era of midwife-led care their responsibilities will extend
across the whole domain of antenatal management. If pregnancy is to be used as one
gateway to genetic screening then there is a pressing need for midwives to develop skills
in counselling and to know how to co-ordinate the care of women with obstetric-genetic
needs with experts in genetic counselling The concept of women-centred care ties in
well with the ethos of genetic counsellors. Indeed continuity of care in midwifery will
lend itself particularly well to the needs of women who undergo genetic screening.
Ideally the same counsellor should be available to help women reach the right decision for
them in the context of their unique social, moral and medical situation (Modell 1992).
Although it seems unlikely that genetic screening causes harm to women who test
negative there may be subtle impairment in the form of overloading of antenatal
information. As the number of prenatal screening tests increase the risk of information
overload, blocking of information and misinterpretation of other antenatal health care
messages could foreseeably occur. This could affect a woman's attitude both to
pregnancy and to the midwife. Further research is needed to clarify these uncertainties.
As molecular biology increases knowledge about the cause of genetic diseases and
develops ways of preventing them, so too will it continue to try to remedy the effects
through gene therapy. Increasingly pre-screening counselling will involve providing
information not only about preventive strategies but about therapies. However, most
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pregnancies do not result in fetal abnormality but in the birth of a healthy infant and
herein may He one of the most important roles of the midwife in the area of prenatal
screening: safeguarding the balance of antenatal information so that discussion of
abnormalities ofpregnancy is not allowed to outweigh description ofthe normal.
A limitation of the research carried out in this thesis is that it fails to address the question
of midwives' attitudes to genetic screening per se; to the offer of a genetic screening test
to pregnant women; and more specifically how midwives view their taking the
responsibility for presenting genetic screening. There is a need for these questions to be
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One in every 25 men and women carry a single cystic fibrosis gene (CF
gene). A single CF gene is completely harmless. But if a woman who carries
a single CF gene has a child by a man who also carries a single CF gene, there
is a 1 in 4 chance that their child will have the disease cystic fibrosis (CF).
AT EACH PREGNANCY. THIS COUPLE HAS A















N = normal gene
C = CF gene
THE DISEASE -
CYSTIC FIBROSIS
CF is serious. The averagelife expectancyis 25 years. CF causes thick mucus togather in the lungs and gut. Childrenwith CF need chest physiotherapyseveral times a day and antibiotics tofight chest infections. If they live longenough they will probably need a heartand lung transplant.
Children with CF require abalanced diet, with 50% morefood than the average childtheir age and tablets given daily tohelp digestion.
MOST CHILDREN WITH CF ARE BORNTO PARENTS WHO HAVE NOFAMILY HISTORY OF THE DISEASEIn 1 in 600 couples, both partners carry a single CFgene. Most of these couples have no family history ofthe disease and are unaware they have a 1 in 4 chanceof having a child with CF. Even if you already havehealthy children, you may still be a CF carrier.
WE THINK THAT A WOMAN WHO IS HAVING A BABYWILL WANT TO KNOW THE ANSWERS TO THREEIMPORTANT QUESTIONS
l.AMIA CF CARRIER?
2. IS MY PARTNER
A CF CARRIER?




A mouthwash sample is used to test
if you are a CF carrier. You will be
contacted in 1 week, only if the test
shows you are a carrier.
Testing for the CF gene is successful in 85%
of cases. This means we cannot guarantee that
you will not have a child with CF. However,
if the test is negative it will
greatly reduce the risk.
If you wish your negative test result,
bring a S.A.E. to the clinic.
TESTING YOUR PARTNER
If you are found to carry a single CF gene
we would be able to test your partner.
He also has a 1 in 25 chance
of being a CF carrier.
If your partner's test is negative then your risk of
having a baby with CF is very low.
A special leaflet and genetic counselling are available
for all couples where one partner only has a
positive carrier test.
If however, you don't know
who the father of your
baby is, we advise against
taking the CF carrier test.
PRENATAL CARRIER TESTING
FOR CYSTIC FIBROSIS
WISH TO PARTICIPATE IN THE CYSTIC FIBROSIS CARRIER
TESTING SCREENING TRIAL.
I UNDERSTAND THAT THE CARRIER TEST FOR THE CYSTIC
FIBROSIS GENE DOES NOT GUARANTEE THAT I WILL NOT HAVE
A CHILD WITH CYSTIC FIBROSIS.
I UNDERSTAND THAT I CAN WITHDRAW FROM THE SCREENING




COUPLES WHO ARE BOTH CARRIERS OF
A SINGLE CYSTIC FIBROSIS GENE
Genetic counselling is available to couples where both partners
are found to be CF carriers.
The various options open to you will be fully explained. You will
have time to think through these options and discuss them at
length with the counsellor.
One option is prenatal diagnosis. It is possible to diagnose CF
in the fetus. If the prenatal diagnostic test shows that the unborn
child is going to have CF, you may wish to have a termination.
Prenatal diagnosis is not recommended for those couples who
find termination unacceptable.
FURTHER INFORMATION AND ADVICE ABOUT
PRENATAL CARRIER TESTING FOR
CYSTIC FIBROSIS
There will be time at the antenatal booking clinic to ask
questions, or discuss concerns you may have about prenatal
carrier testing for cystic fibrosis. Counselling is available at any
stage of the screening trial. A nurse counsellor is available at the
antenatal booking clinic.
We think it is important that we find out a number of things
about screening for CF during pregnancy. Firstly, are we giving
you the information you need in our leaflet? Are we causing you
any upset by screening you during pregnancy? Do you and your
partner find this an acceptable time to be screened? The
enclosed questionnaire is designed to answer these questions
and help us give you the service you need. Please complete it
before you come along to the clinic and give it to the midwife
who is caring for you at the clinic.
PRENATAL CARRIER TESTING FOR
CYSTIC FIBROSIS IS VOLUNT ARY
Prenatal carrier testing for CP is entirely voluntary
If you would like to be tested please complete the
enclosed consent form and bring it with you to the
antenatal booking clinic. You can, of course, with
draw at any time from the screening trial.
Printed and Designed by the University of Edinburgh
IMPORTANT POINTS TO REMEMBER ABOUT
PRENATAL CARRIER TESTING FOR CYSTIC FIBROSIS
Carrying a single CF gene is completely harmless.
e Only if both partners carry a single CF gene will there be
a 1 in 4 chance that their child will have the disease CF.
o Most children are born to couples who have no family
history of the disease.
o Ifyou don't Know who the father ofyour baby is, we advise
against taking the CF carrier test.
Testing for the CF gene is still only successful in 85% of
cases.
o Genetic counselling is available for all couples where
both partners are found to carry a single CF gene.
The prenatal cystic fibrosis carrier screening trial is
entirely voluntary.
o Remember there are trained staff to give you information




Hie cystic fibrosis carrier screening test is new. This is why we are running a
prenatal screening trial. You can tell us if pregnancy is a good or a bad time
to be offering you this test.
This questionnaire is designed to answer two important questions. Firstly, are we
giving you and your partner the information you need to help you rrake up your rnind
whether or not to have the CF screening test? Secondly, are we causing you any upset
by testing you when you are pregnant?
Please fill in the questionnaire at heme and bring it with you to the booking clinic.
The midwife looking after you at the clinic will collect it from you. If you have
decided NOT to have the CF carrier test, or are UNDECIDED we would still like you to
fill in the questionnaire.
THANK YOU PC® YOUR HELP.
Please tick the appropriate box or boxes.
1. Had you heard of cystic fibrosis, before you read the CF leaflet?
a) yes b) no □ c) don't know □
2. If you had heard of cystic fibrosis, where did you hear about it?










h) can't remember □
3. Is the leaflet describing the CF carrier test?
a) difficult to understand □ b) easy to understand □
4. Has your partner read the leaflet?
a) yes □ b) no □ c) don't know □
5. If he read it did he find it?
a) difficult to understand □ b) easy to understand □ c) don't know
6. Do you know what your chance of carrying a single IF gene is?
a) 1 in 4
d) 1 in 200
□
□




c) 1 in 100 □
7. Have you discussed the CF carrier test with anyone?





f) other (state who) □
8. Have you decided? a)
b)
c)
to have the test
not to have the test
not decided
9. In a few words can you say why you have trade this decision,
(please write your reasons in the space below)
10. Does the thought of the CF test make you feel?
a) anxious □
b) reassured □
c) dcai' t know
11. Do you think the leaflet should give you more information?
a) yes □ b) no □ c) don't know □
12. If yes, what would you like to know?
a) I'd like to know more about the disease CF
b) I'd like to know more about the treatment for CF
c) I'd like to know more about how CF is passed on to children
d) I'd like to know more about the CF carrier screening test
e) I'd like to know more about diagnosing CF in the unborn child






PLEASE READ THIS CAREIULLY - We should like to know how you have been feeling generally
over the past few weeks. Please answer all the questions by circling the answer which you
think most nearly applies to you.
REMEMBER - we want to know about present or recent complaints, not those you have had
in the past.
It is important that you try to answer ALL the questions.
HAVE YOU RECENTLY:
1 - been able to concentrate car better same less much less
whatever you're doing? than usual as usual than usual than usual






3 - felt that you are playing a more so same less useful much less
useful part in things? than usual as usual than usual useful
4 - felt capable of making more so same less so much less
decisions about things? than usual as usual than usual capable
5 - Felt constantly under strain? not no more rather more much more
at all than usual than usual than usual
6 - felt you couldn't overcome not no more rather more much more
your difficulties? at all than usual than usual than usual
7 - been able to enjoy your normal rrore so same less so much less
day-to-day activities? than usual as usual than usual than usual
8 - been able to face up to your more so same less able much less
problems? than usual as usual than usual able
9 - been feeling unhappy and not no more rather more much more
depressed? at all than usual than usual than usual
10 - been losing confidence in not no more rather more much more
yourself? at all than usual than usual than usual
11 - been thinking of yourself not no more rather more much more
as a worthless person? at all than usual than usual than usual
12 - been feeling reasonably happy more so about same less so much less
all things considered? than usual as usual than usual than usual
Thank you for taking the trouble to fill in this questionnaire
REMEMBER - to bring the questionnaire with you to the clinic
CYSTIC FIBROSIS CARRIER TESTING
PRENATAL SCREENING TRIAL
Describe how you have felt during the PAST WEEK ,











Headaches or head pains /












Headaches or head pains /










I Feeling dizzy or faint
2 Feeling tired or a lack of energy
J Nervous
4 Feelings of pressure or tightness
in head or body
5 Scared or frightened
6 Poor appetite
/ Heart beating quickly or strongly
without reason (throbbing or pounding)
8 Feeling that there was no hope
9 testless or jumpy
10 Poor memory
11 Chest pains or breathing difficulties
or feeling of not having enough air
12 Feeling guilty
13 Worrying
14 Muscle pains, aches or rheumatism
15 Feeling that people look down on
you or think badly of you
16 Trembling or shaking
17 Difficulty in thinking clearly or
difficulty in making up your mind
18 Feeling unworthy or a failure
19 Feeling tense or "wound up"
20 Feeling inferior to other people
21 Parts of body feel numb or tingling
22 Irritable
23 Thoughts which you cannot push
out of your mind
24 Lost interest in most things
25 Unhappy or depressed
26 Attacks of panic
27 Parts of your body feel weak
28 Cannot concentrate
29 It takes a long time to fall asleep,
or restless sleep or nightmares
30 Awakening too early and not being
able to fall asleep again
CYSTIC FIBROSIS CARRIER TESTING
PRENATAL S GREENING TRIAL
FACTS AND FEELINGS QUESTIONNAIRE
FACTS QUESTIONNAIRE
Here are a number of statements, please tick the ones you think are true.
1 any couple can have a child with cystic fibrosis
true
2 a couple can have a child with cystic fibrosis if
a) only one partner carries a single cystic fibrosis gene true
b) both partners carry a single cystic fibrosis gene true
3 if both partners carry a single cystic fibrosis gene their
chance of having a child with the disease cystic fibrosis is
□a) 1 in 2 true b) 1 in 4 true
c) 1 in 20 true □
d) all their children will have cystic fibrosis true □
4 one in 25 people in Britain carry a single cystic fibrosis gene
5 if you carry a single cystic fibrosis gene this means that
a) your health will be affected true
b) you will develop the disease cystic fibrosis true
c) it is only important if your partner also carries
a single cystic fibrosis gene true
6 even, if you have no family history of cystic fibrosis
you can carry a single cystic fibrosis gene
true
FEELINGS QUESTIONNAIRE
please tick which statement is CLOSEST to the way you feel
feel the information I was given about the cystic fibrosis
arrier test was
before the antenatal booking clinic












feel I understood what the cystic fibrosis carrier test was all













10 I feel I am in favour of testing for cystic fibrosis carriers
a) in schools
b) in family planning clinics
c) in GP health centres
11 I feel that the cystic fibrosis carrier test should be routinely




12 if I turned out to carry a single cystic fibrosis gene, I
feel I would tell
yes no don't know
~ \ 4-^
a/ uijr pat ciicjl




d) my other relatives
e) my friends




thank you for filling in this questionnaire
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PRENATAL CYSTIC FIBROSIS CARRIER
SCREENING: FACTORS IN A WOMAN'S
DECISION TO DECLINE TESTING
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Human Genetics Unit. Department of Medicine. University of Edinburgh, Western General Hospital.
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SUMMARY
Among 2207 women eligible to be screened for cystic fibrosis (CF) carrier status during
pregnancy, 325 (15 per cent) declined to be tested. Of these, 260 (80 per cent) answered a
questionnaire soliciting their reasons for not participating. The main factor was opposition
to termination of pregnancy, with 43 per cent being against termination for any reason and
another 11 per cent against termination of a CF fetus. Other reasons given were partner's
disapproval or non-participation (10 per cent), perceived risk of a CF child being low
(7 per cent), the error rate of the test (6 per cent), and the generation of unacceptable
levels of anxiety (5 per cent). Eleven women (4 per cent) said that they did not wish to be
tested during pregnancy, but only six of these would have accepted screening at another
time.
key words Cystic fibrosis Prenatal carrier screening Decision-making
INTRODUCTION
The main objective of cystic fibrosis (CF) carrier screening during pregnancy is to
identify high-risk couples and to allow them to avoid the birth of an affected child
through prenatal diagnosis. For the past 2 years, we have conducted a pilot trial
of CF carrier screening in the major Edinburgh maternity hospital. Details of the
information leaflet inviting participation and the protocol used have been
published elsewhere (Mennie et al., 1992a,b). During this period, about 15 per cent
of women declined to enter the trial. This study examines the reasons given by
women who have not wished to be screened during pregnancy.
SUBJECTS AND METHODS
Between May 1991 and January 1992, a total of 2541 women booking to have their
babies at the Simpson Memorial Maternity Pavilion, Edinburgh were invited to
enter the CF carrier screening trial. Details of the recruitment method are given
elsewhere (Mennie et al., 1992b). Of these, 334 (13 per cent) were not eligible for
reasons given (Mennie et al., 1992b). A total of 2207 (87 per cent) women met the
criteria for screening, of whom 325 (15 per cent) declined and 1882 (85 per cent)
were screened. Those who declined screening are the subjects of this study.
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Table 1. Back cover of the CF carrier test information leaflet summarizing the important
points of screening
IMPORTANT POINTS TO REMEMBER ABOUT PRENATAL CARRIER TESTING
FOR CYSTIC FIBROSIS
1. Carrying a CF gene is completely harmless
2. Only if both partners carry a single CF gene will there be a 1 in 4 chance that their child
will have the disease CF
3. Most children are born to couples who have no family history of the disease
4. If you don't know who the father of your baby is, we advise against taking the CF
carrier test
5. Testing for the CF gene is still only successful in 85 per cent of cases
6. Genetic counselling is available for all couples where both partners are found to carry
a single CF gene
7. The prenatal cystic fibrosis carrier screening trial is entirely voluntary
8. Remember there are trained staff to give you information and advice—please do ask
Women were invited to enter the trial by means of an information leaflet sent
with their antenatal booking appointment. The designing of the leaflet is described
elsewhere (Mennie et al., 1992a). The leaflet briefly acquainted women and their
partners with the disease cystic fibrosis and the mode of inheritance. It outlined the
purpose of prenatal CF carrier screening and explained the testing procedure. The
leaflet emphasized that the test was entirely voluntary, was 85 per cent successful,
and that a negative test result did not guarantee that a child would not have CF,
but would greatly reduce the risk. It further emphasized that most couples who
had a child with CF had no previous family history of the disease. The leaflet also
stated that if a woman did not know who the father of her baby was, then it was
inadvisable to take the test.
Prenatal diagnosis was discussed as an option for couples where both partners
were CF carriers, and termination of pregnancy was cited as a further option if the
prenatal diagnostic test showed that the baby had the disease CF. At this adjunct,
it was stressed that prenatal diagnosis was not recommended for couples who
found termination of pregnancy unacceptable. The back cover of the leaflet
highlighted the important points for patients to note (see Table 1).
A self-administered prescreening questionnaire was included with the informa¬
tion leaflet. Women were asked to complete this at home and bring it with them
to the clinic. The questionnaire asked if a woman had (a) decided to have the test,
(b) decided not to have the test, or (c) not decided. It further asked if they would
write in a few words why they had made this decision or remained undecided.
Quotations were transcribed to a computer database and examined word by word
to abstract meanings or themes, which were categorized and then coded (Field and
Morse, 1990). The evaluation of the transcribed quotations and categories was
independently carried out by two research colleagues.
Socio-demographic data including details of a woman's decision to participate
in the alpha-fetoprotein (AFP) screening programme were obtained from the
antenatal records.
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RESULTS
At booking, 1812 (82 per cent) of the 2207 women eligible for screening had
decided to be tested, of whom 1728 returned a questionnaire. Two hundred and
seventy-nine (13 per cent) of the women declined the test, of whom 214 returned
a questionnaire commenting on why they had made their decision. A further
group of 116 (5 per cent) were undecided about the test at booking. Those who
were undecided were counselled by a genetic nurse and commented on why they
were uncertain. Of this group, 70 (60 per cent) were subsequently screened and 46
(40 per cent) declined. Questionnaires were therefore completed by 1798 women
accepting and 260 women declining screening.
Demographic data showed that multiparous women (68 per cent) were
more likely to decline CF carrier testing than primiparous women (60 per cent)
Or P<0'05; Table 2). Women who declined CF screening were also very much
more likely to decline AFP screening (/2 p< 0-001). There were no other sig¬
nificant differences in socio-demographic data on the accepting and declining
groups.
Two hundred and fourteen women commented on why they had declined the
test and 46 who were initially uncertain and subsequently declined also com¬
mented on the reasons for their uncertainty. The categories derived from these
comments are listed in Table 3 and examples of quotations are given in Table 4.
One hundred and forty (54 per cent) women declined to enter the trial because
they did not wish to terminate the pregnancy. The majority of this category (111)
were completely opposed to termination of pregnancy. However, 29 stated that
they held this opinion specifically with regard to the disorder CF.
The CF carrier test is distinct from other prenatal screening tests with respect to
involving the male partner. Indeed, prior indication that he would be willing to be
tested if necessary was paramount. Twenty-six (10 per cent) of those who declined
screening did so because their partner had indicated his reluctance to participate.
Perceiving one's risk of having an affected child as low clearly influenced women
to decline the test. Nineteen (7 per cent) stated this to be their reason for refusing
to be involved in the trial. Of these, 14 were multiparous women.
The inability of the CF carrier test to detect all carriers was a factor which
influenced 15 (6 per cent) to refuse screening. This reason frequently overlapped
with their concern that an inconclusive test result would generate anxiety
throughout the remainder of the pregnancy.
Thirteen (15 per cent) of the women stated that the test would generate
unacceptable levels of anxiety for them, and for this reason they would prefer not
to be screened.
Of the 11 (4 per cent) subjects who stated that they did not wish to be tested
during pregnancy, six would have accepted screening either preconceptually or in
the postnatal period as part of future reproductive decision-making.
For a group of ten (4 per cent), the dilemma of deciding among options raised
by a positive test result was the reason why they declined to enter the trial. Of this
group six had either a history of infertility or previous pregnancy loss, which they
felt contributed to their apprehension at being faced with a major decision
regarding continuing a much-wanted pregnancy.
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Table 2. Socio-demographic data
Accepted screening Declined screening





















































































Nine (3 per cent) simply 'did not want to know', and a further five (2 per cent)
stated that they had no reason for refusing, but just did not wish to be screened.
Only one woman who declined the test did so because of advances in treatment for
CF and ongoing research.
Of the 46 women who were initially undecided, but subsequently refused the
test, ten wished more information about the implications of screening. In this
CF CARRIER SCREENING 8 1 1







Against termination of pregnancy
Against termination for CF
For reasons of partner
Consider risk of CF child low
Error rate test unacceptable
Test causes anxiety or worry
Don't want test during pregnancy
Require more information
Too difficult decision if test positive
Don't want to know
No reason





































group, four wished to discuss the test further with their partner before making a
decision, but made no further contact with the clinic, while six felt that they were
unlikely to terminate the pregnancy and on this basis declined.
Unquestionably, women's opinion on termination of pregnancy was the factor
which motivated most to decline the test. This is a similar finding to previous
studies (Davies and Doran, 1982).
Of the 111 women who were completely against termination of pregnancy, 78
(70 per cent) had declined AFP screening. In contrast, only six of the 29 (21 per
cent) against termination specifically for CF declined AFP screening. It is
interesting that 33 (30 per cent) of those who stated that they were completely
against termination of pregnancy were planning to participate in the AFP
screening programme. One reason for this may be that no reference is made to
termination of pregnancy in the hospital's leaflet describing this test, whereas our
own CF carrier screening leaflet particularly draws attention to this as a possible
consequence. It is noteworthy that two CF carriers identified in the trial
subsequently declined AFP screening. This may have been directly due to the
anxiety experienced while awaiting their partner's carrier test result, but could
arguably be a result of the in-depth counselling carried out in the trial which
encouraged couples to address their attitude toward termination of pregnancy.
Prenatal CF carrier screening introduced a new concept of screening in its
involvement of the male partner. Some women were reluctant to admit a stable
relationship with their partner for fear of jeopardizing their entitlement to state
financial benefits. Many made it clear, however, that their partner would be
available for screening if required. Twenty-eight per cent of male partners did not
read the prescreening information leaflet, a figure comparable to the partners of
DISCUSSION
812 M. E. MENNIE ET AL.
Table 4. Examples of quotations from women who declined CF carrier screening
Completely against termination ofpregnane}'
'For us, killing our unborn child because of any disability is not an acceptable option.
I know of no other reason why the test would be helpful, so I wouldn't have it.'
Against termination specifically for CF
'I don't think in these circumstances I would find termination acceptable, so I'd prefer
not to start on this route.'
For reasons ofpartner
'My husband would be far too busy to have the test if it became necessary.'
'It's my partner—he doesn't really know about the pregnancy and he says he hasn't got
anything like that—he says it will take some time for him to think about it.'
Consider risk of having a child with CF is low
'As I already have a completely healthy child I don't think I am at high risk of having
a child with CF. Also there is no family history.'
Don't want to know
'I would prefer not to know.'
Test causes anxiety or worry
'The worry of finding out I have a single gene until my partner is tested. If he is
negative, the worry is unnecessary. If he is positive, even more worry would result until
the prenatal diagnosis when if the baby is negative, again the worry has been
unnecessary.'
Error rate of the test unacceptable
'As only 85 per cent of cases tested are successful, if my test was negative I'm still going
to be anxious that I might be that 15 per cent and as you state you cannot guarantee
the child will not have CF.'
Require more information
'Want to know more about the tests that are carried out before making a decision.'
Don't want test during pregnancy
'I feel it is now too late for the test to be relevant. If the test was available for someone
intending to become pregnant but not yet pregnant I would have had it at that stage.'
Too difficult a decision if test positive
'I think I would face a very difficult moral dilemma if I discovered, whilst pregnant,
that both my husband and I were CF carriers. I would then want to have the baby
screened and if it had CF I would be very worried about making a decision to have an
abortion, which in theory I'm opposed to, but realistically, don't know what I'd do.'
'My husband and I have decided against the test because we have waited a while for
this baby. To find out something was wrong would be shattering for us both, we would
rather take our chances and hope everything will be okay.'
No reason
"Don't know—just don't want to have test done.'
Because of advances in treatment for CF
'I would not terminate a pregnancy if CF was diagnosed. Having worked with cystic
children and adolescents, medical advances are being made which increase both the
quality of life and the life expectancy of the CF sufferer.'
women who accepted the test. This may reflect the findings of previous work,
which suggests that it is a minority of men who feel that the couple should together
decide about prenatal diagnosis (Sjogren, 1992).
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Perhaps not surprisingly, multiparous women were inclined to feel their risk of
having a child with CF was low. As one subject stated, 'I have five healthy children
already and feel 110 need for this test.' Genetic conditions are frequently equated
with a family history and despite the prescreening leaflet emphasizing that a family
history was not a prior condition to being a CF carrier, this was quite a difficult
concept for some to comprehend. A previous study has shown that perceived risk
rather than actual risk influences women's uptake of prenatal screening tests
(Marteau et al., 1991).
In some instances, satisfaction with the care given in previous pregnancies was
a factor: 'happy with my last two pregnancies and will just have the usual tests'.
The incompleteness of CF carrier testing was not a major concern and when it
was cited as a reason for declining the test, it was frequently connected with
concern: 'With the test only being 85 per cent accurate I do not feel it is worth
putting myself through the worry.' Nine (69 per cent) of those who declined the
CF test on the basis that it would provoke unacceptable levels of stress did accept
AFP screening. This could lead one to conclude that it was the false-negative rate
of the CF test which likewise deterred most of this anxious group. Data from this
trial on the psychological effects of identifying women as CF carriers during
pregnancy has been reported (Mennie et al., 1993).
Only 11 (4 per cent) of women actually stated that they were against being
screened during pregnancy. 'Feel it is too late to be having the test. Before
pregnancy I would have wanted it, including tests for other genetic diseases." A
study of attitudes of recent parents to CF carrier testing found that approximately
half of the sample were in favour of screening in early pregnancy (Green, 1992).
In this trial, women who have stated a preference to being screened outside
pregnancy are invited to request the test in the immediate postnatal period.
A recurring question amongst those who requested further information was the
availability of the test if termination of pregnancy was not considered an option
or induced feelings of uncertainty. Prenatal diagnosis for those who would not
consider abortion has generated argument (Clark and DeVore, 1989; Thorp and
Bowes, 1989) and many obstetricians are reluctant to carry out a risk-associated
procedure in such circumstances. Nevertheless, 'to be prepared' is a reason that
many women cite for wishing to be screened for CF carrier status, and collectively
this group constitutes a substantial prescreening counselling component. Cer¬
tainly, couples where both partners test positive can be given advance warning that
their child will be at a 1 in 4 risk of having the disease and can opt not to pursue
prenatal diagnosis. As one woman commented, 'it's a non-invasive test and there
are a number of points where one can decide whether or not to proceed further'.
In Britain, it is believed that more than one in ten couples experience difficulty
in either achieving a pregnancy or having a live-born child (Page, 1988). Studies
indicate that couples who have undergone infertility investigations and subse¬
quently encounter prenatal diagnostic procedures experience elements of the
psychological trauma associated with their infertility (Sandelowski et al., 1991).
The CF screening test is offered early in pregnancy, at the woman's first
antenatal clinic visit. It is understandable that having only just achieved a
pregnancy, the prospect of being confronted with a decision to continue or end it
is a situation that these couples would prefer to avoid.
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The importance of good prescreening information cannot be overemphasized.
Studies indicate that informed decision-making requires time (Lorenz et al., 1985).
The aim of the prescreening leaflet in this trial was to present a global view of CF
carrier screening to women and their partners well in advance of screening, in
order that they might make the correct decision with regard to accepting or
declining the test. Few came to the clinic undecided; nonetheless, frequent
evaluation of the content and delivery of prescreening information and counselling
should be part of the on-going evaluation of any prenatal screening programme.
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Negative investigations
Abdominal pain, headache, tiredness, and chest
pain are common complaints1 that are sometimes
troublesome enough to prompt a visit to the family
physician. A small proportion of patients will be
referred for further investigation and treatment. As
people prosper they expect to feel healthier and to
have good health care, so they are more inclined to
consult and to demand specialist attention.2
Ultimately, there is a rise in both the absolute
numbers and the proportion of patients attending
clinics with no diagnosis. If outpatient facilities are to
be inundated with patients who have no organic
disease but who demand to know what is wrong, we
need to know whether investigating them is
worthwhile. Doing tests is generally presumed to be
beneficial. The results may confirm or refute a
diagnosis, allow treatment to be targeted and
monitored, and reassure both doctor and patient that
there is no serious disease. Ordering a test may
sometimes enhance the doctor's income and protect
against litigation.3 On the negative side it may
encourage illness behaviour, reinforce a belief that
there is something to find, and ultimately lead to
crippling somatisation.4
The decision to conduct an investigation to look for
disease is influenced by the seriousness and
treatability of the disease as well as by the likelihood of
finding it. A serious disease is worth diagnosing even
when it is not treatable, because of the need to give a
prognosis. This is not always the case for benign
untreatable diseases; and for some benign treatable
conditions such as peptic ulcer and reflux oesophagitis
empirical treatment is usually safe. One could make a
case for not investigating dyspepsia with endoscopy in
patients aged less than 50 because empirical therapy is
safe, effective, and cheap and because the likelihood of
missing a treatable cancer is very small.
Occasionally a test is done with the specific purpose
of reassuring the patient that nothing is wrong. When
used in this way the investigation can be regarded as
part of treatment. A benign or possibly irrelevant
diagnosis such as hiatus hemia or diverticular disease
may be more reassuring than no diagnosis; a peg for
the symptoms may aid attribution and legitimise the
complaints by giving the patient something to tell
relatives and friends. In a study of oesophageal
function in patients with angiography-negative chest
pain, those who accepted that their pain was related to
oesophageal disorder did better than those who did
not.5 This finding suggests that concern about the
chest pain is more important than the abnormality that
is supposed to underly it. The important question
arising from this study is whether the oesophageal
tests were necessary for correct attribution and the
resulting wellbeing.
Some patients will not be convinced that there is
nothing treatable or seriously wrong until a test is
done, but many will accept a simple explanation and
reassurance for their symptom. Favourable outcome
for patients with headache presenting to a neurology
clinic was associated with satisfaction with
consultation and not with the extent of investigation.1,6
For those who are difficult to reassure, with or without
investigation, there is an alternative to more opinions
or tests. Klimes et al,7 in a randomised trial of a
"difficult" group of patients with non-cardiac chest
pain, who were not getting any better despite negative
test results and reassurance, showed that successful
reattribution of symptoms and reduced suffering can
be achieved with a cognitive-behavioural intervention
programme.
Doctors need to reassess their priorities when
investigating patients and to ask themselves three
questions. Will a positive investigation really make a
difference to my management of this patient? Will a
negative investigation help me reassure the patient
and help the patient attribute the symptoms to a
benign disorder? Is there an alternative, cheaper
strategy for managing the patient? The doctor is well
equipped to deal with the first question but not the
other two. Management trials in which patients are
randomly assigned to conventional treatment with
and without investigation will help answer the second
question. A further intervention arm such as an
education and reassurance package will help answer
the third. Economic endpoints such as time lost from
work, further consultation, and cost of the
intervention, as well as symptoms, would also need to
be included.
1. Creed F, Mayou R, Hopkins A. Medical symptoms not explained by
organic disease. London: Royal College of Psychiatrists and Royal
College of Physicians, 1992.
2. Valori RM. Nutcracker, neurosis or sampling bias? Gut 1990; 31:736-37.
3. Kastor JA. Pacemaker mania. N EnglJ Med 1988; 318: 182-83.
4. Bass C, Murphy M. The chronic somatizer and the government white
paper. J R Soc Med 1990; 83: 203-05.
5. Ward BW, Wu WC, Richter JE, Hackshaw BT, Castell DO. Long-term
follow-up of symptomatic status of patients with non-cardiac chest
pain: is diagnosis of esophageal etiology helpful? Am J Gastroenterol
1987; 82:215-18.
6. Fitzpatrick RM, Hopkins A. Referrals to neurologists for headaches not
due to structural disease. J Neurol Neurosurg Psychiatry 1981; 44:
1061-67.
7. Klimes I, Mayou RA, Pearce MJ, Coles L, Fagg JR. Psychological
treatment for atypical non-cardiac chest pain: a controlled evaluation.
Pychol Med 1990; 20: 605-11.
214 the lancet vol 340: july 25, 1991
Prenatal screening for cystic fibrosis
Moira E. Mennie Annette Gilfillan Mary Compton
Lucy Curtis W. A. Liston I. Pullen Dorothy A. Whyte
D. J. H. Brock
PUBLIC HEALTH
Screening for carriers of CF (cystic fibrosis) is now
possible but the best way of delivering such a service
is unknown. In one model 4348 women attending
antenatal clinics in an Edinburgh maternity hospital
were invited to participate in a trial of prenatal
screening. Mouthwash samples were tested for six
CF alleles (85% of mutant genes) and when a
woman was found to be a CF carrier her partner was
also tested. Heterozygous couples were offered
prenatal diagnosis.
609 (14%) women declined to enter the trial and
another 574 (13%) were not screened, usually
because of late booking. Among the remaining 3165
women there were 111 carriers of a CF gene (1 in
29). 4 of these 111 had carrier partners and these
couples opted for prenatal diagnosis, the 1
pregnancy with an affected fetus being terminated.
The psychological impact of screening was assessed
by the general health questionnaire. There was a
significant increase in stress at the time of the test
result among women identified as carriers. However,
this disappeared when their male partners tested
normal and did not reappear iater in the pregnancy.
By providing time for couples to discuss the
possibility of screening and by offering the test at a
point (the antenatal booking clinic) at which most
pregnant women are seen, this approach has
advantages, provided that counselling is readily
available.
Lancet 1992: 340: 214-16.
Introduction
The cloning of the cystic fibrosis (CF) gene in 198913 and
the demonstration that 70% or so of mutations are the
AF508 allele,4 made it possible to contemplate prenatal
screening. In the UK the Cystic Fibrosis Research Trust
solicited bids for trial projects aimed at delivering screening
either through community health services (family-planning
clinics or general practitioners) or in antenatal clinics.
Although there are some advantages in focusing testing on
individuals or couples before conception experience in
screening for other autosomal recessive genetic disorders
suggests that testing during pregnancy is more effective.5
In our trial project we assessed screening in the antenatal
clinic of Edinburgh's largest maternity hospital, the
Simpson Memorial Maternity Pavilion, which has about
5000 deliveries a year. Although couple screening has
recently been proposed6 we used the more conventional
two-step model. Women were offered testing at their first
antenatal clinic visit; if they were negative no further action
was taken but if they were positive the partner was tested.
When both parents carried CF alleles—ie, there was a 1 -in-4
risk of an affected child—prenatal diagnosis was offered. If
the father was negative the residual risk was explained to the
couple in a counselling session, but no further action was
taken.
The difficulty with this and any other method of
screening lies in the molecular heterogeneity of CF. Over
one hundred and fifty mutant CF alleles have been
described (International CF Genetics Analysis Consortium,
personal communication), many very rare. It is only possible
to test for the more prevalent mutations in a specific
population and to calculate residual risks on the basis of
known allele frequencies. We have looked for six mutations
representing some 85% of those found in Scotland.7
Residual risks are outlined in fig 1.
Methods
Recruitment
Before the full trial 180 women were sent an information leaflet
and questionnaire to test their reactions.8 On the basis of the
responses received (81 %), a printed leaflet was designed describing
the main features of CF and the methodology of the screening trial.
This leaflet was sent to all women with their booking clinic
appointment; they were asked to discuss it with their partners and
were invited to join the trial by signing a consent form. The leaflet
emphasised that screening is imperfect; it reduces but does not
abolish the risk of an affected child. Women were advised not to
participate if they could not identify the baby's father. Other
exclusions are shown in the table.
Counselling
At the clinic the midwife responsible for booking asked the
patient whether she had read the leaflet, understood it, and wished
to join the trial. Women who had not read the leaflet (often because
of reading difficulties) or found it too complex were counselled with
visual aids by a genetics nurse. Women carrying a CF allele were
ADDRESSES: Human Genetics Unit (M. E. Mennie, HV, A. Gilfillan,
BSc, M. Compton, RM, L. Curtis, BSc, Prof D. J. H. Brock, PhD); and
Departments of Obstetrics and Gynaecology (W. A. Liston, MB);
Psychiatry (I. M. Pullen, MB); and Nursing Studies (D. A. Whyte,
PhD), University of Edinburgh, Edinburgh, UK. Correspondence to
Prof D J. H. Brock, Human Genetics Unit, Western General Hospital,
Edinburgh EH4 2XU, UK.
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0.1%, 1 in 4 risk
72% of CF fetuses detectable
Fig 1-Two-step screening.
later seen with their partners for further counselling by the nurse. If
both had CF alleles they were referred to a consultant obstetrician
for discussion of possible prenatal diagnosis.
Psychological status
All women entering the trial were asked to complete a
twelve-item general health questionnaire (GHQ)'! before testing
(threshold GHQ). Carriers filled in a GHQ at the time of their test
result (GHQ1), at the time of their painter's test result (GHQ2),
and again 6 weeks later (GHQ3). For every carrier 2 control women
of the same parity who had received negative results were selected
from the same clinic and tested at comparable times.
Laboratory analyses
In the early part of the trial blood samples were collected from
women and mouthwash samples from their partners. However,
mouthwash samples had fewer difficulties and all participants were
subsequently asked to rinse their mouths briefly with 10-15 ml
tap-water which was transferred to a Universal container. Buccal
cells were pelleted by centrifugation, suspended in 50 mmol/1
sodium hydroxide, heated in a boiling water bath for 20 min,
neutralised, and centrifuged.
Two assay systems were used, with overlap in the mutant alleles
detected. In the in-house assay7 exons 10 and 11 were
simultaneously amplified by the polymerase chain reaction; the
AF508 and AI507 alleles in exon 10 were detected by
electrophoresis on polyacrylamide gels, whereas the G551D and
R553X alleles in exon 11 were detected by differential restriction
enzyme digestion. The commercial assay (courtesy of Cellmark)10
used the amplification refractory mutation system (ARMS) to
DELIVERY OF PRENATAL SCREENING (OCTOBER, 1990, TO
APRIL, 1992)
Women offered screening 4348
Declined offer 609 (14%)
Not screened













*1 2 women from ethnic groups where incidence of CF is low and whose command
of English was inadequate; 1 with a triplet pregnancy; 1 pregnant by artificial










Percentages of carriers (□) and controls (•) with positive responses
(3 +) shown for each test period.
Numbers of carriers and controls tested shown below figure.
detect AF508, G551D, G542X, and 621 + 1G->T. The in-house
assay detected 79% and the ARMS system 83% of mutations; in
combination they allowed scanning for 85% of mutations.
Reporting of results
Participants were told that initial testing would take 7 days and
that at that time they could assume that no mutant alleles had been
detected. Women who tested positive were informed by telephone if
possible or by letter otherwise and an appointment was made for
counselling, together with their partner. Parmer's samples were
tested as quickly as possible and the results communicated by
telephone. All results were recorded in the obstetric notes; positive
results were also communicated by letter to the woman, her general
practitioner, and the consultant obstetrician.
Results
Screening was introduced in October, 1990, the offer
being made initially in just one of nine weekly antenatal
clinics. By April, 1992, 4348 women in 431 clinics had
received the information leaflet and an invitation to
participate (table). Most of the 609 women who refused to
take part gave their reason as non-acceptance of the
possibility of termination in the event of an affected fetus. A
further 574 women were not screened because they were
already over 18 weeks' gestation (430), because of abnormal
pregnancies (mainly blighted ova) (73), or because their
partner would not participate (56). Other reasons are shown
in the table.
Among the 3165 women tested there were 111 CF
heterozygotes, giving a carrier rate of 1 in 29. Since the
detection rate of CF alleles was 85%, the true heterozygote
frequency is 1 in 24. Partners of 110 of these 111 carriers
were screened and 4 (3 AF508, 1 G551D) were found to be
positive. All 4 of these couples opted for prenatal diagnosis, 3
via amniocentesis and 1 via a transabdominal chorionic
villus biopsy. 1 woman was found to be carrying a AF508
homozygote and she decided on termination; the diagnosis
was confirmed on fetal tissues. The other 3 women were
carrying unaffected fetuses and are proceeding to term.
GHQs were regarded as positive if the score was 3 or
more.11 At the time of the test result (GHQ1), 53% (95%
confidence interval [CI] 41-66%) of carriers had positive
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(p<0 01). This difference had disappeared by the time of
the partner's negative test result (GHQ2) (fig 2).
Discussion
The cloning of the CF gene prompted considerable
discussion about population heterozygote screening and the
consensus was that trial projects of different modes of
delivery, not necessarily mutually exclusive, were needed.
One method is preconception screening, which provides
carrier couples with several options (such as changing
partners, artificial insemination by a screened donor,
forgoing reproduction, or prenatal diagnosis) and time for
reflection and an unpressured choice. However, it is difficult
to see how delivery through general practices and family-
planning clinics could reach a broad range of the population,
and bias towards take-up by the educationally and socially
advantaged seems unavoidable.
CF heterozygosity is of medical significance when a
pregnancy is planned or in progress, so it makes sense to
target screening close to pregnancy. Evidence from other
recessively inherited disorders suggests that screening
during pregnancy is the most practicable time. In a 1989 US
report on screening for Tay- Sachs disease, in which
participants could be tested before or during pregnancy,
80% of respondents were already pregnant when the test
was sought.13 In the UK almost all pregnant women now
attend hospital at some stage and the antenatal clinic is an
effective way ofensuring that screening is offered to as many
woman as possible. Reducing the number ofdelivery points
would be of great importance if screening for CF is to
become routine, because of the need for back-up counselling
at every point.
In the two-step model ofdelivery tested here, the take-up
rate was high (86%) but because of late booking and other
reasons the proportion of women screened was 73%. This
may represent an effective upper limit for this type of
programme. An earlier study showed that some 40% of
women decided to enter the programme without reference
to their partners8 but we found that only 1 of the 111 female
carriers was unable (or unwilling) to persuade her partner to
be tested. This suggests that the motivation of the woman is
an important contributor to a good take-up rate—and that
non-patermty14 is not likely to be an important source of
error. We have also noted that first-degree relatives of 15 of
the 111 carriers detected by screening have made
appointments with the genetic counselling clinic to establish
their carrier status.
One concern in this trial was stress in women identified as
carriers. 20-30% ofwomen had positive GHQ scores before
they were tested, a result which accords with previous
findings of 35% in pregnancy.15 Women identified as
carriers were significantly more likely to record a positive
GHQ than controls but this difference disappeared once
their partners had been tested and found not to carry a
detectable CF allele. Thus stress would appear to be ofshort
duration in carrier women, despite their being warned that
their residual risk of bearing a CF child was still 1 in 600 or
so.
The model of prenatal screening for CF tested here has
considerable merit. Information leaflets about CF and
screening can be studied by women and their partners at
home, since couples have 4 weeks or so before any decisions
need to be made. Most oftheir questions can be answered by
midwives during the booking-in procedure. More than 96%
of screened women had no detectable CF alleles in our series
and there is no evidence for an increase in stress amongst this
negative group. For an allele detection rate of85% only 1 in
every 865 couples will need to be referrred to a doctor for
detailed discussion of prenatal diagnosis.
Ifabout 73% ofwomen offered testing are screened and if
the detection rate for CF alleles continues at 85% we would
expect to identify about half (0-73 x 0-85 x 0-85) the l-in-4
risk couples in our population. We do not know what
proportion of these would opt for prenatal diagnosis and
termination of pregnancy if the fetus were affected; all 4 of
our couples indicated that this was their intention. However,
even if only half the parents of an affected ferns chose
termination, this would still lead to the reduction in
live-born incidence of 1 case of CF for every 10 000 tests.
The Royal College of Physicians16 estimates the cost of
treating a CF child at least £5000 per year (1986 figures);
over an expected life-span of 25 years this represents a sum
of £125 000. Laboratory costs for 10 000 tests are about
£30 000, while the total programme costs (including
laboratory) are about £80 000. Thus a crude cost-benefit
calculation suggests that screening of this kind represents
good value. The major resource implicated is in the
management of carrier women in the period between their
test result and that of their partner. At least one counselling
session is needed to answer questions, allay fears, and place
risks in perspective. This can be done by informed
non-medical personnel with good communication and
counselling skills. In our experience a specialist genetics
nurse is essential to the smooth delivery of this type of
programme.
We thank the medical and nursing staff of the Simpson Memorial
Maternity Pavilion for making this trial possible. The study was funded by
grants from the Cystic Fibrosis Research Trust and the Scottish Home and
Health Department.
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Abstract
A questionnaire was given to 180 patients
in an antenatal clinic, who were eligible
to enter a pilot trial of cystic fibrosis (CF)
carrier testing, seeking their views on the
information leaflet inviting them to par¬
ticipate; 161 patients (89%) entered the
trial and 145 patients (81%) responded to
the questionnaire, including 10 who did
not enter the trial. Ninety-six percent of
these found the leaflet easy to under¬
stand, and 97% of those partners who
read the leaflet also found it easy to
understand. Fifteen percent of patients
thought the leaflet should give additional
information. Most (92%) had heard of CF
before reading the leaflet, television
being the most common source of in¬
formation. Although avoiding the birth
of a child with CF was the reason most
patients gave for wishing to be screened,
almost as many were interested to know
their carrier status. The decision to ac¬
cept or decline testing was taken in con¬
junction with their partner by 63% of
women. Of those who were screened, 59%
stated that taking the test made them feel
reassured, while 38% felt slightly appre¬
hensive. It was concluded that, with a
number of minor amendments, the leaf¬
let met the specific needs of the target
patient population.
The cloning of the cystic fibrosis (CF) gene in
1989 and the subsequent description of a
number of mutant CF alleles has made it
possible to detect CF carriers in the general
population. A survey of Scottish CF patients
and their parents shows that about 85% of
carriers can be identified by testing for just
four mutations.1 Although this is less than
ideal for a screening test, it has been argued
that the severity of the disorder demands an
immediate start to pilot trials of carrier detec¬
tion.2 Accordingly we have initiated such a
trial in selected antenatal clinics of the major
Edinburgh maternity hospital.
Pregnant women are offered the chance of
joining the trial by means of a leaflet sent with
their antenatal booking clinic appointment.
The leaflet emphasises the incomplete nature
of thej£st and that it cannot guarantee against
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partners are found to be carriers are offered
prenatal diagnosis.
A prerequisite to an informed decision to
undergo any screening or diagnostic test is
knowledge of the test.3 Indeed, some argue
that the effectiveness of such a screening pro¬
gramme should be assessed by whether the
participants have become fully informed.4
However, to be effective and useful, educa¬
tional materials must meet the specific needs of
the target population.5
The use of a questionnaire to assess patients'
attitudes to information leaflets has been de¬
scribed.67 Before committing ourselves to a
final version of the information leaflet designed
for this trial, we tested the acceptability and
usefulness of a preliminary version on our
target population, by means of a self adminis¬
tered questionnaire.
Subjects and methods
A pilot trial was run in one antenatal booking
clinic for a period of 14 weeks. Along with
their booking clinic appointment, patients
received a copy of the information leaflet out¬
lining the purpose and process of prenatal CF
carrier screening (table 1). The leaflet also
incorporated a consent form to be signed by
patients entering the screening trial.
A total of 200 antenatal patients attended the
booking clinic during the pilot trial. Twenty of
these patients were not eligible to enter the
screening trial for reasons of late gestation
(greater than 18 weeks), abnormality of preg¬
nancy (for example, blighted ovum), or
unavailability of partner. Questionnaires were
not issued to this group. The remaining 180
antenatal patients were given a questionnaire
and a stamped addressed envelope at the book¬
ing clinic and asked to complete it at home and
return it. Patients were not asked to identify
themselves. A total of 145 (81%) returned
their questionnaire. Of the 161 patients who
entered the trial, 135 responded. Of the 19
patients declining to enter, 10 responded.
Results
PATIENTS' PREVIOUS KNOWLEDGE OF CF AND
SOURCE OF INFORMATION
The questions were;
(1) Had you heard of the disease cystic
fibrosis before you read the leaflet?
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Table 1 The information leaflet.
Cystic fibrosis carrier testing
Prenatal screening trial
One in every 25 men and women carry a single cystic fibrosis
gene. A single cystic fibrosis gene is completely harmless. But,
if a woman who carries a single cystic fibrosis gene has a child
by a man who also carries a single cystic fibrosis gene, there is a
1 in 4 chance that their child will have the disease cystic fibrosis.
(diagram of cystic fibrosis genetics)
Cystic fibrosis
Cystic fibrosis is serious. The average life expectancy is 19
years. Children with cystic fibrosis have repeated chest infec¬
tions and are usually underweight and undersize. They may
need daily physiotherapy and large numbers of tablets to assist
digestion. If they live long enough they will probably need a
heart and lung transplant.
We think that a woman who is having a baby will want to
know the answers to three important questions:
(1) Am I a carrier?
(2) Is my partner a carrier?
(3) Will my baby be affected?
We are running a trial which tests whether or not you are a
carrier of a single cystic fibrosis gene. If you are not there is no
need for further concern.
If you are a carrier it is possible to tell if your husband or
partner is also a carrier.
Only if both of you are carriers will you have a 1 in 4 chance of
having an affected child.
If you and your partner are both carriers, a prenatal test can
tell whether or not your baby will be affected.
Prenatal diagnosis
This is one option available to couples who have a 1 in 4 chance
of having a child with cystic fibrosis. It is possible to diagnose
cystic fibrosis in the fetus. If the prenatal diagnostic test shows
that the unborn child is going to have cystic fibrosis, you may
wish to have an abortion.
Prenatal diagnosis is not recommended for those couples who
find abortion unacceptable.
The cystic fibrosis carrier screening test
A small sample of the blood taken for your other antenatal tests
will be used to test if you are a carrier. You will be contacted
only if the test shows you are a carrier.
Testing for the cystic fibrosis gene is still only possible in
85% of cases. This means we cannot guarantee that you will not
have a child with cystic fibrosis. However, if the test is negative
it will greatly reduce that risk.
Testing your partner
If you are found to carry a single cystic fibrosis gene we would
be able to test your partner.
A small mouth wash sample will be used to test your partner,
so he will not have to give a blood sample.
If your partner's test is negative then your risk of having a
baby with cystic fibrosis is low.
A special leaflet and genetic counselling is available for all
couples where one partner has a positive carrier test.
Couples who are both carriers of a single cystic fibrosis gene
Genetic counselling is available to couples where both partners
are found to be carriers.
The various options open to you will be fully explained. You
will have time to think through these options and to discuss them
at length with the counsellor.
Further information and advice about prenatal carrier testing
for cystic fibrosis
There will be time at the booking clinic to ask any questions, or
discuss any concerns you may have about prenatal carrier
testing for cystic fibrosis. Counselling is available at any stage of
the screening trial. There will be a nurse counsellor available at
the antenatal booking clinic.
Prenatal carrier testing for cystic fibrosis is voluntary
Prenatal carrier testing for cystic fibrosis is entirely voluntary.
If you would like to be tested please complete the enclosed
form and bring it with you to the antenatal booking clinic.
Important points to remember about prenatal carrier testing for
cystic fibrosis
(1) Carrying a single cystic fibrosis gene is completely harm¬
less.
(2) Only if both partners carry a single cystic fibrosis gene will
there be a 1 in 4 chance that their child will have cystic
fibrosis.
(3) Testing for the cystic fibrosis gene is still only possible in
85% of cases.
(4) Genetic counselling is available for all couples where both
partners are found to carry a single cystic fibrosis gene.
(5) The prenatal cystic fibrosis carrier screening trial is entirely
voluntary.
(6) Remember there are trained staff to give you information
and advice - please do ask.
(2) If you had heard of cystic fibrosis, where
did you hear about it? (Tick as many
options as required.)
There were 145 responses, with 134 (92%)
saying yes. Major sources of information were
TV, women's journals, and charity appeal.
patients' assessment of the leaflet and
understanding of the purpose of cf
carrier testing
The questions were:
(3) In your opinion, is the leaflet introduc¬
ing the cystic fibrosis carrier screening
test difficult or easy to understand?
(4) How many times did you read the leaflet
before you felt you understood it?
(5) Do you feel you understand the purpose
of cystic fibrosis carrier testing?
(6) Do you feel the leaflet should give more
information?
(7) Has your partner read the leaflet?
(8) If your partner read the leaflet, was it, in
his opinion, difficult or easy to under¬
stand?
(9) Did you make the decision to accept or
refuse the screening test alone or with
your partner?
The answers of the 145 respondents are listed
in table 2.
patients' reasons for being screened
(numbers based on those 135 respondents
who entered the screening trial)
The question asked was:
(10) If you have decided to take the screening
test, is this because (tick as many options
as required)
(a) I am interested to know if I carry a
single cystic fibrosis gene.
(96 respondents)
(b) I do not want my child to have cystic
fibrosis.
(102 respondents)
(c) My partner wanted me to have the
screening test.
(22 respondents)
(d) Other (please state reason).
(10 respondents)
patients' reasons for not being screened
(numbers based on the 10 respondents who
did not enter the trial)
The question asked was:
(11) If you have decided not to take the
screening test is this because (tick as
many options as required)
(a) I would prefer not to know if I carry
a single cystic fibrosis gene.
(No respondents)
(b) I am against termination of preg¬
nancy.
(10 respondents)
(c) My partner did not want me to take
the screening test.
(3 respondents)
(d) Other (please state reason).
(No respondents)
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Table 2 Patients' assessment of information leaflet and their understanding of CP carrier testing: numbers (and
percentages).
Assessment of leaflet Difficult to understand Easy to understand
6(4) 139 (96)
Times leaflet read before understanding Once Twice Thrice Four times Many times
94 (65) 46 (32) 2(1) 1(1) 2(1)
Assessment of understanding of the purpose of Understand Don't understand
CF screening 141 (97) 4(3)
Wish for more information in the leaflet Yes No Don't know
21 (15) 108 (74) 16(11)
Number of partners who read the leaflet Yes No Don't know
92 (63) 50 (35) 3(2)
Partner's assessment of the leaflet Difficult to understand Easy to understand
3(3) 89 (97)
Partners who participated in the screening Decision taken with partner Decision taken without partner
decision 91 (63) 54 (37)
PERSONS WITH WHOM PATIENTS DISCUSSED THE
SCREENING TEST (NUMBERS BASED ON
RESPONDENTS WHO ENTERED THE TRIAL)
The question asked was:
(12) Have you discussed taking the screening
test with anyone? (Tick as many options
as required)
(a) Partner (112 respondents)
(b) Relative (18 respondents)
(c) Friend (21 respondents)
(d) GP (5 respondents)
(e) Health visitor (1 respondent)
(f) Other (state who) (no respondents)
PATIENTS' ESTIMATION OF THEIR LIKELIHOOD
OF BEING A CF CARRIER AND ATTITUDE TO
BEING TESTED (NUMBERS BASED ON THOSE 135
PATIENTS WHO ENTERED THE SCREENING TRIAL)
The questions were:
(13) How likely do you think it is that you
will carry a single cystic fibrosis gene?
(14) How does the thought of the cystic
fibrosis carrier test make you feel?
Four options were listed (table 3).
Discussion
The cystic fibrosis pilot trial began in the
antenatal clinic of the Simpson Memorial
Maternity Pavilion in October 1990. Since the
first programmes of maternal serum AFP
screening were developed and started in Edin¬
burgh in 1975, we already had in place ante¬
natal staff broadly trained in the process of
explaining the concepts of screening.
With their antenatal booking clinic appoint¬
ment, patients received a CF prescreening
information leaflet incorporating a consent
form. The midwife carrying out the booking
procedure ensured that her patient had
received a leaflet, had read it (or been able to
read it), and was fully aware of the conse¬
quences of CF carrier screening. A genetic
nurse was on duty at the clinic to answer
patient or staff questions and to offer counsell¬
ing and one to one sessions, using visual aids,
to patients and couples with difficulty in read¬
ing or understanding the leaflet. Patients wish¬
ing to enter the trial signed a consent form.
Information given before prenatal genetic
screening must be adapted to a woman's cir¬
cumstances and be sufficient to enable her tc
reach a fully informed decision.8 Only toe
frequently, when educational protocols arc
being developed, the target population reac¬
tion is not sought.9 For information and educa¬
tion to be effective, this group needs to be
consulted to determine what they need tc
know or learn. This study attempts to consul:
antenatal patients about a leaflet designed tc
inform them about prenatal CF carrier testing
The response to the questionnaire was higf
(81%). All questionnaires were completed ir
full and many respondents commented a:
length on the questions. Most (92%) claimec
they had heard of CF before they read the
information leaflet, and many were able to cite
the source of their knowledge. This probablj
reflects the high profile of the Cystic Fibrosi:
Research Trust in the UK and may not be
applicable to other European countries.
There was no correlation between absence
of previous information and difficulty under¬
standing the leaflet. Of the six respondent:
who had difficulty understanding the leaflei
(table 2), five had previously heard of CF
However, of the four women who felt they die
not understand the purpose of CF screening
(table 2), three stated they had not previousl}
heard of CF. Comments indicated that man}
of this antenatal patient population were alsc
familiar with one major clinical feature of CF
namely lung disease. A concern raised regard¬
ing the initiating of CF carrier screening pro¬
grammes is that only a small percentage of tht
population are at present familiar with tht
disease.4 This study did not attempt to test
subjects' knowledge of CF and it would bt
misleading to suggest that patients hat
detailed knowledge. Indeed, more detail:
about the disease itself were requested by al
15% of respondents (table 2) who felt that the
leaflet should give more information. Never¬
theless, it is encouraging that so many womer
were previously aware of the disorder.
The Council of Europe, in their official
statement on genetic screening, note the rok
that the media can play in informing and
educating the public and recommend they be
Table 3 Patients' estimation of their likelihood of being a CF carrier and their attitude to being screened: numbers
(and percentages).
Estimated likelihood of being a CF carrier
















79 (59) 1 (1)
'retiatal cystic fibrosis carrier testing
kept informed of all aspects of antenatal gen¬
etic screening." In this study, television was
the leading source of information about CF. A
considerable number of respondents were
acquainted with the disease through women's
journals and charity appeals. Knowledge of
CF was acquired by a number of women
through their occupation and in three cases by
virtue of having a distant family history of the
disorder.
The majority (96%) of antenatal patients
stated that they found the leaflet easy to under¬
stand (table 3). There was no correlation
between difficulty understanding the leaflet, or
failing to understand the purpose of CF
screening, and declining the test. All 10 re¬
spondents who declined the test found the
leaflet easy to understand and stated that they
felt they understood the purpose of CF screen¬
ing. One woman took the CF test, despite
finding the leaflet difficult to understand and
not understanding the purpose of CF screen¬
ing.
There is a danger in designing an informa¬
tion leaflet that one may make it either too
simple or too complex. Many women are con¬
fident and articulate users of the antenatal care
system and can cope with detailed informa¬
tion. Others lack the basic knowledge to know
the right questions to ask. Our solution has
been to design a comparatively simple leaflet
and to train midwives to pick up those cases
who are unsure about what is being offered. A
genetic nurse is on standby to give one to one
counselling and answer the more sophisticated
questions.
Most women (65%) stated they had only
read the leaflet once before feeling they under¬
stood it (table 2). Antenatal bookers receive a
considerable volume of material to read along
with their clinic appointment and may find
they have limited time to read and absorb it all.
Those who enter the CF screening trial must
sign a consent form and in addition the mid¬
wife responsible for booking a patient is
instructed to do his or her utmost to ensure
that a participant understands the purpose of
the screening test. Nevertheless, studies do
indicate that a lack of knowledge and under¬
standing of women participating in prenatal
screening programmes is an area for concern10
and researchers have attempted to design
instruments whereby knowledge of such tests
can be measured.3 CF carrier screening may
carry more obscure risks and considerations
than other antenatal screening tests, notably
Decision to be tested
'aken alone
Partner read leaflet Partner did not read
est discussed Test discussed Test discussed Test discussed Test discussed
with partner with friend with relative with genetic nurse with no-one
9 2 44 13
\nalysis of discussion with significant others, among those women who took the decision
lone, to enter the CF screening trial.
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perceived change of self image in those identi¬
fied as gene carriers.11
A prerequisite of prenatal CF carrier screen¬
ing is cooperation of the male partner. Most
partners (63%) read the prescreening leaflet
and were involved in the test decision (table 2).
The partners of all 10 women who declined the
test had read the leaflet. Although two of these
women took the decision to decline the test
alone, they had discussed it with their partner.
Of those who found the leaflet difficult to
understand, five partners read the leaflet and
three also found it difficult to understand.
Nevertheless, they were party to the decision
to be screened. All partners of those women
who felt they did not understand the purpose
of CF screening were involved in discussion
and decision making, although only one had
read the leaflet.
Twenty-one respondents (14%) who
entered the trial discussed taking the test with
a friend and 18(12%) with a relative. Only five
respondents had talked with their GP and one
woman to her health visitor. Fifty-two women
made the decision to take the test alone. A
concern which emerged from this study is that
13 (9%) women took the decision to be tested
without discussing the test with either their
partner or other significant person (figure).
Evidence suggests that social network and
social support play an important role in health,
individual decision making, and behaviour.
Moreover, social support is known to serve a
protective function by moderating the impact
of stress and facilitating coping.12 It could be
hypothesised that good social support will con¬
tribute positively to a woman's adjustment to
being a CF carrier. It has been pointed out that
the whole area of psychosocial support has
been neglected in the provision of antenatal
care and that careful assessment of a woman's
social support system should be an integral
part of the antenatal booking procedure.13
Identifying vulnerable women in advance of
any screening test is important. This study
suggests that around 10% of women booking
at the antenatal clinic may have reduced per¬
ceived or received social support. Further re¬
search is needed to substantiate this.
Those women who decided to accept the CF
screening test did so, in 76% of cases, to avoid
the birth of a child with CF. In addition, 71%
stated, either with or without saying they
wished to avoid having a CF child, that they
were interested to know if they carried a single
CF gene. In 16% of cases, the male partner's
wishes had been instrumental in their decision
to be tested. Those who gave additional
reasons for being screened (7%) stated they
wished to help with research or contribute to
a better understanding of the disorder. Com¬
mendable though this is, we have subsequently
discouraged women from entering the trial for
these reasons. A positive test result has far
reaching consequences which prospective par¬
ticipants must consider carefully.
A vast majority (99%) of women who accep¬
ted the screening test thought it 'not very
likely' or 'most unlikely' that they would be
found to be carriers (table 3). Nevertheless,
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41% were still 'anxious' or 'slightly apprehen¬
sive' about being screened. There was no cor¬
relation between difficulty in understanding
the leaflet or understanding the purpose of CF
screening and feelings of anxiety towards
being tested. The one participant who stated
the test made her feel anxious had taken the
decision to be tested only after discussion with
her GP. She did not think it very likely that
she would carry a single CF gene. The whole
area of anxiety generated by this programme of
screening will be explored in greater depth.
"More about people with the disease, effects,
lifespan, etc" was a typical request made by the
15% of respondents who felt that the leaflet
should give more information (table 2). How¬
ever, those who felt the leaflet offered suffi¬
cient information frequently commented that,
although they would like to know more about
the disease, additional information in the leaf¬
let might only serve to confuse. As a comprom¬
ise we expanded, slightly, the section of the
leaflet entitled 'The disease cystic fibrosis' and,
as an adjunct, designed a separate leaflet
devoted to the disorder. This leaflet is made
readily available at the antenatal clinic.
Good quality educational materials can help
promote the relationship between the patient
and the health care professional as well as
enhancing patient knowledge and self care.5
Quality of text will be determined by its read¬
ability and must, therefore, be written on a
level that is appropriate for the target popula¬
tion. Moreover, readability will be influenced
by the content, style, layout, colour, and illus¬
trations. It is unrealistic to believe that a leaflet
can provide blanket coverage of all aspects of
antenatal CF carrier screening. A mixture of
information giving, teaching, and counselling
is needed. Nevertheless, the delivery of infor
mation by leaflet is one very importan
strategy. We shall, therefore, continue t
evaluate the delivery of prescreening informa
tion by leaflet for the duration of this trial.
We are grateful to all the antenatal patient
who responded to the questionnaire and too
time to comment about the CF carrier testin
prescreening information leaflet. Copies of th
leaflet may be obtained from the authors o
request. This work was supported by a gran
from the Cystic Fibrosis Research Trust.
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Prenatal screening for cystic fibrosis:
psychological effects on carriers and their
partners
M H Mcnnie, M E Compton, A Gilrillan, W A Listen, I Puller.. D A Whyte.
D J H Brock
Abstract
This study aimed to assess the psycho¬
logical impact of screening for cystic
fibrosis (CF) carrier status in a popula¬
tion of pregnant women. A cohort of 179S
women, who accepted the offer of testing
before 18 weeks of pregnancy, filled in a
self administered questionnaire seeking
information on their perceived risk of
carrier status and their emotional re¬
sponse, as well as a general health ques¬
tionnaire (GHQ). Sixty-four women
identified as CF carriers had partners
who received a negative test result. This
group and their partners were assessed,
together with selected controls, on four
further occasions: (1) on receiving the
carrier's positive test result; (2) on
receiving the partner's negative test re¬
sult; (3) six weeks later; (4) six weeks after
delivery. The instruments used were the
GF1Q and the Symptom Rating Test
(SRT).
When compared to control subjects,
carriers showed a significant increase in
generalised psychological disturbance
which could be attributed specifically to
symptoms of anxiety and depression dur¬
ing the period (average four days) that
they awaited their partner's test result.
On receiving a partner's negative test
result, the carriers returned to control
levels and maintained this equilibrium.
Although there was no significant dif¬
ference in generalised psychological dis¬
turbance between partners and their
selected controls, partners did become
significantly more anxious and mani¬
fested feelings of inadequacy while
awaiting their own test result. Both male
partners and male control subjects were
more likely to become anxious if their
partner was distressed.
(J Med Genet 1993;30:543-8
Population carrier screening for cystic fibrosis
(CF) has become possible since the identifica¬
tion of the cystic fibrosis gene' and the dis¬
covery that a relatively small number of muta¬
tions account for the majority of CF
chromosomes in the UK population.-' One
objective of carrier screening is to provide
information to individual persons or couples so
that they can make reproductive plans for the
future. Another objective is to allow pregnant
women to avoid the birth of a child with CF.
There are a number of possible approaches
to CF earner screening and The Cystic Fibro¬
sis Trust has funded three trials to assess the
feasibility of delivering screening by alternat¬
ive routes.'' In Edinburgh a prenatal approach
has been adopted. The principal steps in this
trial are: (1 to offer pregnant women, attend¬
ing the antenatal booking clinics of a major
maternity hospital. CF carrier screening by
way of a mouthwash sample, and to test for six
mutations accounting for 85° o of CF chromo¬
somes,' (2 to offer the partners of women who
test positive for the CF gene a carrier test, and
(3) to offer prenatal diagnosis to heterozygous
couples.
Many of the arguments about CF carrier
screening concern the incompleteness of
screening. Because the test fails to account for
15% of CF mutations, couples in which
neither partner has an identifiable mutation
have a residual 1 in 104 000 risk of having an
affected child. However, in approximately 4%
of couples the women will test posiuve and her
partner negative. These couples face a 1 in 640
risk of having a CF child, substantially greater
than their starting risk of 1 in 2500. This study
aimed to measure the psychological impact of
prenatal CF carrier testing on those couples
faced with this intermediate risk.
Subjects and methods
Women up to 18 weeks' gestation presenting
for antenatal care at the Simpson Memorial
Maternity Pavilion, Edinburgh, were eligible
for inclusion in the screening trial. Details of
the recruitment and screening method are
given elsewhere.5 The protocol and adminis¬
tration of psychological tests is outlined in
fig 1.
From May 1991 to January 1992 a total of
1798 women was screened and 69 (4%) were
identified as CF carriers. In all cases the male
partner was screened. Excluded from this
study were three couples where both partners
proved heterozygous. Further exclusions were
one couple who sutfered a pregnancy loss, one
couple who failed to complete the question¬
naires, and one screened partner who
requested exclusion from the study even
though his carrier partner expressed a wish to
be included. A total of 64 carrier women and
63 male partners entered the study. One cou¬
ple subsequently separated resulting in only 62
partners completing the final questionnaires.
For each carrier, two control subjects of the
same paritv were selected. Control subjects
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shortest version, the 12 item GHQ, was chosen
using the 3/4 cut off point.
The nature of psychological response was
assessed bv the SRT.' Composed of 30 symp¬
toms bricflv defined in simple language, the
SRT allows separate scores to be derived for
anxiety, depression, inadequacy, and somatic
symptoms. Unlike the GHQ, it is not a case
finding instrument but will measure psycho¬
logical distress and is very sensitive to change.
The GHQ scored respondents as positive
or negative. The significance of differences
between groups was evaluated by the %2 test-
The SRT ascribed scores to subjects. As the
scores were not normally distributed (skew to
notified if requested higher values'), the significance of differences

























Figure I Screening protocol and administration of psychological tests.
as the carrier, had received a negative test
result, and had a male partner willing to act as
a control subject. A total of 116 female controls
and 1 15 male controls agreed to participate. Of
these, 13 couples failed to complete all the
questionnaires and two suffered a pregnancy
loss. A total of 101 female controls and 100
male controls completed the study to stage 3.
Failure to trace two couples resulted in 99
female controls and 98 male controls complet¬
ing the final questionnaires.
Measures
Sociodemographic data were obtained from
subjects' antenatal records. A self adminis¬
tered pre-screentng questionnaire assessed
perceived carrier nsk and emotional response
to screening. Threshold psychological assess¬
ment and the impact of screening on carriers
was assessed by two self rating questionnaires,
the General Health Questionnaire (GHQ) and
the Symptom Rating Test (SRT).
The GHQr is a screening tool which identi¬
fies two main classes of problem: inability to
carry out one's normal 'healthy" functions
and the appearance of new phenomena of a
distressing nature. Given that time is at a
premium in an antenatal booking clinic the
Procedure
An information leaflet was sent to all antenatal
patients with their booking clinic appoint¬
ment. Details of the leaflet have been described
previously.' Enclosed with the leaflet was a
pre-screening questionnaire incorporating a
GHQ (termed threshold GHQ). Thus, women
suffering from psychological disturbance
before receiving a positive CF test result could
be ascertained. Women were invited to com¬
plete the questionnaire at home and to bring it
with them to the clinic. Those women entering
the trial who had not completed the question¬
naire at home were asked to complete one at
the clinic.
Pre-screening counselling and obtaining a
mouthwash sample for DNA analysis was car¬
ried out by the midwife responsible for book¬
ing the patient. Activity at the clinic limited
data collection, so only women presenting with
a positive GHQ were asked to complete a SRT
(termed threshold SRT) to determine the
nature of their distress. These women were
interviewed by a genetic nurse to ascertain the
likely source of their psychological disturb¬
ance. GHQ and SRT scores along with inter¬
view data were stored on a computer database
for ease of storage and recall when a carrier was
ascertained.
Women identified as CF carriers were con¬
tacted a week later by telephone or, in a minor¬
ity of cases, by letter and invited to attend the
hospital for counselling along with their
partner. The couple were seen by a genetic
nurse who, before counselling, asked each
partner to complete a GHQ and a SRT
(termed GHQl and SRTl). Counselling was
carried out using visual aids and couples were
given a detailed information leaflet with a
contact telephone number. A consent form and
a mouthwash sample for DNA analysis were
obtained from the partner.
On receipt of the partner's negative test
result (average four days) the couple were
contacted in all cases by telephone and
informed of the result. A letter was sent con¬
firming the partner's negative test result and
reiterating the residual risk of 1 in 640 of
having an affected child. Enclosed were a
stamped addressed envelope and a GHQ and a
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Carrie's n = 64 n = 64
Controls n = 101 n = 101
c = NS <0 001
Results
SOCIODEMOGRAPHIC DATA
The sociodemographic characteristics of tb
screened population, carriers, and controls ar
shown in table 1. The sample was weights
toward the higher socioeconomic group
(assessed from the occupation of the head c
the household using the Registrar General
classification). This reflects the tendency fc
women of the higher social classes to preser
earlier for antenatal care and to have a stab
partnership. Furthermore, a majority c
women from a sizeable area housing those c
the lower socioeconomic groups booked fc
antenatal care at a clinic within that area.
SRT (termed GHQ2 and SRT2 . Six weeks
later the couple were sent a further postal
GHQ and a SRT (termed GHQ3 and SRT3)
and finally six weeks after delivery the same
two measures were sent (termed GHQ4 and
SRT4).
Control couples received a postal GHQ and
a SRT at comparable intervals to carriers and
partners.
Perception of carrier risk and emotional response to screening ' percentages in
ANXIETY AND PERCEIVED CARRIER RISK
The pre-screening questionnaire assessed pe:
ceived carrier risk. Five carrier risk optior
were stated and women were asked to selei
one (table 2). Of the 1798 women screenec
1055 (59°,o) perceived their risk correctly,
substantial number (378, 21 %) had no percet
tion of their risk, and a minority (36, 2°/
perceived their risk to be considerably lowt
than the 1 in 25 risk stated in the pre-screenin
information leaflet. A further 329 (18%) pe:
ceived their risk to be 1 in 4.
Asked to indicate their emotional respon:
to being screened, 880 (49%) stated they we:
reassured and 494 (28%) did not know ho
they felt. Anxiety was felt by 422 (23%) i
women and there was no response in two case
There was no correlation between anxie:
about being screened and perceiving one's ris
to be higher than 1 in 25 (table 2).
Figure 2 GHQ results. Percentages of earners and controls -uh postti-.e responses
— shozen for each assessment point. Xwriters ol carriers and controls tested shots i
re.ou -.core
RESULTS ON THE GENERAL HEALTH
QUESTIONNAIRE (GHQ)
Preliminary results of GHQ data on carri
and control subjects have been reported els.
where.5 In this extended study a total of 57
(32%) of the screened population presente
with a positive threshold GHQ. Many womc
(44%) cited symptoms of pregnancy as t.
problem. Twelve percent stated their pre
nancy was unplanned, 10% had a poor obst
trie history, and a further 7% felt general
anxious about the pregnancy. Two perce:
were worried about other antenatal diagnost
tests but only two women were concernc
about the CF screening test. Four percent
women had a psychiatric history.
Of the 64 carriers, 14 (22%) had a positi
GHQ against 25 (25%) among the contrc
(fig 2). On receiving positive test results, i.
proportion of carriers (53%) with a positi
GHQ1 score was significantly greater th
the proportion of control subjects (27%) (;
p < 0 001). At the time of their partner's neg
tive test result (GHQ2), at six weeks after t.
test (GHQ3) and at six weeks after delive
(GHQ4), carriers showed no significant d:
ference in the proportion of positive scor
when compared to selected controls (fig 2).
No significant difference was found betwe
the proportion of partners and their select
controls with a positive GHQ score at any
the four assessment points ffig 3). However, 14
of 15 (93%, partners with a positive GHQl
had a female partner who had also scored
positive. Nine of the 10 (90% male controls
who had positive GHQl scores had a female
partner with a positive GHQ score. Males
were, therefore, significantly more likely to
present with psychological distress if their
female counterpart was also distressed (y:,
p< 0-001.:.
Table 3 Median of symptom rating test I SRT) scores




















p < 0 005
p< 0-001


























SYMPTOM RATING TEST (SRT,
Five hundred and nineteen of the 576 '90o) of
the total screened population with a positive
threshold GHQ were interviewed and com¬
pleted a threshold SRT. Among this group
were 14 (22%, carriers and 25 ,25% selected
controls. There was no significant difference in
the threshold SRT scores of the three groups.
However, at SRT1 (carrier receiving positive
test result) there was a significant difference
between carriers and controls in the total score
for generalised psychological disturbance
(median test, p< 0-005) and specifically in the
subscores for anxiety and depression (median
test, p< 0-001, table 3).
On receiving their partner's negative test
result (SRT2) the scores of carriers returned to
control levels and remained there at the six
week post-test point (SRT3) and again ai the
six week post-delivery point (SRT4) (table 3).
There was no significant difference between
SRT scores for generalised psychological dis¬
turbance of the partners of carriers when com¬
pared with their selected controls (table 4).
Anxiety and inadequacy subscores were signi¬
ficantly higher than those of controls at the
time when carriers were given their positive
test results (median test, p<0 05 and p<0-02
respectively, table 4).
There was a significant decrease in the sub-
scores of anxiety in SRT1 and SRT2 scores in
SRT3 Carriers n = 64 Controls (n = 101)
Total 5 0 70 NS
Anxiety 1-0 1-0 NS
Depression 2 0 2 0 NS
Somatic 10 2-0 NS
Inadequacy 2 0 2 0 NS
SRT4 Carriers . n = 64 Controls (n = 99)
Total 60 7-0 NS
Anxiety- 10 10 NS
Depression 2-0 2 0 NS
Somatic 0 0 0 0 NS
Inadequacy 20 20 NS
Table 4 Aiedian of symptom rating test ( SRT) scores
of partners and controls.
SRT1 Partners (n = 63 Controls (n = 100)
Total 5 0 3 0 NS
Anxiety- 2 0 10 p<0 05
Depression 1-0 10 NS
Somatic 00 00 NS
Inadequacy 1-0 0 0 p < 0 02
SRT2 Partners (n = 63) Controls (n= 100)
Total 30 20 NS
Anxi cry- 1-0 0-0 NS
Depression 10 10 NS
Somatic 0 0 00 NS
Inadequacy 10 00 NS
SRT3 Partners (n = 63) Controls (n = 100)
Total 2 0 2 5 NS
Anxicry 00 05 NS
Depression 0 0 10 NS
Somatic 00 00 NS
Inadequacy 10 00 NS
SRT4 Partners (n = 62) Controls (n = 98)
Total 30 30 NS
.Anxi cry- 00 00 NS
Depression 1-0 10 NS
Somatic 0 0 00 NS
Inadequacy 10 10 NS
Partners
Controls
Figure 3 GHQ results. Percentages of partners and controls with positive rcsenses
i 3 ~ / shenen for each assessment point. Plumbers of partners and controls tested shcnvti
belcnc figure.
both carriers and their partners (table 5). Thi
also showed up in the subscores for depressio:
among carriers.
Discussion
The findings from this study show that pre
natal carrier screening delivered in two stage
does generate some psychological disturbance
In the identified carrier there is a significar.
Table 5 Comparison of median of SRT1 and SRT2
scores in carriers (rt = 64) and partners (n = 63).
Carrier's scores SRTl SRT2
Total 115 7-0 NS
Anxiety- 4-5 2 0 p<0 001
Depression 4 0 2 0 p < 0 02
Somatic 10 1-0 NS
Inadequacy 2-5 2 0 NS
Partner's scores SRTl SRT2
Total 5 0 3 0 NS
Anxiety 2-0 10 p< 0 005
Depression 10 10 NS
Somatic 0 0 00 NS
Inadequacy 10 1 0 N'S
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increase in generalised psychological disturb¬
ance, specifically anxiety and depression, when
compared to a control population. This reac¬
tion occurs in response to learning of their
carrier status and lasts for the period .(approx-
imately four days in this study) awaiting their
partner's test result. On receiving their
partner's negative test result the distress sub¬
sides and there is no indication of a resurgence
during the pregnancy or in the immediate
postnatal period. Although the longer term
effects are unknown, three carriers from this
study have subsequently embarked upon a
further pregnancy.
Male partners manifested symptoms of
anxiety and inadequacy during the period
awaiting their test result, but this disappeared
on receipt of a negative result. Both partners
and male control subjects were significantly
more likely to manifest psychological disturb¬
ance if their female partner was distressed.
Thirty-two percent of women presented at
the antenatal booking clinic with a positive
GHQ score. This is comparable with other
studies.10 Previous work has shown that ran¬
domly selected samples from the community
will contain quite high proportions of persons
with degrees of psychological disturbance
ranging from mild to severe." Indeed it is
estimated that 25% of patients seen in general
practice have anxiety as a clinically significant
component of their condition.12
In this study subjects presenting with nega¬
tive GHQ scores submitted mean SRT scores
comparable with normal subjects in previous
studies.8'3 Carriers with positive GHQ1 scores
submitted SRT1 scores well below those
reported for psychiatric patients814 and com¬
parable with scores generated by the Symptom
Questionnaire in patients undergoing amnio¬
centesis." This is a point worth noting as
previous studies have suggested that levels of
anxiety in pregnant women who receive a
positive test result can be extremely high,
above those for psychiatric patients." It is
clear that a substantial number of women will
enter a prenatal screening programme with
concurrent stress. Indeed, five of the 14 car¬
riers who presented with a positive threshold
GHQ score maintained these scores through¬
out; for reasons of recent bereavement (three
cases), diagnosis of chronic illness in the
partner (one case), and regular ECG monitor¬
ing throughout pregnancy for attacks of
breathlessness (one case). Eleven out of 25
control subjects who presented with positive
threshold scores maintained these scores
throughout the study for a variety of reasons.
Threshold psychological assessment on all
women screened served not only to ensure for
the purposes of this study that there was no
significant psychological difference between
carriers and control subjects at the outset, but
proved valuable in the wider screening trial for
ascertaining women identified as CF carriers
who were already experiencing stress and
might require extra counselling and support.
Previous studies on patients undergoing
prenatal screening have indicated that once a
woman perceives her pregnancy has been
threatened she continues to be concerned."'
Conversely, others have shown a dramatic
return to normal once a negative test result is
given.11'■ The results of this study agree with
the findings of the latter. A notable effect of
prenatal CF carrier screening upon two car¬
riers was their subsequently declining i feto¬
protein (AFP) screening. A further two car¬
riers received abnormal AFP screening results
and underwent amniocentesis for chromosome
studies. Despite this only one of these four
women was included in the 6% o: carriers who
stated they were against the test being offered
routinely to pregnant women. A concern must
be that some women may no: be so resilient to
multiple provoking agents during pregnancy,
which could foreseeably occur if a woman
experiences several positive screening tes: re¬
sults, and particularly were she already suffer¬
ing from concurrent stress. A positive aspect is
that the developing area of prenatal screening
will help us to consider more carefully the
whole area of psychosocial support in the pro¬
vision of antenatal care, which some perceive
to have been neglected."
Psychological disturbance is considered a
normal rather than a pathological response to
prenatal diagnosis.20 It has been suggested that
counselling efforts should support the person's
attempt to cope with stress accompanying the
procedure rather than not provide screening.21
The results of this study suggests that stress
resulting from being identified as a CF carrier
during pregnancy is short lived and that those
couples faced with an intermediate risk of
having a CF child cope satisfactorily.
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sible. The study was funded by grants from
The Cystic Fibrosis Trust and the Scottish
Home and Health Department.
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controls. Although the two groups of controls received far less direct
information than the carriers and their partners, all four groups were
well informed about the genetics of cystic fibrosis and the significance of
being a gene carrier. A majority of each group felt that adequate infor¬
mation had been given in the information leaflet, that they understood
the purpose of screening and that they were glad to have participated.
There was a consensus that CF carrier testing should be routinely offered
to pregnant women, and also that it should be available in family planning
clinics and GP health centres, but not in schools.
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The cloning of the cystic fibrosis (CF) gene (Rom-
mens et al. 1989), together with the demonstration
that up to 85% of mutant alleles may be detected
relatively easily (Shrimpton et al. 1991), has made
it possible to institute programmes of population
heterozygote screening. Amongst various models
for delivery of such programmes, those using ante¬
natal clinics have obvious attractions (Mennie et
al. 1992a, b). Pregnant women and their partners
are highly motivated to establish their heterozygote
status and, through prenatal diagnosis, to avoid
the risk of delivering a CF child. Although testing
during pregnancy generates some stress, it is com¬
paratively short-lived and effectively disappears
once partners have been shown to be negative for
detectable CF alleles (Mennie et al. 1992b, 1993).
The absence of significant anxiety amongst the
participating population, though important, does
not necessarily make a screening programme valid.
It is essential to have some idea of the attitude of
mind of carriers and their partners, their under¬
standing of the processes involved and their re¬
sponse to the discovery of their genetic status. In this




Women booking for delivery of their babies at the
Simpson Memorial Maternity Pavilion, Edin¬
burgh, were invited to enter a two-step prenatal
screening trial for CF. Details of the protocol and
recruitment methods for this trial have been pub¬
lished previously (Mennie et al. 1992a, b).
Between May 1991 and January 1992, 69 women
were identified as CF carriers amongst a total of
1798 screened. In each case the male partner was
also screened, and amongst the 69 there were three
1 in 4 risk couples. These three couples were ex¬
cluded from this study, along with one couple
whose pregnancy failed to continue, and a further
couple and one male partner who failed to com¬
plete the questionnaire. A total of 64 carriers and
63 partners participated in the study.
Two control subjects were selected for each car¬
rier. The controls had attended the same booking
clinic as the carrier, were of the same parity and had
received a negative test result. The male partners of
these female controls were also invited to participate
in the study, and served as controls for the partners
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carriers. In all, 1 16 female controls and 115 male
■ntrols agreed to take part, ofwhom 13 couples did
)t respond to the questionnaire, while a further two
iuples had pregnancies which failed to continue. A
tal of 101 female controls and 100 male controls
implcted the questionnaires.
ethods
ogether with their booking clinic appointment,
1 antenatal patients attending the Simpson Me-
lorial Maternity Pavilion received a leaflet outlin-
ig the aims of prenatal CF carrier testing and
escribing the procedure. The designing of the leaf-
it has been described (Mennie et al. 1992a). The
:aflet stated the CF carrier frequency, displayed
re mode of inheritance of CF in diagrammatic
orm, and emphasized that carrier couples had a 1
4 risk of an affected child. It pointed out that a
imily history of CF was not a prerequisite to
eing a CF carrier. Care was taken to stress the
ict that being a carrier was unimportant unless
le partner was also a carrier.
Women identified as CF carriers were invited to
ttend the hospital with their partner for coun¬
ting. An additional leaflet was given to all car¬
riers and their partners reiterating in greater detail
the pre-screening information. This leaflet gave the
risk of heterozygosity amongst the siblings of car¬
riers, recommended that relatives should be
screened before pregnancy and advised how to go
about this. Partners received test results after an
average of 4 days' wait. After 6 weeks, carriers
and their negative partners were sent a "facts and
feelings" questionnaire by post, with a stamped
addressed envelope for return. The "facts" section
was composed of six statements derived from the
pre-screening information booklet. Subjects were
asked to tick which statements they thought to be
true. The "feelings" section of the questionnaire
was composed of a further six statements designed
to assess subject's attitudes towards the prenatal
screening trial specifically, and also towards CF
carrier testing in general.
Sociodemographic data were obtained from the
hospital antenatal records. Significance was as¬
sessed by the yj test with Yates' correction.
Results
Sociodemographic data showed no significant dif¬
ferences between carriers and controls or between
ble 1. Percentage of true and false responses to "facts" questionnaire (part
. No one failed to respond
lestion True False
Any couple can have a child with CF
female carriers 39 61
female controls 41 59
male partners 43 57
male controls 42 58
A couple can have a child with CF if:
a) Only one partner carries a single CF gene
female carriers 11 89
female controls 10 90
male partners 13 87
male controls 18 82
b) If both partners carry a single CF gene
female carriers 95 5
female controls 92 8
male partners 98 2 I "
male controls 84 16 '
One in 25 people in Britain carry a single CF gene
female carriers 100 0 1 +
female controls 77 23 1
male partners 92 8 1 *
male controls 74 26 1
Even if you have no family history of CF you can carry
a single CF gene
female carriers 91 9
female controls 94 6
male partners 89 11
male controls 96 4
Table 2. Percentage responses to "facts" questionnaire (part 2). No one failed
to respond
Question
5. If both partners carry a single CF gene their chance of having a child
with CF is:
a) 1 in 2
b) 1 in 4
c) 1 in 20
d) All their children will have CF
Response
test on case versus control; ' p < 0.01. + p< 0.001.
a b c d
Female carriers 2 98 0 0
Female controls 0 94 6 0
Male partners 2 97 IV 1 0
Male controls 4 81 ) 14 1
Question
6. If you carry a single CF gene this means:
a) Your health will be affected
b) You will develop the disease CF
c) It is only important if your partner carries a single CF gene
Response
a b c
True False True False True False
Female carriers 0 100 0 100 100 0
Female controls 0 100 1 99 96 4
Male partners 0 100 0 100 100 0
Male controls 1 99 2 98 93 7
■/} test on cases versus controls: ' p < 0.01.
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Table 3. Percentages responding to "feelings" questionnaire (part 1)
Question 1:1 feel that the information l/my partner was given about the CF
carrier test (a) before the antenatal clinic (b) at the antenatal clinic was
about right, too much or not enough
(a) Before the antenatal clinic
About right Too much Not enough
Female carriers 62 2 35
Female controls 65 0 35
Male partners 62 2 36
Male controls 54 0 46
(b) At the antenatal clinic
About right Too much Not enough
Female carriers 75 2 231,
Female controls (1 no response) 88 0 12/
Male partners 87 2 11
Male controls (1 no response) 87 2 11
Question 2:1 feel that I understood what the CF test was all about before
l/my partner was tested.
Yes No/don't know
Female carriers 70 30
Female controls 83 17
Male partners 54 46
Male controls 60 40
Question 3:1 am glad that l/my partner had the CF carrier test
Yes No/don't know
Female carriers 80 20 1
.
Female controls 97 3 /
Male partners 90 10
Male controls 98 2
Question 4: I feel that the CF carrier test should routinely be offered to
pregnant women
Yes No/don't know
Female carriers 88 12
Female controls 96 4
Male partners 94 6
Male controls 94 6
X2 test on cases versus controls; ' p< 0.001.
male partners and their respective controls in any
of the factors examined.
The six questions in the "facts" questionnaire
are shown in Tables 1 and 2, along with the re¬
sponses. The most significant differences between
cases (i.e. carriers or their partners) and their re¬
spective controls are to be seen in question 3, the
population frequency of CF heterozygosity, with
almost a quarter of controls of both sexes misiden-
tifying the correct figure. Controls of male partners
were also significantly different to their cases in
Table 4. Percentages responding yes to "feelings" questionnaire (part 2). No
one failed to respond
Question 5:1 teel that I am in favour of testing for CF carriers in:
Schools Family planning clinics GP health centres
Female carriers 30 86 89
Female control 36 89 93
Male partners 32 81 87
Male controls 38 81 89
Question 6: It I turned out to carry a CF gene, I feel I would tell;
My My My Other Friends
partner sibs children relatives
Female carriers 100 921 921. 59 45
Female controls 100 78/ 78/ 53 31
Male partners 100 791 87 49 30
Male controls 100 63/ 79 34 22
X2 test on cases versus contorls (agreement/non-agreement);' p < 0.05.
response to questions 2b and 5. It must also be
noted that the unexpected range of response to
question 1 suggests imprecision.
Questions and responses to the "feelings" ques¬
tionnaire are shown in Tables 3 and 4. Carriers
were significantly more likely than controls to feel
that the information given at the antenatal clinic
was insufficient (question lb), and to have ambiva¬
lent feelings about having been screened (question
3). A high proportion of each group (88-96%) felt
that the CF carrier test should routinely be offered
to pregnant women (question 4). There was also
strong support for carrier screening in family plan¬
ning clinics and GP health centres, but not in
schools (question 5). Carriers and their partners
were significantly more likely than their respective
controls to tell their sibs and their children that
they carried a CF gene (question 6).
Discussion
In this study we have attempted to assess two
important aspects of a screening programme: the
understanding by the participants of the genetic
facts of the disease and their feelings about having
agreed to take part. The four groups involved had
rather different access to information and also dif¬
ferent experiences of the programme. Those iden¬
tified as carrying mutant CF alleles and their part¬
ners had experienced some anxiety while awaiting
the partner's test result (Mennie et al. 1992b, 1993).
Both carriers and partners had been counselled in
one-on-one sessions with a genetic nurse and had
received additional written information. In con¬
trast, the two control groups would have derived
most of their knowledge of CF from the infor-
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mation leaflet sent out at the time of their booking
appointment, 2 to 3 months before they completed
the "facts" and "feelings" questionnaire. Although
the information leaflet was presumably still avail¬
able for consultation, it is gratifying that in some
sections of the "facts" questionnaire all four groups
had near maximum scores. This is seen in the re¬
sponse to whether it is possible to carry a CF gene
if you have no family history of CF (question 4,
Table 1) and in the response to the question about
the effect of CF heterozygosity on general health
(question 6, Table 2). Concern has been raised that
being a carrier of a recessive gene may cause an
individual to have a less positive view of his or her
health (Marteau et al. 1992).
Three of the four groups had an excellent idea
of the risk of having a child with CF when both
partners carried a mutant gene (question 5, Table
2). However, even though controls of the female
carriers were well informed on this point, the male
controls of their partners proved fallible. An earlier
study found that only 63% of males had read the
prescreening leaflet and had participated in the
screening decision (Mennie et al. 1992a).
We were not surprised that controls scored poor¬
ly in comparison to cases in the question about CF
heterozygosity frequency in Britain (question 3).
They had far less access to this information, and
as they screened negative, it no longer really con¬
cerned them. Similar findings have been reported
by others (Watson et al. 1992).
Responses to the "facts" questionnaire also
allowed us to focus on shortcomings in our infor¬
mation leaflets. Approximately 40% of all groups
thought the statement "any couple can have a child
with CF" to be true (question 1, Table 1). Although
the leaflet showed in diagrammatic form that each
partner had to be a carrier, it also emphasized that
current heterozygote tests are incomplete. Thus in
a literal sense the statement is true, even though
we expected respondents to find it false. This illus¬
trates how easy it is to introduce ambiguities into
a questionnaire. Field & Renfrew (1991) have criti¬
cized the failure of health care professionals to
inspect in detail the content of printed information
issued to patients.
From.the "feelings" questionnaire, it would seem
that there is a desire amongst all four groups for-
more information on the carrier test before attend¬
ing the antenatal clinic (question la. Table 3). Fur¬
thermore, there was a significant difference be¬
tween carriers and their controls in feelings about
whether enough information had been supplied at
the antenatal clinic (question lb. Table 3). A much
larger proportion of men than women did not feel
that they knew what the CF test was all about
before either they or their partners were tested
(question 2). Again this may reflect the fact that
around 37% of men do not read the prescreening
information leaflet nor enter into the decision to
participate in the screening programme (Mennie et
al. 1992a). Nonetheless, a very large majority of
all four groups were glad that they or their partner
had taken the CF carrier test (question 3). The
only ambivalence appeared amongst the carriers
themselves.
There seems to be considerable tolerance for the
timing of the CF carrier test. High proportions of
all four groups felt that it should be routinely of¬
fered in pregnancy, as well as being available at
family planning clinics and GP health centres.
There was minority support for screening in
schools (question 5); yet other studies have found
this to be the popular option (Green 1992, Zeesman
et al. 1984).
All respondents stated that they would tell their
partner if they turned out to be a CF carrier (ques¬
tion 6, Table 4). Carriers and their partners were
more likely to tell their sibs, children, other rela¬
tives and friends about being a carrier than were
their respective controls. This undoubtedly reflects
the one-on-one counselling sessions where a family
tree was drawn and risks to siblings explained, in
addition to giving carriers and their partners a
leaflet outlining the screening procedure for rela¬
tives.
Loader et al. (1991), studying prenatal screening
for haemoglobinopathies, have pointed out that
learning during genetic counselling sessions is often
below expectations. Problems may also arise when
the provider rather than the counsellor initiates
the testing, a feature of population screening. It is
suggested that videotape presentations and home
visits might be advantageous. However, in this pro¬
gramme we present evidence that a simple, care¬
fully-designed leaflet (Mennie et al. 1992a) can be
very effective in communicating essential genetic
facts. Although all our female controls were given
a great deal of information on a variety of topics
during the booking-in procedure, in both verbal
and written form, they had retained and under¬
stood most of the key features of the CF leaflet
sent to them several months before they answered
the questionnaire. We presume that many re-read
the leaflet before attempting to answer questions.
Our findings document a high level of understand¬
ing and a positive view of the screening procedure.
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